| | |
|---|---|
| **From:** | Brian Bird <bhbird@ucdavis.edu> |
| **To:** | Andrew Clements <aclements@usaid.gov>;Jonna Mazet <jkmazet@ucdavis.edu>;Corina Grigorescu Monagin <cgmonagin@ucdavis.edu>;Tracey Goldstein <tgoldstein@ucdavis.edu> |
| **CC:** | David J Wolking <djwolking@ucdavis.edu>;Pereira, Alisa (GH/HIDN) <apereira@usaid.gov> |
| **Sent:** | 2/6/2018 8:45:34 AM |
| **Subject:** | Re: Passing of Dr. Foday Dafae |

Thanks Andrew,

Yes, the past day has been extremely sad for the PREDICT family as Prof Gbakima and James Bangura were quite close with Dr. Dafae.

A massive and sad loss for the country.

-Brian

**From:** Andrew Clements
**Date:** Tuesday, February 6, 2018 at 8:08 AM
**To:** Jonna Mazet , Brian Bird , Corina Grigorescu Monagin , Tracey Goldstein
**Cc:** David J Wolking , "Pereira, Alisa (GH/HIDN)"
**Subject:** Passing of Dr. Foday Dafae

FYI. We got a note today from our mission in SL saying that
Dr. Foday Dafae, Director of Disease Prevention and Control and Incident Manager of the Sierra Leone National Emergency Operation Centre (PHNEOC), Ministry of Health and Sanitation (and a key POC for GHSA) died in the Brussels' airport on the way back from PMAC.

Andrew Clements, Ph.D.
Senior Scientific Advisor
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
E-mail: aclements@usaid.gov

*For more information on USAID's Emerging Pandemic Threats program, see:* http://www.usaid.gov/ept2

**Sent:** Mon, 19 Mar 2018 22:26:33 +0800
**From:** George F GAO <gaof@im.ac.cn>
**To:** Carlos Morel [redacted]
**Cc:** Peter Daszak <daszak@ecohealthalliance.org>, "Subhash (FAORAP) Morzaria ([redacted]" <[redacted]>, "Subhash P Morzaria [redacted] Ariel Pablos-Mendez [redacted] Oyewale Tomori <[redacted] "ap39@cumc.columbia.edu" <ap39@cumc.columbia.edu>, Carlos Medicis Morel [redacted] "Dennis Carroll (DCarroll@usaid.gov)" <DCarroll@usaid.gov>, Nathan Wolfe <nwolfe@metabiota.com>, Jonna Mazet <jkmazet@ucdavis.edu>, Brooke Watson <watson@ecohealthalliance.org>, Cara Chrisman <cchrisman@usaid.gov>, [redacted] Anthony Ramos <ramos@ecohealthalliance.org>, Hongying Li <li@ecohealthalliance.org>
**Subject:** Re: Re: Time sensitive - needs your response
GaoResponse to Branco and Garry--George.docx

Dear Peter,

Thank you for your brilliant draft. Here is my comments.

Best

George

-----原始邮件-----
**发件人:**"Carlos Morel" <cmmorel@gmail.com>
**发送时间:**2018-03-17 19:33:50 (星期六)
**收件人:** "Peter Daszak" <daszak@ecohealthalliance.org>
**抄送:** "George F Gao (gaof@im.ac.cn)" <gaof@im.ac.cn>, "Subhash (FAORAP) Morzaria ([redacted]" <[redacted]>, "Ariel Pablos-Mendez" <[redacted]>, "Oyewale Tomori" <oyewaletomori@gmail.com>, "ap39@cumc.columbia.edu" <ap39@cumc.columbia.edu>, "Carlos Medicis Morel" <[redacted]>, "Dennis Carroll (DCarroll@usaid.gov)" <DCarroll@usaid.gov>, "Nathan Wolfe" <nwolfe@metabiota.com>, "Jonna Mazet" <jkmazet@ucdavis.edu>, "Brooke Watson" <watson@ecohealthalliance.org>, "Cara Chrisman" <cchrisman@usaid.gov>, [redacted], "Anthony Ramos" <ramos@ecohealthalliance.org>, "Hongying Li" <li@ecohealthalliance.org>
**主题:** Re: Time sensitive - needs your response

Dear Peter,
I made a few suggestions to the draft response. Please feel free to revise them as you wish.

I would agree being listed as a coauthor of this response.

Best regards from Rio,

Carlos

**Response to Branco and Garry**

We welcome Branco and Garry's comment on our Policy Forum. However, we believe they have misinterpreted both the goal of the USAID EPT/PREDICT program, and its differentiation from the Global Virome Project (GVP). The PREDICT program was set up to model and analyze high risk pathways for disease emergence, build capacity to prevent emerging diseases in countries where they are most likely to originate, identify potentially zoonotic viruses in wildlife *before* they infect people, and conduct behavioral risk surveillance and testing in people at high risk disease emergence interfaces(*1*). It is therefore not a key success metric of this program to identify viruses in wildlife that then emerge in people, rather it is a key goal to help prevent them from emerging. Continuous surveillance is the key to prevent and control of any emerging pathogens (Ref.),

That said, the USAID EPT/PREDICT field teams are located in regions where known and novel viruses spillover from wildlife regularly, and staff have been able to support national, regional and international agencies in investigating the source of viral emergence in humans, livestock and wild animals, and providing field and laboratory support during outbreaks(*1, 2*). This includes, for example, laboratory support during a yellow fever outbreak in Uganda (*2*), identification of the wildlife origin of a novel coronavirus causing die-offsof pigs in southern China (*3*), and investigations into the wildlife origin of Nipah virus and into avian influenza virus (AIV) as the cause of crow die-offs in Bangladesh (*4, 5*). More importantly, even the major gene segments of the human-infecting H7N9 AIV, the most worrisome AIV to be the source of a potential pandemic, emerged in China in 2013 was wild migratory birds' origin (Ref.). In this way, members of PREDICT staff were involved in the identification of Bas-Congo virus in the blood of patients from an outbreak of acute hemorrhagic fever (*6*). While Bruno and Garry argue that this outbreak was not caused by the Bas-Congo virus, they provide only circumstantial evidence in support of this, and we believe a great deal of further evidence would be necessary to refute the original paper. Indeed, one of the authors states in a recent article reporting two other rhabdoviruses found in healthy people, that "While the prevalence and clinical significance of these viruses are currently unknown, these viruses could have previously unrecognized impacts on human health"(*7*). Furthermore, the authors even argued about the 2013-2016 Ebola outbreak in West Africa, which is obviously wrong. There might be some other pathogens but Ebola virus was for sure the major cause.

Throughout their comment, Bruno and Garry misinterpret the goals of theGVP and are incorrect in their assumption that it is a "major expansion and redirection of the EPT PREDICT program", or that it is designed to "eliminate the need to sequence any newly emerged human viral pathogen". The GVP differs fundamentally from PREDICT in its international governance structure, and itscentral goal of conducting viral discovery in mammalian and water bird taxa to identify the majority of the likely unknown zoonotic viral threats to humans residing in wildlife. As we clearly state in our paper, the GVP's goal is to improve our collaborative efforts to combat emerging viruses "by enhancing (not replacing) current pandemic surveillance, prevention, and control strategies"(*8*). We look forward to the GVP collaborating with agencies and research groups focused on identifying viruses that have already emerged, while recognizing that these probably represent less than 0.1% of the viruses capable of

emerging in the future(*8*). Identifying the majority of the remaining >99.9% of unknown potentially zoonotic viral diversity remains the unique, and central goal of the GVP.


1. PREDICT_Consortium, "Reducing pandemic risk. Promoting Global Health," (One Health Institute, University of California Davis, 2014).
2. data.predict.global.
3. P. Zhou *et al.*, Fatal swine acute diarrhea syndrome caused by an HKU2-related coronavirus of bat origin. *Nature***In press**, (2018).
4. S. U. Khan *et al.*, Investigating a crow die-off in January-February 2011 during the introduction of a new clade of highly pathogenic avian influenza virus H5N1 into Bangladesh. *Archives of Virology***159**, 509-518 (2014).
5. E. S. Gurley *et al.*, Convergence of humans, bats, trees, and culture in Nipah virus transmission, Bangladesh. *Emerging Infectious Diseases***23**, 1446-1453 (2017).
6. G. Grard *et al.*, A novel rhabdovirus associated with acute hemorrhagic fever in central Africa. *PLoS pathogens***8**, e1002924 (2012).
7. M. H. Stremlau *et al.*, Discovery of novel rhabdoviruses in the blood of healthy individuals from West Africa. *Plos Neglect. Trop. Dis.***9**, (2015).
8. D. Carroll *et al.*, The Global Virome Project. *Science***359**, 872-874 (2018).

**Sent:** Mon, 23 Apr 2018 14:15:10 -0700
**Subject:** Re: Serendipity....
**From:** Jonna Mazet <jkmazet@ucdavis.edu>
**To:** Andrew Clements <aclements@usaid.gov>

Okay -- thanks.
We'll get scheduled as soon as possible.
J

On Mon, Apr 23, 2018 at 12:13 PM, Andrew Clements <aclements@usaid.gov> wrote:

> Hi Jonna,
> Best to do when others are available and not plan around me.
>
> Andrew
>
> *Andrew P. Clements, Ph.D.*
> *Senior Scientific Advisor*
> *Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health*
> *U.S. Agency for International Development*
> *Mobile phone: 1-571-345-4253*
> *Email: aclements@usaid.gov*
>
> On Apr 23, 2018, at 8:30 PM, Jonna Mazet <jkmazet@ucdavis.edu> wrote:
>
> > Hey Andrew,
> > Is this the kind of meeting we should just do soon, or do do you want to be there?
> > Thanks,
> > Jonna
> >
> > ---------- Forwarded message ----------
> > From: **Alisa Pereira** <apereira@usaid.gov>
> > Date: Fri, Apr 13, 2018 at 11:18 AM
> > Subject: Serendipity....
> > To: Jonna Mazet <jkmazet@ucdavis.edu>, PREDICTMGT <predictmgt@usaid.gov>, Predict inbox <predict@ucdavis.edu>, "Andrew (GH/HIDN) Clements" <AClements@usaid.gov>, David J Wolking <djwolking@ucdavis.edu>, Cara Chrisman <cchrisman@usaid.gov>
> >
> > Hi All!
> >
> > As you will remember, I mentioned at the end of the P2 meeting this week that I was really impressed with so many aspects of what you are doing, and wanted to make more of an effort to get some of this information shared with our colleagues at USAID, and then a broader audience later in the year with the Smithsonian-type briefing.
> >
> > As luck would have it, Ricardo circulated an article today with the catchy title "Did Deforestation cause the Ebola Outbreak?" That sparked a discussion around P2's work in Land Use Change, the preliminary analysis on the Deep Forest Project, and thoughts around Land Use Change being a focus of the "deep dive" for the behavioral work.
> >
> > And just like that.....people are incredibly interested to hear P2's thoughts and preliminary analysis and plans. Andrew and I agree that you guys can decide what is ready for prime time and what is not, but there is an interest for a briefing in DC at USAID on this specific topic. Consider it more like a brown bag than a full court press event.
> >
> > Please let me know if this is doable, and who I should coordinate with on your team to make it happen. This request is not intended to CREATE work. It is a more casual discussion about your work, progress, and plans.
> >
> > Thanks
> > alisa

**Alisa Pereira, Senior Public Health Advisor**
Bureau for Global Health, Office of Infectious Disease, Emerging Threats Division
2100 Crystal Drive, CP3-0001, Arlington, VA 22202
Phone:202-997-9966
Email: apereira@usaid.gov

USAID Contractor
*GHSI-III - Social Solutions International, Inc.*

**From:** "Katherine Leasure" <kaleasure@ucdavis.edu>
**To:** "'Brooke Watson'" <watson@ecohealthalliance.org>, "'Morzaria, Subhash \(TCE\)'" <[redacted]>
**Cc:** "'Jonna Mazet'" <jkmazet@ucdavis.edu>, [redacted], "'Cara Chrisman'" <cchrisman@usaid.gov>
**Subject:** RE: Response needed by May 8: GVP meeting June 11
**Sent:** Wed, 23 May 2018 10:04:17 -0700

Dear Subhash,

Thank you for your email, and confirming that you will not need travel support for this meeting.

With regard to your hotel reservation, can you confirm your date of arrival and departure?

Best,
Katie

**From:** Brooke Watson [mailto:watson@ecohealthalliance.org]
**Sent:** Tuesday, May 22, 2018 7:54 AM
**To:** Morzaria, Subhash (TCE)
**Cc:** Jonna Mazet; Katherine Leasure; [redacted]; Cara Chrisman
**Subject:** Re: Response needed by May 8: GVP meeting June 11

Subhash,

Thank you! We'll be sure to make a hotel reservation for you with the rest of the group. Thanks for letting us know.

Best,

Brooke

On Tue, May 22, 2018 at 10:49 AM, Morzaria, Subhash (TCE) <[redacted]> wrote:
Dear Brooke,
I will arrange for my ticket so I will not any support for this. I would appreciate if you could make a hotel reservation for me at the same venue as the meeting.
Thanks and best regards,
Subhash

---

**From:** Morzaria, Subhash (TCE)
**Sent:** Friday, May 04, 2018 4:35 PM
**To:** Brooke Watson <watson@ecohealthalliance.org>
**Cc:** Jonna Mazet <jkmazet@ucdavis.edu>; Katherine Leasure <kaleasure@ucdavis.edu>; [redacted]; Cara Chrisman <cchrisman@usaid.gov>
**Subject:** RE: Response needed by May 8: GVP meeting June 11

Dear Brooke,
This is to confirm that I will be able to attend. I will let you know soonest if I will need support for travel.
With best regards,
Subhash

**From:** Brooke Watson [mailto:watson@ecohealthalliance.org]
**Sent:** Friday, May 04, 2018 4:31 PM
**To:** Jonna Mazet <jkmazet@ucdavis.edu>; Katherine Leasure <kaleasure@ucdavis.edu>; [redacted]; Cara Chrisman <cchrisman@usaid.gov>
**Subject:** Response needed by May 8: GVP meeting June 11

Dear GVP Steering Committee colleagues,

In order to secure approval for international travel and confirm support if it is needed to facilitate travel arrangements for

our meeting on Monday, June 11 in Washington, it is important to know which of you will be in attendance. We know that some of you will be in town for the National Academies workshop on June 12 and 13, but for others, will you **please respond to Jonna, Eri, Katie and myself (all cc'd) by 5 PM EST next Tuesday, May 8,** indicating**:**

1. Whether you will be able to attend the meeting on June 11 in person in Washington. DC
2. If not, whether you will be able to call in for all or some of the meeting from 10 AM - 4 PM EDT
3. If there are any caveats to your attendance (e.g., you can only attend after 12 PM EDT)
4. If you will need any support for your travel to Washington DC

If we do not receive your response by May 8, we will assume that you will not be joining in person.

Many thanks for your quick responses, and please don't hesitate to ask if you have any questions. A full agenda is forthcoming, but we want to ensure that the logistics teams have a full attendee list well in advance so we can move forward with preparations.

Best,

Brooke Watson

--

**Brooke Watson, MSc**
*Research Scientist*

EcoHealth Alliance
460 West 34th Street – 17th floor
New York, NY 10001

1.212.380.4497 (direct)
REDACTED (mobile)
1.212.380.4465 (fax)
www.ecohealthalliance.org

***EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that promote conservation and prevent pandemics.***

--

**Brooke Watson, MSc**
*Research Scientist*

EcoHealth Alliance
460 West 34th Street – 17th floor
New York, NY 10001

1.212.380.4497 (direct)
REDACTED (mobile)
1.212.380.4465 (fax)
www.ecohealthalliance.org

***EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that promote conservation and prevent pandemics.***

**From:** Sudarat Damrongwatanapokin <sdamrongwatanapokin@usaid.gov>
**Sent:** Tue, 30 Oct 2018 18:55:21 +0700
**Subject:** Re: TVPP
**To:** Kevin Olival <olival@ecohealthalliance.org>, Dennis Carroll <dcarroll@usaid.gov>, Jonna Mazet <jkmazet@ucdavis.edu>, sfh9@georgetown.edu, David McIver <dmciver@metabiota.com>, Hongying Li <li@ecohealthalliance.org>
**Cc:** REDACTED u, Cara Chrisman <cchrisman@usaid.gov>, Daniel Schar <dSchar@usaid.gov>, Anchalee Jatapai <ajatapai@usaid.gov>, Siana Tackett <stackett@usaid.gov>

Dear All,
Can the organizer share your ppt presented at Thailand National Virome Project with Thai colleagues who participated in the meeting? DMSC team is preparing the minutes of the meeting and wants to do final check with you all that the presentation can be shared in PDF format.

Thank you very and look forward to hearing from you,

Best regards,
Sudarat Damrongwatanapokin, D.V.M., Ph.D.
Regional Animal Health Advisor
USAID Regional Development Mission Asia
Bangkok, 10330
E-mail: sdamrongwatanapokin@usaid.gov
Tel: +662-257-3243, Fax:+662 -2573099

>> On Oct 25, 2018, at 10:36 PM, Sudarat Damrongwatanapokin <sdamrongwatanapokin@usaid.gov> wrote:
>>
>> Dear Dennis, GVP and FAO teams,
>>
>> I want to convey the good news to you all. I got a phone call from Dr.
>> Lot (Patarapol Maneeorn),Director of Wildlife Health Division ( new
>> Division), DNP, right after the meeting He apologized for not being
>> able to attend the meeting due to the meeting at Cabinet and the Tetra
>> Ministerial meeting this afternoon. He strongly supports TVPP and
>> express DNP willingness to join the program and be one of the core
>> team. He is on the same page with other colleagues regarding 20 years
>> National Strategic plan and DNP EID strategic and implementation
>> plan.
>>
>> I think this is the right time with all stakeholders on board to move
>> forward in establishing sustainable TVPP.
>>
>> Thank you very much for your time and efforts to make round table
>> dialogue of TVPP happen with very interactive and fruitful outcomes.
>> Our special thanks to Dr. Wantanee and FAO team for her inspiration
>> and tireless efforts.
>>
>> We look forward to collaboratively working with the teams and RTG
>> networks in the coming months.
>>
>> Safe travel.
>>
>> Best regards,
>> Sudarat
>>
>> Sent from my mobile.

**From:** Peter Daszak <daszak@ecohealthalliance.org>
**To:** [redacted] "jkmazet@ucdavis.edu" <jkmazet@ucdavis.edu>
**Subject:** ITA
**Sent:** Tue, 2 Jul 2019 21:26:47 +0000

Hi Jonna,

I put the ITA below in and it was rejected. The timing was bad – it coincided with all the issues 2 weeks ago around the PREDICT funds, but now that these have come through, can we re-assess. The trip to Glasgow was planned almost a year ago when I was invited to present at the meeting, with the idea that some of the UK and European virologists have been quite snarky re the GVP and PREDICT and this is an important opportunity to explain the value of these projects to them.

I do remember you saying that having the GVP in the goals of an ITA should help, so let me know what's possible. If I can't fund this from PREDICT, I'm digging into EHA unrestricted funding to support something that's really work for PREDICT and GVP. If I cancel the trip, it looks really messy to the people in the audience who are already criticizing our work on PREDICT and GVP…

Let me know what you can do… Would it help if I fund the London section of this trip (airfare Glasgow-london, hotel etc.) from other funding?

Peter

**1. EcoHealth Alliance** would like to request travel approval for **Peter Daszak** to travel from **Newark, NJ** to **Glasgow and London, UK** from **July 9-12, 2019** to **present a keynote lecture at the 8th Congress of European Microbiologists**.

Dr. Daszak has been asked to present a keynote lecture at the most significant meeting of infectious disease researchers in Europe: the FEMS (Federation of European Microbiological Scientists) 2019 Annual meeting, the 8th Congress of European Microbiologists. The Congress organizers specifically requested that Dr. Daszak present on the PREDICT project and how it helps predict and prevent pandemics. This is an excellent opportunity to communicate the value of PREDICT to these stakeholders.

On the 9th of July, Dr. Daszak will travel for one day to **London, UK** to attend a **Workshop on Designing a Planetary Health Watch System at the Wellcome Trust** and then return to **Glasgow, UK**.

At both meetings, Dr. Daszak will be presenting GVP ideas and talking with European scientists about how they might be able to form partnerships within the GVP.

The flight for Dr. Daszak is estimated at **$7,961** for a business class ticket **EWR <-> GLA.** A round trip train fare from **Glasgow to London** is estimated at **$650** and the maximum per diem rate for London is **$482**.

Cheers,

Peter

**Peter Daszak**
*President*

EcoHealth Alliance
460 West 34th Street – 17th Floor
New York, NY 10001

Tel. +1 212-380-4474
Website: www.ecohealthalliance.org
Twitter: @PeterDaszak

*EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that prevent pandemics and promote conservation.*

**From:** Eddy Rubin <erubin@metabiota.com>
**To:** Amy Kistler <amy.kistler@czbiohub.org>
**Cc:** Dennis Carroll <dcarroll@usaid.gov>, Nathan Wolfe <nwolfe@metabiota.com>, Jonna Mazet REDACTED
**Subject:** Re: 1/24 Biohub South Global Viral Project meeting
**Sent:** Mon, 16 Jan 2017 22:30:47 +0000

Amy,
Good. We are set. Just send us where we meet and info about parking.
Eddy

---

**From:** Amy Kistler <amy.kistler@czbiohub.org>
**Date:** Monday, January 16, 2017 at 11:07 AM
**To:** Eddy Rubin <erubin@metabiota.com>
**Subject:** Re: 1/24 Biohub South Global Viral Project meeting

Hi Eddy,

Thumbs up all around on your proposed timing and scope for the Global Virome Project discussion at Biohub South meeting on 1/24.
We'll plan for 1h total time for this. Let me know if anything comes up in the meantime to change things up on your end.

I requested they get an invite out to you when we nailed down day/time the other week (would be from Cynthia Nogoy, Peter Kim's administrative assistant). Are you and your counterparts all set with that?

Best,
Amy

On Fri, Jan 13, 2017 at 5:18 PM, Amy Kistler <amy.kistler@czbiohub.org> wrote:

Hi Eddy,
I like the idea you propose below & thanks for urging forward in advance so we can optimize the time! Sounds like a good plan.

I'll run this by Joe/Steve/Peter to double check if there are any adjustments or specific suggestions. Will update you either way, hopefully early next week.

Thanks again,
Amy

On Jan 13, 2017, at 4:59 PM, Eddy Rubin <erubin@metabiota.com> wrote:

> Hi Amy,
> We have had some discussion how to best structure the Global Virome Project/ BioHub meeting. Our goals for the visit include to both describe the project and to see if there are ways for the BioHub to possibly interact with it. Accordingly, we are thinking that rather than a formal high level 50 min seminar on the Global Virome Project it might better for us to give a ~25 minute informal presentation about the project, someone from BioHub talk a bit about what the BioHub is followed by a discussion that might include potential ways to interact. Let me know how this sounds and maybe we can chat next week to get a better sense of each others terrain and ways to maximize the utility of the meeting.
> Regards,
> Eddy

--
**Amy Kistler PhD, MPH**
**Group Leader, Infectious Diseases**
Chan Zuckerberg Biohub
499 Illinois St

4th Floor
San Francisco CA 94158

Phone: 415-310-0701
Email: amy.kistler@czbiohub.org

**From:** Andrew Clements <aclements@usaid.gov>
**Sent:** Wed, 18 Jan 2017 10:38:35 +0100
**Subject:** Re: Change to approved ITA: N. Weber travel to Sierra Leone delayed
**To:** Elizabeth Leasure <ealeasure@ucdavis.edu>
**Cc:** PREDICTMGT <predictmgt@usaid.gov>, Jonna Mazet <jkmazet@ucdavis.edu>, David John Wolking <djwolking@ucdavis.edu>, Katherine Leasure <kaleasure@ucdavis.edu>, Cassandra Louis Duthil <clouisduthil@usaid.gov>

Thanks, Liz. No problem.

Cassandra: please note the change below.

*Andrew P. Clements, Ph.D.*
*Senior Scientific Adviser*
*Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health*
*U.S. Agency for International Development*
*Mobile phone: 1-571-345-4253*
*Email: aclements@usaid.gov*

On Jan 18, 2017, at 2:10 AM, Elizabeth Leasure <ealeasure@ucdavis.edu> wrote:

> Hi Andrew. Due to delays in getting the required visas, the travel dates for Natalie Weber have been slightly revised. Instead of traveling to Sierra Leone from January 10-20 and to Guinea from January 20-28, she will travel to Guinea from January 22-29 and to Sierra Leone from January 30-February 8. My apologies for the late notice. Please let me know if you have any questions or require any additional information. Thanks!
>
> Metabiota would like to request travel approval for Natalie Weber, Ecological Consultant for Metabiota, to travel from Nuremberg, Germany to Freetown, Sierra Leone from January 10-20, 2017, then from Freetown, Sierra Leone, to Conakry, Guinea from January 20-28, 2017 to train field staff in bat capture and identification for implementation of project activities.
>
> **Trip purpose:** Sierra Leone and Guinea - Natalie Weber will provide training for field staff on bat capture and identification. Training will include field and classroom activities, and discussion of challenges and best practices. Field training activities will coincide with regular sampling trips for year 3.
>
> Elizabeth Leasure
> One Health Institute
> University of California, Davis
> REDACTED

--

You received this message because you are subscribed to the Google Groups "PREDICTMGT" group.
To unsubscribe from this group and stop receiving emails from it, send an email to predictmgt+unsubscribe@usaid.gov.
To post to this group, send email to predictmgt@usaid.gov.
To view this discussion on the web visit https://groups.google.com/a/usaid.gov/d/msgid/predictmgt/BN1PR08MB1238042729C9D3FCEF99DC0A27F0%40BN1PR08MB123.namprd08.prod.outlook.com.

**From:** Amy Kistler <amy.kistler@czbiohub.org>
**Sent:** Thu, 19 Jan 2017 08:22:36 -0800
**Subject:** Re: 1/24 Biohub South Global Viral Project meeting
**To:** Eddy Rubin <erubin@metabiota.com>
**Cc:** Dennis Carroll <dcarroll@usaid.gov>, Nathan Wolfe <nwolfe@metabiota.com>, Jonna Mazet REDACTED
Parking Map.pdf
Stanford Campus map.pdf

Hi Eddy,
The meeting will be held on Stanford campus, in Shriram 102.
I've attached campus and parking map, with directions. Let me know if any questions.
My cell is 415-310-0701 in case any questions changes arise on day of the meeting.

-Amy

On Mon, Jan 16, 2017 at 2:30 PM, Eddy Rubin <erubin@metabiota.com> wrote:

> Amy,
>
> Good. We are set. Just send us where we meet and info about parking.
>
> Eddy
>
> ---
>
> **From:** Amy Kistler <amy.kistler@czbiohub.org>
> **Date:** Monday, January 16, 2017 at 11:07 AM
> **To:** Eddy Rubin <erubin@metabiota.com>
> **Subject:** Re: 1/24 Biohub South Global Viral Project meeting
>
> Hi Eddy,
>
> Thumbs up all around on your proposed timing and scope for the Global Virome Project discussion at Biohub South meeting on 1/24.
>
> We'll plan for 1h total time for this. Let me know if anything comes up in the meantime to change things up on your end.
>
> I requested they get an invite out to you when we nailed down day/time the other week (would be from Cynthia Nogoy, Peter Kim's administrative assistant). Are you and your counterparts all set with that?
>
> Best,
>
> Amy
>
> On Fri, Jan 13, 2017 at 5:18 PM, Amy Kistler <amy.kistler@czbiohub.org> wrote:
>
> > Hi Eddy,
> >
> > I like the idea you propose below & thanks for urging forward in advance so we can optimize the time! Sounds like a good plan.

I'll run this by Joe/Steve/Peter to double check if there are any adjustments or specific suggestions. Will update you either way, hopefully early next week.

Thanks again,
Amy

On Jan 13, 2017, at 4:59 PM, Eddy Rubin <erubin@metabiota.com> wrote:

> Hi Amy,
>
> We have had some discussion how to best structure the Global Virome Project/ BioHub meeting. Our goals for the visit include to both describe the project and to see if there are ways for the BioHub to possibly interact with it. Accordingly, we are thinking that rather than a formal high level 50 min seminar on the Global Virome Project it might better for us to give a ~25 minute informal presentation about the project, someone from BioHub talk a bit about what the BioHub is followed by a discussion that might include potential ways to interact. Let me know how this sounds and maybe we can chat next week to get a better sense of each others terrain and ways to maximize the utility of the meeting.
>
> Regards,
>
> Eddy

--

**Amy Kistler PhD, MPH**

**Group Leader, Infectious Diseases**

Chan Zuckerberg Biohub

499 Illinois St

4th Floor

San Francisco CA 94158

Phone: 415-310-0701

Email: amy.kistler@czbiohub.org

--

**Amy Kistler PhD, MPH**
**Group Leader, Infectious Diseases**
Chan Zuckerberg Biohub
499 Illinois St

4th Floor
San Francisco CA 94158

Phone: 415-310-0701
Email: amy.kistler@czbiohub.org




# STANFORD UNIVERSITY

## PARKING AND CIRCULATION MAP 2016-17

**Parking & Transportation Services**
*Parking permit sales, 7:30am - 5pm (M-F)*
*transportation.stanford.edu*
*650.723.9362*

**Time Limit Parking 20 Minutes**
*6am - 4pm, M-F (unless otherwise posted)*

**Visitor Pay Parking**
*8am - 4pm, M-F (unless otherwise posted)*
*2, 3 or 4 hour time limits may apply.*
*Payment options may vary.*
*For more information, please refer to:*
*transportation.stanford.edu/how-purchase-visitor-parking*

**Reserved Bus Parking**
*24 hours, 7 days*

**P&TS Authorized On-Street Bus Parking**
*24 hours, 7 days*

**Motorcycle Parking**
*6am - 4pm, M-F (unless otherwise posted)*

### Event Parking

**Galvez Lot** (L-96)
*Reserved event parking*

**Event Permit**
*6am - 4pm, M-F (unless otherwise posted)*

### Commuter Parking

*6am - 4pm, M-F (unless otherwise posted)*

A Permit · C Permit · Z Permit

### Resident Parking

*24 hours, 7 days (unless otherwise posted)*

EA Permit · SH Permit · SO Permit · ES Permit · SJ Permit · WE Permit

Many lots are signed only at the entrance. In "shared" lots (e.g., those posted "EA or C") you may park with either permit designated.

### Disability Parking

Any state-issued disability parking placard or plate is considered valid in any disabled, commuter, residential, service vehicle, metered or visitor parking space. Payment and observation of time limits is required in some locations as posted. For more information, please refer to: *transportation.stanford.edu/ada*

**Parking Lot Number** (L- #)

**Visitor Center**
*650.723.2560*

**Police Department**
*Emergency: 9-1-1 (9-9-1-1 from a campus phone)*
*police.stanford.edu*

**Fire Department**
*Emergency: 9-1-1 (9-9-1-1 from a campus phone)*
*www.cityofpaloalto.org/fire*

**Car Rental**
*650.833.8060*

**Car-Sharing Vehicle**
*transportation.stanford.edu/zipcar*

**Athletic Field** · **Parking Garage Under Field**

**Construction**

**Pedestrian Zone / Restricted Vehicular Access**

**Gate / Pneumatic Bollard / Restricted Access**

**Electric Vehicle Charging Stations**

**Service and Delivery Only**

**Loading Zone**

**Truck Route**
*ibre.stanford.edu/truck_routes*

### Inset 2

**Vehicle Exclusion Zone**

**No Parking Zone**

For more information on designated cart routes, cart parking, and other details related to pedestrian zone access, please refer to the **Pedestrian Zone Access Protocol and Map:** *transportation.stanford.edu/pedzone*

**Online Parking and Transportation Related Maps**
*transportation.stanford.edu/maps*
**University Telephone Operator**
*650.723.2300*

Map revised November 2016 by Maps & Records and Parking & Transportation Services. COPYRIGHT © Board of Trustees of Stanford University. Reproduction only with permission of the Office of Maps and Records. All Rights Reserved.

MAP PART # D223957719

UCDUSR0011675

# Index for Parking and Circulation Map (see reverse side)


| BUILDING | GRID |
|---|---|
| 30 Alta Road | K-3 |
| 408 Panama Mall: *Housing Assignments Office* | H-7 |
| Advanced Medicine Center: *ASC, Cancer Center* | C-3/5 |
| Anderson Collection | D-6 |
| Arrillaga Alumni Center | F-10 |
| Art Gallery | G-9 |
| Artist's Studio | K-3 |
| Automotive Innovation Facility | F-2 |
| Bambi | H-5/6 |
| Barnum Center | L-5/6 |
| Barnes | G-2 |
| Bechtel International Center | J-7 |
| Beckman Center | E-3 |
| Bing Nursery School | J/K-13/14 |
| Bing Concert Hall | E-9/10 |
| Bing Wing (Green Library) | H-9 |
| Biology Greenhouses | G-3 |
| Birch | F-5 |
| Black Community Services Center | I-7 |
| Blake Wilbur Clinic | C-5 |
| Buildings 1-370 (See Main Quad) | G/H-7/8 |
| Buildings 500-810 | H/I-7/8 |
| Bleeker | G-2 |
| Bolivar House | I/J-10 |
| Bookstore | I-9/9 |
| Braun Music Center | I-8 |
| Brick Barn | I-1 |
| Cantor Arts Center (Museum) | E-7/8 |
| Carnegie Foundation | L-3 |
| Carnegie Institution | C-4 |
| Cedar Hall | G-5 |
| Center for Advanced Study in the Behavioral Sciences | K/L-4 |
| Center for Clinical Sciences Research (CCSR) | E-5 |
| Center for Educational Research at Stanford (CERAS) | I-8 |
| Center for Turbulence Research (CTR) | H-8 |
| Central Energy Facility | G-2 |
| Central Process Steam Plant | E-3 |
| Children's Center of the Stanford Community (CCSC) | F-14 |
| C. J. Huang Building | B-5 |
| Clinic, Stanford (Bobwell) | E-5 |
| Clock Tower | H-8 |
| Clubhouse | I-6 |
| Cordura Hall (CSLI) | F-4 |
| CROC (Codigo Resource Recovery Center) | G-14 |
| Credit Union (also branch in Tresidder Union) | G-14 |
| Cypress Hall | G-5 |
| David Packard Electrical Engineering | G-6 |
| Dinkelspiel Auditorium | I-5 |
| Dnall | J-9 |
| Durand (William F.) Building | H-6/7 |
| East Wing (Green Library) | H-9 |
| Education, School of | H-3/9 |
| Elliott Program Center: *HFD* | I-4/5 |
| Encina Commons | H-10 |
| Encina Hall | H-10 |
| Environmental Safety Facility and ESF Annex | F-1/2 |
| Escondido Village Center: *Rainbow School* | J-14 |
| Escondido Elementary School | K-14 |
| Escondite Cottage: *HFD* | J-14 |
| Faculty Club | I-7 |
| Fairchild Center | E-6 |
| Falk Center | D-5 |
| Field Conservation Facility | F-2 |
| Fire Department | H-13 |
| Fire Truck House | I-7 |
| Forsythe Hall | G-5 |
| Fredericksen Center for Translational Research | C-3 |
| Frost Amphitheater | F-9/10 |
| Galvez Modular | H/I-9 |
| Gates Computer Science | F-6/7 |
| Geology Corner (320) | H-7 |
| Gilbert Biological Sciences | F-7 |
| Golf Clubhouse | K-2 |
| Golf Maintenance Shop | I-1 |
| Gould Center | J-9 |
| Graduate Community Center | J-13 |
| Graduate School of Business: Knight Management Center: Bass Center, CEMEX Auditorium, Faculty Building East and West, Gunn Building, MBA Class of 1968 Building, McClelland Building, Oberndorf Event Center, Patterson Building, Zambrano Hall | G-11/12 |
| Green Earth Sciences | H-6 |
| Green Library | H-9 |
| Gunn (SEPH) | G-10 |
| Haas Center | J-9 |
| Hagey Pediatric Regenerative Med | E-4 |
| Harmony House | I-7 |
| Herrin Hall, Herrin Labs | F-7 |
| Health Research & Policy: A-H, Redwood | E-4 |
| Hansen Experimental Physics Lab (HEPL South) | H-6 |
| Hillel-Ziff Center | J-8 |
| History Corner (200) | G-8/9 |
| Hoover Memorial Building, Herbert | H-9/10 |
| Hoover House, Lou Henry | L-5 |
| Hoover Bldg., Lou Henry | G/H-9/10 |
| Hoover Pavilion | B-1 |
| Hoover Tower | G/H-9 |
| Housing Maintenance Center and Annex | J-13 |
| James H. Clark Center | E/F-6 |
| Jen-Hsun Huang Engineering Center | G-6 |
| Johnson Pediatric Ambulatory Care Center | B-5 |
| Jordan (420) | G-7/8 |
| Jordan Quad | F-5 |
| Juniper | F-5 |
| Keck Science | E-7 |
| Knight Building | F-9 |
| Knoll, The (CCRMA) | K-7 |
| Koret Pavilion | I-9 |
| Lake House | I-6 |
| Landau Economics | G-10 |
| Language Corner (260) | H-8 |
| Lathrop Barn | L-3 |
| Lathrop Gate House | K-3 |
| Lathrop Library | G-9 |
| Law School | I-9 |
| Li Ka Shing Center | E-5/6 |
| Littlefield Center | F-9 |
| Lorry Lokey Labs | E-7 |
| Lorry Lokey Stem Cell Research Building (SIM 1) | E/F-5 |
| Lucas Center (MRSLS) | F-4 |
| Lucile Packard Children's Hospital at Stanford | C/D |
| Main Quad | G/H-7/8 |
| Maples Pavilion | F/G-12 |
| Margaret Jacks (460) | G-6 |
| Mariposa | J-7 |
| Math Corner (380) | G-7 |
| Mausoleum | C-8 |
| McClatchy (120) | G-9 |
| McCullough | G-7 |
| McMurtry Building | E-7 |
| Mechanical Engineering Research Lab (MERL) | H/I-7 |
| Medical School Office Building | E-4 |
| Medicine, School of: Alway, Edwards, Grant & Lane | D/E-5/6 |
| Memorial Church | H-8 |
| Memorial Hall & Auditorium | G-9/10 |
| Mitchell Earth Sciences | H-7 |
| Montag Hall | G-10 |
| Moore Materials Research | G-7 |
| Mudd Chemistry | E/F-7 |
| Music Rehearsal Facility | F-12 |
| Neukom Student Center | I-2 |
| Neuroscience Health Center | A-3 (also B-1) |
| Nora Suppes Hall | F-4 |
| Northwest Data Center and Comm. Hub | D/E-3/4 |
| Oak | F-5 |
| Observatory | L-3 |
| Otterman Family Stanford Educational Farm: Green House, Lathe House, Shade Structure | H-2/3 |
| Old Union | I-8 |
| Old Winery (700 Welch Road) | B/C-7 |
| Organic Chemistry | E-7 |
| Owen | J-9 |
| Palo Alto Train Station & Transit Center | A-3 |
| Parking & Transportation Services | G/H-13 |
| Paul G. Allen Building | F-5 |
| Paul Allen Center for Integrated Systems Annex | F-6 |
| Pepper Tree House | J-14 |
| Peterson (d.school) (550) | H-7 |
| Physics and Astrophysics | G-7 |
| Pine Hall | F/G-5 |
| Price | F-3 |
| Police Department | G-13 |
| Polya Hall | G-5 |
| Poplar | F-5 |
| Post Office | I-8 |
| Press Building | I-7 |
| Psychiatry | B-4 |
| Puchon | G-2 |
| Recycling Center | G-13 |
| Red Barn | I-2 |
| Redwood Hall | F-5 |
| Rogers: *The Bridge Peer Counseling Center* | I-6 |
| Science Teaching and Learning Center (Old Chemistry Building) | F-7 |
| Sequoia Hall | G-7 |
| Serra (589 Capistrano Way) | J-7 |
| SHC-LPCH Steam Plant | D-6/7 |
| Shriram Center Bioengineering & Chemical Engineering | G-5 |
| Skilling | H-7 |
| SOM Loading Dock | E-4 |
| Spilker Engineering and Applied Sciences | G-6 |
| Spruce Hall | G-5 |
| Stanford Arboretum Children's Center | A-9 (also C-1) |
| Stanford Athletics Shop | E-11 |
| Stanford Auxiliary Library (SAL) | F-14 |
| Stanford Community Recreation Association (SCRA) | K-13 |
| Stanford Daily | H/I-8 |
| Stanford Dining, Hospitality & Auxiliaries | G-14 |
| Stanford Hospital | D-6 |
| Stanford Humanities Center | I-7 |
| Stanford Madera Grove Children's Center: Acorn House, Mulberry House | F/G-15/16 |
| Stauffer I & II | E/F-7 |
| Stock Farm Road Child Care Center | F-3 |
| Storage Buildings | F-3 |
| Student Housing Management | K-11 |
| Student Services Building | I-9 |
| Sweet Hall | H/I-9 |
| Thornton Center | H-6 |
| Tower House | J-14 |
| Tresidder Union | I-7/8 |
| Varian Health Center | J-10/11 |
| Varian Physics | G-7 |
| Ventura Hall | F-4 |
| Visitor Center | E-11 |
| Wadsworth | F-2 |
| Wallenberg (160) | G-8 |
| William H. Neukom Building | I/J-9 |
| William R. Hewlett Teaching Center | F/G-7 |
| Windsor | H/I-6 |
| Y2E2 | G-5/6 |

| RESIDENCE | GRID |
|---|---|
| 1047 Campus | K-7/8 |
| 576 Alvarado | J-10 |
| 670 Lomita | K-7 |
| 680 Lomita | K-7 |
| 717 Dolores | L-9/10 |
| Arrillaga Family Dining Commons | I-10/11 |
| BOB (Robert Moore South) | K-8 |
| Brainerd Hall: Brainer, Dining | H/I-11 |
| Columbae | J-8 |
| Cowell Houses: Delta Delta Delta (ΔΔΔ), Kappa Alpha Theta (ΚΑΘ), Pi Beta Phi (ΠΒΦ), Terra, ZAP | J/K-11 |
| Crothers Hall: Crothers, Crothers Memorial, Crothers Mark Taper Center: *HFD* | I-8 |
| Durand | L-9/10 |
| Enchanted Broccoli Forest | K/L-8 |
| Escondido Village: 1-36, 38-95, 155, 160 G-16 to I-12 & J-14 | |
| Escondido Village: Abrams | H-15/16 |
| Escondido Village: Barnes | H-15 |
| Escondido Village: Hoskins | H-14 |
| Escondido Village: Hulme | H-15 |
| Escondido Village: Kennedy Graduate Residences: Hastorf, Kennedy Commons, Lieberman, Miller, Rosse | I/J-13/14 |
| Escondido Village: McFarland | H-14 |
| Escondido Village: Blackwelder | I-13 |
| Escondido Village: Gullen | H/I-12/13 |
| Escondido Village: Studios 1-2 | I/J-12 |
| Escondido Village: Studios 3-4 | H/I-14 |
| Escondido Village: Studios 5-8, Studios 5/6 Commons, Studios 5/6 Laundry | I-15 |
| Escondido South: 127-144 | J-12/13 |
| Florence Moore Hall: Admin: *HFD*, Alondra, Cardenal, Fabian, Gavilan, Loro, Mirlo, Paloma | J/K-7 |
| Gardiner Apts | L-9 |
| Gerhard Casper Quad: Castaño, Dining Commons: *HFD*, Kimball Hall, Lantana, Lantana/Castaño Commons, Ng | H/I-11/12 |
| Governor's Corner, Dining Societies: Avanti, Beefeater's, Bolero, Middle Earth | I-3 |
| Governor's Corner: Guest Cottages | I-5 |
| Governor's Corner, Independent Houses: Murray, EAST (Treat), Yost | H/I-4 |
| Governor's Corner, Sterling Quad: Potter, Ricker Dining, Robinson | I-4 |
| Freshman Sophomore College: Adams, Schiff | H-3/4 |
| Governor's Corner, Suites: Anderson, Griffin, Jenkins, Marx | J-14 |
| Graduate Package Center | L-9 |
| GSB Residences: Highland Hall, Schwab Residential Center, The GSB Common, Tower, Videtakis Dining | H-10/11/12 |
| Grove | K-9 |
| Hammarskjöld | J-10 |
| Haus Mitteleuropa | L-9 |
| Jerry | K-6 |
| Kenroe | K-9 |
| Kappa Alpha (ΚΑ) | K-8 |
| Kappa Alpha Theta (ΚΑΘ) | K-8 |
| Kappa Sigma (ΚΣ) | K-8 |
| Lagunita Court, Admin: *HFD*, Adelfa, Eucalipto, Granada, Lakeside Dining, Meier, Naranja, Nordfeldt, Ujamaa A & B | H/I-5/6 |
| La Casa Italiana (Robert Moore North) | J/K-8 |
| La Maison Française | K-8 |
| Lasuen: *HFD* | K-8/9 |
| Lyman Graduate Residences: Bldg 1, Bldg 3, Lyman Commons | H/I-3 |
| Mars | J-8 |
| Mirrielees | J-12 |
| Munger Graduate Residence: Bldgs 1-3, 4: *Brest Hall*, Jacobson-Sorensen Hall: *HFD* | J-9/10 |
| Muwekma-Tah-Ruk | I-8 |
| Narnia | K/L-6 |
| Oak Creek Apartments | D/E-1/2 |
| Olmsted Road Staff Housing | G/H-16 |
| Pearce Mitchell Houses | K-9 |
| Phi Kappa Psi (ΦΚΨ) | K/L-9 |
| Phi Sig | K-8 |
| Ram's Houses: 201-202, 206-218, 220-229, 232-238, Bailey, Buttery, Fairclough, Hacienda Commons: *HFD*, Timoshanko, Willis | J/K-12/13 |
| Roble Hall | I-6 |
| Roth | L-9 |
| Sigma Chi (ΣΧ) | I-9 |
| Sigma Nu (ΣΝ) | J-8/9 |
| Slaikeu/Ujamaa Dorm | L-10 |
| Stanford West Apartments | K-3/4 |
| Stern Hall: Burbank, Casa Zapata, Donner, Dining, Larkin North & West: *HFD*, Serra, Twain North & South | I-9/10 |
| Storey | J-8 |
| Synergy | L-8 |
| Theta Delta Chi (ΘΔΧ) | K-8 |
| Toyon Hall | H-10/11 |
| Wilbur Hall: Admin: *HFD*, Arroyo, Cedro, Dining, Junipero, Okada, Otero, Rinconada, Soto, Trancos | I-10/11 |
| Yamazaki | J-8 |

| OUTDOOR SPACE | GRID |
|---|---|
| Angel of Grief | C-8/9 |
| Arboretum Grove | B/C-11 |
| Arguello Park | I-10 |
| Avery Plaza | E/F-12 |
| Cactus Garden | C-7/8 |
| Cantwell Court | I-9 |
| Dohrmann Grove | E-6 |
| East Oval Grove | F/G-9 |
| El Camino Grove | C-12/13 |
| Eucalyptus Grove | C-10 |
| Ford Plaza | F-10/11 |
| Frost Amphitheater | F-9/10 |
| Gibbons Grove | H-6/7 |
| John Gardner Courtyard | H-9 |
| Kennedy Grove | I-7 |
| Koret Park | H-9 |
| Koret Plaza | F-10/11 |
| Lasuen Grove | C/D-8 |
| Levin Field | J-8 |
| LSRE Corp. Yard | G-13 |
| Masters Grove | E-13/14 |
| Mausoleum | C-8 |
| Memorial Court | G-8 |
| Meyer Green | H/I-9 |
| Oval, The | F/G-8 |
| PAC 12 Plaza | E-12 |
| Pepua New Guinea Sculpture Garden | I-6 |
| Petrarch Courtyard | J-9 |
| Roble Field (on Roble Field Garage) | H-5/6 |
| Rodin Sculpture Garden | E-7/8 |
| Serra Grove | G-7 |
| SEQ Courtyard | G-8 |
| Taylor Grove, Chuck | E-11/12 |
| Terman Site | H-6 |
| Toyon Grove | D-10/11 |
| West Oval Grove | F/G-8 |
| White Plaza | I-8 |
| Wilbur Field (on Wilbur Field Garage) | I-10/11 |

| STREET | GRID |
|---|---|
| Abrams Court | H-10 |
| Alta Road | K-3/4 |
| Alvarado Row | J-10 to L-12 |
| Arbor Way | D-1 |
| Amherst Street | L-13/14 |
| Angell Court | L-14/15 |
| Arboretum Road | A-6 to C-11 |
| Arguello Way and Arguello Mall | G-11 to J-10 |
| Arrillaga Mall | F-11/12 |
| Ayrshire Farm Lane | J-12 |
| Barnes Court | G/H-15 |
| Bay Laurel Drive | C/D-2 |
| Blake Wilbur Drive | C/D-5 |
| Bolivar Siding | G-12/13 |
| Bowdoin Lane | J-9/10/11 |
| Bowdoin Street | J-12 to L-14 |
| Buckeye Lane | H-10/11 |
| Capitilo Avenue | L-5/6 |
| California Avenue | K/L-16 |
| Campus Drive | D-9 to H-12 to L-7 to I-3 |
| Capistrano Way | J-7 |
| Charles Marx Way | B/C-4 |
| Churchill Ave | E-14/15 |
| Churchill Mall | E/F-13/14 |
| Clark Way | A-6 to C-3 |
| College Avenue | I-16 to L-14 |
| Columbia Street | L-14/15 |
| Comstock Circle | I-13 to J-14 |
| Comell Street | J-15/16 |
| Cooksey Lane | K/L-8 |
| Cowper Lane | E-5/6 |
| Coronado Avenue | L/K-10/11 |
| Constanzo Street | L-8 to L-11 |
| Cowell Lane | J-10 |
| Crothers Way | H-9/10 |
| Dartmouth Street | K-14 to L-15 |
| Discovery Walk | E-5 to F-6 |
| Dolores Street | L-9/10 |
| Dudley Lane | H/I-15 |
| Duena Street | H/I-7/8 |
| Durand Way | B-4/5 |
| East-West Axis | G-7 |
| El Camino Real | A-10 to G-16 |
| El Escarpado | L-6/7 |
| Electioneer Road | G-1 to H-3 |
| Embarcadero Road | B-13 to C-12 |
| Encina Ave | A-13 to B-12 |
| Escondido Mall | H-7/8 |
| Escondido Road | I-10 to J-14 |
| Esplanada Way | L-11 to L-13 |
| Foundations Way | E/F-5/6 |
| Fremont Road | G-2 to I-1 |
| Galvez Mall | H-9 to I-9 |
| Galvez Street | B-12 to G-10 |
| Gerona Road | I-5 |
| Governor's Avenue | G/H-4/5 |
| Governor's Avenue South | I-3/4 |
| Governor's Lane | E/F-5 |
| Hanover Street | K-14 to L-16 |
| Harvard Street | K-15 to L-16 |
| Hulme Court | G-14/15 |
| Lasuen Mall | F-9 to I-8 |
| Lasuen Street | F-9 to B-10 |
| Lewis Road | K-9 to L-9 |
| Lomita Court | K-8 to J-7 |
| Lomita Drive | D/E/F-5 & I-5 to K-7 |
| Lomita Mall | H-15 |
| Los Arbolles Avenue | H-3 to G-4 |
| Masons Mall | E-13 |
| Mayfield Avenue | J-7 to L-10 |
| Memorial Way | E-9/10 |
| Mosher Way | B-3 to C-4 |
| Museum Way | E-8/9 |
| Nathan Abbott Way | H-8 |
| Nelson Mall | E-12 to F-13 |
| Nelson Road | E-11/12 |
| North Service Road | E-8/7 |
| North-South Axis | E/F-7 |
| O'Connor Lane | I-8/9 |
| Oak Road | E-4 to C-2 |
| Oak Creek Drive | D-3 to E-1 |
| Oberlin Street | J-15 to K-16 |
| Olmsted Road | H-12 to J-14 |
| Orchard Lane | A-7 |
| Palm Drive | A-10 to E-8 |
| Palo Road | E-9/10 |
| Pampas Lane | F-13 to G-14 |
| Panama Mall | H-6 to I-8 |
| Panama Street | F-4 to H-5 |
| Park Ave | F/G-16 |
| Park Boulevard | E-10 |
| Pasteur Drive | D-3 to D/E-5 |
| Pear Lane | A-1 |
| Pierce Mitchell Place | K-9 |
| Pine Hill Court | K-13 |
| Pine Hill Road | L-12/13 |
| Princeton Street | J-15 to K-16 |
| Quarry Road | A-8 to E-6 |
| Roble Drive | L-9 |
| Roth Way | E-6 to F-9 |
| Roose Lane | J-13 to K-12 |
| Running Farm Lane | J-13 to K-12 |
| Salvatierra Street | J-9 to L-11 |
| Sam McDonald Mall | E/F-11/12 |
| Sam McDonald Road | D-13 |
| Samuel Morris Way | H-8 |
| San Francisco Court | K-11/12 |
| San Francisco Terrace | K-12 to L-11 |
| San Juan Street | L-8/9 |
| Sand Hill Road | A-6 to F-1 |
| Santa Teresa Lane | H-4 |
| Santa Teresa Street | H-3 to I-7 |
| Santa Ynez Street | L-8 to K-10 |
| Searsville Road | G-2 to G-4 |
| Sequoia Way | I-9 |
| Serra Mall | F-6 to G-10 |
| Serra Street | G-10 to F-15 |
| South Service Road | G/H-5/6 |
| Stanford Avenue | L-13 to H-16 |
| Stock Farm Road | E-1 to F-3 |
| Stern Way | K/L-9 |
| Valparaiso Street | K/L-10 |
| Via Ortega | F-6 to H-5 |
| Via Palou | G/F-6 |
| Via Pueblo | G-6/7 |
| Vista Lane | K-2 to L-3 |
| Vineyard Lane | B-6/7 |
| Welch Road | B-7 to F-4 |
| Wellesley Street | I/J-16 |
| Wells Ave | A-11/12 |
| Wilbur Way | J-11 |
| Williams Street | L-16 |
| Yale Street | H/I-16 |

| PARKING GARAGE | LOCATION |
|---|---|
| Hoover Pavilion Garage | B/C-1 |
| Knight Management Center Garage | G-11/12 |
| Pasteur Visitor Garage A | D-4/5 |
| Roble Field Garage (Opens Nov. 2016) | H-5 |
| Roth Way Garage | D/E-7 |
| Stock Farm Garage | E-3 |
| Via Ortega Garage | G-5 |
| Wilbur Field Garage | I/J-10/11 |

| PERFORMANCE/MEETING VENUE | LOCATION |
|---|---|
| Baldo Chamber Hall | Braun Music Center |
| Behavioral Auditorium | Grad. School of Bus. |
| Braun Rehearsal Hall | Braun Music Center |
| Breer Library | Breer Library |
| *Brest Hall* | J-9 |
| Campbell Recital Hall | Braun Music Center |
| CEMEX Auditorium | Zambrano Hall/North Bldg |
| Cubberley Auditorium | School of Education |
| Dinkelspiel Auditorium | Dinkelspiel Auditorium |
| Jordan Hall | Bldg. 420, Main Quad |
| Little Theater | Memorial Hall |
| Memorial Auditorium | Memorial Hall |
| Nitery, The | Bldg. 590, Old Union |
| Pigott Theater | Memorial Hall |
| Prosser Theater | Memorial Hall |
| Skilling Auditorium | Skilling |
| Stauffer Auditorium | Herbert Hoover Memorial Bldg. |
| Terman Auditorium | Bldg. 500 |
| Tresidder Auditorium | Polya Hall |

| SPORT FACILITY | GRID |
|---|---|
| Arrillaga Center for Sports and Recreation | F-10/11 |
| Arrillaga Family Sports Center | F-11 |
| Arrillaga Fieldhouse | D/E-12 |
| Arrillaga Gymnasium and Weight Room | G-12 |
| Arrillaga Outdoor Education and Recreation Center | H-5 |
| Avery Aquatic Center | F-12 |
| Boyd & Jill Smith Family Stadium (women's softball) | E/F-15 |
| Brick Barn | I-1 |
| Bud Klein Clubhouse | E-12 |
| Burnham Pavilion (basketball, volleyball, wrestling) | G-10 |
| Cobb Track & Angell Field | E-11 |
| Covered Riding Ring | J-2 |
| Dan Elliott Practice Fields (football practice) | F-12/13 |
| Doyle Family Rugby Clubhouse | E-14 |
| Ford Center (aerobics, badminton, basketball, gymnastics, martial arts, wrestling) | G-10/11 |
| Fowler Field | D-11/12 |
| Golf Clubhouse | K-2 |
| Golf Shop | J-2 |
| Hammer Throw | E-11/12 |
| IM South | E/F-14/15 |
| Johnson Field (men and women's soccer, women's lacrosse) | F-14 |
| Klein Field at Sunken Diamond | E/F-12/13 |
| Laird Q. Cagan Stadium (men and women's soccer, women's lacrosse) | E-13 |
| Maloney Field (men and women's soccer, women's lacrosse) | E-13 |
| Manzanita Field | H-12 |
| Maples Pavilion (basketball and women's volleyball) | F/G-12 |
| Red Barn (stables, riding rings) | I-2 |
| Roble Gym | H-8 |
| Sand Hill Fields, Stanford Athletics | D/E-2/3 |
| Sand Volleyball | F/G-11 |
| Siebel Field (football) | F/G-12/13 |
| Siebel Varsity Golf Training Complex | F/G-1/2 |
| Softball Field House | F-13 |
| Stanford Equestrian Center | G-1/2 |
| Stanford Golf Course | K-1 |
| Stanford Sand Volleyball Stadium | F/G-13 |
| Stanford Stadium (football) | C/D-11/12 |
| Stanford Stadium Skybox | D-11 |
| Stanford Varsity Golf Clubhouse | F-2 |
| Steuber Rugby Stadium | E-13/14 |
| Sunken Diamond (baseball) | E-12/13 |
| Taube Family Tennis Stadium | F-11 |
| Taube South | F/G-11 |
| Ticket Booth | E-11 |
| Ticket Office | D-12 |
| Wicket Field (men and women's soccer, women's lacrosse) | D/E-13 |
| Varsity Field Hockey Stadium | F-13 |
| West Campus Tennis Courts | H/I-2/3 |



Palo Alto Transit Center (PATC)
Caltrain platform
Bus depot
DB
TECH
RP
EL CAMINO REAL
UNIVERSITY AVE
HIGH ST
ALMA ST
LYTTON
EVERETT
EMBARCADERO RD
WILLOW RD
MIDDLEFIELD RD
RAMONA
HOMER
FOREST
HAMILTON
Downtown Palo Alto
Lytton Plaza
Palo Alto Transit Center
Menlo Park
Stanford Shopping Center
Vi at Palo Alto
Hoover Pavilion
Bike/ped bridge
(PM only)
Crate & Barrel
Palo Alto Medical Foundation
Bike/ped underpass
To Palo Alto Tech Center
Town & Country Shopping Center
Palo Alto High School
Stanford West Apartments
Stanford Barn
Psychiatry
Packard
Stanford Hospital
Falk
Anderson Collection
Cantor Arts Center
Stadium
Bing Concert Hall
Visitor Center
Sunken Diamond
Arrillaga Family Sports Center
Parking & Transportation Services (P&TS)
Oak Creek Apartments
School of Medicine
LKSC
Lucas Center
Stock Farm garage
MSOR
Jordan Quad
Allen (CIS)
Gates
Y2E2
Green Earth Sciences
Main Quad
Hoover Tower
Green Library
Schwab Res. Center
Mem Aud
Montag Hall
GSB/Knight Mgmt. Ctr.
Maples
Governor's Corner
Lagunita Court
Old Union
Bookstore
Tresidder
Law School
Munger
Wilbur Field Garage
Florence Moore
Escondido Village
Stanford Golf Course
Stanford Shopping Center
Stanford Sand Volleyball Stadium
Stanford Stadium
Stanford Stadium Skybox
Stanford Varsity Golf Clubhouse
Stanford Equestrian Center
Stanford Varsity Golf Training Complex
Stanford Softball Field House
Stanford Sand Hill Fields, Stanford Athletics
Stanford Siebel Field (football)
Stanford Steuber Rugby Stadium
Stanford Sunken Diamond (baseball)
Stanford Taube Family Tennis Stadium
Stanford Taube South
Stanford Ticket Booth
Stanford Ticket Office
Stanford Wicket Field (men and women's soccer, women's lacrosse)
Stanford Varsity Field Hockey Stadium
Stanford West Campus Tennis Courts
Stanford Arrillaga Family Dining Commons
Stanford Arrillaga Family Outdoor Education and Recreation Center
Stanford Arrillaga Fieldhouse
Stanford Arrillaga Gymnasium and Weight Room
Stanford Arrillaga Outdoor Education and Recreation Center
Stanford Avery Aquatic Center
Stanford Boyd & Jill Smith Family Stadium (women's softball)
Stanford Bud Klein Clubhouse
Stanford Burnham Pavilion (basketball, volleyball, wrestling)
Stanford Cobb Track & Angell Field
Stanford Covered Riding Ring
Stanford Dan Elliott Practice Fields (football practice)
Stanford Doyle Family Rugby Clubhouse
Stanford Ford Center (aerobics, badminton, basketball, gymnastics, martial arts, wrestling)
Stanford Fowler Field
Stanford Golf Clubhouse
Stanford Golf Shop
Stanford Hammer Throw
Stanford IM South
Stanford Johnson Field (men and women's soccer, women's lacrosse)
Stanford Klein Field at Sunken Diamond
Stanford Laird Q. Cagan Stadium (men and women's soccer, women's lacrosse)
Stanford Maloney Field (men and women's soccer, women's lacrosse)
Stanford Manzanita Field
Stanford Maples Pavilion (basketball and women's volleyball)
Stanford Red Barn (stables, riding rings)
Stanford Roble Gym
Stanford Sand Hill Fields, Stanford Athletics
Stanford Sand Volleyball
Stanford Siebel Field (football)
Stanford Siebel Varsity Golf Training Complex
Stanford Softball Field House
Stanford Stanford Equestrian Center
Stanford Stanford Golf Course
Stanford Stanford Sand Volleyball Stadium
Stanford Stanford Stadium (football)
Stanford Stanford Stadium Skybox
Stanford Stanford Varsity Golf Clubhouse

# DIRECTIONS TO THE LAB

## Walking to Shriram Center from Parking Structure 2 (Via Ortega Garage)

Upon exiting the parking structure, head north on Via Ortega. The building should be located to your right.

Visitor pay parking is available on the first floor of the parking structure. Pay at machine, 8am-4pm, Monday through Friday.

## Visiting the Lab?

The Kim Lab is located on the second floor of the Shriram Center for Bioengineering & Chemical Engineering.

Shriram Center, 268
Stanford University
443 Via Ortega
Stanford, CA 94305



**From:** Damien Joly <djoly@metabiota.com>
**To:** Eddy Rubin <erubin@metabiota.com>, Jonna Mazet <jkmazet@ucdavis.edu>, "Beth Edison" <bedison@metabiota.com>
**Subject:** Fw: One Health Short-course Training - Tanzania and Rwanda
**Sent:** Thu, 2 Feb 2017 17:18:57 +0000
rx-one-health-2017-flyer.pdf

FYI - Jonna gave a last pitch on the M&A call if we have a particular person in mind we want to send to the attached course she'd like a name in the next couple days.

Thanks,

Damien

---

**From:** [redacted] on behalf of Jonna Mazet <jkmazet@ucdavis.edu>
**Sent:** January 4, 2017 10:59 AM
**To:** Amanda Fine; Brian Bird; Christine Kreuder Johnson; Damien Joly; Eddy Rubin; Elizabeth Leasure; Helen Lee; Jon; Karen Saylors; Murray, Suzan; Peter Daszak; Prof. Woutrina Smith; Simon Anthony; Tracey Goldstein; William Karesh; Corina Monagin
**Cc:** Taylor Elnicki; Alison Andre; Amanda Fuchs; Ava Sullivan; Celina Roy; Emma Lane; Evelyn Luciano; Megan Doyle; Molly Turner
**Subject:** One Health Short-course Training - Tanzania and Rwanda

Dear Predict EB,

Attached is an announcement for our summer Rx One Health short course offered by UC Davis, University of Rwanda, and Sokoine University of Agriculture developed as an adjunct to other training programs to help fill some of the One Health training void.

The course builds upon our previously very successful Envirovet Summer Institute. That course was also for health professionals but with a more specific wildlife and veterinary focus. We decided to reinvent the course after a hiatus, now offering it with a solid One Health focus. As you know, especially with GHSA and rapid on-boarding needs for local and global projects in health, we are finding that the pool of local professionals trained in One Health and available for hire is quite shallow. The Tanzania portion of the course is being primarily developed by me, Woutrina Smith, our medical school and veterinary faculty, Prof Kazwala, and our fabulous Tanzanian collaborators. The Rwanda portion is being led by Kirsten Gilardi from our side with the same med & vet school faculty, as well as University of Rwanda and our other Rwandan collaborators.

We hope to have a mix of international trainees. I would appreciate your support in circulating the flyer to your networks and your consideration of supporting some of your developing professionals to attend.

Happy New Year to all!
Jonna

Jonna AK Mazet, DVM, MPVM, PhD
Professor of Epidemiology & Disease Ecology
Executive Director, One Health Institute
Global Director, PREDICT Project of USAID Emerging Pandemic Threats Program

School of Veterinary Medicine
University of California
1089 Veterinary Medicine Drive
Davis, CA 95616, USA
+1-530-752-3630
onehealthinstitute.net

For scheduling and logistical issues, please contact:
Ms. Liz Chase

eschase@ucdavis.edu
+1-530-752-3630



# Rx One Health 2017

**Interested in One Health problem-solving at the animal/human/environmental health interface?**

Want to learn as a part of an interdisciplinary team working in the field? Do you want to gain skills related to leadership, communication, cultural competency, and field & laboratory assessments? If so, then this educational Rx (or prescription) is just right for you!

Join us for an intensive **4-week course** (4 June - 30 June 2017) aimed at early career health, agriculture, and conservation professionals who wish to gain knowledge and skills in the principles and practices of **One Health**. A maximum of 22 participants, mentored by dozens of faculty experts, will be accepted for the program, so please apply early!

*More information: http://rx.onehealth.institute*

**Course Fee:** US $4,500/participant inclusive of all travel within & between Tanzania and Rwanda during the course.

*Enrolled participants will be responsible for their own travel costs to Tanzania at the start of the course and from Rwanda at the end of the course.*

**Application packets are due by:**
5 pm PST on January 30, 2017

## Part 1: TANZANIA

***4 – 16 June: Southern Highlands and Coast***

Building transdisciplinary collaborations to solve health problems and to recognize interdependence among animals, humans, and their environments in Tanzania, you will gain first-hand knowledge and experience with diverse One Health challenges. You will design solutions around the following themes: planetary health, zoonotic disease and mitigation strategies, field and laboratory study designs, biosafety & security, wildlife conservation, food safety and sustainability, and community engagement. You will travel the country and build new friendships and skills.

## Part 2: RWANDA

***17 – 30 June: Volcanoes Nat'l Park Communities***

In Rwanda, you will experience the beauty and complexity of a rapidly developing country that strives to balance health, livelihoods, cultural sensitivity, and environmental change. You will engage with mentors and stakeholders to develop One Health strategies for meeting community needs such as improved human health through enhanced nutrition and maternal/child health, reduced infectious disease, improved animal health through sustainable livestock production, and improved ecosystem health through conservation. You will innovate and immerse in One Health ideas.

**FACULTY OVERSIGHT COMMITTEE**

**UCD School of Veterinary Medicine | UCD School of Medicine | Sokoine University of Agriculture | University of Rwanda**

UCDAVIS VETERINARY MEDICINE

UCDAVIS SCHOOL OF MEDICINE

UC GLOBAL HEALTH INSTITUTE University of California

UNIVERSITY OF RWANDA

**From:** Andrew Clements <aclements@usaid.gov>
**Sent:** Thu, 16 Feb 2017 15:02:59 +0100
**Subject:** Fwd: MERS CoV in Pakistan
**To:** Jonna Mazet <jkmazet@ucdavis.edu>, William Karesh <Karesh@ecohealthalliance.org>, REDACTED, Kevin Olival PhD <olival@ecohealthalliance.org>, Christine Kreuder Johnson <ckjohnson@ucdavis.edu>

FYI

*Andrew P. Clements, Ph.D.*
*Senior Scientific Adviser*
*Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health*
*U.S. Agency for International Development*
*Mobile phone: 1-571-345-4253*
*Email: aclements@usaid.gov*

Begin forwarded message:

**From:** Andrew Clements <aclements@usaid.gov>
**Date:** February 16, 2017 at 11:44:54 AM GMT+1
**To:** "Morzaria, Subhash (TCE)" <REDACTED>
**Cc:** Dennis Carroll <dcarroll@usaid.gov>, Lisa Kramer <lkramer@usaid.gov>, "lparish (lparish@usaid.gov)" <lparish@usaid.gov>, "Daniel Schar (RDMA/OPH)" <dSchar@usaid.gov>, "Sudarat Damrongwatanapokin (RDMA/OPH)" <sDamrongwatanapokin@usaid.gov>
**Subject: Re: MERS CoV**

Seems premature to say "Dromedary camels from **Africa** and Arabia are an established source for zoonotic Middle East respiratory syndrome coronavirus (MERS-CoV) infection among humans." since we don't know if Africa and Arabian Peninsula viruses are the same and both have the ability to infect people

Copying Dan and Sudarat.

*Andrew P. Clements, Ph.D.*
*Senior Scientific Adviser*
*Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health*
*U.S. Agency for International Development*
*Mobile phone: 1-571-345-4253*
*Email: aclements@usaid.gov*

On Feb 16, 2017, at 10:09 AM, Morzaria, Subhash (TCE) <REDACTED> wrote:

Fyi MERS CoV in Pakistan
Best,
Subhash

https://wwwnc.cdc.gov/eid/article/23/3/16-1285_article

**From:** Andrew Clements <aclements@usaid.gov>
**Sent:** Fri, 24 Feb 2017 21:44:27 +0100
**To:** "predict@ucdavis.edu" <predict@ucdavis.edu>
**Cc:** PREDICTMGT <predictmgt@usaid.gov>
**Subject:** [predict] PREDICT AOR

You may have noticed that I've stepped out of the background today. I just signed the AOR designation letter and Shana signed the alternate AOR letter, so we're switching things on you again. Sorry!

Have a good weekend.

Andrew

--

Andrew Clements, Ph.D.
Senior Scientific Adviser
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
E-mail: aclements@usaid.gov

*For more information on USAID's Emerging Pandemic Threats program, see:* http://www.usaid.gov/ept2

**From:** "William B. Karesh" <karesh@ecohealthalliance.org>
**To:** "predict@ucdavis.edu" <predict@ucdavis.edu>, Evelyn Luciano <luciano@ecohealthalliance.org>, Ava Sullivan <sullivan@ecohealthalliance.org>, Anthony Ramos <ramos@ecohealthalliance.org>, Patrick Dawson <dawson@ecohealthalliance.org>
**Sent:** Wed, 1 Mar 2017 15:47:12 +0000
**Subject:** [predict] Fwd: PREDICT Jordan event Press release
PREDICT Jordan Event Press Release Feb 28, 2017
ATT00001.htm

Begin forwarded message:

**From:** Maysa Al-Khateeb <malkhateeb@usaid.gov>
**Subject: PREDICT event Press release**
**Date:** March 1, 2017 at 9:24:27 AM EST
**To:** Ehab Abu-Basha <abubasha@just.edu.jo>
**Cc:** "William B. Karesh" <karesh@ecohealthalliance.org>, Nicolas Kaufman <nkaufman@usaid.gov>, Philmon Hiale <phaile@usaid.gov>, Saxton Stewart <sstewart2@usaid.gov>

Dear Dr Ehab,

Kindly find a cleared version of PREDICT`S event press release, you can distribute this version through your media channels.

Best Regards

MaysMaysa Al-Khateeb, RN,MPH,PMP
Population and Family Health Office /USAID
Tel:+962-659-06124
Mobile:[REDACTED]

P Think Green - don't print this email unless you really need to

USAID | JORDAN
FROM THE AMERICAN PEOPLE

PRESS RELEASE

***FOR IMMEDIATE RELEASE***
DATE: February 26, 2017
For more information, please contact:
Maysa Al-Khateeb
T: 06/5906124
Mobile: 0795492211
E-mail:malkhateeb@usaid.gov

# U.S.-Supported Project Supports One Health Approach in Jordan To Reduce Infectious Zoonotic Disease Threats

**Amman(February 26, 2017)**-- PREDICT-Jordan, EcoHealth Alliance, and USAID/Jordan organized a technical coordination workshop titled, "Advancing Health Security in Jordan - Linking People, Animals and Environment " on February 26, 2017 at the Geneva Hotel in Amman. The event was attended by senior officials from USAID/Jordan, World Health Organization (WHO), Food and Agriculture Organization of the United Nations (FAO), The World Organization for Animal Health (OIE), the Ministries of Agriculture, Health, and the Environment, as well as several deans , professors and students from the Jordan University of Science and Technology (JUST) and representatives from international organizations.

The USAID-funded PREDICT-Jordan project is a three year project, launched in 2016. Its main objective is to develop early zoonotic disease warning systems and strengthen collaboration between Jordanian government agencies and academic institutions to protect the public from disease outbreaks. Working with Jordan's existing academic and research institutions, Jordanian PREDICT researchers have collaborated with local farmers and other stakeholders to conduct over 30 field visits, testing hundreds of samples from bats and camels, and publishing a peer-reviewed academic paper reporting their findings.

Addressing the US government's commitment to PREDICT, USAID/Jordan Deputy Mission Director Dr. Lewis Tatem said, "The pressures on Jordan's health system are immense, and we at USAID are committed to standing side by side with Jordan to help shoulder this burden. As Jordan's health system strains to respond to these extraordinary pressures, the consequences of a new zoonotic disease outbreak could be dire. That is why this project, which is helping Jordan identify and stop zoonotic disease outbreaks before they take hold, is so important." The United States government, through USAID, has provided foreign assistance from the American people to Jordan for more than 60 years.

### END ###

For more information about USAID/Jordan, log on to http://www.usaid.gov/Jordan and https://www.facebook.com/USAIDJordan.

USAID | JORDAN
FROM THE AMERICAN PEOPLE

# PRESS RELEASE

Drafted by: Philmon/Haile/PFH/6471

Cleared by: USAID PFH:
USAID DOC: Sstewart
USAID DMD:
PAS:
DCM:

**From:** Elizabeth Leasure <ealeasure@ucdavis.edu>
**To:** Andrew Clements <aclements@usaid.gov>, "predict@ucdavis.edu" <predict@ucdavis.edu>
**Cc:** "predictmgt@usaid.gov" <predictmgt@usaid.gov>, David John Wolking <djwolking@ucdavis.edu>
**Sent:** Mon, 20 Mar 2017 20:44:11 +0000
**Subject:** RE: [predict] Fwd: ACTION Due March 31: Data Call on New Partnerships with U.S. Higher Education Institutions

Hi Andrew. Sorry, we're not going to be able to make the COB today deadline. Can we submit late, or is it today or nothing? Please advise.

Thanks,
Liz

Elizabeth Leasure
One Health Institute
University of California, Davis
530-754-9034 (office)
REDACTED

---

**From:** predict-request@ucdavis.edu [mailto:predict-request@ucdavis.edu] **On Behalf Of** Andrew Clements
**Sent:** Monday, March 20, 2017 11:07 AM
**To:** predict@ucdavis.edu
**Cc:** predictmgt@usaid.gov
**Subject:** [predict] Fwd: ACTION Due March 31: Data Call on New Partnerships with U.S. Higher Education Institutions

See request below. If you can't make the deadline (COB today, sorry) please let me know. We got this late last week without the attachements which only came through today.

In response to Congressional directives and inquiries, BRM is attempting to capture information regarding the Agency's investments, across all sectors, between U.S. based, and host countries Higher Education Institutions (HEI) that support capacity development.

*Andrew P. Clements, Ph.D.*
*Senior Scientific Adviser*
*Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health*
*U.S. Agency for International Development*
*Mobile phone: 1-571-345-4253*
*Email: aclements@usaid.gov*
Begin forwarded message:

**From:** Marilyn Crane <mcrane@usaid.gov>
**Date:** March 20, 2017 at 5:43:35 PM GMT+1
**To:** Shana Gillette <sgillette@usaid.gov>, Andrew Clements <aclements@usaid.gov>, Alisa Pereira <apereira@usaid.gov>
**Subject: Fwd: ACTION Due March 31: Data Call on New Partnerships with U.S. Higher Education Institutions**

Attachments finally came through!

Marilyn

---------- Forwarded message ----------
From: **Miruna Mosincat** <mmosincat@usaid.gov>
Date: Mon, Mar 20, 2017 at 11:37 AM
Subject: Re: ACTION Due March 31: Data Call on New Partnerships with U.S. Higher Education Institutions
To: Marilyn Crane <mcrane@usaid.gov>
Cc: Megan Fotheringham <mfotheringham@usaid.gov>, Dennis Carroll <dcarroll@usaid.gov>, "Alisa (GH/HIDN) Pereira" <apereira@usaid.gov>, "Vincent, Cheri (GH/HIDN/ID)" <CVincent@usaid.gov>, "Fox, Elizabeth(GH/HIDN)" <EFox@usaid.gov>, Brittany Carlsen <bcarlsen@usaid.gov>

Hi Marilyn,

Sorry about that! Here are the attachments!

Miruna

On Mon, Mar 20, 2017 at 11:22 AM, Marilyn Crane <mcrane@usaid.gov> wrote:
Hi Miruna,

The attachments have been lost somewhere in all of the forwards. Would you kindly resend the attachments so that I can complete them for One Health Workforce?

Thanks,
Marilyn

On Mon, Mar 20, 2017 at 11:16 AM, Miruna Mosincat <mmosincat@usaid.gov> wrote:
Hello all,

Please not that this is due back to me by **COB today**! Please let me know if I can help with this request in anyway.

Thank you,

Miruna

On Thu, Mar 16, 2017 at 4:47 PM, Megan Fotheringham <mfotheringham@usaid.gov> wrote:
All,
Please see below for a tasker that P3 is collecting information on.

If any of the projects that you manage support efforts between US based Higher Edication Institutions and host country Higher Education Institutions to increase capacity development (as defined below and in the attachments), please complete the attached forms and send them to **Miruna Mosincat by COB March 20th**. We will compile the answers for the ID Office and submit on behalf of everyone by teh requested deadline of noon on March 21st.

Thank you
Megan

Megan Fotheringham, MPP, MPH
Acting Deputy Office Director
Office of Infectious Diseases
Bureau for Global Health
US Agency for International Development
+1-571-551-7429
mfotheringham@usaid.gov

---------- Forwarded message ----------
From: **Clairmont Austin** <caustin@usaid.gov>
Date: Thu, Mar 16, 2017 at 1:36 PM
Subject: Fwd: ACTION Due March 31: Data Call on New Partnerships with U.S. Higher Education Institutions

To: "Saldana, Kelly (GH/HIDN)" <KSaldana@usaid.gov>, Doug Arbuckle <darbuckle@usaid.gov>, "Fox, Elizabeth(GH/HIDN)" <EFox@usaid.gov>, Barbara Hughes <bhughes@usaid.gov>, Sharon Carney <SCarney@usaid.gov>, Elise Jensen <ejensen@usaid.gov>, "Lloyd, Wallace (GH/SPBO/OPS)" <wlloyd@usaid.gov>, David Milestone <dmilestone@usaid.gov>, "Starbird, Ellen" <EStarbird@usaid.gov>
Cc: Shyami DeSilva <sdesilva@usaid.gov>, Tara Lewing <tlewing@usaid.gov>, Kendra Phillips <kphillips@usaid.gov>, Lin Liu <liliu@usaid.gov>, Michele Russell <mrussell@usaid.gov>, Megan Fotheringham <mfotheringham@usaid.gov>, "JBorrazzo@usaid.gov" <JBorrazzo@usaid.gov>, "Melton, Deborah (HR/CSP/RS)" <dmelton@usaid.gov>, "WPressman@usaid.gov" <WPressman@usaid.gov>, "Johnson, Claire (OFM/HAITI)" <cljohnson@usaid.gov>, Robbin Boyer <rboyer@usaid.gov>, "bgustafson@usaid.gov" <bgustafson@usaid.gov>

Greetings Office Directors/Deputies/Team Leads:

In response to Congressional directives and inquiries, BRM is attempting to capture information regarding the Agency's investments, across all sectors, between U.S. based, and host countries Higher Education Institutions (HEI) that support capacity development.

The Bureau for Global Health has been tasked to provide historical/projected information in response to this Data Call on New Partnerships with U.S. Higher Education Institutions. In addition to Mark Murray's email, attached are three items: a memo, directive definition, and a data entry template/sheet, that will guide you through the process.

Please complete and e-mail me (caustin@usaid.gov) the attached template by 12 noon on the 21st of March (next Tuesday). I would like to provide a consolidated response to BRM by 12 noon on the 22nd of March (next Wednesday). I am available at 571-551-7103 if you have questions, or need clarification or guidance on this tasking.

Thanks,

Clairmont (Andy) Austin (GH/OPPP/PIBM)

Budget Analyst

571-551-7103

Service! Always!

---------- Forwarded message ----------
From: **Mark Murray** <mmurray@usaid.gov>
Date: Wed, Mar 15, 2017 at 4:01 PM
Subject: ACTION Due March 31: Data Call on New Partnerships with U.S. Higher Education Institutions
To: "BRM's Program Offices Mail List (USAID)" <brmsprogramoffices@usaid.gov>
Cc: BRM <brm@usaid.gov>, "Kowal, Stephen (EGAT/ED/PT)" <skowal@usaid.gov>, Grace Lang <glang@usaid.gov>, Monica Pons <mpons@usaid.gov>

ATTACHMENTS: (1) Memo; (2) directive definition; (3) data entry template/sheet

Hi Program Officers,

The FY 2016 appropriations act (HR 2029 Omnibus, p. 1403-1405) contains a $35 million directive related to new higher education partnerships focused on capacity development:

> (2) HIGHER EDUCATION.—Of the funds appropriated by title III of this Act, not less than $225,000,000 shall be made available for assistance for higher education, including not less than $35,000,000 for new partnerships between higher education institutions in the United States and developing countries: Provided, That such funds may be made available

notwithstanding any other provision of law that restricts assistance to foreign countries, and shall be subject to the regular notification procedures of the Committees on Appropriations.

Given the limited information available at this level of detail and granularity in existing Agency planning and reporting systems (e.g. the Operational Plan), we have identified the need for a data call to collect additional information. More information is provided in the attached memo and its annexes.

**Purpose**

The purpose of this data call is to gain additional information regarding the Agency's investments, across all sectors, related to active programs that involve partnerships with U.S. higher education institutions to support capacity development in host country higher education institutions. This is in response to Congressional directives and inquiries focused on this issue.

**Instructions**

Using the attached table/template, please send a comprehensive list of all ongoing and planned/new activities with U.S. higher education institutions (including funding from any program area in the standard program structure) that meets the following description:

Activity focuses on or includes a major component supporting institutional capacity development of a host country higher education institution. "ES.2-1 Number of host country tertiary education institutions receiving capacity development support with USG assistance" is a standard foreign assistance indicator that provides a working definition for capacity development. While USAID has no single definition of capacity or capacity development, the following excerpt from the indicator reference sheet can be used to define institutional capacity development:

- "Capacity development support is comprised of a range of activities, interventions, processes, and approaches that may include, but are not limited to: institutional partnerships; professional development; training; coaching; technical assistance; participatory assessments; process mapping and improvement; etc. These may be focused on a range of specific topics, including but not limited to: human resources, management and administration, instruction, research, infrastructure, facilities, fund raising, etc."

Thanks,
Mark

Mark Murray
Budget Analyst for Economic Growth, Education, and Environment
USAID Office of Budget and Resource Management
1300 Pennsylvania Avenue NW | RRB 6.09-061 | Washington, DC 20523
phone 202-712-1656 | direct email mmurray@usaid.gov | office email brm@usaid.gov

--

You received this message because you are subscribed to the Google Groups "BRM's Program Offices Mail List (USAID)" group.
To post to this group, send email to brmsprogramoffices@usaid.gov.

--

**Miruna Mosincat**
Administrative Assistant
**USAID** I Office of Infectious Disease
Phone: (571) 551-7096
REDACTED

--

Marilyn Crane
Senior International Higher Education Advisor
Emerging Threats Division
Office of Infectious Disease
Bureau for Global Health
U.S. Agency for International Development (USAID)
Telephone: (202) 712-4724
REDACTED
E-mail: mcrane@usaid.gov

--

**Miruna Mosincat**
Administrative Assistant
**USAID** I Office of Infectious Disease
Phone: (571) 551-7096
Cell: (571) 215-4924

--

Marilyn Crane
Senior International Higher Education Advisor
Emerging Threats Division
Office of Infectious Disease
Bureau for Global Health
U.S. Agency for International Development (USAID)
Telephone: (202) 712-4724
REDACTED
E-mail: mcrane@usaid.gov

**From:** Andrew Clements <aclements@usaid.gov>
**Sent:** Fri, 31 Mar 2017 13:21:08 +0200
**Subject:** Re: PREDICT Year 3 Equipment Purchase Request #4
**To:** Elizabeth Leasure <ealeasure@ucdavis.edu>
**Cc:** PREDICTMGT <predictmgt@usaid.gov>, Jonna Mazet <jkmazet@ucdavis.edu>, David John Wolking <djwolking@ucdavis.edu>, Helen C Thompson <hcthompson@ucdavis.edu>, Predict inbox <predict@ucdavis.edu>

Hi Liz and Helen,

I approve these equipment requests for Ghana and Senegal.

Andrew

On Fri, Mar 31, 2017 at 1:29 AM, Elizabeth Leasure <ealeasure@ucdavis.edu> wrote:

> Hi Andrew. Please find attached a request for authorization to purchase equipment to enable in-country work for PREDICT in Ghana and Senegal. These items were not originally included in the proposal budget and now require approval. Please let me know if you have any questions or require any additional information to proceed.
>
> Please also note that future equipment requests will be submitted by Helen Thompson (copied here). Helen joined the PREDICT team at UCD late last year and will also be assisting with motor vehicle requests and new subcontract requests (we have some of each in the pipeline, so stay tuned).
>
> Thanks!
>
> Liz
>
> Elizabeth Leasure
>
> One Health Institute
>
> University of California, Davis
>
> 530-754-9034 (office)
>
> REDACTED

--
You received this message because you are subscribed to the Google Groups "PREDICTMGT" group.
To unsubscribe from this group and stop receiving emails from it, send an email to predictmgt+unsubscribe@usaid.gov.
To post to this group, send email to predictmgt@usaid.gov.
To view this discussion on the web visit https://groups.google.com/a/usaid.gov/d/msgid/predictmgt/CY4PR08MB274294D5858ABBA489CE62E1A2340%40CY4PR08MB2742.namprd08.prod.outlook.com.

--

Andrew Clements, Ph.D.
Senior Scientific Adviser
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health

U.S. Agency for International Development
Mobile phone: 1-571-345-4253
E-mail: aclements@usaid.gov

*For more information on USAID's Emerging Pandemic Threats program, see:* http://www.usaid.gov/ept2

**Sent:** Tue, 25 Apr 2017 20:46:18 -0700
**Subject:** Re: PREDICT Management Team Review-- Essential Role of the Environment in One Health and National Health Security
**From:** Jonna Mazet <jkmazet@ucdavis.edu>
**To:** Catherine Machalaba <Machalaba@ecohealthalliance.org>, Billy Karesh <karesh@ecohealthalliance.org>
**Cc:** Christine Kreuder Johnson <ckjohnson@ucdavis.edu>, Peter Daszak <daszak@ecohealthalliance.org>, "predict@ucdavis.edu" <predict@ucdavis.edu>
Role of Environment- National Health Security Planning JM.pdf

Hi -- a few minor suggestions.
Thanks for keeping up the environmental advocacy,
Jonna

On Fri, Apr 21, 2017 at 11:11 AM, David J Wolking <djwolking@ucdavis.edu> wrote:

> Hi PREDICT Management Team,
> At Billy and Catherine's request, I am forwarding a briefing document developed with P&R intended to support countries with engaging the environmental sector in national planning for health security. Billy and Catherine would greatly appreciate your review and feedback by April 26th as there are plans to distribute the final version at the WHO-CBD meeting in Geneva on May 3rd.

Thanks in advance!

David

---------- Forwarded message ----------
From: **Catherine Machalaba** <machalaba@ecohealthalliance.org>
Date: Wed, Apr 19, 2017 at 2:59 PM
Subject: PREDICT Management Team Review-- Essential Role of the Environment in One Health and National Health Security
To: David J Wolking <djwolking@ucdavis.edu>
Cc: "William B. Karesh" <karesh@ecohealthalliance.org>, Amanda Andre <amanda.andre@ecohealthalliance.org>

Dear David,
Please find attached a short briefing document on the role of the environment sector in One Health and health security that we developed with P&R, intended to assist countries in engaging the environment sector in national action planning for health security.

May we kindly ask for it to be reviewed by Senior Management Team by April 26th so that comments can be incorporated and the document distributed at the WHO-CBD meeting that we are facilitating in Geneva on May 3rd? Thank you so much, and we greatly appreciate the team's help and insight as always!

Kind regards,
Catherine

**Catherine Machalaba, MPH**
*Health and Policy Program Coordinator*

EcoHealth Alliance
460 West 34th Street – 17th floor
New York, NY 10001

1.212.380.4472 (direct)
REDACTED
1.212.380.4465 (fax)
www.ecohealthalliance.org

*Science Officer,* Future Earth oneHEALTH Project

*Chair*, Veterinary Public Health Special Primary Interest Group, American Public Health Association

*Program Officer*, IUCN SSC Wildlife Health Specialist Group

*EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that promote conservation and prevent pandemics.*

# THE ROLE OF ENVIRONMENT IN ONE HEALTH AND NATIONAL HEALTH SECURITY

The environment plays an essential role in public health, yet, to date, it has been an under utilized partner for health security in most countries. While authorities from each of the human health, animal health, and environment sectors may not be aware of the benefits of collaboration with one another, the "One Health" concept recognizes the connections between human, animal, and ecosystem health, which will hopefully allow the concept to reach its full potential in practice at the local, national, and global levels. By utilizing data, expertise, and management approaches in the environment natural resource sector, we can enhance our understanding of the root causes of diseases, better account for complexity of environmental factors, and ultimately encourage protection of natural resources for the benefits of health. The environment needs to be recognized for the value of its contributions to the promotion of population health and well-being, particularly in "health security" efforts to prevent and prepare for endemic, epidemic, and pandemic threats.

## LINKS BETWEEN ENVIRONMENT AND HEALTH

The links between biodiversity, ecosystems, and public health are well documented in recent publications (e.g., WHO-CBD *State of Knowledge Review on Biodiversity and Human Health* 2015; WHO *Millennium Ecosystem Assessment* 2005). These links range from ecosystem services that contribute to human health—provision of food, water, and medicines—to pollution remediation, to pathogen regulation. Particularly relevant connections for health security include:

- The majority of known pathogens infectious to human have animal origins ("zoonotic diseases"). Of these, approximately three-quarters emerged from wildlife, such as HIV/AIDS, Ebola, and SARS;
- The drivers of biodiversity loss, ecosystem degradation, and disease emergence, including changes in land use/habitat or hunting and trade, overlap, which modifies disease ecology dynamics and put humans and wildlife into new or increasing contact.

Under broad guidance from the World Health Organization, *countries are currently undertaking national action planning for health security, a process intended to promote multi-sectoral partnerships to prevent, prepare, and respond to disease threats.* The environmental community should advocate for their crucial role in this process, and seek to inform and support animal and human health partners in identifying synergies. National Biodiversity Strategies and Action Plans and other land use planning tools provide important information for health security planning.

In 2014 parties to the United Nations Convention on Biological Diversity agreed to recognize *"the value of the "One Health" approach to address the cross-cutting issue of biodiversity and human health, as an integrated approach consistent with the ecosystem approach (decision V/6) that integrates the complex relationships between humans, microorganisms, animals, plants, agriculture, wildlife and the environment" (UNEP/CBD/COP/DEC/XII/21)*

## VALUE OF THE ENVIRONMENTAL AND NATURAL RESOURCE SECTOR TO THE PUBLIC HEALTH SECTOR

Across the world, ministries of environment and natural resources and/or environmental protection agencies have different mandates and missions, but many of them focus on the protection of the environment with the goal of protecting public health. Environmental health practitioners monitor food safety from farm to table; are responsible for vector and vermin monitoring and control; and monitor microbial and chemical pollution of the land, water, and air. Natural resource managers monitor ecosystems and landscapes, and the creatures that occupy them. They often see trends in the natural world before they are seen in the urban world. For example, unusual wildlife morbidity and mortality can indicate presence of pathogenic or toxic agents that could potentially be detrimental to human health.

Environmental and natural resource professionals, and the data that they collect, must be included in any serious effort to obtain a comprehensive picture of the factors that affect human health. Data includes:

- Climate/weather forecasting to predict and inform vaccination campaigns, particularly for climate-sensitive vector-borne diseases.
- Water quality monitoring for bacterial, algal, and inorganic contaminants that can cause human and animal illness.
- The linkages between environmental contamination and animal and human health, including waste management practices and dissemination of antimicrobials, pesticides, and insecticides.
- Dynamics (ecological) and drivers (anthropogenic) leading to zoonotic and vector-borne disease emergence.
- Sentinel monitoring of wildlife to identify diseases before potential spillover to domestic animals and/or humans (e.g., for the predictive value of Ebola virus in great apes).
- Appropriate control strategies to balance immediate public health concerns and potential long-term damages to ecological systems and associated ecosystem services that may result from control measures (e.g. insecticide spraying, wildlife culling).

- Assessing outcomes from ecosystem modification (e.g. land use change for agriculture or extractive industries, invasive species introductions) and likely consequences (positive or negative) for human and animal health that might be associated with declining species habitat, changing presence of "generalist" species along fragmented landscapes, change in animal migration, changes in suitable habitat for disease vectors, changes in food chain, etc.
- Risk assessment for known and novel disease presence and/or introduction/establishment, based on species range and ecological niche, behavior, and inter-species spillover potential.

Environmental authorities may also detect and monitor diseases in wildlife that do not pose a direct threat to humans. However, even non-zoonotic diseases may have implications for the health and functioning of ecosystems in ways that can indirectly affects humans (e.g. via pest control, pollination, etc.).

The environmental sector plays a key role in early warning, detection, and identifying disease risk, as well as in response. For example, environmental health professionals in Liberia were responsible for dead body management during the Ebola crisis.

Expertise and infrastructure from environmental services serves is a valuable component of health security, and should be incuded in national processes to maximize protection of the public's health.

For more information, please visit: www.preparednessandresponse.org and www.predict.global
Contact: predictonehealth@ecohealthalliance.org



UCDUSR0011696

**From:** "William B. Karesh" <karesh@ecohealthalliance.org>
**To:** Jonna Mazet <jkmazet@ucdavis.edu>
**Cc:** Catherine Machalaba <machalaba@ecohealthalliance.org>, Chris Johnson <ckjohnson@ucdavis.edu>, Peter Daszak <daszak@ecohealthalliance.org>, "predict@ucdavis.edu" <predict@ucdavis.edu>
**Subject:** Re: PREDICT Management Team Review-- Essential Role of the Environment in One Health and National Health Security
**Sent:** Wed, 26 Apr 2017 15:48:46 +0000

Thanks !!
BK

**William B. Karesh, D.V.M**
*Executive Vice President for Health and Policy*

EcoHealth Alliance
460 West 34th Street - 17th Floor
New York, NY 10001 USA

+1.212.380.4463 (direct)
+1.212.380.4465 (fax)
www.ecohealthalliance.org

President, OIE Working Group on Wildlife

Co-chair, IUCN Species Survival Commission - Wildlife Health Specialist Group

EPT Partners Liaison, USAID Emerging Pandemic Threats - PREDICT-2 Program

***EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that promote conservation and prevent pandemics.***

On Apr 25, 2017, at 11:46 PM, Jonna Mazet <jkmazet@ucdavis.edu> wrote:

Hi -- a few minor suggestions.
Thanks for keeping up the environmental advocacy,
Jonna

On Fri, Apr 21, 2017 at 11:11 AM, David J Wolking <djwolking@ucdavis.edu> wrote:

> Hi PREDICT Management Team,
> At Billy and Catherine's request, I am forwarding a briefing document developed with P&R intended to support countries with engaging the environmental sector in national planning for health security. Billy and Catherine would greatly appreciate your review and feedback by April 26th as there are plans to distribute the final version at the WHO-CBD meeting in Geneva on May 3rd.

Thanks in advance!

David

---------- Forwarded message ----------
From: **Catherine Machalaba** <machalaba@ecohealthalliance.org>
Date: Wed, Apr 19, 2017 at 2:59 PM
Subject: PREDICT Management Team Review-- Essential Role of the Environment in One Health and National Health Security
To: David J Wolking <djwolking@ucdavis.edu>

Cc: "William B. Karesh" <karesh@ecohealthalliance.org>, Amanda Andre <amanda.andre@ecohealthalliance.org>

Dear David,

Please find attached a short briefing document on the role of the environment sector in One Health and health security that we developed with P&R, intended to assist countries in engaging the environment sector in national action planning for health security.

May we kindly ask for it to be reviewed by Senior Management Team by April 26th so that comments can be incorporated and the document distributed at the WHO-CBD meeting that we are facilitating in Geneva on May 3rd? Thank you so much, and we greatly appreciate the team's help and insight as always!

Kind regards,

Catherine

**Catherine Machalaba, MPH**
*Health and Policy Program Coordinator*

EcoHealth Alliance
460 West 34th Street – 17th floor
New York, NY 10001

1.212.380.4472 (direct)
REDACTED
1.212.380.4465 (fax)
www.ecohealthalliance.org

*Science Officer,* Future Earth oneHEALTH Project

*Chair*, Veterinary Public Health Special Primary Interest Group, American Public Health Association

*Program Officer*, IUCN SSC Wildlife Health Specialist Group

***EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that promote conservation and prevent pandemics.***

<Role of Environment- National Health Security Planning JM.pdf>

**From:** David J Wolking <djwolking@ucdavis.edu>
**Sent:** Mon, 15 May 2017 11:05:18 -0700
**Subject:** Re: PREDICT Management Team call (Monday May 15, 2017 @ 10AMPDT/1PM EDT)
**To:** David J Wolking <djwolking@ucdavis.edu>
**Cc:** Alisa Pereira Emerging Threats Division <apereira@usaid.gov>, Cassandra Louis Duthil <clouisduthil@usaid.gov>, Christine Kreuder Johnson <ckjohnson@ucdavis.edu>, "Clements, Andrew (GH/HIDN)" <AClements@usaid.gov>, Eddy Rubin <erubin@metabiota.com>, Elizabeth Leasure <ealeasure@ucdavis.edu>, Leilani Francisco <francisco@ecohealthalliance.org>, Lindsay Parish <lparish@usaid.gov>, Peter Daszak <daszak@ecohealthalliance.org>, "Prof. Jonna Mazet" <jkmazet@ucdavis.edu>, Shana Gillette <sgillette@usaid.gov>, William Karesh <karesh@ecohealthalliance.org>, "Cara J. Chrisman" <cchrisman@usaid.gov>, Molly Turner <turner@ecohealthalliance.org>, Evelyn Luciano <luciano@ecohealthalliance.org>, PREDICTMGT <predictmgt@usaid.gov>, Alison Andre <andre@ecohealthalliance.org>, Ava Sullivan <sullivan@ecohealthalliance.org>, Amanda Fuchs <fuchs@ecohealthalliance.org>, Catherine Machalaba <Machalaba@ecohealthalliance.org>, Taylor Elnicki <telnicki@metabiota.com>

Hi there,
Here is a link to the Uppsala Health Summit 2017: Tackling Infectious Disease Threats.

David

On Fri, May 12, 2017 at 3:10 PM, David J Wolking <djwolking@ucdavis.edu> wrote:

> Hi there,
> We have a PREDICT Management Team call scheduled for Monday, May 15th at 10AM PDT/1PM EDT. Below (and attached) is the agenda and call-in information. I'll follow-up with the calendar invite next.

Best,

David

**PREDICT Management Team Agenda**

**Monday, May 15, 2017**

**10:00-11:00 PDT/1:00-2:00pm EDT**

**Standing items**

**USAID Updates**

1. **Administrative items**
   a. Budget planning, country caps, and project ceiling
   b. Pending subawards and subcontracts
   c. Travel approval concurrence procedures
   d. Country-level M&E and GHSA workplan requests
2. **Follow-up on April 12th DC meeting**
3. **Ebola Host Project updates**
4. **Outbreak updates** (Ebola in DRC, MPOX in ROC, etc.)
5. **EPT partner collaboration/coordination updates and external panel report (Billy)**

6. **Publication and conference updates** (HP3, global CoVs, others; Upsala pandemics meeting, etc.)

**From:** Andrew Clements <aclements@usaid.gov>
**To:** Jonna Mazet <jkmazet@ucdavis.edu>
**CC:** Alisa Pereira <apereira@usaid.gov>
**Sent:** 5/15/2017 11:08:13 AM
**Subject:** Re: RoC follow up

Following up on this. Didn't want to ask on the call with everyone on the line.

*Andrew P. Clements, Ph.D.*
*Senior Scientific Adviser*
*Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health*
*U.S. Agency for International Development*
*Mobile phone: 1-571-345-4253*
*Email: aclements@usaid.gov*

On May 9, 2017, at 10:38 PM, Andrew Clements <aclements@usaid.gov> wrote:

Jonna,

Following up on the phone call, what is the current status of the market work in ROC? Has it started, is it producing results, etc.?

If it has started and produced results, will there likely be any impact of changing management and upgrading ethical and financial oversight? Specifically, would these changes likely result in significant delays in implementation or affect delivery of results?

Thanks!

Andrew

*Andrew P. Clements, Ph.D.*
*Senior Scientific Adviser*
*Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health*
*U.S. Agency for International Development*
*Mobile phone: 1-571-345-4253*
*Email: aclements@usaid.gov*

**From:** "William B. Karesh" <karesh@ecohealthalliance.org>
**To:** Elizabeth Leasure <ealeasure@UCDAVIS.EDU>
**Cc:** Molly Turner <turner@ecohealthalliance.org>, Evelyn Luciano <luciano@ecohealthalliance.org>, "predict@ucdavis.edu" <predict@UCDAVIS.EDU>, Jonna Mazet <jkmazet@UCDAVIS.EDU>
**Subject:** Re: Vehicle requests for Jordan and Malaysia approved (PREDICT)
**Sent:** Fri, 19 May 2017 20:48:46 +0000

Thanks!!!

Sent from my iPhone

On May 19, 2017, at 4:10 PM, Elizabeth Leasure <ealeasure@ucdavis.edu> wrote:

> Hi Molly and Billy. We just received the official approval from USAID for the Jordan (Chevy Silverado) and Malaysia (Toyota Hilux) vehicles, so please proceed with those purchases.
>
> Thanks,
> Liz
>
> Elizabeth Leasure
> One Health Institute
> University of California, Davis
> 530-754-9034 (office)
> REDACTED

**From:** Brooke Genovese <bgenovese@ucdavis.edu>
**To:** Andrew Clements <aclements@usaid.gov>, Elizabeth Leasure <ealeasure@ucdavis.edu>, Christine Kreuder Johnson <ckjohnson@ucdavis.edu>, Jonna Mazet <jkmazet@ucdavis.edu>, David John Wolking <djwolking@ucdavis.edu>, Cara Chrisman <cchrisman@usaid.gov>, Molly Turner <turner@ecohealthalliance.org>, Shana Gillette <sgillette@usaid.gov>, "Eddy Rubin" <erubin@metabiota.com>, Alison Andre <andre@ecohealthalliance.org>, Alisa Pereira <apereira@usaid.gov>, "William B. Karesh" <karesh@ecohealthalliance.org>, Cassandra Duthil <clouisduthil@usaid.gov>, Evelyn Luciano <luciano@ecohealthalliance.org>, Amanda Fuchs <fuchs@ecohealthalliance.org>, Jake Athanas <jathanas@metabiota.com>, "Peter Daszak" <daszak@ecohealthalliance.org>
**Subject:** [predict] Sr. Mgmt Team Schedule - fall 2017
**Sent:** Tue, 18 Jul 2017 23:14:03 +0000

Hello everyone,

Thank you for participating in the Doodle Poll I circulated to determine a new day/time for Sr. Management Team calls. Beginning **September 19,** SMT calls will move to **bi-weekly Tuesdays, from 10:00 – 11:00 am PDT / 1:00 – 2:00 EDT / 7:00 – 8:00 pm CEST**. Until then, MT calls will remain on the same bi-weekly Monday schedule.

We did our best to accommodate as many individual schedules as possible – apologies if the new day/time is not ideal. Our hope is that by delaying the new schedule until late-September, everyone will have a chance to restructure their calendar accordingly (if need be). I will send out a reminder closer to September as well.

*Note: The next scheduled SMT call is on Monday, July 24 from 10-11am PDT.*

Please reach out if you have any concerns.

Thank you!

Best,
Brooke Genovese
Project Manager
Executive Analyst
One Health Institute
School of Veterinary Medicine
Tel: 530-752-6459
bgenovese@ucdavis.edu

**From:** "Morzaria, Subhash (TCE)" <[redacted]>
**To:** Andrew Clements <aclements@usaid.gov>, "ghsdunitmaillistusaid@usaid.gov" <ghsdunitmaillistusaid@usaid.gov>, "Lisa Kramer (Nairobi/EA/RHH)" <lkramer@usaid.gov>, "Daniel Schar (RDMA/OPH)" <dSchar@usaid.gov>, "Sudarat Damrongwatanapokin (RDMA/OPH)" <sDamrongwatanapokin@usaid.gov>, Jonna Mazet <jkmazet@ucdavis.edu>, William Karesh <Karesh@ecohealthalliance.org>, "erubin@metabiota.com" <erubin@metabiota.com>
**Subject:** RE: Science - Special Issue on Emerging Infectious Diseases
**Sent:** Wed, 19 Jul 2017 15:38:32 +0000

Dear Andrew,
Thank you for sharing. An interesting and highly relevant set of articles.
Best,
Subhash

---

**From:** Andrew Clements [mailto:aclements@usaid.gov]
**Sent:** Wednesday, July 19, 2017 5:18 PM
**To:** ghsdunitmaillistusaid@usaid.gov; Lisa Kramer (Nairobi/EA/RHH) <lkramer@usaid.gov>; Daniel Schar (RDMA/OPH) <dSchar@usaid.gov>; Sudarat Damrongwatanapokin (RDMA/OPH) <sDamrongwatanapokin@usaid.gov>; Jonna Mazet <jkmazet@ucdavis.edu>; William Karesh <Karesh@ecohealthalliance.org>; erubin@metabiota.com; Morzaria, Subhash (TCE) [redacted]
**Subject:** Science - Special Issue on Emerging Infectious Diseases

FYI

**Science - Special Issue on Emerging Infectious Diseases**
Articles:

- **Introduction to special issue - Outbreak**
- **Driving improvements in emerging disease surveillance through locally relevant capacity strengthening**
- **Opportunities and challenges in modeling emerging infectious diseases**
- **Improving vaccine trials in infectious disease emergencies**
- **When an emerging disease becomes endemic**

*Andrew P. Clements, Ph.D.*
*Senior Scientific Adviser*
*Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health*
*U.S. Agency for International Development*
*Mobile phone: 1-571-345-4253*
*Email: aclements@usaid.gov*

**From:** Andrew Clements <aclements@usaid.gov>
**Sent:** Thu, 27 Jul 2017 17:06:03 +0200
**To:** Lisa Kramer <lkramer@usaid.gov>
**Cc:** "djwolking@ucdavis.edu" <djwolking@ucdavis.edu>, "predict@ucdavis.edu" <predict@ucdavis.edu>, "sgillette@usaid.gov" <sgillette@usaid.gov>, "dcarroll@usaid.gov" <dcarroll@usaid.gov>, "ckjohnson@ucdavis.edu" <ckjohnson@ucdavis.edu>, "murrays@si.edu" <murrays@si.edu>, "apereira@usaid.gov" <apereira@usaid.gov>, "vodzakme@si.edu" <vodzakme@si.edu>, "zimmermand@si.edu" <zimmermand@si.edu>
**Subject:** [predict] Re: PREDICT - USAID Call

Sorry, I haven't been able to get through on the phone line. I'll keep trying.

*Andrew P. Clements, Ph.D.*
*Senior Scientific Adviser*
*Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health*
*U.S. Agency for International Development*
*Mobile phone: 1-571-345-4253*
*Email: aclements@usaid.gov*

On Jul 27, 2017, at 9:31 AM, Lisa Kramer <lkramer@usaid.gov> wrote:

This event has been changed.

Title: PREDICT - USAID Call
REDACTED

When: Thu Jul 27, 2017 5pm – 6pm Zurich (changed)
Calendar: aclements@usaid.gov
Who:
* lkramer@usaid.gov - organizer
* djwolking@ucdavis.edu
* predict@ucdavis.edu
* sgillette@usaid.gov
* aclements@usaid.gov
* dcarroll@usaid.gov
* ckjohnson@ucdavis.edu
* murrays@si.edu
* apereira@usaid.gov
* vodzakme@si.edu
* zimmermand@si.edu

Event details:
https://www.google.com/calendar/event?action=VIEW&eid=MHZwYTM5czk5ZTY2NGFzcW5jdm42NHE5M20gYWNsZW1lbnRzQHVzYWlkLmdvdg&tok=MTcjbGtyYW1lckB1c2FpZC5nb3ZhOTZhYWRiN2JkZmI4OGNmZjRlZDE5NjU5YTU3ZDY0YjE3MTgxODlj&ctz=Europe/Zurich&hl=en

Invitation from Google Calendar: https://www.google.com/calendar/

You are receiving this email at the account aclements@usaid.gov because you are subscribed for updated invitations on calendar aclements@usaid.gov.

To stop receiving these emails, please log in to https://www.google.com/calendar/ and change your notification settings for this calendar.

Forwarding this invitation could allow any recipient to modify your RSVP response. Learn more at

https://support.google.com/calendar/answer/37135#forwarding

<meeting.ics>

**From:** David J Wolking <djwolking@ucdavis.edu>
**Sent:** Thu, 27 Jul 2017 16:12:24 -0700
**Subject:** Fwd: P&R P4P EPT2 Partner Webinar
**To:** Alison Andre <andre@ecohealthalliance.org>, Amanda Fine [REDACTED], Amanda Fuchs <fuchs@ecohealthalliance.org>, Ava Sullivan <sullivan@ecohealthalliance.org>, Brian Bird [REDACTED], Brooke Genovese <bgenovese@ucdavis.edu>, Christine Kreuder Johnson <ckjohnson@ucdavis.edu>, Damien Joly <djoly@metabiota.com>, Dawn Zimmerman [REDACTED] Eddy Rubin <erubin@metabiota.com>, Elizabeth Leasure <ealeasure@ucdavis.edu>, Emma Lane <lane@ecohealthalliance.org>, Evelyn Luciano <luciano@ecohealthalliance.org>, Jon Epstein <epstein@ecohealthalliance.org>, Karen Saylors <ksaylors@metabiota.com>, Leilani Francisco <francisco@ecohealthalliance.org>, Megan Doyle <mmdoyle@ucdavis.edu>, Molly Turner <turner@ecohealthalliance.org>, "Murray, Suzan" <MurrayS@si.edu>, Peter Daszak <daszak@ecohealthalliance.org>, "Prof. Jonna Mazet" <jkmazet@ucdavis.edu>, "Prof. Woutrina Smith" <wasmith@ucdavis.edu>, Sarah Olson [REDACTED] Simon Anthony <sja2127@columbia.edu>, Tracey Goldstein <tgoldstein@ucdavis.edu>, William Karesh <karesh@ecohealthalliance.org>
JoinMe Guidance.pdf

Hi there,
For any of you with an interest in P&R's Planning for Performance (P4P) process, they are doing a webinar for the EPT M&E working group. If you'd like to join just let me know and I'll inform Rob.

Cheers,

David

---------- Forwarded message ----------
From: **Robert Salerno** <Robert_Salerno@dai.com>
Date: Thu, Jul 27, 2017 at 10:13 AM
Subject: P&R P4P EPT2 Partner Webinar
To: "hpctrozzola_trg-inc.com" <hpctrozzola@trg-inc.com>, Katc Zimmcrman <[REDACTED] Sarah Martin [redacted], Tiffany D'Mello <tdmello@usaid.gov>, "rechalar_usaid.gov" <rechalar@usaid.gov>, [redacted] Susan Mugwe <[REDACTED]>, Frank Pumipuntu [REDACTED], Ian Allen <allen595@umn.edu>, Amy Pekol <pekol@umn.edu>, Dawn Terkla <dawn.terkla@tufts.edu>, "Jarvin, Linda" <linda.jarvin@paris.edu>, Corina Grigorescu Monagin <cgmonagin@ucdavis.edu>, David J Wolking <djwolking@ucdavis.edu>, Kidan Araya <karaya@ucdavis.edu>, Marilyn Crane <mcrane@usaid.gov>, "VANDEMAELE, Katelijn A.H." <vandemaelek@who.int>, Amy McMillen <amcmille@umn.edu>, Catherine Machalaba <machalaba@ecohealthalliance.org>
Cc: Susan Scribner <[REDACTED]>, Sambe Duale <[REDACTED], Mark Rasmuson <[REDACTED]>, Katie Taratus <[REDACTED]

At the request of our EPT2 partners from the monthly OHW, P&R, PREDICT call and from the ETD M&E Working Group - we are offering an overview webinar with partners to explain the P4P process, demonstrate the tool, and discuss preliminary results. We will also use this as a chance to discuss a process to incorporate your feedback into the tool and process for future implementation.

For this webinar we will use Join.Me.

**You have been invited to a join.me meeting**

**Join the meeting:** REDACTED

Conference ID:
REDACTED

Thursday, August 10, 2017 11:00 AM
Eastern Time (US & Canada)
In my time zone?

Need to share screen? Download the app

----The DAI email disclaimer can be found at http://www.dai.com/disclaimer.----

# Using JoinMe for Conference Calls

The P&R project uses JoinMe as its online conferencing provider. JoinMe was selected in extensive consultation with DAI's IT department, based on the project's stated need to have a voiceover IP conference software solution. (Other competitors, such as WebEx or GoTo Meeting, were considered but dismissed because of cost. The feature sets are similar.) Unfortuntately, more familiar person-to-person voiceover IP software, such as Skype, is simply too bandwidth-intensive to handle multi-person conference calls, especially internationally.

The guidance below is intended to walk P&R users through joining a call on JoinMe. While the process is relatively simple, there are certainly considerations for how you can use the system to improve your experience as a user. That said, if you are routinely having trouble using the software, on every JoinMe call there is an option to call in to the international 800 numbers. While there are not frequently 800 numbers for the countries where we work – on JoinMe or any other conferencing solution – for important meetings it is preferable to use the telephone to call in, rather than skip the meeting.

If you would like to schedule JoinMe calls in your region, please don't hesitate to ask Kate Zimmerman [redacted] and she will arrange for a seat on the system to schedule these calls. You can also hold immediate conferences as just a registered user on the system, so it can be a valuable tool for conference calls for almost any staff on the project.

## How to Use JoinMe's Conferencing Software

**STEP ONE: Follow the link provided in the invite.**

Invites to JoinMe meetings will be accompanied by both a web address and a 800 numbers for calling in via telephone. If you're using the Internet to connect to the call, follow the link in the invitation.

If you've never used the service before, it may require a short download of the software, much the same way WebEx requires a Citrix download. (And here, you may need to make sure your pop-up blockers are turned off on your web browser.) Once the download completes, the application will launch and take you to your "meeting home" screen.

**STEP TWO: Knock to enter.**

The application will take you to the "meeting home" screen, without full access to the meeting. It will ask you to a.) enter your name, and then b.) knock to "enter" the meeting. Your name will be the name displayed in the list of meeting participants. Knocking sends a note to the meeting organizer to let them know you've joined and accept your request.

Once the organizer accepts your request, you'll have full access to the "meeting home" screen. That will look similar to this:




Unless you are joining midway through a meeting with an active screen sharing feature, you will see a message similar to the above, noting that the presenter has not shared content. *That does not mean the audio portion of the meeting is not underway.* It only means there is no screen sharing feature of the meeting. You'll need to enable audio once you've joined the meeting.

**STEP THREE: Enable your audio, and video if desired.**

On the top bar of the meeting home, there are two choices to the far left – the telephone icon and the video camera icon. The telephone icon manages audio, and the video icon manages video. Since the great majority of our meetings are audio only, we'll start with this option to enable our audio.

If you click on the telephone icon, here's what you'll see:




Let's choose the first option, call via Internet. This allows you to use your office (or home) Internet service provider to connect your audio, an option sometimes referred to as voiceover IP, or VOIP. VOIP is an attractive option for many office staff because you don't incur the long-distance or mobile charges that using a telephone will.

Here are the options that will be presented:




You'll see that the default options presented are the built-in microphone (input) and speakers (output) on the computer. Since most frequently you will be the only person connecting to the conference through that computer, that's the correct input and output for audio. Choose call and it will take you directly to the audio of the conference.

If you wish to connect with video, click on the video camera icon and it will walk you through a similar dialogue with the built-in camera on your computer.

If multiple people are participating using that computer, you'll want to connect an external speaker to the computer that will have its own built-in microphone. (And potentially, use an external conferencing webcam.) You can choose that specific speaker and microphone (or webcam) from the drop down menus provided in these telephone and video camera dialogues.

**STEP FOUR: Participate in the call.**

Once you've joined the meeting and your audio is enabled, you're ready to participate in the call. Feel free to explore the software – along the center of the top bar, it offers a few nice features that improve your participation.




Two useful features: the person with the number underneath indicates how many participants are on the call; clicking on that button will show you the display names of the participants. The chat bubble allows you to chat with the meeting organizer if you have technical difficulties or questions.

Frequently important is the mute feature. Available under the telephone icon by clicking on the dropdown list next to the bell, there will be an option to mute your microphone. Meeting organizers may ask you to do this at the start of the call to limit audio disruption.

Also in order to limit audio disruption, the organizer may mute participants microphones for them. If you've found that this has happened and wish to participate or ask a question, using the chat feature is a great way to present that question to the organizer.

## Contact

If you have any questions, please do not hesitate to reach out to Kate Zimmerman: REDACTED or +1-301-771-7532. She will be happy to answer questions as they arise, or conduct one-on-one trainings by conference call when needed.

Thanks in advance for your participation in team conference calls. It's always a challenge with an international team, but we appreciate your commitment to staying in contact.

**From:** Mario Mondele <mmondele@usaid.gov>
**Sent:** Wed, 2 Aug 2017 13:20:23 +0100
**To:** "William B. Karesh" <karesh@ecohealthalliance.org>
**Cc:** Nadia C Shepherd <ShepherdNC@state.gov>, "GeeEA@state.gov" <GeeEA@state.gov>, Ava Sullivan <sullivan@ecohealthalliance.org>, Amanda Andre <amanda.andre@ecohealthalliance.org>, Andrew Clements <AClements@usaid.gov>, Predict inbox <predict@ucdavis.edu>
**Subject:** [predict] Re: Post - EHA visit to Embassy

It works for now. Will need to confirm on Monday as there will be a US Forest Service workshop in Brazzaville that I will attend.

Mario

Sent from my iPhone

On Aug 2, 2017, at 12:35, William B. Karesh <karesh@ecohealthalliance.org> wrote:

> Thanks Mario,
> Might I suggest Wednesday, 9 August at 15:00 Brazzaville time (10:00 New York time)?

Billy

**William B. Karesh, D.V.M**
*Executive Vice President for Health and Policy*

EcoHealth Alliance
460 West 34th Street - 17th Floor
New York, NY 10001 USA

+1.212.380.4463 (direct)
+1.212.380.4465 (fax)
www.ecohealthalliance.org

President, OIE Working Group on Wildlife

Co-chair, IUCN Species Survival Commission - Wildlife Health Specialist Group

EPT Partners Liaison, USAID Emerging Pandemic Threats - PREDICT-2 Program

***EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that promote conservation and prevent pandemics.***

> On Aug 2, 2017, at 4:29 AM, Mario Mondele <mmondele@usaid.gov> wrote:

Hi Billy and thank you for reaching out.

Next week would be perfect as I will have resumed work as of Monday 7.

Looking forward to hearing from you.

Thanks again,

Mario

Sent from my iPhone

On Aug 1, 2017, at 21:13, William B. Karesh <karesh@ecohealthalliance.org> wrote:

> Hi Mario,
> I hope this finds you well and settled back in Brazzaville.
>
> I'm wondering if you have time for a "de-brief" phone call from our visit in July and I can catch you up on what we are envisioning for the immediate future. It would be great to get your input and advice on our thinking.
>
> This Thursday (3 August) or next week on Wednesday or Thursday would be great if it fits with your schedule.
>
> Look forward to speaking with you,
>
> Billy

**William B. Karesh, D.V.M**
*Executive Vice President for Health and Policy*

EcoHealth Alliance
460 West 34th Street - 17th Floor
New York, NY 10001 USA

+1.212.380.4463 (direct)
+1.212.380.4465 (fax)
www.ecohealthalliance.org

President, OIE Working Group on Wildlife

Co-chair, IUCN Species Survival Commission - Wildlife Health Specialist Group

EPT Partners Liaison, USAID Emerging Pandemic Threats - PREDICT-2 Program

***EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that promote conservation and prevent pandemics.***

> On Jun 22, 2017, at 3:09 PM, Mario Mondele <mmondele@usaid.gov> wrote:
>
> Let's take a raincheck on that!
>
> Mario
>
> Sent from my iPhone

On Jun 22, 2017, at 19:59, William B. Karesh <karesh@ecohealthalliance.org> wrote:

Dear Mario, Beth and Nadia.
We are working on our schedule for July 9th and would like to visit with you at the US Embassy. Is there a time of day that is best for you? 'Id like to arrange meetings with various PREDICT partners in Brazzaville on Monday around a schedule that is best for you at the Embassy.

Joining us will be the four of us from Ecohealth Alliance (named in the visa letter) and Karen Saylors from Metabiota.

Sorry that we will miss you in town Mario.

All the Best,

Billy

**William B. Karesh, D.V.M**
*Executive Vice President for Health and Policy*

EcoHealth Alliance
460 West 34th Street - 17th Floor
New York, NY 10001 USA

+1.212.380.4463 (direct)
+1.212.380.4465 (fax)
www.ecohealthalliance.org

President, OIE Working Group on Wildlife

Co-chair, IUCN Species Survival Commission - Wildlife Health Specialist Group

EPT Partners Liaison, USAID Emerging Pandemic Threats - PREDICT-2 Program

***EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that promote conservation and prevent pandemics.***

On Jun 21, 2017, at 2:02 PM, Shepherd, Nadia C <ShepherdNC@state.gov> wrote:

To Whom It May Concern:

Please find attached a visa support letter for EcoHealth Alliance from the Charge d'Affaires Mary E. Daschbach at the U.S. Embassy in Brazzaville. If you have any questions, please let me know.

Regards,
Nadia

**Nadia C. Shepherd**
Executive Assistant
U.S. Embassy Brazzaville, Republic of Congo
Tel: +242-06-612-2025
Email: shepherdnc@state.gov
Embassy Website | Facebook Page

<[Untitled].pdf>

**Sent:** Mon, 07 Aug 2017 14:41:14 +0000
**Subject:** [Update] EPT2 - GHSA Workplan Coordination Call - DRC
**From:** spaige@usaid.gov
**To:** rechalar@usaid.gov, [redacted] predict@ucdavis.edu, [redacted] janetrix.amuguni@tufts.edu, bhaberer@usaid.gov, dcarroll@usaid.gov, [redacted] apereira@usaid.gov, lparish@usaid.gov, [redacted] [redacted] mcrane@usaid.gov, wanza003@umn.edu, isimmons@usaid.gov, jnumbi@usaid.gov, pelicank@umn.edu, jpettit@usaid.gov, diafuka.saila_ngita@tufts.edu, kvgilardi@ucdavis.edu, [redacted] bende002@umn.edu, lkramer@usaid.gov, sgillette@usaid.gov, [redacted] djwolking@ucdavis.edu, nkabir@usaid.gov, pmbala@metabiota.com, irwego@umn.edu, jkmazet@ucdavis.edu, [redacted] aclements@usaid.gov, saul.tzipori@tufts.edu, okitow@yahoo.fr, alongwagar@usaid.gov, [redacted] akibria@usaid.gov, spaige@usaid.gov, pmulembakani@metabiota.com, prince.kimpanga@unikin.ac.cd

Dear Colleagues,

In place of our regularly scheduled monthly check-in, please note we will be meeting for 2 hours on Thursday in order to discuss workplans for the upcoming year. Lisa Kramer shared the message below.

Dear Colleagues,

It's Workplan season and we appreciate the time that most, if not all, of you are devoting to developing your project's FY18 workplans. In past years, the USAID/ETD team has organized a regional workplan coordination meeting. We were very happy to have many of you join us last year in Kampala for that meeting. These meetings have been an opportunity for us to strengthen collaboration across the EPT2 program and to discuss plans prior to workplan submission. Unfortunately, schedules and timing issues this year have forced us to forego the annual meeting.

In place of the annual regional meeting, USAID is organizing a Special Workplan Edition of our monthly country-level coordination calls. We are scheduling these calls in August so that each project will have time to make adjustments to draft workplans prior to submitting these to your USAID AORs. The USAID AOR has ultimate responsibility for approving workplans. However, the AORs look to USAID regional and bilateral staff to help them ground truth activities, identify alignment with host country priorities, and identify opportunities and challenges from the field perspective. All of us at USAID thank you for taking the time to participate in these country calls.

Attached is an agenda and objectives for the country call. We will have a great deal of ground to cover and limited time. Therefore, we ask each project to prepare as follows:
Ensure that at least one person is on the call for each applicable country with sufficient authority to assign follow-up actions as needed.
Identify one person from your project to be prepared to list project activity highlights, by GHSA Action Package. Please be succinct when presenting. We will not have time for detailed descriptions. Activities that require additional discussion will be noted for follow-up discussion/action.
If/when a country-level draft workplan is available, sending it to the USAID country team for comment can save time in the long-run. Please remove proprietary and/or budget information prior to sending a draft workplan.

**EPT2 - GHSA Workplan Coordination Call - DRC**
ALL AFRICA-BASED PARTICIPANTS, Please phone into the call a few minutes early to ensure that you are able to connect. If you are unable to connect, please contact Sarah or Lisa. Lisa will initiate the call and we plan to start the meeting promptly at 15:00 EAT. Thank you.

Toll-free dial-in number (US and Canada): (888) 330-1716
International: +1 (713) 353-7024
Participant Code: 9903206

When Thu Aug 10, 2017 8am – 10am Eastern Time

Who
- lkramer@usaid.gov - organizer
- dcarroll@usaid.gov
- sgillette@usaid.gov
- nkabir@usaid.gov

- William Bazeyo
- apereira@usaid.gov
- bhaberer@usaid.gov
- jpettit@usaid.gov
- saul.tzipori@tufts.edu
- REDACTED
- spaige@usaid.gov
- jnumbi@usaid.gov
- pmulembakani@metabiota.com
- janetrix.amuguni@tufts.edu
- Innocent Rwego
- REDACTED
- REDACTED
- Prince Kimpanga
- pmbala@metabiota.com
- Katey Pelican
- alongwagar@usaid.gov
- REDACTED
- aclements@usaid.gov
- predict@ucdavis.edu
- REDACTED
- akibria@usaid.gov
- Jeff Bender
- rechalar@usaid.gov
- kvgilardi@ucdavis.edu
- REDACTED
- lparish@usaid.gov
- mcrane@usaid.gov
- diafuka.saila_ngita@tufts.edu
- REDACTED
- jkmazet@ucdavis.edu
- Sylvia Wanzala
- isimmons@usaid.gov
- REDACTED
- REDACTED
- djwolking@ucdavis.edu

- Irene Naigaga

**From:** Andrew Clements <aclements@usaid.gov>
**Sent:** Wed, 23 Aug 2017 11:33:17 -0400
**To:** predict@ucdavis.edu
**Cc:** Alisa Pereira <apereira@usaid.gov>, Shana Gillette <sgillette@usaid.gov>, Amalhin Shek <ashek@usaid.gov>, Cara Chrisman <cchrisman@usaid.gov>
**Subject:** [predict] ACTION: Separate Congressional INFORMATION REQUEST on ROC

See request below on ROC with a deadline of today. Sorry about the short turn-around.

*Andrew P. Clements, Ph.D.*
*Senior Scientific Advisor*
*Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health*
*U.S. Agency for International Development*
*Mobile phone: 1-571-345-4253*
*Email: aclements@usaid.gov*

Begin forwarded message:

**From:** Andrea Long-Wagar <alongwagar@usaid.gov>
**Date:** August 23, 2017 at 9:57:21 AM EDT
**To:** PREDICTMGT <predictmgt@usaid.gov>
**Subject: Fwd: ACTION: Separate Congressional INFORMATION REQUEST on ROC**

Hello Andrew and Predict Management team,
The ROC Desk officer is fielding questions from a congressional appropriator via LPA on USAID funded projects in ROC.

Can you help me answer these 2 questions:
1) Does Predict have any permanent staff in country? Do they fund a local ROC organization?
2) Do any funds go to the ROC government or a local ROC organization?

Thank you
Andrea

**Andrea Long-Wagar, ScM, MPH, CPH**
**Senior Infectious Disease Advisor**
**USAID Africa Bureau**
**Phone: 202-712-4514**
**Cell Phone:** REDACTED
**E-mail: alongwagar@usaid.gov**

---------- Forwarded message ----------
From: **Samantha Schasberger** <sschasberger@usaid.gov>
Date: Wed, Aug 23, 2017 at 9:50 AM
Subject: Re: ACTION: Separate Congressional INFORMATION REQUEST on ROC
To: Andrea Long-Wagar <alongwagar@usaid.gov>

Dear Andrea,
Per our discussion, there has been a follow-up to the Congressional inquiry. They would like to know what organizations are serving as our implementing partners in ROC and do they have permanent staff there. I discussed with LPA and it is okay if we identify the Prime. It would also be good to confirm that the Prime is receiving all the funding for this award.

If possible could you respond to me today on this? (If not by noon tomorrow would be okay)
thanks,
Samantha

On Wed, Aug 16, 2017 at 4:13 PM, Samantha Schasberger <sschasberger@usaid.gov> wrote:

> Andrew,
> We've received a Congressional request on what USAID is doing in ROC. Would you be comfortable with us pulling the language from the first paragraph from the cleared fact-sheet as part of our Congressional response?--I've inserted ROC in first sentence below. (NB: The response will all be going through LPA.) -- Good to also know if you would be comfortable with that factsheet being shared with Congressional staff?

> PREDICT 2 works in 33 countries, including the Republic of Congo, to strengthen global capacity for detection and discovery of zoonotic viruses with epidemic and pandemic potential, including the Ebola, influenza, and Zika viruses that have caused devastating disease and required dramatic and resource-intensive responses. Project activities aim to develop and operationalize strategies to improve disease detection and reduce zoonotic pathogen spillover, amplification, and spread using standardized methods for training, surveillance, lab testing, and
> analysis. The combined activities in all countries will greatly enhance knowledge about local and global public health risk associated with animal diseases in order to reduce risk.

> thanks,
> Samantha

**From:** "William B. Karesh" <karesh@ecohealthalliance.org>
**To:** David Wolking <djwolking@ucdavis.edu>, Elizabeth Leasure <ealeasure@ucdavis.edu>, Karen Saylors <ksaylors@metabiota.com>
**Cc:** Alice Latinne <latinne@ecohealthalliance.org>, Amanda Andre <amanda.andre@ecohealthalliance.org>, Jonna Mazet <jkmazet@ucdavis.edu>, "predict@ucdavis.edu" <predict@ucdavis.edu>, Eddy Rubin <erubin@metabiota.com>, Ava Sullivan <sullivan@ecohealthalliance.org>, "Evelyn Luciano" <luciano@ecohealthalliance.org>, Molly Turner <turner@ecohealthalliance.org>
**Subject:** Re: [predict] ACTION: Separate Congressional INFORMATION REQUEST on ROC
**Sent:** Wed, 23 Aug 2017 16:07:27 +0000

David, see below. Karen and Liz, please make changes if Mb is still funding people or organzations. Liz, not sure how you want to handle transfer of contracts from Mb to UCDavis in the interim.
BK

On Aug 23, 2017, at 5:44 PM, David J Wolking <djwolking@ucdavis.edu> wrote:

Hey Billy,
We have one of our favorite last minute requests for information from USAID, this time on ROC and of course with a same day deadline. I'm not sure where things are operationally with the transition so think you and Karen and best poised to address these 2 (really 3) questions (my notes in blue scraped from Y4 workplan and budget content):

**1) Does Predict have any permanent staff in country?** Y4 budget = 8 total (LNSP = 3; LDVB = 3; Health centre = 2)

Currently, EHA has none. We are planning to establish contracts with possibly 3 private individuals (two behavioral studies personnel and one finance/admin coordinator) previously working for Metabiota

**Do they fund a local ROC organization?** LNSP and LDVB? Meyangui Health Centre?

Currently, EHA has none. We are hoping to establish sub awards with LNSP and possibly VDVB.

**2) Do any funds go to the ROC government or a local ROC organization?** Again, LNSP and LDVB?

Currently, EHA has no agreements in place. We are hoping to establish sub awards with LNSP and possibly VDVB.

BK

---------- Forwarded message ----------
From: **Andrew Clements** <aclements@usaid.gov>
Date: Wed, Aug 23, 2017 at 8:33 AM
Subject: [predict] ACTION: Separate Congressional INFORMATION REQUEST on ROC
To: predict@ucdavis.edu
Cc: Alisa Pereira <apereira@usaid.gov>, Shana Gillette <sgillette@usaid.gov>, Amalhin Shek <ashek@usaid.gov>, Cara Chrisman <cchrisman@usaid.gov>

See request below on ROC with a deadline of today. Sorry about the short turn-around.

*Andrew P. Clements, Ph.D.*
*Senior Scientific Advisor*
*Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health*

*U.S. Agency for International Development*
*Mobile phone: 1-571-345-4253*
*Email: aclements@usaid.gov*

Begin forwarded message:

**From:** Andrea Long-Wagar <alongwagar@usaid.gov>
**Date:** August 23, 2017 at 9:57:21 AM EDT
**To:** PREDICTMGT <predictmgt@usaid.gov>
**Subject: Fwd: ACTION: Separate Congressional INFORMATION REQUEST on ROC**

Hello Andrew and Predict Management team,
The ROC Desk officer is fielding questions from a congressional appropriator via LPA on USAID funded projects in ROC.

Can you help me answer these 2 questions:
1) Does Predict have any permanent staff in country? Do they fund a local ROC organization?
2) Do any funds go to the ROC government or a local ROC organization?

Thank you
Andrea

**Andrea Long-Wagar, ScM, MPH, CPH**
**Senior Infectious Disease Advisor**
**USAID Africa Bureau**
REDACTED
**E-mail: alongwagar@usaid.gov**

---------- Forwarded message ----------
From: **Samantha Schasberger** <sschasberger@usaid.gov>
Date: Wed, Aug 23, 2017 at 9:50 AM
Subject: Re: ACTION: Separate Congressional INFORMATION REQUEST on ROC
To: Andrea Long-Wagar <alongwagar@usaid.gov>

Dear Andrea,
Per our discussion, there has been a follow-up to the Congressional inquiry. They would like to know what organizations are serving as our implementing partners in ROC and do they have permanent staff there. I discussed with LPA and it is okay if we identify the Prime. It would also be good to confirm that the Prime is receiving all the funding for this award.

If possible could you respond to me today on this? (If not by noon tomorrow would be okay)
thanks,
Samantha

On Wed, Aug 16, 2017 at 4:13 PM, Samantha Schasberger <sschasberger@usaid.gov> wrote:

Andrew,
We've received a Congressional request on what USAID is doing in ROC. Would you be comfortable with us pulling the language from the first paragraph from the cleared fact-sheet as part of our Congressional response?--I've inserted ROC in first sentence below. (NB: The

response will all be going through LPA.) --Good to also know if you would be comfortable with that factsheet being shared with Congressional staff?

PREDICT 2 works in 33 countries, including the Republic of Congo, to strengthen global capacity for detection and discovery of zoonotic viruses with epidemic and pandemic potential, including the Ebola, influenza, and Zika viruses that have caused devastating disease and required dramatic and resource-intensive responses. Project activities aim to develop and operationalize strategies to improve disease detection and reduce zoonotic pathogen spillover, amplification, and spread using standardized methods for training, surveillance, lab testing, and analysis. The combined activities in all countries will greatly enhance knowledge about local and global public health risk associated with animal diseases in order to reduce risk.

thanks,
Samantha

**From:** "William B. Karesh" <karesh@ecohealthalliance.org>
**To:** Jonna Mazet <jkmazet@ucdavis.edu>
**Subject:** Saskatoon
**Sent:** Wed, 23 Aug 2017 17:51:26 +0000

One suggestion is Prof. Ehab Abu-Basha, ished a P-2 Country Coordinator, Jordan. Professor, Jordan University of Science and Technology abubasha@just.edu.jo
Good speaker and he has been doing the camel work for FAO and our bat and human surveillance, published the MERS-CoV findings in Camels in Jordan. He established a one health working group based on PREDICT work with Min of Health, Min of Ag, and Min. of Env. taking turns hosting the bimonthly meetings.

BK

**William B. Karesh, D.V.M**
*Executive Vice President for Health and Policy*

EcoHealth Alliance
460 West 34th Street - 17th Floor
New York, NY 10001 USA

+1.212.380.4463 (direct)
+1.212.380.4465 (fax)
www.ecohealthalliance.org

President, OIE Working Group on Wildlife

Co-chair, IUCN Species Survival Commission - Wildlife Health Specialist Group

EPT Partners Liaison, USAID Emerging Pandemic Threats - PREDICT-2 Program

***EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that promote conservation and prevent pandemics.***

**From:** David J Wolking <djwolking@ucdavis.edu>
**Sent:** Wed, 23 Aug 2017 12:24:53 -0700
**Subject:** Re: [predict] ACTION: Separate Congressional INFORMATION REQUEST on ROC
**To:** Karen Saylors <ksaylors@metabiota.com>
**Cc:** "William B. Karesh" <karesh@ecohealthalliance.org>, David John Wolking <djwolking@ucdavis.edu>, Elizabeth Leasure <ealeasure@ucdavis.edu>, Alice Latinne <latinne@ecohealthalliance.org>, Amanda Andre <amanda.andre@ecohealthalliance.org>, Jonna Mazet <jkmazet@ucdavis.edu>, "predict@ucdavis.edu" <predict@ucdavis.edu>, Eddy Rubin <erubin@metabiota.com>, Ava Sullivan <sullivan@ecohealthalliance.org>, Evelyn Luciano <luciano@ecohealthalliance.org>, Molly Turner <turner@ecohealthalliance.org>

Thanks everyone! I'll consult with Liz and turn this around to USAID.
David

On Wed, Aug 23, 2017 at 11:31 AM, Karen Saylors <ksaylors@metabiota.com> wrote:

Hi David.
My comments in red, below.
Thanks,
Karen

---

**From:** "William B. Karesh" <karesh@ecohealthalliance.org>
**Date:** Wednesday, August 23, 2017 at 9:07 AM
**To:** David John Wolking <djwolking@ucdavis.edu>, Elizabeth Leasure <ealeasure@ucdavis.edu>, Karen Saylors <ksaylors@metabiota.com>
**Cc:** Alice Latinne <latinne@ecohealthalliance.org>, Amanda Andre <amanda.andre@ecohealthalliance.org>, Jonna Mazet <jkmazet@ucdavis.edu>, "predict@ucdavis.edu" <predict@ucdavis.edu>, Eddy Rubin <erubin@metabiota.com>, Ava Sullivan <sullivan@ecohealthalliance.org>, Evelyn Luciano <luciano@ecohealthalliance.org>, Molly Turner <turner@ecohealthalliance.org>
**Subject:** Re: [predict] ACTION: Separate Congressional INFORMATION REQUEST on ROC

David, see below. Karen and Liz, please make changes if Mb is still funding people or organzations. Liz, not sure how you want to handle transfer of contracts from Mb to UCDavis in the interim.
BK

On Aug 23, 2017, at 5:44 PM, David J Wolking <djwolking@ucdavis.edu> wrote:

Hey Billy,
We have one of our favorite last minute requests for information from USAID, this time on ROC and of course with a same day deadline. I'm not sure where things are operationally with the transition so think you and Karen and best poised to address these 2 (really 3) questions (my notes in blue scraped from Y4 workplan and budget content):

1) **Does Predict have any permanent staff in country?** Y4 budget = 8 total (LNSP = 3; LDVB = 3; Health centre = 2)

Currently, EHA has none. We are planning to establish contracts with possibly 3 private individuals (two behavioral studies personnel and one finance/admin coordinator) previously working for Metabiota.
For the conclusion of Year 3, Metabiota has 3 consultant staff (two behavioral studies personnel and one finance/admin coordinator).

**Do they fund a local ROC organization?** LNSP and LDVB? Meyangui Health Centre?

Currently, EHA has none. We are hoping to establish sub awards with LNSP and possibly VDVB. For the remainder of Yr3, no, Metabiota does not fund a local ROC organization.

2) **Do any funds go to the ROC government or a local ROC organization?** Again, LNSP and LDVB?

Currently, EHA has no agreements in place. We are hoping to establish sub awards with LNSP and possibly VDVB. For Metabiota, no funds go to the ROC government or to a local ROC organization.

BK

---------- Forwarded message ----------
From: **Andrew Clements** <aclements@usaid.gov>
Date: Wed, Aug 23, 2017 at 8:33 AM
Subject: [predict] ACTION: Separate Congressional INFORMATION REQUEST on ROC
To: predict@ucdavis.edu
Cc: Alisa Pereira <apereira@usaid.gov>, Shana Gillette <sgillette@usaid.gov>, Amalhin Shek <ashek@usaid.gov>, Cara Chrisman <cchrisman@usaid.gov>

See request below on ROC with a deadline of today. Sorry about the short turn-around.

*Andrew P. Clements, Ph.D.*
*Senior Scientific Advisor*
*Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health*
*U.S. Agency for International Development*
*Mobile phone: 1-571-345-4253*
*Email: aclements@usaid.gov*

Begin forwarded message:

**From:** Andrea Long-Wagar <alongwagar@usaid.gov>
**Date:** August 23, 2017 at 9:57:21 AM EDT
**To:** PREDICTMGT <predictmgt@usaid.gov>
**Subject: Fwd: ACTION: Separate Congressional INFORMATION REQUEST on ROC**

Hello Andrew and Predict Management team,
The ROC Desk officer is fielding questions from a congressional appropriator via LPA on USAID funded projects in ROC.

Can you help me answer these 2 questions:
1) Does Predict have any permanent staff in country? Do they fund a local ROC organization?
2) Do any funds go to the ROC government or a local ROC organization?

Thank you
Andrea

**Andrea Long-Wagar, ScM, MPH, CPH**
**Senior Infectious Disease Advisor**
**USAID Africa Bureau**
**Phone: 202-712-4514**
**Cell Phone:** REDACTED
**E-mail: alongwagar@usaid.gov**

---------- Forwarded message ----------
From: **Samantha Schasberger** <sschasberger@usaid.gov>
Date: Wed, Aug 23, 2017 at 9:50 AM
Subject: Re: ACTION: Separate Congressional INFORMATION REQUEST on ROC
To: Andrea Long-Wagar <alongwagar@usaid.gov>

Dear Andrea,
Per our discussion, there has been a follow-up to the Congressional inquiry. They would like to know what organizations are serving as our implementing partners in ROC and do they have permanent staff there. I discussed with LPA and it is okay if we identify the Prime. It would also be good to confirm that the Prime is receiving all the funding for this award.

If possible could you respond to me today on this? (If not by noon tomorrow would be okay)
thanks,
Samantha

On Wed, Aug 16, 2017 at 4:13 PM, Samantha Schasberger <sschasberger@usaid.gov> wrote:

> Andrew,
> We've received a Congressional request on what USAID is doing in ROC. Would you be comfortable with us pulling the language from the first paragraph from the cleared fact-sheet as part of our Congressional response?--I've inserted ROC in first sentence below. (NB: The response will all be going through LPA.) -- Good to also know if you would be comfortable with that factsheet being shared with Congressional staff?

PREDICT 2 works in 33 countries, including the Republic of Congo, to strengthen global capacity for detection and discovery of zoonotic viruses with epidemic and pandemic potential, including the Ebola, influenza, and Zika viruses that have caused devastating disease and required dramatic and resource-intensive responses. Project activities aim to develop and operationalize strategies to improve disease detection and reduce zoonotic pathogen spillover, amplification, and spread using standardized methods for training, surveillance, lab testing, and
analysis. The combined activities in all countries will greatly enhance knowledge about local and global public health risk associated with animal diseases in order to reduce risk.

thanks,
Samantha

**From:** Monica Dea <mdea@usaid.gov>
**Sent:** Tue, 29 Aug 2017 11:45:40 +0000
**To:** James Desmond <REDACTED>
**Cc:** Tara Milani <tmilani@usaid.gov>, Mildred Howard <mphoward@usaid.gov>, Jon Epstein <epstein@ecohealthalliance.org>, "predict@ucdavis.edu" <predict@ucdavis.edu>, Andrew Clements <aclements@usaid.gov>, "Alisa (GH/HIDN) Pereira" <apereira@usaid.gov>, Evelyn Luciano <luciano@ecohealthalliance.org>, Emma Lane <lane@ecohealthalliance.org>
**Subject:** [predict] Re: PREDICT Liberia Workplan
PARTNER NAME FY18 GHSA Workplan (1).xlsx
FY18 GHSA Workplan Guidance (2).docx
Y4 WP Country Brief Liberia Draft MD August 2017.docx

Hi Jim,
Thank you again for submitting the draft workplan for review. I am not sure if you or EchoHealth Alliance is submitting a workplan based on the guidance and the template received from HQ? I am re-sending the guidance and the template, as the guidance is clear. Please let me know if you have the JEE scores, as you need to list the JEE and the GHSA Action Packages that your project will focus on increasing the score/capacities (surveillance, laboratory, biosafety/biosecurity, etc).
Also it is not clear if your focus in YR04 will be to test only wildlife?
Please let me know if you need additional help. Thank you, Monica

On Tue, Aug 8, 2017 at 1:43 PM, James Desmond <REDACTED> wrote:

> Hi Monica,
> Please find a draft of the PREDICT Liberia workplan attached. We have submitted this to UC Davis as a component of the overall PREDICT workplan. Please review and get back to me with any concerns or critical changes as it relates to Liberia. I need to get back to the NY office with any comments or changes no later than August 14th.

Perhaps we could discuss this tomorrow at the One Health meeting or later this week at the lab meeting. Let me know what works best for you.

Regards,

Jim

**James S. Desmond, DVM, MS**
**Email:** REDACTED
**Phone:** REDACTED **(Kenya)**
**Phone:** **(Liberia)**
**Phone:** **USA)**
**Skype: jim.desmond**

--
Monica N. Dea
Sr. Public Health Advisor
Health Team
USAID Liberia
502 Benson Street, Monrovia

Tel (Reception): +(231) 77 677 7000
Tel (Direct): +(231) 77 677 7226
Mobile: + REDACTED

Produced in Native Format

**Liberia**
**Year 4 (October 2017-September 2018)**

**Implementing Partners:** EcoHealth Alliance (EHA), The Society for Conservation of Nature of Liberia (SCNL)
**Global Point of Contact:** Dr. Jon Epstein, EcoHealth Alliance
**Country Coordinator**: Dr. Jim Desmond

**Existing and Prospective Partners**

- Ministry of Agriculture (MoA), Monrovia, Liberia*
- Ministry of Health (MoH), Monrovia, Liberia*
- Forestry Development Authority (FDA), Monrovia, Liberia
- National Public Health Institute of Liberia (NPHIL), Monrovia, Liberia*
- Liberian Institute for Biomedical Research (LIBR), Charlesville, Liberia*
- National Reference Laboratory (NRL), Charlesville, Liberia*
- Food and Agriculture Organization (FAO) Liberia, Monrovia, Liberia*
- Preparedness & Response (P&R), Monrovia, Liberia*
- USAID Mission Liberia, Monrovia, Liberia

*Partnership in development

**Liberia is an Ebola Host Project country.**

Liberia is an Ebola Host Project country and activities will deviate accordingly from the all-country workplan. Activities in Liberia will be focused on identifying wildlife species that may act as reservoirs for Ebola virus and related filoviruses.

Wildlife samples may also be screened for the remaining four priority viral families (coronavirus, paramyxovirus, flavivirus, and influenza virus) if resources are available.

**Surveillance Plans**

PREDICT-2 Liberia plans to build partnerships and initiate biological and behavioral surveillance activities targeting animals and humans at key interfaces for disease emergence, amplification, and spread, and evaluate opportunities for expansion of activities for in-depth targeted and longitudinal surveillance in 2017-2018.

**Where we work**

**Lofa County** – Foya and Zorzor Districts. Both Foya and Zorzor districts are mixed habitats of natural forest surrounded by 'slash and burn' agricultural areas. Foya District was an area with a high incidence of human Ebola cases.

**Montserrado County** - Montserrado Country houses Monrovia, Liberia's capital. There are several large, seasonal, urban bat colonies where people are highly

exposed to excreta. Montserrado also contains areas subjected to recent deforestation near human dwellings and agricultural sites, and active bushmeat hunting which creates additional high risk interfaces.

**Nimba County** – Nimba country houses Yekepa on the Guinea border within the Arcelor Mittal mining concession. Some sampling takes place in and around adits, forested areas in old exploratory mine shafts, targeting extractive industry interfaces.

**Grand Cape Mount** –Grand Cape Mount has several areas with pristine forest in the Gola National Forest and other areas with mixed forest/agricultural landscapes. We have identified many sampling sites within this county that are expected to have high wildlife biodiversity and human-wildlife interfaces at agricultural and peridomestic sites.

**Bong County** – if resources allow. Bong Country houses Suakoko, Panta and Kpai Districts and provides the opportunity to target areas with increasing land use change and to target the market and value chain within the area.

**Surveillance Sites**

- Lofa County (Foya & Voinjama districts; Wenegizi Forest): Land use change, market and value chain
  - Sampling targets at location:
    - Wildlife (primates, bats, rodents) in areas with recent deforestation near human dwellings and agricultural sites. Targeting bush meat value chain from hunting to trade to consumption as a potential hosts for Ebola.
    - Human populations with frequent exposure to wildlife and patients presenting in health clinics (quantitative surveys only, contingent upon IRB approval)

- Montserrado County (Central Monrovia & St. Paul's River Districts): Land use change, market and value chain
  - Sampling targets at location
    - Wildlife (primates, bats, rodents) in areas with recent deforestation near human dwellings and agricultural sites. Targeting bush meat value chain from hunting to trade to consumption as potential hosts for Ebola.
    - Human populations with frequent exposure to wildlife and patients presenting in health clinics (quantitative surveys only, contingent upon IRB approval)

- Nimba County (Yekepa in Yarmein District): Extractive industry, land use change, market and value chain
  - Sampling targets at location
    - Wildlife (primates, bats, rodents) in areas with recent deforestation near human dwellings and agricultural sites. Targeting bush meat value chain from hunting to trade to consumption as potential hosts for Ebola.
    - Large iron ore mining concession operated by Arcelor Mittal provides the opportunity to target extractive industry. Bat colonies present in closed

adits which may reopen presenting the possibility of bat dispersal and increased risk of human contact.
        - Human populations with frequent exposure to wildlife and patients presenting in health clinics (quantitative surveys only, contingent upon IRB approval)

- Bong (Suakoko, Panta & Kpai Districts): Land use change, market and value chain
    - Sampling targets at location
        - Wildlife (primates, bats, rodents) in areas with recent deforestation near human dwellings and agricultural sites. Targeting bush meat value chain from hunting to trade to consumption as potential hosts for Ebola.
        - Human populations with frequent exposure to wildlife and patients presenting in health clinics (quantitative surveys only, contingent upon IRB approval)

- Grand Cape Mount (Tewor, Gola Konneh & Gowular Districts): Land use change, market and value chain
    - Sampling targets at location
        - Wildlife (primates, bats, rodents) in areas with recent deforestation near human dwellings and agricultural sites. Targeting bush meat value chain from hunting to trade to consumption as potential hosts for Ebola.
        - Human populations with frequent exposure to wildlife and patients presenting in health clinics (quantitative surveys only, contingent upon IRB approval)

*Also planned if resources allow:*

- Grand Bassa County (Buchanan District): Land use change, market and value chain
    - Sampling targets at location
        - Wildlife (primates, bats, rodents) in areas with recent deforestation near human dwellings and agricultural sites. Targeting bush meat value chain from hunting to trade to consumption as potential hosts for Ebola.
        - Human populations with frequent exposure to wildlife and patients presenting in health clinics (quantitative surveys only, contingent upon IRB approval)

**Laboratory Systems Plans**

This year, PREDICT will engage the National Public Health Institute of Liberia (NPHIL), for wildlife testing with ongoing outreach to the Central Veterinary Diagnostic Laboratory and incorporation of Ministry of Agriculture staff for biosafety, biosecurity, and training of PREDICT assays.

Specific plans for engaging with NPHIL include building capacity by identifying equipment needs and assisting with necessary procurement; continuing training for identified staff with experience from the Ebola outbreak, specifically on PREDICT laboratory protocols and assays

The final laboratory development stage will be limited testing of wildlife samples in-country, planned for Y4.

**Animal lab:** National Public Health Institute, Liberia (NPHIL)
Viral families planned for testing: corona, filo, influenza, paramyxo, and flaviviruses

**Operationalizing One Health and Capacity Strengthening Plans**
Communication processes have been initiated with Ministry of Agriculture (MoA), Ministry of Health (MoH), Forestry Development Authority (FDA), the National Public Health Institute of Liberia (NHPIL), the Liberian Institute for Biomedical Research (LIBR), National Reference Laboratory (NRL), and our EPT-2 partners FAO and P&R. PREDICT will work to solidify collaborations, develop plans for project implementation, and expand communications to other stakeholders, as appropriate, to strengthen One Health platforms and improve the ease of dissemination of relevant animal, human, epidemiological, and ecological data. Scoping visits and ongoing discussions will continue to solidify relationships with partners for the implementation of animal and human surveillance activities.

## Overall Workplan Guidance

See below for overall guidance on the FY18 GHSA work-planning process. Before beginning to fill in activities in the excel template, be sure to read the instructions tab thoroughly.

- Provide a narrative to further contextualize the excel template. The format will be agreed upon between partner and AOR.
- Partners should provide a matrix of all countries with FY18 workplan budget figures (see tab- Overview Budget)
- As required, resources may be used for outbreak response as appropriate, in conjunction and with approval by AORs.
- The bulk of activities supported with GHSA funds should fall on the critical path to achieving higher Action Package (AP) capacity levels. For example, for laboratory support (the National Laboratory System Action Package) GHSA is mostly interested in establishing national laboratory systems for the ten priority lab tests outlined in the JEE tool (6 standard and 4 country specific), as well as lab detection for the priority zoonotic diseases under the Zoonotic Action Package. Please remember that a lab system involves more than one lab and builds toward national coverage so that labs at the district level are also strengthened.
- As mentioned, the focus of the GHSA work-plans is to make progress on the AP capacity levels. Other activities supported by partners should be included in the 'Other' category of the template (see instructions tab).
- USAID partners only address selected Action Package technical areas and are not expected to include activities for the areas beyond each partner's scope.
- Attached are the topline definitions or additional information that many partners assisted in developing for selected GHSA technical areas. However some partners support activities beyond these seven technical areas. Definitions for the remainder of the GHSA AP areas will be developed in the coming year.
- The workplan is auto-populated for column A for the Action Packages that align best with USAID's objective.
- Baseline scores (via the JEE or GHSA self-assessment) will be provided by USAID (see attached).

**From:** Andrew Clements <aclements@usaid.gov>
**To:** Katherine Leasure <kaleasure@ucdavis.edu>
**CC:** PREDICTMGT <predictmgt@usaid.gov>;Predict inbox <predict@ucdavis.edu>;Jonna Mazet <jkmazet@ucdavis.edu>
**Sent:** 9/1/2017 6:41:50 PM
**Subject:** Re: PREDICT International Travel Requests

Thanks!

Both Karesh trips approved.

*Andrew P. Clements, Ph.D.*
*Senior Scientific Advisor*
*Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health*
*U.S. Agency for International Development*
*Mobile phone: 1-571-345-4253*
*Email: aclements@usaid.gov*

On Sep 2, 2017, at 6:58 AM, Katherine Leasure <kaleasure@ucdavis.edu> wrote:

Hi Andrew. Response from EHA regarding airfare for Billy's trips:

*The most economical flight identified for Germany travel is priced at $6,900, based on other commitments restricting travel days as well as the start date and time of the meeting. The most economical flight identified for Switzerland travel is priced at $6,400, taking into account similar factors.*

**From:** Andrew Clements [mailto:aclements@usaid.gov]
**Sent:** Friday, August 18, 2017 3:25 PM
**To:** Katherine Leasure
**Cc:** PREDICTMGT; Predict inbox; Jonna Mazet
**Subject:** Re: PREDICT International Travel Requests

Goldstein approved. Lucas approved subject to mission concurrence.

Any chance of finding a lower fare for both of Billy's trips?

*Andrew P. Clements, Ph.D.*
*Senior Scientific Advisor*
*Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health*
*U.S. Agency for International Development*
*Mobile phone: 1-571-345-4253*
*Email: aclements@usaid.gov*

On Aug 18, 2017, at 6:14 PM, Katherine Leasure <kaleasure@ucdavis.edu> wrote:

*Please find below international travel requests for your review and approval. Please let me know if you have any questions. Thanks!!*

1. Lucas (Cameroon): $1,628 airfare/$246 (Yaounde) max daily per diem
2. Karesh (Germany): $8,000 airfare *[redacted]/$287 (Other) max daily per diem
3. Karesh (Switzerland): $9,000 airfare **business class required due to medical need*/$478 (Geneva) max daily per diem
4. Goldstein (Switzerland): $3,300 airfare/$478 (Geneva) max daily per diem

Travel Requests –

1. Metabiota would like to request travel approval for Ashley Lucas, Clinical Specialist to travel from

San Francisco, CA, USA to Yaoundé, Cameroon from September 10-23, 2017 to conduct hospital surveillance training and launch human surveillance activities in two sites, Sangmelima and Myomessala.

**Trip purpose:** Ashley Lucas will travel to Cameroon to conduct hospital surveillance training and launch human surveillance activities in two sites, Sangmelima and Myomessala. She will spend one week at each site, first conducting the training with hospital staff for the human syndromic surveillance for 2-3 days, then spending time with the staff in hospital launching the implementation phase of the syndromic surveillance for another 2-3 days. Ashley will work with the behavioral team on year 3 implementation activities, finalizing the behavioral implementation plan for year 4, and discuss the plan for community biologic surveillance. She will also assist in training a new interim Human Surveillance Coordinator during the maternity leave of the full-time Human Surveillance Coordinator.

2. EcoHealth Alliance would like to request travel approval for Dr. William Karesh to travel from New York City, NY, USA to Greifswald, Germany from September 17-22, 2017 to participate in the annual meeting of the German Society of Mammalogy.

**Trip purpose:** Dr. Karesh has been invited to meet with the Directors of the Friedrich-Loeffler Institute, site of the German governments BSL 3 and 4 labs, to discuss engagement with the Global Virome Project. He will also attend the annual meeting of the German Society of Mammalogy to present on PREDICT and GVP activities.

3. EcoHealth Alliance would like to request travel approval for Dr. William Karesh to travel from New York City, NY, USA to Geneva, Switzerland from September 25-28, 2017 to participate in the MERS-CoV Technical meeting.

**Trip purpose:** Dr. Karesh will participate in the MERS-CoV Technical meeting with representatives from WHO, FAO and OIE to discuss ongoing research and potential intervention strategies. The meeting will bring together public health and academic professionals from affected and at risk countries and subject matter experts. The objectives of the meeting are to summarize and communicate research progress made, with a focus on new research and knowledge gained; improve coordination and communication between animal health and public health sectors; and review and update previous recommendations based on latest scientific evidence.

4. UC Davis would like to request travel approval for Dr. Tracey Goldstein to travel from Sacramento, CA, USA to Geneva, Switzerland from September 24-27, 2017 to participate in the MERS-CoV Technical Meeting.

**Trip purpose:** Dr. Goldstein will participate in the MERS-CoV Technical meeting with representatives from WHO, FAO and OIE to discuss ongoing research and potential intervention strategies. The meeting will bring together public health and academic professionals from affected and at risk countries and subject matter experts. The objectives of the meeting are to summarize and communicate research progress made, with a focus on new research and knowledge gained; improve coordination and communication between animal health and public health sectors; and review and update previous recommendations based on latest scientific evidence.

**Katherine Leasure**
HR/Payroll/Financial Assistant
One Health Institute
University of California, Davis
530-752-7526
530-752-3318 FAX
kaleasure@ucdavis.edu

--

You received this message because you are subscribed to the Google Groups "PREDICTMGT" group.
To unsubscribe from this group and stop receiving emails from it, send an email to predictmgt+unsubscribe@usaid.gov.
To post to this group, send email to predictmgt@usaid.gov.
To view this discussion on the web visit https://groups.google.com/a/usaid.gov/d/msgid/predictmgt/028901d3186f%242ec4eb10%248c4ec130%24%40ucdavis.edu.

**From:** Kirsten Gilardi <kvgilardi@ucdavis.edu>
**To:** Andrew Clements <aclements@usaid.gov>
**Cc:** David John Wolking <djwolking@ucdavis.edu>, Jonna Mazet <jkmazet@ucdavis.edu>, "predictmgt@usaid.gov" <predictmgt@usaid.gov>
**Subject:** Re: Invitation - Save the Dates - Monthly USAID Uganda Chief of Party/Head of Office and EPT-2 Implementing Partners' Meetings
**Sent:** Wed, 13 Sep 2017 11:58:24 +0000

Thank you Andrew. I'll confirm with Benard Ssebide that he plans to attend these meetings — they are scheduled during the weeks he is usually in Kampala, so should work well. -Kirsten

On Sep 13, 2017, at 4:51 AM, Andrew Clements <aclements@usaid.gov> wrote:

FYI

*Andrew P. Clements, Ph.D.*
*Senior Scientific Advisor*
*Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health*
*U.S. Agency for International Development*
*Mobile phone: 1-571-345-4253*
*Email: aclements@usaid.gov*

Begin forwarded message:

**From:** Gregory Adams <gadams@usaid.gov>
**Date:** September 13, 2017 at 4:49:24 AM EDT
**To:** Andrew Kitua <[redacted]>, Esther Buregyeya <eburegyeya@musph.ac.ug>, "Fredrick Kivaria (FAOUG)" <[redacted]>, Innocent Rwego <irwego@umn.edu>, Peninah Nsamba <[redacted]>, Sambe Duale <[redacted]>, "Susan Ndyanabo (FAOUG)" [redacted], Susan Scribner <[redacted], Winyi Kaboyo <[redacted], "Yilma Makonnen (FAOKE)" [redacted]>, "Ayebazibwe, Chrisostom (FAOUG)" [redacted], David Mutonga <david.mutonga@thepalladiumgroup.com>, "Okori, Edward (FAOUG)" [redacted], "predict@ucdavis.edu" <predict@ucdavis.edu>, Sylvia Wanzala <wanza003@umn.edu>, Benard Ssebide <[redacted]>, Amanda MCCLELLAND <amanda.mcclelland@ifrc.org>, Mike Cranfield [redacted], Irene Naigaga <[redacted]
**Cc:** Andrew Clements <aclements@usaid.gov>, Nadira Kabir <nkabir@usaid.gov>, Marilyn Crane <mcrane@usaid.gov>, Lindsay Parish <lparish@usaid.gov>, Ricardo Echalar <rechalar@usaid.gov>, Ashna Kibria <akibria@usaid.gov>, Kassahun Belay <kbelay@usaid.gov>, Lisa Kramer <lkramer@usaid.gov>, Michelle Lang-Alli <mlang-alli@usaid.gov>, Sarah Paige <spaige@usaid.gov>
**Subject: Invitation - Save the Dates - Monthly USAID Uganda Chief of Party/Head of Office and EPT-2 Implementing Partners' Meetings**

Dear EPT-2 Implementing Partners,
This is a message to invite you to save the date for two standing meetings:

- The Chief of Party/Head of Office Meeting is held on the last Friday of each month (Friday, September 29th) from 9:15 a.m. - 11:45 a.m. venue TBD - An invitation with agenda will be sent out closer to the date of the meeting;
- The next EPT-2 Implementing Partners' Meeting will be held at the USAID Mission on Thursday, October 5, 2017 from 3:00 p.m. - 4:30 p.m.

This EPT-2 Implementing Partners' meeting will maintain the same standard agenda but will be held "in-person" at the USAID Mission Kampala to allow face to face interaction. AORs from USAID/Washington and Lisa Kramer from Nairobi, Kenya will call into the meeting. The agenda will include the following items:

1. USAID updates for the Partners

- 4th GHSA High Level Ministerial Event October 25-27
  - Poster Session
  - Partner Invitation/Registration
  - EPT-2 Implementing Partners' Meeting with Richard Greene and Dennis Carroll

2. Project updates (5 min each) including upcoming events/meetings/TDYers:

- P&R
- PREDICT
- FAO
- OHW
- IFRC (?)

3. Coordination issues (e.g. Year 4 work plans) and next steps

Thank you for your partnership,

Gregory J. Adams
Global Health Security Agenda (GHSA) Advisor
USAID Mission Kampala
Cellphone: REDACTED
Office Phone: +256 0414 306001 ext. 6599
Email: gadams@usaid.gov

**From:** Andrew Clements <aclements@usaid.gov>
**Sent:** Wed, 13 Sep 2017 08:03:43 -0400
**Subject:** Re: Invitation - Save the Dates - Monthly USAID Uganda Chief of Party/Head of Office and EPT-2 Implementing Partners' Meetings
**To:** Kirsten Gilardi <kvgilardi@ucdavis.edu>
**Cc:** David John Wolking <djwolking@ucdavis.edu>, Jonna Mazet <jkmazet@ucdavis.edu>, "predictmgt@usaid.gov" <predictmgt@usaid.gov>

Thanks!

*Andrew P. Clements, Ph.D.*
*Senior Scientific Advisor*
*Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health*
*U.S. Agency for International Development*
*Mobile phone: 1-571-345-4253*
*Email: aclements@usaid.gov*

On Sep 13, 2017, at 7:58 AM, Kirsten Gilardi <kvgilardi@ucdavis.edu> wrote:

> Thank you Andrew. I'll confirm with Benard Ssebide that he plans to attend these meetings — they are scheduled during the weeks he is usually in Kampala, so should work well. -Kirsten
>
> > On Sep 13, 2017, at 4:51 AM, Andrew Clements <aclements@usaid.gov> wrote:

FYI

*Andrew P. Clements, Ph.D.*
*Senior Scientific Advisor*
*Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health*
*U.S. Agency for International Development*
*Mobile phone: 1-571-345-4253*
*Email: aclements@usaid.gov*

Begin forwarded message:

**From:** Gregory Adams <gadams@usaid.gov>
**Date:** September 13, 2017 at 4:49:24 AM EDT
**To:** Andrew Kitua <andrew_kitua@dai.com>, Esther Buregyeya <eburegyeya@musph.ac.ug>, "Fredrick Kivaria (FAOUG)" <[redacted]>, Innocent Rwego <irwego@umn.edu>, Peninah Nsamba <[redacted]>, Sambe Duale <[redacted]>, "Susan Ndyanabo (FAOUG)" <[redacted]>, Susan Scribner <[redacted]>, Winyi Kaboyo <[redacted]>, "Yilma Makonnen (FAOKE)" <[redacted]>, "Ayebazibwe, Chrisostom (FAOUG)" <[redacted]>, David Mutonga <david.mutonga@thepalladiumgroup.com>, "Okori, Edward (FAOUG)" <[redacted]>, "predict@ucdavis.edu" <predict@ucdavis.edu>, Sylvia Wanzala <wanza003@umn.edu>, Benard Ssebide <[redacted]>, Amanda MCCLELLAND <amanda.mcclelland@ifrc.org>, Mike Cranfield <[redacted]>, Irene Naigaga <[redacted]>
**Cc:** Andrew Clements <aclements@usaid.gov>, Nadira Kabir <nkabir@usaid.gov>, Marilyn Crane <mcrane@usaid.gov>, Lindsay Parish <lparish@usaid.gov>, Ricardo Echalar <rechalar@usaid.gov>, Ashna Kibria <akibria@usaid.gov>, Kassahun Belay <kbelay@usaid.gov>, Lisa Kramer <lkramer@usaid.gov>, Michelle Lang-Alli <mlang-alli@usaid.gov>, Sarah Paige <spaige@usaid.gov>

**Subject: Invitation - Save the Dates - Monthly USAID Uganda Chief of Party/Head of Office and EPT-2 Implementing Partners' Meetings**

Dear EPT-2 Implementing Partners,
This is a message to invite you to save the date for two standing meetings:

- The Chief of Party/Head of Office Meeting is held on the last Friday of each month (Friday, September 29th) from 9:15 a.m. - 11:45 a.m. venue TBD - An invitation with agenda will be sent out closer to the date of the meeting;
- The next EPT-2 Implementing Partners' Meeting will be held at the USAID Mission on Thursday, October 5, 2017 from 3:00 p.m. - 4:30 p.m.

This EPT-2 Implementing Partners' meeting will maintain the same standard agenda but will be held "in-person" at the USAID Mission Kampala to allow face to face interaction. AORs from USAID/Washington and Lisa Kramer from Nairobi, Kenya will call into the meeting. The agenda will include the following items:

1. USAID updates for the Partners

   - 4th GHSA High Level Ministerial Event October 25-27

     - Poster Session

     - Partner Invitation/Registration

     - EPT-2 Implementing Partners' Meeting with Richard Greene and Dennis Carroll

2. Project updates (5 min each) including upcoming events/meetings/TDYers:

   - P&R

   - PREDICT

   - FAO

   - OHW

   - IFRC (?)

3. Coordination issues (e.g. Year 4 work plans) and next steps

Thank you for your partnership,

Gregory J. Adams
Global Health Security Agenda (GHSA) Advisor
USAID Mission Kampala
Cellphone: [redacted]
Office Phone: +256 0414 306001 ext. 6599
Email: gadams@usaid.gov

| | |
|---|---|
| **From:** | Jonna Mazet <jkmazet@ucdavis.edu> |
| **To:** | Billy Karesh <karesh@ecohealthalliance.org>;Kevin J. Olival <olival@ecohealthalliance.org> |
| **CC:** | Peter Daszak <daszak@ecohealthalliance.org> |
| **Sent:** | 9/19/2017 10:25:36 AM |
| **Subject:** | Fwd: Request for protocol/rationale for Predict's prioritization of samples for testing |

FYI -- BIlly can fill you in on concerns from USAID. Of course, my concern remains the lobbying that occurs in Thailand (likely socially) that makes waves in DC and for us in management.
If the justifications/reasons for the need for globalized prioritization isn't making it to the countries, that's a concern, too.
Thanks for exploring and addressing,
Jonna

---------- Forwarded message ----------
From: **Andrew Clements** <aclements@usaid.gov>
Date: Tue, Sep 19, 2017 at 12:42 AM
Subject: Request for protocol/rationale for Predict's prioritization of samples for testing
To: David J Wolking <djwolking@ucdavis.edu>
Cc: Jonna Mazet <jkmazet@ucdavis.edu>, Tracey Goldstein <tgoldstein@ucdavis.edu>, predictmgt@usaid.gov

Hi David,

I've been having an email conversation with Thailand about why certain samples are prioritized over others and--despite the discussion at last week's meeting in NY--I don't know your procedures well enough to be able to make a convincing defense.

The issue being raised is why oral + fecal and but not blood or urine (I explained limited funds for testing) in the context of community based surveillance. I think there may be a perception that CBS is supposed to be for early detection of individual spillover events. To me, CBS in the Predict context is part of identifying overall trends (where, when, how, why) associated with spillover in general (and not individual spillovers).

Can you send me the actual protocols/rationale so I can share them? There may be continued philosophical differences of opinion, but at least they can see the actual plan.

Thanks!

Andrew

P.S. I continue to make the point that other samples can be tested with non-ETD resources, but that doesn't ever seem to happen. I find it interesting that there is strong interest in the Predict work, but apparently not enough to use other funds.

*Andrew P. Clements, Ph.D.*
*Senior Scientific Advisor*
*Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health*
*U.S. Agency for International Development*
*Mobile phone: 1-571-345-4253*
*Email: aclements@usaid.gov*

| | |
|---|---|
| **From:** | Andrew Clements <aclements@usaid.gov> |
| **To:** | Katherine Leasure <kaleasure@ucdavis.edu> |
| **CC:** | PREDICTMGT <predictmgt@usaid.gov>;Jonna Mazet <jkmazet@ucdavis.edu>;Predict inbox <predict@ucdavis.edu> |
| **Sent:** | 9/20/2017 11:26:24 AM |
| **Subject:** | Re: Change to Pending ITA - J. Mazet to Sweden Cancelled |

Thanks.

*Andrew P. Clements, Ph.D.*
*Senior Scientific Advisor*
*Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health*
*U.S. Agency for International Development*
*Mobile phone: 1-571-345-4253*
*Email: aclements@usaid.gov*

On Sep 20, 2017, at 5:33 PM, Katherine Leasure <kaleasure@ucdavis.edu> wrote:

Hi Andrew. Jonna Mazet's travel to Sweden (pending ITA below for reference) has been cancelled. Please let me know if you have any questions. Thanks!

UC Davis would like to request travel approval for Dr. Jonna Mazet to travel from San Francisco, CA, USA to Uppsala, Sweden from October 8-11, 2017 to participate in the Uppsala Health Summit 2017: Tackling Infectious Disease.

**Trip purpose:** Dr. Mazet will engage as an invited participant in the Uppsala Health Summit on 'Infectious Disease Threats – Prevent, Detect, Respond with a One Health Approach' at Uppsala Castle, Sweden. The participants will discuss and work to develop practice guidelines and mechanisms to empower local research capacities, and will strategically convene as international leaders working on One Health approaches to reduce risk behavior in low-income settings. While attending the Uppsala Health Summit, Dr. Mazet will also conduct meetings with PREDICT consortium members and EPT-2 partners, as well as identify useful stakeholders and collaborators to encourage continued support for the Emerging Pandemic Threats program and promote Global Virome Project engagement.

**Katherine Leasure**
HR/Payroll/Financial Assistant
One Health Institute
University of California, Davis
530-752-7526
530-752-3318 FAX
kaleasure@ucdavis.edu

--
You received this message because you are subscribed to the Google Groups "PREDICTMGT" group.
To unsubscribe from this group and stop receiving emails from it, send an email to predictmgt+unsubscribe@usaid.gov.
To post to this group, send email to predictmgt@usaid.gov.
To view this discussion on the web visit https://groups.google.com/a/usaid.gov/d/msgid/predictmgt/009901d33225%24b4a4bbf0%241dee33d0%24%40ucdavis.edu.

**From:** Andrew Clements <aclements@usaid.gov>
**Sent:** Fri, 29 Sep 2017 11:51:59 +0200
**Subject:** Re: Quarterly surveillance activities summary June 2017
**To:** Christine Kreuder Johnson <ckjohnson@ucdavis.edu>
**Cc:** "predictmgt@usaid.gov" <predictmgt@usaid.gov>, Jonna Mazet <jkmazet@ucdavis.edu>, Peter Daszak <daszak@ecohealthalliance.org>, Tracey Goldstein <tgoldstein@ucdavis.edu>, "William B. Karesh" <karesh@ecohealthalliance.org>, Leilani Francisco <francisco@ecohealthalliance.org>, Megan M Doyle <mmdoyle@ucdavis.edu>, "predict@ucdavis.edu" <predict@ucdavis.edu>
PREDICT surveillance activities June 2017__suggested additions.xlsx

Hi Chris and Leilani,

Your quarterly surveillance matrix has rapidly become a go-to reference guide for our team in USAID/W and we're looking forward to the new update next week. We find it extremely useful for showing what PREDICT is accomplishing across all countries as well as for managing expectations.

For your consideration for the new update, I made some suggestions in the attached version of your previous report. My changes are in red font with the cells also highlighted in yellow. We already discussed adding a column for results approved for release.

Please let me know if you have any questions.

Thanks!

Andrew

On Fri, Jun 9, 2017 at 12:04 AM, Christine Kreuder Johnson <ckjohnson@ucdavis.edu> wrote:

> Hi everyone,
>
> Attached is our summary of surveillance activities in each country. All wildlife, human, and livestock counts and test counts are based on data in EIDITH to date.
>
> We've added a quick view 'summary' on the 2nd tab as well. Once we have findings approved for release, we will add a column for this too.
>
> Please let Leilani and I know if there are any questions or if there's anything else you need.
>
> Kind regards,
>
> Chris
>
> Christine Kreuder Johnson, VMD, PhD
>
> Professor of Epidemiology and Ecosystem Health
>
> Senior Biological and Ecological Surveillance Coordinator, Emerging Pandemic Threats PREDICT Project
>
> One Health Institute
>
> VM3B 1089 Veterinary Medicine Drive
>
> One Health Institute
>
> School of Veterinary Medicine
>
> University of California
>
> Davis, California 95618
>
> +1.530.752.1238

**From:** Leilani Francisco <francisco@ecohealthalliance.org>
**Date:** Thursday, June 8, 2017 at 12:15 PM
**To:** "predictmgt@usaid.gov" <predictmgt@usaid.gov>
**Cc:** Jonna Mazet <jkmazet@ucdavis.edu>, Peter Daszak <daszak@ecohealthalliance.org>, Christine Kreuder Johnson <ckjohnson@UCDAVIS.EDU>, Tracey Goldstein <tgoldstein@ucdavis.edu>, Billy Karesh <karesh@ecohealthalliance.org>
**Subject:** 2-page behavioral risk plan

Dear Andrew, Dennis, Alisa, and Shana,

Please find attached a 2-page summary of the behavioral risk surveillance plan.

Chris will be sending the complementary PREDICT country activities tracker shortly.

We look forward to your thoughts and feedback.

Best regards,

Leilani

--

**Leilani Francisco, PhD, MA, PMP**
*Senior Scientist | PREDICT-2 Senior Behavioral Risk Surveillance Coordinator*

EcoHealth Alliance
460 West 34th Street – 17th floor
New York, NY 10001

1.212.380.4493 (direct)
REDACTED (mobile)
1.212.380.4465 (fax)
www.ecohealthalliance.org

***EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that promote conservation and prevent pandemics.***

--
You received this message because you are subscribed to the Google Groups "PREDICTMGT" group.
To unsubscribe from this group and stop receiving emails from it, send an email to predictmgt+unsubscribe@usaid.gov.
To post to this group, send email to predictmgt@usaid.gov.
To view this discussion on the web visit https://groups.google.com/a/usaid.gov/d/msgid/predictmgt/32FFA488-C4AC-465B-BA7E-A78F989E0330%40ucdavis.edu.

--

Andrew Clements, Ph.D.
Senior Scientific Advisor

Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
E-mail: aclements@usaid.gov

*For more information on USAID's Emerging Pandemic Threats program, see:* http://www.usaid.gov/ept2

## PREDICT-2 quarterly surveillance update

Updated through May 2017

Source: EIDITH database

Note: The PREDICT surveillance protocol focuses on: (1) priority animals (including humans, bats, rodent, n
PREDICT-2 routinely collects multiple sample types from target species; however, due to budget limitation

| Country | # Site/Events Characterized to date | Site Characterization-Risk Interfaces Characterized | Actual (or estimated) start date for surveillance (month, year) | Actual (or estimated) end date for surveillance (month, year) |
|---|---|---|---|---|
| China | 23/103 | crop production; dwellings and temporary settlements; human hospital; natural areas | | |
| Nepal | 7/39 | animal production; crop production; dwellings and temporary settlements; market and value chain; natural areas; wildlife restaurant | | |
| India | subaward approved recently | | | |
| Mongolia | 22/26 | natural areas | | |
| Bangladesh | 157/241 | animal production; crop production; dwellings and temporary settlements; market and value chain; natural areas; outbreak investigation; zoos and sanctuaries | | |
| Myanmar | 10/26 | animal production; dwellings and temporary settlements; natural areas; zoos and sanctuaries | | |

| | | |
|---|---|---|
| **Malaysia, Peninsular** | 23/29 | dwellings and temporary settlements |
| **Malaysia, Sabah** | 43/84 | crop production; dwellings and temporary settlements; natural areas; wildlife restaurant; zoos and sanctuaries |
| **Thailand** | 19/36 | dwellings and temporary settlements; human hospital; market and value chain; natural areas |
| **Cambodia** | 3/11 | animal production; crop production; extractive industry; market and value chain |
| **Lao PDR** | 2/14 | dwellings and temporary settlements; market and value chain |
| **Vietnam** | 33/44 | animal production; market and value chain; natural areas; outbreak investigation; wildlife restaurant; zoos and sanctuaries |
| **Indonesia** | 12/15 | market and value chain; natural areas |
| **Egypt** | 12/29 | animal production; crop production; market and value chain; natural areas |
| **Jordan** | 5/17 | animal production; crop production; natural areas |

| | | |
|---|---|---|
| **Ethiopia** | 4/7 | animal production; crop production; dwellings and temporary settlements; market and value chain; natural areas |
| **Kenya** | 3/5 | animal production; dwellings and temporary settlements; market and value chain; natural areas |
| **Tanzania** | 10/14 | animal production; crop production; extractive industry |
| **Uganda** | 14/29 | crop production; dwellings and temporary settlements; extractive industry; human hospital; market and value chain; natural areas; zoos and sanctuaries |
| **Rwanda** | 21/40 | crop production; dwellings and temporary settlements; human hospital; natural areas |
| **DR Congo** | 50/102 | crop production; dwellings and temporary settlements; extractive industry; human hospital; market and value chain; natural areas; outbreak investigation; wildlife restaurant; zoos and sanctuaries |

| | | |
|---|---|---|
| **Republic of Congo** | 5/5 | animal production; crop production; dwellings and temporary settlements; extractive industry |
| **Cameroon** | 22/50 | crop production; dwellings and temporary settlements; extractive industry; market and value chain; natural areas; wildlife restaurant; zoos and sanctuaries |
| **Ghana** | 3/6 | animal production; crop production; dwellings and temporary settlements; market and value chain; natural areas |
| **Ivory Coast** | 1/1 | dwellings and temporary settlements; natural areas; outbreak investigation |
| **Senegal** | subaward approved recently | |
| **Guinea** | 40/40 | animal production; crop production; extractive industry; market and value chain; natural areas; outbreak investigation |
| **Liberia** | 14/20 | extractive industry; natural areas |
| **Sierra Leone** | 45/66 | animal production; crop production; dwellings and temporary settlements; market and value chain; natural areas; outbreak investigation |

on-human primates, and sometimes livestock) at animal-human interfaces where there is high-potential f
s, PREDICT-2 may not be able to test all individuals sampled or all sample types from each individual.

| # Wild Animals Sampled to date | Wildlife Taxa Sampled (n) | # Domestic Animals Sampled to date |
|---|---|---|
| 629 | rodents/shrews(87); bats(542) | not planned |
| 1205 | rodents/shrews(260); birds(154); non-human primates(693); bats(98) | sampling supported by FAO |
| subaward approved recently | planning phase | not planned |
| 1362 | birds(1362) | not planned |
| 8077 | rodents/shrews(417); birds(632); non-human primates(6226); bats(802) | 716 |
| 904 | rodents/shrews(103); carnivores(1); non-human primates(148); bats(652) | 52 |

| | | |
|---|---|---|
| 253 | rodents/shrews(28); ungulates(1); carnivores(1); non-human primates(184); bats(39) | 298 |
| 828 | rodents/shrews(180); pangolins(41); ungulates(2); carnivores(39); non-human primates(58); bats(508) | not planned |
| 1087 | rodents/shrews(174); non-human primates(159); bats(754) | sampling supported by FAO |
| 2528 | rodents/shrews(666); birds(5); bats(1857) | 1390 (sampling supported by FAO) |
| 378 | rodents/shrews(309); bats(69) | 325 (sampling supported by FAO) |
| 310 | rodents/shrews(30); pangolins(176); ungulates(3); birds(3); carnivores(7); non-human primates(17); bats(74) | 185 (animals sampled by FAO) |
| 858 | rodents/shrews(158); bats(700) | 784 animals |
| 545 | bats(545) | sampling supported by FAO |
| 250 | bats(250) | sampling supported by FAO |

| | | |
|---|---|---|
| 249 | non-human primates(156); bats(93) | sampling initiated by FAO |
| 134 | rodents/shrews(15); non-human primates(69); bats(50) | 100 |
| 555 | rodents/shrews(278); bats(277) | sampling initiated by FAO |
| 338 | rodents/shrews(81); non-human primates(121); bats(136) | 80 |
| 698 | rodents/shrews(105); non-human primates(93); bats(500) | not planned |
| 519 | rodents/shrews(142); non-human primates(137); bats(240) | 24 |

| | | |
|---|---|---|
| 346 | rodents/shrews(145); carnivores(1); bats(200) | not planned |
| 2166 | rodents/shrews(1144); pangolins(39); ungulates(21); carnivores(38); non-human primates(279); bats(645) | not planned |
| 577 | rodents/shrews(93); non-human primates(179); bats(305) | not planned |
| 136 | rodents/shrews(4); birds(12); bats(120) | not planned |
| pending | pending | not planned |
| 415 | rodents/shrews(141); bats(274) | 194 |
| 1141 | bats(1141) | planning phase |
| 2280 | rodents/shrews(313); non-human primates(10); bats(1957) | 2173 |

or zoonotic spillover; and (2) five viral families (influenzas, coronaviruses, filoviruses, flaviviruses, and para

| Domestic Species Sampled (n) | Plan for triangulation with FAO | # Humans Sampled to date | # Human Questionnaires to date |
|---|---|---|---|
| not planned | FAO does not have resources to support at this time | 142 | 142 |
| sampling at one concurrent site supported by FAO | sampling at one concurrent site supported by FAO | 613 | 666 |
| not planned | not planned | planning phase | planning phase |
| not planned | not planned | not planned | not planned |
| poultry/other fowl(560); camels(103); goats/sheep(44); dogs(3); cattle/buffalo(6) | PREDICT sampling livestock within budget; FAO has agreed to do animals at one site (border of India/Bangladesh) | IRB has been pre-approved by UCD and being submitted to IEDCR for ethical review | IRB has been pre-approved by UCD and being submitted to IEDCR for ethical review |
| poultry/other fowl(52) | FAO supporting livestock | In-country IRB approved; pending post submission approval; implementing human surveillance July 2017 | approved; pending post submission approval; implementing human surveillance July 2017 |

| | | | |
|---|---|---|---|
| poultry/other fowl(145); goats/sheep(11); dogs(142) | PREDICT sampling livestock within budget | data entry ongoing (estimated 300 individuals) | data entry ongoing |
| not planned | PREDICT sampling livestock within budget | not planned | not planned |
| sampling supported by FAO | FAO supporting livestock | 2 | 2 |
| poultry/other fowl(806); goats/sheep(25); dogs(61); cats(10); horses(5); cattle/buffalo(304); swine(179) | FAO supporting livestock | 203 | 323 |
| poultry/other fowl(169); cattle/buffalo(73); swine(83) | FAO supporting livestock | subaward in development; subcontract with hospital in development | IRB approved |
| swine(185) | FAO supporting livestock | local IRB pending | local IRB pending |
| cattle, pigs, goats, and horses (concurrently within a month) | FAO planning to support livestock | local IRB pending | local IRB pending |
| sampling supported by FAO | FAO supporting livestock | 539 | 540 |
| sampling supported by FAO | FAO supporting livestock | planning phase | planning phase |

| | | | |
|---|---|---|---|
| sampling initiated by FAO | Requested for funds for sampling and testing 600 camels | planning phase | planning phase |
| camels(100) | Requested funds for sampling and testing 800 camels | IRB approved; implementing human surveillance June 2017 | IRB approved; implementing human surveillance June 2017 |
| sampling initiated by FAO | testing of livestock (400 specimens) collected by FAO in Uvinza region; sampling and tesing hunting dogs (1,200 specimens), and sampling and testing cattle, sheep and goats (1,200 specimens) in game reserves where P2 is sampling | 0 | 87 |
| camels(80) | not planned | 60 | 75 |
| not planned | not planned | 100 | 100 |
| poultry/other fowl(7); goats/sheep(16); swine(1) | not planned | 71 | 95 |

| | | | |
|---|---|---|---|
| not planned | not planned | IRB approved | IRB approved |
| not planned | not planned | local IRB pending | local IRB pending |
| not planned | not planned | local IRB pending; subcontracts with hospitals (2) in development | IRB approval pending; subcontracts with clinics (2) in exploratory phase |
| not planned | not planned | IRB approved | IRB approved |
| not planned | not planned | local IRB approved | enrolled 4 participants |
| goats/sheep(185); dogs(1); swine(8) | PREDICT sampling livestock | not planned | local IRB (EHP behavioral work only) pending |
| planning phase | PREDICT sampling livestock | not planned | local IRB (EHP behavioral work only) pending |
| goats/sheep(855); dogs(313); cats(5); swine(1000) | PREDICT sampling livestock | not planned | local IRB (EHP behavioral work only) pending |

myxoviruses) which contain members that have caused epidemics and pandemics.

| Human Questionnaire Risk Characterized (n) | # Ethnographic Interviews to date | # Focus Groups to date | # Focus Group Participants to date |
|---|---|---|---|
| construction(2); health professional(1); human hospital or clinic (199) ; migrant laborer(3); other(136) | 132 | 5 | 40 |
| abattoir(138); construction(47); crop production(243); health professional(2); hunter(3); market & value chain(9); migrant laborer(3); other(373); protected area worker(1) | 40 | 3 | 32 |
| planning phase | not planned | not planned | not planned |
| | not planned | not planned | not planned |
| | 73 | 3 | 31 |
| In-country IRB approved; pending post submission approval; implementing human surveillance July 2017 | not planned | not planned | not planned |

| | | | |
|---|---|---|---|
| | not planned | not planned | not planned |
| | not planned | not planned | not planned |
| crop production(1); human hospital or clinic (2) ; other(1) | not planned | not planned | not planned |
| animal production or abattoir(85); construction(13); crop production(123); hunter(8); market & value chain(17); migrant laborer(2); other(194); wildlife restaurant(2); zoos & sanctuaries(1) | not planned | not planned | not planned |
| | 2 | 0 | 0 |
| | 5 | 0 | 0 |
| | 47 | 2 | 29 |
| animal production or abattoir(411); crop production(14); forager/gatherer(1); health professional(3); hunter(3); market & value chain(107); other(48) | not planned | not planned | not planned |
| | not planned | not planned | not planned |

| | | | |
|---|---|---|---|
| | not planned | not planned | not planned |
| IRB approved; implementing human surveillance June 2017 | not planned | not planned | not planned |
| animal production or abattoir(64); construction(2); crop production(78); extractive industry worker(3); forager/gatherer(10); health professional(2); hunter(5); market & value chain(4); other(5) | 23 | 4 | 37 |
| animal production or abattoir(22); crop production(53); human hospital or clinic (90) ; other(9); protected area worker(16) | 46 | 2 | 20 |
| construction(7); crop production(45); health professional(5); human hospital or clinic (345) ; migrant laborer(1); other(42); zoos & sanctuaries(1) | not planned | not planned | not planned |
| abattoir(2); crop production(5); extractive industry worker(1); health professional(1); human hospital or clinic (185) ; hunter(3); market & value chain(24); migrant laborer(6); other(63); wildlife restaurant(1); zoos & sanctuaries(1) | 166 | 10 | 85 |

| | | | |
|---|---|---|---|
| | 0 | 0 | 0 |
| | 112 | 8 | 89 |
| | not planned | not planned | not planned |
| | 14 | 9 | 72 |
| | not planned | not planned | not planned |
| | local IRB pending | local IRB pending | local IRB pending |
| | local IRB pending | local IRB pending | local IRB pending |
| | 94 | 6 | 85 |

| # Wild Animals Tested to date | # Domestic Animals Tested to date | # Humans Tested to date | # individual animals/people with testing results approved for release by host government | Notes |
|---|---|---|---|---|
| 495 | 0 | 62 | | |
| 666 | 0 | 69 | | |
| subaward approved recently | subaward approved recently | subaward approved recently | | |
| 1202 | 0 | 0 | | |
| 308 | 150 | 0 | | |
| 105 | 0 | 0 | | |

| | | |
|---|---|---|
| 51 | 164 | 0 |
| 57 | not planned | 0 |
| 726 | 0 | 0 |
| 512 | 0 | 0 |
| 153 | 0 | subaward for human testing in development |
| 97 | 185 | 0 |
| 409 | 0 | 0 |
| data entry ongoing (estimated n=250) | 0 | 300 |
| 88 | 0 | 0 |

| | | |
|---|---|---|
| in exploratory phase for animal testing | 0 | 0 |
| testing initiated and ongoing | 100 | 0 |
| 75 | 0 | 0 |
| 68 | 80 | subaward in place, MOU in development |
| 92 | 0 | 0 |
| 324 | 24 | 60 |

| | | | |
|---|---|---|---|
| 143 | 0 | 0 | |
| 984 | 0 | 0 | |
| 0 | 0 | 0 | |
| 0 | 0 | 0 | |
| testing approved recently | 0 | 0 | |
| subaward for testing approved recently | subaward for testing approved recently | subaward for testing approved recently | will not test livestock samples due to lack of budget |
| 75 | 0 | 0 | livestock samples due to lack of budget |
| 289 | 245 | 0 | will not test livestock samples due to lack of budget |

In most cases, testing has been initiated, but data has not been entered yet.

Liberia has released results

| Country | Wildlife sampling | Human sampling | P2 livestock sampling | FAO supported livestock activities |
|---|---|---|---|---|
| India | pending | pending | not planned | not planned |
| Bangladesh | Yes | pending | Yes | Yes |
| China | Yes | Yes | not planned | not planned |
| Mongolia | Yes | not planned | not planned | not planned |
| Cambodia | Yes | Yes | not planned | Yes |
| Malaysia | Yes | Yes | Yes | not planned |
| Nepal | Yes | Yes | not planned | Yes |
| Thailand | Yes | Yes | not planned | Yes |
| Lao PDR | Yes | pending | not planned | Yes |
| Myanmar | Yes | pending | not planned | Yes |
| Vietnam | Yes | pending | not planned | Yes |
| Indonesia | Yes | pending | not planned | Yes |
| Egypt | Yes | Yes | not planned | Yes |
| Jordan | Yes | pending | not planned | Yes |
| Ethiopia | Yes | pending | not planned | not planned |
| Kenya | Yes | pending | not planned | not planned |
| Uganda | Yes | Yes | not planned | not planned |
| Cameroon | Yes | pending | not planned | not planned |
| Rwanda | Yes | Yes | not planned | not planned |
| Dem. Republic of | Yes | Yes | not planned | not planned |
| Cote d'Ivoire | Yes | pending | not planned | not planned |
| Ghana | Yes | pending | not planned | not planned |
| Republic of Cong | Yes | pending | not planned | not planned |
| Tanzania | Yes | pending | not planned | not planned |
| Guinea | Yes | not planned | Yes | not planned |
| Liberia | Yes | not planned | Yes | not planned |
| Sierra Leone | Yes | not planned | Yes | not planned |
| Senegal | pending | pending | not planned | not planned |

**From:** "William B. Karesh" <karesh@ecohealthalliance.org>
**To:** Elizabeth Leasure <ealeasure@ucdavis.edu>
**Cc:** Peter Daszak <daszak@ecohealthalliance.org>, Jon Epstein <epstein@ecohealthalliance.org>, "Kevin Olival, PhD" <olival@ecohealthalliance.org>, Leilani Francisco <francisco@ecohealthalliance.org>, Beth Edison <bedison@metabiota.com>, "Karen Saylors" <ksaylors@metabiota.com>, Eddy Rubin <erubin@metabiota.com>, "Evelyn Luciano" <luciano@ecohealthalliance.org>, "Dr. Damien Joly" <djoly@metabiota.com>, Ava Sullivan <sullivan@ecohealthalliance.org>, "Molly Turner" <turner@ecohealthalliance.org>, Emily Hagan <hagan@ecohealthalliance.org>, "Tammie O'Rourke" <torourke@metabiota.com>, David McIver <dmciver@metabiota.com>, Suzan Murray <MurrayS@si.edu>, "Zimmerman, Dawn" <ZimmermanD@si.edu>, "Vodzak, Megan E." <VodzakME@si.edu>, Marc Valitutto <ValituttoM@si.edu>, "East, Larissa" <EastL@si.edu>, "Churchill, Carolina" <[REDACTED]>, Amanda Fine <[REDACTED]>, "predict@ucdavis.edu" <predict@ucdavis.edu>, Jonna Mazet <jkmazet@ucdavis.edu>, David Wolking <djwolking@ucdavis.edu>, Karen L Wood <klwood@ucdavis.edu>
**Subject:** Re: Farewell
**Sent:** Mon, 2 Oct 2017 15:51:09 +0000

Liz, thanks for all of your hard work to keep us moving forward. At times it was like you were an ice breaker cutting through Arctic Sea in winter so we could get our work done - thanks for all of that. We'll miss you.
BK

**William B. Karesh, D.V.M**
*Executive Vice President for Health and Policy*

EcoHealth Alliance
460 West 34th Street - 17th Floor
New York, NY 10001 USA

+1.212.380.4463 (direct)
+1.212.380.4465 (fax)
www.ecohealthalliance.org

President, OIE Working Group on Wildlife

Co-chair, IUCN Species Survival Commission - Wildlife Health Specialist Group

EPT Partners Liaison, USAID Emerging Pandemic Threats - PREDICT-2 Program

***EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that promote conservation and prevent pandemics.***

On Sep 29, 2017, at 5:08 PM, Elizabeth Leasure <ealeasure@ucdavis.edu> wrote:

Hi everyone. I'm writing to let you know that my last day with PREDICT will be Tuesday, October 10th, as I have accepted a position with the Department of Biomedical Engineering (BME) at UC Davis. Karen Wood (who many of you met in New York) and a new Research Administrator (in recruitment now) will take over my job duties, so please be patient as we work out the kinks. We will do our best to make the transition as smooth as possible, but any input or suggestions you may have regarding needs to be covered are welcomed and encouraged.

It has been a pleasure and a privilege to get to know and work with you all, and I wish you all the best.

Thanks,
Liz

Elizabeth Leasure
One Health Institute

University of California, Davis
530-754-9034 (office)
REDACTED (cell)

**From:** David J Wolking <djwolking@ucdavis.edu>
**Sent:** Tue, 3 Oct 2017 09:40:23 -0700
**To:** William Karesh <karesh@ecohealthalliance.org>
**Cc:** Amanda Andre <amanda.andre@ecohealthalliance.org>, Catherine Machalaba <Machalaba@ecohealthalliance.org>, "predict@ucdavis.edu" <predict@ucdavis.edu>
**Subject:** Fwd: [predict] JEE Cameroon 25-29 September 2017
Résumé analytique pour autorités_Cameroon.docx

Billy,
In case you're interested, here's the report from the Cameroon JEE (in French).

D

---------- Forwarded message ----------
From: **Moctar Mouiche** <[redacted]>
Date: Mon, Oct 2, 2017 at 11:38 AM
Subject: Re: [predict] JEE Cameroon 25-29 September 2017
To: David J Wolking <djwolking@ucdavis.edu>
Cc: James Ayukekbong <jayukekbong@metabiota.com>, Eddy Rubin <erubin@metabiota.com>, Karen Saylors <ksaylors@metabiota.com>, "predict@ucdavis.edu" <predict@ucdavis.edu>

Hi David

PREDICT Cameroon participated in the Cameroon Joint External Evaluation (JEE) which took place at the Hilton Hotel in Yaoundé 25-29 of September 2017, in particular in the working groups on Zoonosis, National Laboratory Systems and BSS.

USAID PREDICT's contribution to developing pilot wildlife disease surveillance programs was explicitly mentioned by the GoC presenter during the Zoonoses session.

The JEE experts visited (28 September 2017) the CRESAR laboratory (PREDICT lab partner) during the field site visits for the evaluation of the national laboratory facilities.

Quality of waste management procedures at CRESAR was highlighted by the JEE team in their review of site visits in the restitution session. Dangerous pathogen confinement was noted at all the labs visited. Recommendations related to improving national networks, systems and strategies and to create standardised BS&S training for all staff working in labs.

Please find attached the draft notes and recommendations of the JEE evaluation team's experts (document not validated for diffusion).

Please let me know if you have any question.
Thanks

**Moctar M. Mouiche Mouliom**, DVM, PhD
Cameroon Country Coordinator (Metabiota - USAID Predict)
[redacted]

[redacted]

On Mon, Oct 2, 2017 at 4:22 PM, David J Wolking <djwolking@ucdavis.edu> wrote:

> Hi James and Moctar,
> Any feedback on the JEE meeting? We have a meeting with USAID/Washington tomorrow and would simply appreciate a very informal update to share if you can manage in the short time.

Best,

David

On Wed, Aug 23, 2017 at 7:47 AM, Moctar Mouiche <[redacted]> wrote:

> Hi james
> The JEE will take place betwwen 25 to 29 September.
> Regards

# Evaluation externe conjointe des principales capacités RSI

# de

# la République du Cameroun

**Rapport de mission**

**29 septembre 17**

[Insérer le logo du pays]

World Health Organization

# REMERCIEMENTS

Le Secrétariat de l'OMS pour l'évaluation externe conjointe (EEC) tient à remercier les personnes suivantes, dont le soutien et l'engagement envers les principes du Règlement sanitaire international (2005) ont permis de conduire avec succès cette mission de l'EEC:

- Le gouvernement et les experts nationaux du Cameroun pour leur soutien et leur travail dans la préparation de la mission de l'EEC
- Les gouvernements du Benin, des Etats-Unis d'Amérique, de France, de Mauritanie, du Sénégal et du Royaume-Uni pour la mise à disposition d'experts techniques dans le processus d'examen par les pairs
- L'Organisation des Nations Unies pour l'Alimentation et l'Agriculture (FAO), l'Organisation mondiale de la Santé animale (OIE), pour la participation de leurs experts et leur contribution technique
- Les gouvernements d'Allemagne, de Finlande, et des Etats-Unis d'Amérique pour leur appui financier à cette mission
- Le Bureau de l'OMS Sierra Leone et le Bureau régional OMS pour l'Afrique
- L'Initiative du programme mondial de sécurité sanitaire pour sa collaboration et son soutien.

**Le rapport complet sera bientôt en ligne sur le site internet de l'OMS**

http://www.who.int/ihr/procedures/implementation/en/



UCDUSR0011774

# Résumé



UCDUSR0011775

# Scores et actions prioritaires pour le Cameroun

| Capacités | Indicateurs | Score |
|---|---|---|
| **Législation, Politique et financement nationaux** | P.1.1 La législation, les lois, la réglementation, les prescriptions administratives, les politiques ou autres instruments du gouvernement en place sont suffisants pour pouvoir appliquer le RSI. | **1** |
| | P.1.2 L'État peut démontrer qu'il a adapté et harmonisé la législation, les politiques et les dispositions administratives au niveau national pour permettre l'application du RSI (2005). | **1** |
| **Recommandations** | • Mettre en place un comité intersectoriel de juristes ou de conseillers techniques juridiques des Ministères selon l'approche « Une seule santé » pour procéder à une analyse systématique de la législation/règlementation nationale afin d'identifier les lacunes limitant la mise en œuvre du RSI (2005).<br>• Adapter, au vu des résultats de l'analyse de la législation, les textes par voie réglementaire pour faciliter la mise en œuvre du RSI (2005).<br>• Etablir une stratégie de plaidoyer auprès de l'Etat et des partenaires techniques et financiers pour un soutien technique et financier du processus de mise en conformité des textes pour l'application du RSI (2005).<br>• Plaider auprès du gouvernement pour une source pérenne de financement du RSI (2005). | |
| **Coordination, communication et promotion du RSI** | P.2.1 Un mécanisme fonctionnel est en place pour la coordination et l'intégration des secteurs concernés dans la mise en œuvre du RSI. | **2** |
| **Recommandations** | • Formaliser par voie réglementaire la nomination du Point Focal National RSI en tenant compte pour sa composition des différents domaines du RSI (2005) (santé, agriculture, élevage, commerce industrie, sécurité et transport).<br>• Former les membres du Point Focal National RSI et autres autorités impliquées dans la mise en œuvre du RSI (2005) à leurs fonctions.<br>• Elaborer des procédures opérationnelles standardisées avec la participation de tous les secteurs concernés pour faciliter la coordination, la communication et la Promotion du RSI (2005).<br>• Mettre en place une plateforme d'échange et de communication entre les membres du Point Focal National RSI (2005). | |
| **Résistance aux antimicrobiens** | P.3.1 Détection de la résistance aux antimicrobiens. | **1** |
| | P.3.2 Surveillance des infections causées par des agents pathogènes résistants aux antimicrobiens. | **1** |



UCDUSR0011776

| Capacités | Indicateurs | Score |
|---|---|---|
| | P.3.3 Programme de prévention et de lutte contre les infections associées aux soins de santé. | 1 |
| | P.3.4 Activités de gestion des antimicrobiens. | 1 |
| **Recommandations** | • Finaliser, valider et diffuser le plan national pour la détection et la notification des agents pathogènes résistants aux antimicrobiens en y intégrant le secteur privé.<br>• Mettre en place un groupe technique multidisciplinaire et multisectoriel pour mettre en œuvre ce plan selon l'approche « Une seule santé ».<br>• Renforcer les plateaux techniques des laboratoires pour la détection de la résistance aux antimicrobiens. | |
| **Zoonoses** | P.4.1 Système de surveillance en place pour les zoonoses/agents pathogènes prioritaires. | 3 |
| | P.4.2 Personnels vétérinaires et de santé animale. | 2…3 |
| | P.4.3 Mécanismes établis et fonctionnels pour riposter aux zoonoses infectieuses et aux zoonoses potentielles. | 2 |
| **Recommandations** | • Elaborer et mettre en œuvre des directives nationales de surveillance des zoonoses émergentes selon l'approche « Une Seule Santé ».<br>• Elaborer et diffuser des procédures de collaboration et de partage d'information entre les systèmes de surveillance en santé animale, humaine et environnementale, y compris en dehors des épisodes de crise.<br>• Elaborer, valider et mettre en œuvre les différents plans de lutte contre les zoonoses (contingence, surveillance, éradication, gestion).<br>• Intégrer aux programmes de formation des personnels en santé humaine, animale et environnementale, des formations en épidémiologie de terrain et à la lutte contre les zoonoses.<br>• Réaliser le recensement des animaux domestiques d'une part pour fournir à l'OIE les données requises permettant d'évaluer l'utilisation d'antibiotiques, d'autre part pour permettre l'affectation adéquate des ressources humaines. | |
| **Sécurité sanitaire des aliments** | P.5.1 Mécanismes existants et fonctionnels de détection et de riposte aux maladies d'origine alimentaire et à la contamination des aliments. | 2 |
| **Recommandations** | • Finaliser le processus d'adoption du projet de loi-cadre sur la sécurité sanitaire des aliments.<br>• Création<br>• Elaborer et diffuser des procédures opérationnelles standardisées (POS) de collaboration et de partage d'information entre les parties prenantes impliquées dans la | |



UCDUSR0011777

| Capacités | Indicateurs | Score |
|---|---|---|
| | sécurité sanitaire des aliments en attendant la création d'une Agence de sécurité sanitaire des aliments<br><br>• Elaborer un plan multisectoriel de détection et de riposte aux évènements liés à la sécurité sanitaire des aliments.<br><br>• Rendre opérationnel le laboratoire national de contrôle de la qualité des denrées alimentaires du Ministère de l'Elevage des Pêches et des Industries Animales. | |
| **Sécurité et sûreté biologiques** | P.6.1 Existence d'un système de sécurité et de sûreté biologiques impliquant l'ensemble du gouvernement pour les structures humaines, animales et agricoles. | **2** |
| | P.6.2 Formation et pratiques dans le domaine de la sécurité et de la sûreté biologiques. | **1** |
| **Recommandations** | • Mettre en place des mécanismes permettant d'améliorer la collaboration et la concertation interdisciplinaire et intersectorielle dans le domaine de la biosécurité et biosûreté.<br><br>• Elaborer et mettre en œuvre une législation et réglementation nationale en matière de sécurité et sûreté biologiques selon l'approche « Une seule santé », ainsi que des normes et directives dans ce domaine, notamment pour l'utilisation, l'inventaire, le stockage et l'élimination des agents pathogènes dans les laboratoires, la gestion des accidents et incidents biologiques.<br><br>• Mettre en place un mécanisme de classification officielle des laboratoires en fonctions de leurs capacités de confinement biologique.<br><br>• Elaborer et mettre en œuvre un programme national de formation à la sécurité et à la sûreté biologiques qui intègre les universités.<br><br>• Actualiser et mettre en œuvre le plan de gestion des déchets issus des soins en impliquant les différents secteurs concernés. | |
| **Vaccination** | P.7.1 La couverture vaccinale (rougeole) fait partie intégrante d'un programme national. | **3** |
| | P.7.2 Accès et délivrance de vaccins au niveau national. | **3** |
| **Recommandations** | • Finaliser, valider et mettre en œuvre à 80% au moins le plan d'amélioration de la qualité des données d'ici 3 ans.<br><br>• Etendre l'offre des vaccins aux zoonoses en impliquant systématiquement les autorités de la santé animale lors de l'élaboration des divers plans de vaccination (PPAc, Plan de Travail Annuel du PEV, Plan de Maintenance, Plan logistique, etc.).<br><br>• Poursuivre le renforcement des capacités des acteurs (compétence en logistique, gestion des vaccins, utilisation des outils y afférents) afin d'éviter les ruptures et les | |



UCDUSR0011778

| Capacités | Indicateurs | Score |
|---|---|---|
| | pertes de vaccin, et faire passer la couverture vaccinale anti-rougeole chez les enfants de 0 à 12mois, de 80% à 90% d'ici trois ans.<br><br>• Etablir une stratégie de plaidoyer auprès du Gouvernement et des partenaires techniques et financiers pour doter les districts en matériels de la chaine du froid à énergie solaire, en assurer la maintenance (préventive et curative), et atteindre ainsi une disponibilité en vaccins d'au moins 90% au niveau opérationnel, d'ici 3ans. | |
| **Système national de laboratoires** | D.1.1 Analyses en laboratoire pour la détection des maladies prioritaires. | **4** |
| | D.1.2 Système pour le transfert et le transport d'échantillons. | **1** |
| | D.1.3 Tests diagnostiques modernes et efficaces sur les lieux de soins et en laboratoire. | **2** |
| | D.1.4 Système de qualité des laboratoires. | **2** |
| **Recommandations** | • Mettre en place le réseau intersectoriel de laboratoires de santé humaine, animale et environnementale (sécurité sanitaire des aliments).<br><br>• Renforcer le plateau technique des laboratoires en termes de ressources humaines, d'équipements et consommables de laboratoire, d'approvisionnement régulier en réactifs et kits de diagnostics, mais aussi en termes de formation à la maintenance des équipements.<br><br>• Mettre en place un système de transport/transfert des échantillons harmonisé et sécurisé à tous les niveaux avec des procédures opératoires standardisées.<br><br>• Mettre en place un programme national d'assurance qualité et d'évaluation externe de la qualité pour tous les laboratoires des différents secteurs.<br><br>• Adopter et diffuser les différents documents du plan stratégique national de développement des laboratoires. | |
| **Surveillance en temps réel** | D.2.1 Systèmes de surveillance basée sur des indicateurs et de surveillance des événements. | **3** |
| | D.2.2 Système de notification électronique en temps réel interopérable et interconnecté. | **2** |
| | D.2.3 Analyse des données de surveillance. | **3** |
| | D.2.3 Systèmes de surveillance syndromique. | **4** |
| **Recommandations** | • Elaborer et mettre en œuvre des procédures opérationnelles standardisées pour intégrer les activités de surveillance conformément aux dispositions de la SIMR tout en tenant compte de l'approche « Une seule santé ».<br><br>• Renforcer les capacités des personnels de santé en SIMR à travers notamment la formation, des cours de recyclage et la supervision formative, après analyse | |



UCDUSR0011779

| Capacités | Indicateurs | Score |
|---|---|---|
| | situationnelle des besoins.<br>• Adapter et mettre en œuvre à tous les niveaux de la pyramide sanitaire, les directives techniques de la surveillance à base communautaire de l'OMS AFRO.<br>• Elaborer et mettre en œuvre un plan d'amélioration de la qualité des données ainsi qu'un plan de suivi et d'évaluation de la SIMR.<br>• Développer une plateforme de partage des données et d'information sur la surveillance entre les secteurs de la santé humaine, animale et environnementale dans le cadre de l'approche « Une seule santé ». | |
| **Notification** | D.3.1 Système efficace de notification à l'OMS, à la FAO et à l'OIE. | **3** |
| | D.3.2 Réseau et protocoles de notification dans le pays. | **1** |
| **Recommandations** | • Elaborer et diffuser à tous les acteurs du Point Focal National RSI, des modes opératoires normalisés pour l'approbation et la notification à l'OMS, à l'OIE ou à la FAO des évènements susceptibles de constituer une urgence de santé publique de portée internationale (USPPI) dans le cadre de l'approche une « Une seule santé ».<br>• Renforcer les capacités du Point Focal National RSI à travers la formation, l'appui financier et logistique pour améliorer ses performances, notamment la notification à l'OMS dans les 24 heures.<br>• Organiser des exercices de simulation pour tester la collaboration et la coordination des acteurs impliqués dans la notification des évènements susceptibles de constituer une USPPI. | |
| **Développement du personnel** | D.4.1 Des ressources humaines sont disponibles pour assurer les principales capacités requises au titre du RSI. | **3** |
| | D.4.2 Un programme de formation en épidémiologie appliquée est en place (type FETP). | **4** |
| | D.4.3 Stratégie pour les personnels. | **3** |
| **Recommandations** | • Elaborer et mettre en œuvre un plan national de développement des ressources humaines en tenant compte de l'évaluation des plans existants et de l'approche « Une seule santé », et en y intégrant une stratégie de capitalisation.<br>• Cartographier les ressources humaines selon l'approche « Une seule santé » et mettre en place un mécanisme de déploiement territorial du personnel.<br>• Renforcer la formation des acteurs de la surveillance aux différents niveaux (central, intermédiaire et périphérique) en épidémiologie de terrain type FETP.<br>• Poursuivre et étendre le projet de fidélisation des personnels de santé spécialistes | |



UCDUSR0011780

| Capacités | Indicateurs | Score |
|---|---|---|
| | impliqués dans la mise en œuvre du RSI (2005) dans les zones d'accès difficile. | |
| **Préparation** | R.1.1 Un plan national multirisques de préparation et d'action en cas d'urgence de santé publique existe et est appliqué. | **1** |
| | R.1.2 Les risques et les ressources de santé publique prioritaires sont cartographiés et exploités. | **2** |
| **Recommandations** | • Elaborer un plan national multirisques multisectoriel de préparation et de riposte aux situations d'urgence de santé publique en tenant compte des plans existants et des cartographies déjà réalisées.<br>• Finaliser la cartographie complète de toutes les ressources nationales afin d'élaborer un plan de gestion et de distribution des ressources nécessaires à la mise en œuvre du RSI (2005).<br>• Poursuivre les exercices de simulation concernant les risques cartographiés afin de tester les plans de préparation élaborés.<br>• Plaider pour un renforcement de la ligne budgétaire affectée à la préparation et à la gestion des urgences de santé publique. | |
| **Interventions d'urgence** | R.2.1 Capacité à activer des interventions d'urgence. | **1** |
| | R.2.2 Procédures et plans opérationnels du centre d'opérations d'urgence. | **1** |
| | R.2.3 Programme d'interventions d'urgence. | **3** |
| | R.2.4 Procédures de prise en charge des cas appliquées pour les dangers relevant du RSI. | **2** |
| **Recommandations** | • Finaliser et diffuser les textes règlementaires régissant la création, les missions, le fonctionnement et l'activation du COUSP en précisant les modalités de communication avec les échelons locaux et régionaux ainsi que les partenaires nationaux (information et rétro information)<br>• Rendre opérationnel le COUSP 24h/24 et 7jours/7 avec notamment l'identification d'un point unique, l'attribution de moyens adaptés en termes de personnel, de logistique et de financement<br>• Valider et mettre en œuvre les plans et procédures opérationnels pour les interventions d'urgence<br>• Elaborer et partager un plan stratégique du COUSP en prenant en compte les plans existants et les documents nécessaires à son fonctionnement : gestion des incidents, commandement, planification, financement, prise en charge de cas appliquée pour les dangers relevant du RSI (2005), etc.<br>• | |



UCDUSR0011781

| Capacités | Indicateurs | Score |
|---|---|---|
| **Lien entre la santé publique et les autorités chargées de la sécurité** | R.3.1 La santé publique et les autorités chargées de la sécurité (par exemple, les services chargés de faire appliquer la loi, le contrôle aux frontières et les douanes) sont en liaison lors d'un événement biologique suspecté ou confirmé. | **2** |
| **Recommandations** | • Elaborer et mettre en œuvre un mémorandum d'accord entre la santé publique et les autorités en charge de la sécurité pour la gestion des urgences de santé publique, conformément au RSI (2005).<br>• Elaborer et mettre en œuvre des procédures opératoires standardisées pour la coordination d'une action conjointe et le partage d'information entre la santé publique et les autorités chargées de la sécurité, en cas de situation d'urgence.<br>• Renforcer les capacités des personnels de santé publique et ceux en charge de la sécurité, notamment par la mise en place d'un programme de formations conjointes et des exercices de simulation. | |
| **Moyens médicaux et déploiement de personnel** | R.4.1 Système en place pour l'envoi et la réception de moyens médicaux lors d'une urgence de santé publique. | **2** |
| | R.4.2 Système en place pour l'envoi et la réception de personnels de santé lors d'une urgence de santé publique. | **1** |
| **Recommandations** | • Finaliser, valider, simuler, diffuser et mettre en œuvre le plan national de la chaine d'approvisionnement médicale, intégrant les procédures d'envoi, de réception des moyens médicaux et le déploiement des personnels pour la réponse aux urgences.<br>• Mettre en place un système d'information pour une gestion efficace des moyens médicaux tout au long de la chaîne d'approvisionnement.<br>• Développer un partenariat international pour appuyer l'envoi, la réception et les moyens médicaux et le déploiement des personnels pour la réponse aux urgences sur la base des critères objectifs.<br>• Elaborer un plan pour l'envoi et la réception de personnels de santé lors d'une urgence de santé publique. | |
| **Communication sur les risques** | R.5.1 Systèmes de communication sur les risques (plans, mécanismes, etc.). | **1** |
| | R.5.2 Communication et coordination internes et avec les partenaires. | **2** |
| | R.5.3 Communication publique. | **3** |
| | R.5.4 Communication pour faire participer les communautés touchées. | **2** |
| | R.5.5 Écoute dynamique et gestion des rumeurs. | **2** |
| **Recommandations** | • Elaborer et mettre en œuvre un plan national de communication sur les risques en tenant compte des plans de communication sectoriels existants.<br>• Mettre en place officiellement un cadre multisectoriel de concertation et | |



UCDUSR0011782

| Capacités | Indicateurs | Score |
|---|---|---|
| | d'harmonisation pour la communication en situation d'urgence.<br>• Elaborer et diffuser des procédures opérationnelles pour la communication en situation d'urgence.<br>• Élaborer, diffuser et mettre en œuvre un plan national de collecte et de gestion des rumeurs.<br>• Elaborer et mettre en œuvre un plan de renforcement des capacités de tous les acteurs en matière de communication sur les risques dans l'esprit « Une seule santé ». | |
| **Points d'entrée** | PoE.1 Capacités de routine présentes aux points d'entrée. | **1** |
| | PoE.2 Action de santé publique efficace aux points d'entrée. | **1** |
| **Recommandations** | • Finaliser, valider, diffuser à toutes les parties prenantes le Plan Stratégique de la Surveillance Transfrontalière au Cameroun intégré à d'autres plans d'action de santé publique.<br>• Organiser des exercices de simulation réguliers et intersectoriels.<br>• Réviser et désigner officiellement des points d'entrée par rapport au RSI (2005) et rendre opérationnel à tous les points d'entrée désignés les services médicaux appropriés, y compris personnel, matériels, locaux adéquats et moyens diagnostiques pour l'examen et la prise en charge rapides des voyageurs malades.<br>• Tester et actualiser les outils de collecte de données (notamment le logiciel DHIS2) aux points d'entrée.<br>• Elaborer les POS pour l'inspection des moyens de transport, l'identification et le transfert des patients vers des structures médicales spécialisées. | |
| **Événements d'origine chimique** | CE.1 Mécanismes fonctionnels en place pour la détection et la riposte à des événements/urgences d'origine chimique. | **1** |
| | CE.2 Environnement favorable à la gestion d'événements d'origine chimique. | **1** |
| **Recommandations** | • Elaborer un plan national multisectoriel d'urgence pour la gestion des événements de santé publique d'origine chimique (surveillance et riposte) s'inscrivant dans le plan national de contingence multirisques et créer un organisme national.<br>• Mettre en place un Centre antipoison, et d'ici là, développer des capacités en matière d'information et de conseils en s'appuyant sur les ressources existantes et en établissant des partenariats avec d'autres centres antipoison en Afrique.<br>• Dans le cadre du plan national multisectoriel d'urgence pour la gestion des événements de santé publique d'origine chimique, inventorier les principales sources de risques chimiques (industries, raffineries, entrepôts), établir les priorités et élaborer des plans | |



UCDUSR0011783

| Capacités | Indicateurs | Score |
|---|---|---|
| | d'urgence externe pour minimiser les conséquences en termes de santé publique. | |
| **Situations d'urgence radiologique** | RE.1 Mécanismes fonctionnels en place pour la détection et la riposte aux situations d'urgence radiologique et nucléaire. | **3** |
| | RE.2 Environnement favorable à la gestion des situations d'urgence radiologique | **3** |
| **Recommandations** | • Elaborer un mécanisme d'échange d'information régulier entre les autorités compétentes en radioprotection et l'unité de surveillance du système d'information sanitaire.<br>• Identifier et renforcer les capacités des hôpitaux à accepter et prendre en charge les victimes d'incidents radiologiques.<br>• . | |



UCDUSR0011784

**From:** Christine Kreuder Johnson <ckjohnson@ucdavis.edu>
**To:** "Whc-affiliated@ucdavis.edu" <Whc-affiliated@ucdavis.edu>, "Whc-all@ucdavis.edu" <Whc-all@ucdavis.edu>
**Cc:** Tim Tinker <tinker@biology.ucsc.edu>, Ian Gardner <iagardner@ucdavis.edu>, Ben Gonzales <bgonzale@dfg.ca.gov>, "Torres, Steve@Wildlife" <Steve.Torres@wildlife.ca.gov>, Dave Jessup <wda.manager@gmail.com>, "Frances Gulland" <gullandf@tmmc.org>, Peter Daszak <daszak@ecohealthalliance.org>, Simon Anthony <anthony@ecohealthalliance.org>, Greg Bossart <gbossart@hboi.edu>, Daphne Bremer <[redacted]>, Tristan Burgess <[redacted]>, Tim E Carpenter <tecarpenter@ucdavis.edu>, Bruno Chomel <bbchomel@ucdavis.edu>, Jon Epstein <epstein@ecohealthalliance.org>, Billy Karesh <karesh@ecohealthalliance.org>, James Estes <jestes@ucsc.edu>, Joseph Karl Gaydos <jkgaydos@ucdavis.edu>, Damien Joly <djoly@metabiota.com>, William Reisen <wkreisen@ucdavis.edu>, John Largier <jlargier@ucdavis.edu>, Bruce Rideout <BRideout@sandiegozoo.org>, Karen Shapiro <kshapiro@ucdavis.edu>, "Elizabeth Anne VanWormer" <evanwormer@ucdavis.edu>, Donald Smith <smith@etox.ucsc.edu>, "Stetter,Mark" <Mark.Stetter@colostate.edu>, Walter Boyce <wmboyce@ucdavis.edu>, Jonna Mazet <jkmazet@ucdavis.edu>, Michael Ziccardi <mhziccardi@ucdavis.edu>, Kirsten Gilardi <kvgilardi@ucdavis.edu>, "Matthew Blake" <mblake@ucdavis.edu>, Tracey Goldstein <tgoldstein@ucdavis.edu>
**Subject:** UC Davis position: Assistant Professor of Epidemiology in Climate Adaptation Health
**Sent:** Mon, 9 Oct 2017 22:44:48 +0000
Assist Prof Climate Adaptation.pdf

Dear Colleagues,
Please help spread the word to any potentially qualified candidates for this new faculty position at UCD.
Position description attached here and brief description with link below.

*The University of California at Davis is seeking applicants for a tenure-track faculty position in Climate Adaptation Health. This position is being sought together with four other faculty positions in Civil Infrastructure, Weather Extremes, Plant Genomics, and Urban-Rural Interfaces to form a team together with our faculty to tackle the critical climate adaptation challenges of the next few decades and educate future researchers and practitioners in climate adaptation. The Climate Adaptation Health position will be in the Schools of Medicine and Veterinary Medicine and we are seeing applicants interested in the epidemiology of climate change and impacts on animal and human health. To receive fullest consideration, applications must be received by October 30, 2017; position open until filled.*
*More information can be found at https://recruit.ucdavis.edu/apply/JPF01735.*

Thank you,
Chris

Christine Kreuder Johnson, VMD, PhD
Professor of Epidemiology and Wildlife Health
Director, EpiCenter for Disease Dynamics
One Health Institute
VM: Medicine and Epidemiology
School of Veterinary Medicine
University of California
VM3B 1089 Veterinary Medicine Drive
Davis, California 95618
+1.530.752.1238

*DEPARTMENT OF MEDICINE AND EPIDEMIOLOGY*
*SCHOOL OF VETERINARY MEDICINE*
*UNIVERSITY OF CALIFORNIA, DAVIS*

*DEPARTMENT OF PUBLIC HEALTH SCIENCES*
*SCHOOL OF MEDICINE*
*UNIVERSITY OF CALIFORNIA, DAVIS*

**POSITION AVAILABLE**: Tenure-Track Assistant Professor of Epidemiology in Climate Adaptation Health

**SALARY**: Dependent on qualifications and experience.

**QUALIFICATIONS**: PhD in epidemiology or closely related discipline, or a DVM or MD or equivalent with a Master's degree in epidemiology or a closely related public health discipline, is required. Demonstrated experience, productivity, and creativity in research in the epidemiology of climate change and impacts on health are required. Desirable areas of research experience include risks to animal and human health, vulnerable populations, disease surveillance, disaster epidemiology, zoonotic infectious disease and environmental change, harmful algal blooms, water quality and quantity, and other climate-induced food and/or water concerns, quantitative methods, trans-disciplinary research, and global health research. Demonstrated experience working at the interface of human, animal, and environmental health is preferred. Demonstrated record of effective teaching is desired. Must possess excellent interpersonal and communication skills and a demonstrated ability to work with others in a collegial team atmosphere.

**RESPONSIBILITIES**: Teaching: Responsibilities include: 1) teaching graduate professional (MD and/or DVM) and/or MPVM/MPH, PhD and/or graduate academic course(s) in some of the following: epidemiology, epidemiologic study design, infectious disease epidemiology, surveillance, environmental health science, and modeling of human and/or animal diseases and their risks, and 2) mentoring and directing graduate students.

Research: The development of a creative, independent, and productive basic and/or applied research program in epidemiology related to climate adaptation is a requirement of the position, including publication of results in scientific journals.

Service: University and public service through committee work, participation in professional organizations, continuing education and other appropriate means is required.

**APPLICATION PROCESS**: To receive fullest consideration, applications must be received by October 30, 2017, position open until filled. Interested applicants should submit 1) a letter of intent outlining special interest in the position, overall related qualifications and experience and career goals; 2) curriculum vitae; 3) the names and addresses of three professional references; and 4) a statement summarizing experience and professional contributions in the area of equity and diversity. Application materials may be submitted by using the University's online submission program, https://recruit.ucdavis.edu/apply/JPF01735.

*The University of California, Davis and the Department of Medicine and Epidemiology, School of Veterinary Medicine, and the Department of Public Health Sciences, School of Medicine are interested in candidates who are committed to the highest standards of scholarship and professional activities, and to the development of a campus climate that supports equality and diversity. The University of California is an affirmative action/equal opportunity employer.*

3-19-2017

| | |
|---|---|
| **From:** | Jonna Mazet <jkmazet@ucdavis.edu> |
| **To:** | Peter Daszak <daszak@ecohealthalliance.org>;kvgilardi@ucdavis.edu <kvgilardi@ucdavis.edu> |
| **CC:** | Carlos Zambrana-Torrelio <zambrana@ecohealthalliance.org>;Aleksei Chmura <chmura@ecohealthalliance.org>;Erica Johnson <johnson@ecohealthalliance.org>;Evelyn Luciano <luciano@ecohealthalliance.org> |
| **Sent:** | 10/17/2017 8:50:27 PM |
| **Subject:** | Re: Time Sensitive!! Resurrecting our Coupled Natural-Human Systems proposal to NSF on DEEP FOREST |

I'm supportive, but it's really up to Kirsten to evaluate the feasibility and pros & cons in our current operating climate. She is currently on her way to Uganda & Rwanda, so she may be delayed in responding for a couple of days.
Thanks for asking,
J

On Tue, Oct 17, 2017 at 12:05 PM, Peter Daszak <daszak@ecohealthalliance.org> wrote:

Hi Jonna and Kirsten – a few years ago we submitted a DEEP FOREST proposal to NSF CNH and got semi-decent comments back. We'd like to resurrect it and would like to keep the current focus on DEEP FOREST countries. The plan is to use the DF data from Brazil, Uganda and Malaysia as the basis, but ditch Brazil as a country we're going to continue to work in so that the continued fieldwork will be in Malaysia and Uganda.

The deadline is Nov 21st. Carlos is pulling together the draft and the response to reviewers (reviewer comments attached).

I want to first check with you both that you are interested in doing this – I definitely think it's worth a shot considering the fairly positive reviewers' comments. If so, we'll need to rapidly line up all the paper work, budgets, etc. I've cc'd Carlos and Evelyn who will be able to coordinate.

Hope you'll be part of this and looking forward to getting this grant funded!

Cheers,

Peter

**Peter Daszak**

*President*

EcoHealth Alliance

460 West 34th Street – 17th Floor

New York, NY 10001

Tel. +1 212-380-4473

www.ecohealthalliance.org

*EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that prevent pandemics and promote conservation.*

**From:** Peter Daszak <daszak@ecohealthalliance.org>
**To:** Jonna Mazet <jkmazet@ucdavis.edu>, "kvgilardi@ucdavis.edu" <kvgilardi@ucdavis.edu>
**Cc:** Carlos Zambrana-Torrelio <zambrana@ecohealthalliance.org>, Aleksei Chmura <chmura@ecohealthalliance.org>, Erica Johnson <johnson@ecohealthalliance.org>, Evelyn Luciano <luciano@ecohealthalliance.org>
**Subject:** RE: Time Sensitive!! Resurrecting our Coupled Natural-Human Systems proposal to NSF on DEEP FOREST
**Sent:** Wed, 18 Oct 2017 18:40:21 +0000

No problem. We'll continue right now with the plan of including Uganda and start pulling together the draft.

That said, I hope you'll be interested in doing more work on DF in Uganda Kirsten. I know it was a hassle to organize last time round, but we could simplify it by just focusing on bat/rodent sampling/testing and no extra human behavior work. By the way – the rationale for carrying on the project is that for ecological studies you normally have to do multi-year sampling to make sure that multi-year changes in weather etc. are not driving the patterns.

Anyway – think about it, and let us know as soon as you can. I'm ready to talk by email or phone over the next few days/weeks, and we will be crunching on the re-write during that time…

Cheers,

Peter

**Peter Daszak**
*President*

EcoHealth Alliance
460 West 34th Street – 17th Floor
New York, NY 10001

Tel. +1 212-380-4473
www.ecohealthalliance.org

*EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that prevent pandemics and promote conservation.*

**From:** [redacted] **On Behalf Of** Jonna Mazet
**Sent:** Tuesday, October 17, 2017 11:50 PM
**To:** Peter Daszak; kvgilardi@ucdavis.edu
**Cc:** Carlos Zambrana-Torrelio; Aleksei Chmura; Erica Johnson; Evelyn Luciano
**Subject:** Re: Time Sensitive!! Resurrecting our Coupled Natural-Human Systems proposal to NSF on DEEP FOREST

I'm supportive, but it's really up to Kirsten to evaluate the feasibility and pros & cons in our current operating climate. She is currently on her way to Uganda & Rwanda, so she may be delayed in responding for a couple of days.
Thanks for asking,
J

On Tue, Oct 17, 2017 at 12:05 PM, Peter Daszak <daszak@ecohealthalliance.org> wrote:
Hi Jonna and Kirsten – a few years ago we submitted a DEEP FOREST proposal to NSF CNH and got semi-decent comments back. We'd like to resurrect it and would like to keep the current focus on DEEP FOREST countries. The plan is to use the DF data from Brazil, Uganda and Malaysia as the basis, but ditch Brazil as a country we're going to continue to work in so that the continued fieldwork will be in Malaysia and Uganda.

The deadline is Nov 21st. Carlos is pulling together the draft and the response to reviewers (reviewer comments attached).

I want to first check with you both that you are interested in doing this – I definitely think it's worth a shot considering the fairly positive reviewers' comments. If so, we'll need to rapidly line up all the paper work, budgets, etc. I've cc'd Carlos and Evelyn who will be able to coordinate.

Hope you'll be part of this and looking forward to getting this grant funded!

Cheers,

Peter

**Peter Daszak**
*President*

EcoHealth Alliance
460 West 34th Street – 17th Floor
New York, NY 10001

Tel. +1 212-380-4473
www.ecohealthalliance.org

*EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that prevent pandemics and promote conservation.*

**From:** Corina Grigorescu Monagin <cgmonagin@ucdavis.edu>
**To:** Andrew Clements <aclements@usaid.gov>, Katherine Leasure <kaleasure@ucdavis.edu>, David John Wolking <djwolking@ucdavis.edu>, "Jonna Mazet" <jkmazet@ucdavis.edu>
**Cc:** "predictmgt@usaid.gov" <predictmgt@usaid.gov>
**Subject:** Re: Important Security Information for Senegal
**Sent:** Thu, 19 Oct 2017 20:58:38 +0000

Thanks Andrew.

Corina Monagin, MPH, DrPH

Project Scientist, PREDICT Project of USAID
One Health Institute
School of Veterinary Medicine
University of California Davis
1089 Veterinary Medicine Drive
Davis, CA 95616, USA

Mobile: +1.415.741.6996

---

**From:** Andrew Clements <aclements@usaid.gov>
**Date:** Thursday, October 19, 2017 at 9:27 AM
**To:** Katherine Leasure <kaleasure@ucdavis.edu>, David J Wolking <djwolking@ucdavis.edu>, Corina Grigorescu Monagin <cgmonagin@UCDAVIS.EDU>, Jonna Mazet <jkmazet@ucdavis.edu>
**Cc:** "predictmgt@usaid.gov" <predictmgt@usaid.gov>
**Subject:** Fwd: Important Security Information for Senegal

See below

*Andrew P. Clements, Ph.D.*
*Senior Scientific Advisor*
*Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health*
*U.S. Agency for International Development*
*Mobile phone: 1-571-345-4253*
*Email: aclements@usaid.gov*
Begin forwarded message:

**From:** Christopher Penders <cpenders@usaid.gov>
**Date:** October 19, 2017 at 6:05:34 PM GMT+2
**To:** "GH Mail List (USAID)" <ghmaillist@usaid.gov>
**Subject: Important Security Information for Senegal**
**Reply-To:** cpenders@usaid.gov

Dear AORs and CORs of projects with actvities in Senegal,

We have some important information to share with you regarding security in Senegal. Please see the link below for more information from the U.S. Embassy in Senegal:

https://sn.usembassy.gov/security-message-u-s-citizens-increased-security-awareness-october-18-2017/

Please share the link with this information with your Implementing Partners so that they can make decisions appropriately based on this and other information, their organizational policies, etc.

Kind regards,
Chris Penders

--

**Christopher Penders, MS, MPH**
Africa Regional Team Lead
Global Health Bureau | Office of Country Support
**USAID**|Washington
Phone: +1.571.551.7271
Mobile: REDACTED
Email: cpenders@usaid.gov

*Leading Public Health Development*



Stay connected to **USAID** Global Health

**From:** Peter Daszak <daszak@ecohealthalliance.org>
**To:** Brooke Watson <watson@ecohealthalliance.org>;Dennis Carroll (DCarroll@usaid.gov) <DCarroll@usaid.gov>;Jonna Mazet (jkmazet@ucdavis.edu) <jkmazet@ucdavis.edu>
**Sent:** 10/20/2017 9:14:42 AM
**Subject:** WHO Bull paper

Additions to the paper and to the responses to smooth some of these things out a bit.

Ready to upload and submit…

Cheers,

Peter

**Peter Daszak**
*President*

EcoHealth Alliance
460 West 34th Street – 17th Floor
New York, NY 10001

Tel. +1 212-380-4473
www.ecohealthalliance.org

*EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that prevent pandemics and promote conservation.*

We thank the editorial board and reviewer 1 for agreeing to review a revised draft of our manuscript, and for providing helpful comments and questions. Addressing them has strengthened and clarified our attached revised manuscript. Additional responses and clarifying points are detailed below, from both the editorial board and from Reviewer #1.

**Editorial Board Questions**

**1. If the launch is to be held in 2018, how does this event change the information currently available about the project at http://www.globalviromeproject.org/?**

The website will be updated to reflect progress leading up to and following the 2018 launch as developments occur. Globalviromeproject.org has gone through several revisions as the GVP team clarifies its strategy and responds to feedback, and the website strives to reflect the most up-to-date status of the project. In addition, we strive to be transparent as possible, and include links to previous vision statements for the project in the "archived resources" section.

The currently available information about the project's goals, vision, core team, and strategy are not altered by the fact of the 2018 launch.

**2. Why was a 10-year span chosen and how many viruses will be sequenced, cultured and identified as pathogenic for humans during this decade?**

When defining the boundaries of this ambitious project, the team drew several parallels to the Human Genome Project (HGP). Part of HGP's success came from its well-defined and time-bound scope, and the GVP seeks to imitate that structure. Despite these bounds, we strongly encourage complementary efforts that could work synergistically alongside the GVP or build off of the platform that we seek to build. We have added these details to the revised manuscript.

Because the GVP is necessarily a scientific discovery project, we cannot know how many viruses will be sequenced, let alone cultured and identified as pathogenic, before samples are even collected. However, detailed methods on the number of samples we will collect are included in Reference #4 and referred to in the text. We will be able to supply this text to the editorial board if requested.

**3. Please clarify the amounts and sources of guaranteed funding.**

Funding for phase 1 of the GVP will be announce at the PMAC meeting on Jan 30th. This includes commitments from US Govt sources, and at least one international partner. Given the active fundraising process at the moment, and the likelihood that further donors will come forwards by the time the paper is published, we have not listed out specifics in this manuscript.

**4. Please explain how "virome" - usually understood to be the collection of viruses inhabiting an individual vertebrate - can be redefined as all earthly viruses,**

**pathogenic or otherwise. Please clarify whether mitochondrial DNA is excluded from this definition.**

We draw guidance from previous scientific initiatives, including both the Human Genome Project and the Human Microbiome Project. The community of microbiome researchers have dealt with this confusion recently – we follow their lead in relaxing the "-ome" suffix to include both the genetic material of the microorganisms and the microorganisms themselves. *Nature* recently published on the composition of the "Global Ocean Virome" , which certainly did not entail only a collection of viruses in an individual vertebrate, so we choose to also use this expanded definition of a virome.

We do want to stipulate that although the "virome" might include all earthly viruses, our project does not seek to discover all unknown viruses. We are, for example, not intending to find the viruses of plants, invertebrates, fish, or many other viral hosts. We thank the review board for pointing out this out, and we clarified in the text that we plan to sample only viruses from mammals and water birds.

**5. Please explain how sampling, collection, sequencing, specimen handling, shipping, data analysis, reporting, validation and intellectual property rights management will be handled.**

We appreciate the review boards (appropriate) interest in these issues. Over the past 12 months, we have set in place a series of working groups, each led by two co-chairs representing developed and developing countries, and each comprised of leader in their respective fields, covering appropriate geographic, gender and disciplinary diversity. These working groups cover each of the issues suggested above and have prepared working documents to propose best practices for each. Given the immensity of this work, it is not possible to report all of this information here, but we have now inserted information about the working groups in the manuscript.

**6. Please explain how the signal to noise ratio will be established, and how potential pathogenicity for humans will be ascertained.**

We have added language on our plan to use a combination of machine learning, laboratory science, and partnerships with health facilities near sampling sites to triage viruses with pathogenic potential. An extensive methods section about training and testing algorithms on viral data is outside the scope of this overview and would require an entire article in itself, but we have added a citation discussing similar machine learning methods in the field of genomics.

**7. Please develop further the comparisons with the human genome project and note the critical differences; sequencing one organism rather than hundreds of thousands of viruses, the relative ease of specimen collection from humans and the difficulty of establishing the relevancy of the results.**

We have added a paragraph discussing parallels and differences between the two projects.

**8. Please include a brief discussion on the convention for biodiversity, noting that biological diversity is a necessary feature of the environment in which humans live, elimination of all viral "threats" is not a realistic or desirable goal and that the rapid evolution of viruses and their host microbes mean that such a project would need to be done in continuity.**

We agree, and thank the editors for bringing up this important point. We have added a paragraph discussing the inevitable discovery of non-pathogenic viruses, and the potential discovery of viral symbionts.

We also added language in the final paragraph confirming the reality of rapid viral evolution. Hopefully the editors will agree that the GVP makes no claims to be a “be-all, end-all” dictionary of viruses, but rather a necessary and unprecedented “baseline snapshot” from which broad-scale viral discoveries can begin. We do not envision the GVP as a recurring project, but believe that the capacity built by the project will empower and strengthen existing and future surveillance networks.

**Reviewer 1 Comments**

**The authors of this manuscript claimed that "But recent estimates put the total number of these animal viruses that could threaten us at more than 1.5 million, spanning 24 viral families (4). Compared to the 260+ viruses known from humans (5), this viral "dark matter" represents**
**99.9% of the potential pandemic threat. It means that, for every known strain of the SARS virus**
**there are likely thousands of unknown "SARS-like" viruses (6) circulating in wildlife that could emerge in the future. The same likely holds for other viral families – HIV and retroviruses, Ebola**
**and filoviruses, and Zika and flaviviruses."**

**Further, the authors stated that "The success of the GVP will be measured by its deliverables, which in the course of its 10-year lifespan will include:**
**• Detecting and identifying the vast majority of potential zoonotic viral threats to human, livestock, and wildlife health"; on the webpage of Global Virome Project, they believe that "The success of the GVP will be measured by its deliverables, which in the course of its 10-year lifespan will include:**
**•Detecting and identifying at least 99% of potential zoonotic viral threats to human health and food security." (http://www.globalviromeproject.org/about/).**

**Suppose they work six days a week, and there are about two weeks of public holidays every year, so they only are able to work 300 days a year. If they want to detect 1.5 million new viruses in 10 years, every year they need to find 150,000 new viruses, and every day they should discover 500 new viruses.**

Thank you for this feedback. The GVP does not intend to discover every mammalian virus on earth. Such a goal would be impossible to prove, implausible to execute, and irresponsible to attempt in a world of limited resources – as the reviewer suggests. This was not clear in our first submission, and we have added language in the text to clarify. Although the proposed work is still ambitious, it is based on our experiences of 8 years of work in USAID's PREDICT project, and the feasibility of the approach, and it's likely cost have been worked out accordingly. We have clarified some of this in the text.

We hope that the reviewer will agree that *some* amount of viral discovery is a worthwhile goal, and endeavor to show that global viral discovery, when structured in a systematic way that includes collection of metadata and viral ecology, is 1) valuable, 2) feasible, and 3) a sound investment in scientific discovery.

**Actually, "There are 219 virus species that are known to be able to infect humans. The first of these to be discovered was yellow fever virus in 1901, and three to four new species are still being found every year." (Phil. Trans. R. Soc. B (2012) 367, 2864–2871).**

**Obviously, the authors of this manuscript overestimated the number of new viruses.**

We were not clear enough in our original draft, and have revised according to the reviewer's feedback. Our estimate of the total number of viral species did not refer only to *human* viruses, but to viruses circulating in mammals and waterbirds. We believe that some of these viruses plausibly already have the capacity to infect humans, while others are a few mutations away from human infective potential. We have recently published an extensive analysis of all ICTV data on viruses and their hosts, and have used this information to derive and validate some of the estimates.

We recognize that the vast majority of the viruses we discover will never cause a human pandemic, or even a local outbreak. These viruses could be seen as viral "noise" that distracts from the "signal" viruses that currently infect humans, but we believe that studying the sequence, structure and function of symbiotic viruses may shed light on larger factors that determine a virus's pathogenicity. We liken the discovery of these "harmless" viruses to the sequencing of introns in the human genome. Much as this "junk DNA" was discovered to be critically important to gene promotion and regulation, nonpathogenic viruses could provide key insights into viral transmission and pathogenicity.

**It is very important to predict possible pandemics, however, it is no less important to avoid false alarms. The World Health Organization (WHO) mistakenly raised the level of influenza pandemic alert from phase 5 to the highest phase 6 on June 11, 2009. In August 2009, Minister of Health of Canada announced Canada's order of 50.4 million doses of H1N1 vaccine. In January 2010, Minister of Health of Canada announced five million doses of the H1N1 2009 vaccine to be given to Mexico by the manufacturer (http://www.phac-aspc.gc.ca/about_apropos/evaluation/reports-rapports/2010-2011/h1n1/context-contexte-eng.php).**

**Canada only had about 33.7 million people in 2009, and most Canadians were reluctant to receive H1N1 influenza vaccination. A large number of doses of H1N1 vaccines (millions of dollars' worth) were unused and wasted, even though five million doses of those vaccines were donated to Mexico.**

**Nowadays, we have much better social, economic, and public health systems than 100 years ago. We have much better general population health, communication, transportation, and international cooperation. We know most infectious diseases very well, so we are able to stop and control infectious disease outbreaks by vaccination (except a few pathogens like HIV) and following useful epidemiological procedures. Even if an outbreak caused by an unknown pathogen occurs, we still can stop and control the outbreak by isolating and treating the infected patients in hospitals and performing other practical public health measures. We should learn lessons from the mistakes we made. Overestimation of the number of new viruses and their possible risks will cause overreacting and wasting public resources.**

The reviewer makes a great point, one that we agree with and did not appropriately address in our first submission. We have endeavored to fix this in the revised draft. In striving to identify pathogenic viruses, the GVP seeks to also identify those that are unlikely to cause human infection. This project seeks to make treatment, containment and care of communicable diseases not only accessible, but appropriate, by enabling rapid triage of viral infections of unknown etiology.

**Some minor mistakes:**
**Reference 2 was incomplete.**

Thank you for this note – the reference has been corrected.

**Launching the Global Virome Project:**
**The Beginning of the End of the Pandemic Era**

Summary: At the Prince Mahidol Awards Conference on January 30, 2018, representatives from across the globe – high level policy and decision makers, thought leaders, subject matter experts, researchers, representatives from international organizations working on animal, human and environmental health, as well as donors, foundations, and representatives from the private sector – came together to launch the Global Virome Project, a bold and innovative 10 year partnership to develop a global atlas of the majority of the planet's naturally-occurring viral threats, transforming the world of emerging diseases into a data-rich field – driving the advanced development of prevention efforts and countermeasures against future threats. This international alliance will connect the next generation of local scientists, and promote equitable access to data and benefits.

We live in an era when the number of potential pandemic threats is greater than it has ever been in human history. Previously-unknown viruses emerge with increasing frequency, driven by our expanding population, surging global travel, and our domination of the environment. We live in fear of a new pathogen suddenly emerging and sweeping through every household, through every community, irrespective of borders, or of its hosts' social and economic standing. This fear alone can cost billions, as we saw in the global panic that followed SARS and H1N1



UCDUSR0011800

influenza virus outbreaks, but it is not unfounded, as evidenced by the 35-year HIV/AIDS epidemic that has cost over 35 million lives.

Despite the potential impact of viral threats, the world remains unable to predict when, where, or from what species the next emerging virus will break out. Global trends indicate that over the course of this century, new microbial threats will continue to emerge at an accelerating rate, driven by the world's expanding population, growing interconnectedness, and increasing interactions with animal populations (1). The majority of these global threats originate in a seemingly endless pool of viruses carried by our relatives in the Animal Kingdom (2). Researchers have been able characterize some of these viruses and trace their roots to their mammalian origins – HIV-1 that spilled over from chimpanzees to people, for example, or Ebolavirus carried by bats in Africa (3). But recent estimates put the total number of these animal viruses that could threaten us at more than 1.5 million, spanning 24 viral families (4). Compared to the 260+ viruses known from humans (5), this viral dark matter represents 99.9% of the potential pandemic threat. It means that, for every known strain of the SARS virus there are likely thousands of unknown "SARS-like" viruses (6) circulating in wildlife that could emerge in the future. The same likely holds for other viral families – HIV and retroviruses, Ebola and filoviruses, and Zika and flaviviruses.

However, we believe the dire consequences of epidemic viral infections, such as those experienced from SARS, avian flu, swine flu, Ebola, MERS, and Zika viruses are avoidable. Success in preventing pandemics and the uncontrolled spread of epidemics requires thinking and acting differently. Rapid and revolutionary advances in health science and technology allow



UCDUSR0011801

us to imagine a world without the threat of pandemics. With new knowledge comes the ability to move away from a reactionary approach, to a strategy that focuses ever more on prediction and prevention of these threats. This strategy is captured by the GVP's bold global-scale 'big science' project with its near-term time horizon akin to the Human Genome Project. The recently launched Coalition for Epidemic Preparedness Innovations (CEPI) represents a critical step to address known but long-neglected viral threats, such as MERS-CoV, Lassa Fever, and Nipah Virus (7). This vital work addresses three dangerous but underfunded known viral threats; however, a tremendous challenge remains: how do we best prepare for those "unknown" future threats?

The Global Virome Project (GVP) is designed to complement the efforts of CEPI by targeting the vast pool of "unknown" future threats. Specifically, it will involve sampling and viral discovery in mammal taxa known to host high viral diversity (5) in high-biodiversity emerging disease 'hotspots' (1), as well as water birds. The program aims to identify 70-80% of the uknown viruses in these groups from viral families known to include zoonoses. Following the lead of the Human Genome Project, the GVP's work will take a decade, with measurable targets along the way. The GVP's goal of characterizing viral threats in wildlife – their natural hosts – allows us to prepare for viruses *before they jump to us.* This will transform our public health culture from one that responds to the latest outbreak to one that predicts and prevents future pandemics. The volume of new data produced by the GVP will enable disruptive approaches for the development of biomedical and non-medical countermeasures. This effort will also better prepare us to prevent accidental or intentional release of laboratory-enhanced virus variants.



UCDUSR0011802

Imagine how Big Data virology could transform vaccine and drug development. Tens of thousands of new viruses could allow biotechnology efforts to move from single-virus therapeutics and vaccines to ones that target a whole family of viruses. In addition, as we build up a picture of every virus' ecologic profile – which species it infects, where on the planet it's found, which communities are exposed to it – we can target our vaccines, drugs and behavioral risk mitigation or policy interventions to the people on the front line of the next emerging disease.

The GVP aims at achieving this vision through core principles that:

- Embrace an international scope, while fostering local ownership
- Promote equitable access to data and benefits
- Foster transparency
- Assist countries in building their national capabilities for "prevention, detection, and response" for emerging viral threats in all partner countries on an unprecedented scale
- Foster global participation through an international alliance

The success of the GVP will be measured by its deliverables, which in the course of its 10-year lifespan will include:

- Detecting and identifying the majority of potential zoonotic viral threats to human, livestock, and wildlife health;



UCDUSR0011803

- Characterizing the host range of the detected viruses (reservoirs and transmission hosts);
- Determining the geographic distribution and ecologic scope of nearly all potential zoonotic viruses to inform on risk and surveillance in human and animals;
- Promoting the monitoring of the movement of detected viruses across hosts and regions;
- Improving the assessment of the risk of spillover to humans and epidemic potential;
- Prioritizing high-risk viruses for further characterization, surveillance targeting, research, and mitigation development;
- Strengthening global surveillance networks through local and global capacity enhancements (e.g. surveillance, field biology, lab proficiencies, biosafety);
- Enabling in-country/regional laboratory and surveillance capacities to monitor for high-risk viruses across animal-human interfaces;
- Establishing sample biobank(s) for further research;
- Creating open-access databases that include sequence and metadata;
- Making data and samples available for public health risk assessments and mitigation, as well as further detailed pathogen studies;
- Providing new insights into virus and host biology, conservation, and



UCDUSR0011804

ecology;

- Identifying markers for transmission and pathogenicity for high-risk viruses; and
- Establishing a global ethical framework for sample, data, information, and benefit sharing, including authorship and intellectual property.

To ensure that best practices are adopted for this global effort, the GVP has set up a series of working groups, each led by two co-chairs representing developed and developing countries, and each comprised of leader in their respective fields, covering appropriate geographic, gender and disciplinary diversity. These working groups are focused on issue sush as sampling, collection and sequencing protocols, data analysis and sharing, and intellectual property rights management. They have prepared working documents to propose best practices for each issue. The GVP will likely do for pandemics and large-scale epidemics what the Human Genome Project is just beginning to do for personalized medicine (9). Like the Human Genome Project, the GVP will spark unrelated and often unexpected advances in human and animal health and in science, making the return on investment in the GVP even greater. Pandemics don't just cause sickness, misery and death – they also affect a global economy that is now dependent on open borders, free trade, and the global movement of goods and services. In one single outbreak, in one year, the SARS virus wiped around $30-50 billion of value from Asian stock markets due to disrupted trade and commerce (10, 11). Overall, pandemics likely cause around $570 billion economic damages per year to our globalized way of doing



UCDUSR0011805

business (12), and these costs will only rise as our economies expand and become more interconnected. The GVP will cost less than 0.2% of this figure – less than was spent on the 2014-2015 Ebola response alone. In light of the devastating potential costs of an increasingly inevitable pandemic, the GVP is more than just good economics – it's something we can't afford to delay.

With broad support for the Global Virome Project, the world will be better prepared to deal with the consequences of escalating spillover of deadly viruses, likely in just ten years. The initiative will generate an unprecedented atlas of viral diversity and ecology, build global surveillance and laboratory capacity in the most high-risk areas, catalyze technological advances in diagnostics and vaccines, and establish a global framework for triaging and neutralizing novel viral outbreaks before they spread between humans. In short, the GVP is designed to herald in the beginning of the end of the Pandemic Era.



UCDUSR0011806

**References**


1. Jones KE, Patel NG, Levy MA, Storeygard A, Balk D, Gittleman JL, et al. Global trends in emerging infectious diseases. Nature. 2008;451(7181):990-3.
2. Morse SS, Mazet JAK, Woolhouse M, Parrish CR, Carroll D, Karesh WB, et al. Prediction and prevention of the next pandemic zoonosis. The Lancet. 2012;380:1956-65.
3. Leroy EM, Kumulungui B, Pourrut X, Rouquet P, Hassanin A, Yaba P, et al. Fruit bats as reservoirs of Ebola virus. Nature. 2005;438:575-6.
4. Carroll DD, Peter; Wolfe, Nathan D.; Gao, George F.; Morel, Carlos; Morzaria, Subhash; Tomori, Oyewale; Mazet, Jonna A.K. The Global Virome Project. Science (in review). 2017.
5. Olival KJ, Hosseini PR, Zambrana-Torrelio C, Ross N, Bogich TL, Daszak P. Host and viral traits predict zoonotic spillover from mammals. Nature. 2017;546:646-50.
6. Ge XY, Li JL, Yang XL, Chmura AA, Zhu G, Epstein JH, et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature. 2013;503(7477):535-8.
7. Brende B, Farrar J, Gashumba D, Moedas C, Mundel T, Shiozaki Y, et al. CEPI—a new global R&D organisation for epidemic preparedness and response. The Lancet. 2017;389:233-5.
8. Jones KE, Patel NG, Levy MA, Storeygard A, Balk D, Gittleman JL, et al. Global trends in emerging infectious diseases. Nature. 2008;451:990-3.
9. Wilson BJ, Nicholls SG. The human genome project, and recent advances in personalized genomics. Risk Management and Healthcare Policy. 2015;8:9-20.
10. Institute of Medicine Forum on Microbial Threats. Learning from SARS: Preparing for the Next Disease Outbreak: Workshop Summary. Washington (DC): Institute of Medicine, 2004.
11. World Bank. Flu Outbreaks Reminder of Pandemic Threat. 2013 [cited 2017 Jun 22]; Available from: http://www.worldbank.org/en/news/feature/2013/03/05/flu-outbreaks-reminder-of-pandemic-threat.
12. Fan VY, Jamison DT, Summers LH. The Inclusive Cost of Pandemic Influenza Risk. NBER Working Paper Series. 2015;22137:24.




UCDUSR0011807

| | |
|---|---|
| **From:** | Jonna Mazet <jkmazet@ucdavis.edu> |
| **To:** | AOTR/Grant Manager Andrew Clements <AClements@usaid.gov>;Alisa Pereira <apereira@usaid.gov> |
| **CC:** | PREDICTMGT <predictmgt@usaid.gov>;predict@ucdavis.edu <predict@ucdavis.edu>;Karen L Wood <klwood@ucdavis.edu> |
| **BCC:** | David M Zachgo <dzachgo@ucdavis.edu> |
| **Sent:** | 10/26/2017 3:44:34 PM |
| **Subject:** | Subaward approvals needed -- linked to ceiling increase review and approval |

Dear Andrew & Alisa,

I am following up on the status of the ceiling increase for the PREDICT-2 Cooperative Agreement.

With Year 4 of PREDICT-2 under way, we are eager to issue subawards that have been incorporated in the ceiling increase process for review and approval. As you know, many of these subawards and subcontracts (together: subs) have been waiting for implementation of work planned in Year 3, including surveillance and lab testing activities. We are unable to complete the work planned under those subs until we receive the formal approval of the ceiling increase. Disruption in progress toward finalizing these subs is delaying the performance of the work as described in the Cooperative Agreement Program Description, resulting in an inability to meet all of our obligations under this agreement, and is having an adverse effect on our pipeline.

There are currently 53 new subs pending approval through this process (though it is possible that a couple of them will now not be employed for various reasons). Another 5 subrs incorporated in the ceiling increase approvals were previously approved in Year 3 for one year only; therefore, their continuation is also dependent on the ceiling increase approval.

Please advise on when we might expect to receive the formal approval of these subs through the ceiling increase process.

Thank you in advance,

Jonna

Jonna AK Mazet, DVM, MPVM, PhD
Professor of Epidemiology & Disease Ecology
Executive Director, One Health Institute
Global Director, PREDICT Project of USAID Emerging Pandemic Threats Program

School of Veterinary Medicine
University of California
1089 Veterinary Medicine Drive
Davis, CA 95616, USA
+1-530-752-3630
onehealthinstitute.net

For scheduling and logistical issues, please contact:
Ms. Brooke Genovese
bgenovese@ucdavis.edu

+1-530-752-3630

| | |
|---|---|
| **From:** | Jonna Mazet <jkmazet@ucdavis.edu> |
| **To:** | AOTR/Grant Manager Andrew Clements <AClements@usaid.gov>;Alisa Pereira <apereira@usaid.gov> |
| **CC:** | David J Wolking <djwolking@ucdavis.edu>;Matt Blake <mblake@ucdavis.edu> |
| **Sent:** | 10/26/2017 3:59:25 PM |
| **Subject:** | Re: Subaward approvals needed -- linked to ceiling increase review and approval |

Dear Andrew & Alisa,
I'm sorry this email and the one that will follow shortly on pipeline have taken so long to get to you. We are experiencing a tumultuous transition after the loss of our oh-so-valuable Liz Leasure. Her shoes are big to fill, and despite having had an extended pre-departure training period, Karen is really struggling. The work is difficult and complex, and the constant treadmill of reporting and on-demand inquiries are likely difficult for any individual or team to achieve well. To be honest, the struggles are so much that Karen has already abandoned responsibilities a bit and left on a multi-week vacation without achieving her deadlines and goals. I tell you this not as an excuse but as an acknowledgement of our, hopefully temporary, inability to provide the service you have come to be able to expect from us in the past.

We are all pulling together to fill the gaps and achieve our goals of excellent performance, but I do beg your patience in the short-term, as I am sure some errors will be made. Please keep that in mind when reviewing the pipeline, as that estimate is coming from me without the benefiit of the excellent data analysis and forecasting that Liz used to provide.

Apologies,
Jonna

On Thu, Oct 26, 2017 at 3:44 PM, Jonna Mazet <jkmazet@ucdavis.edu> wrote:

Dear Andrew & Alisa,

I am following up on the status of the ceiling increase for the PREDICT-2 Cooperative Agreement.

With Year 4 of PREDICT-2 under way, we are eager to issue subawards that have been incorporated in the ceiling increase process for review and approval. As you know, many of these subawards and subcontracts (together: subs) have been waiting for implementation of work planned in Year 3, including surveillance and lab testing activities. We are unable to complete the work planned under those subs until we receive the formal approval of the ceiling increase. Disruption in progress toward finalizing these subs is delaying the performance of the work as described in the Cooperative Agreement Program Description, resulting in an inability to meet all of our obligations under this agreement, and is having an adverse effect on our pipeline.

There are currently 53 new subs pending approval through this process (though it is possible that a couple of them will now not be employed for various reasons). Another 5 subrs incorporated in the ceiling increase approvals were previously approved in Year 3 for one year only; therefore, their continuation is also dependent on the ceiling increase approval.

Please advise on when we might expect to receive the formal approval of these subs through the ceiling increase process.

Thank you in advance,

Jonna

Jonna AK Mazet, DVM, MPVM, PhD
Professor of Epidemiology & Disease Ecology
Executive Director, One Health Institute
Global Director, PREDICT Project of USAID Emerging Pandemic Threats Program

School of Veterinary Medicine
University of California
1089 Veterinary Medicine Drive
Davis, CA 95616, USA
+1-530-752-3630
onehealthinstitute.net

For scheduling and logistical issues, please contact:
Ms. Brooke Genovese
bgenovese@ucdavis.edu

+1-530-752-3630

| | |
|---|---|
| **From:** | Andrew Clements <aclements@usaid.gov> |
| **To:** | Jonna Mazet <jkmazet@ucdavis.edu> |
| **CC:** | Alisa Pereira <apereira@usaid.gov>;PREDICTMGT <predictmgt@usaid.gov>;predict@ucdavis.edu <predict@ucdavis.edu>;Karen L Wood <klwood@ucdavis.edu> |
| **Sent:** | 10/27/2017 3:05:43 AM |
| **Subject:** | Re: Subaward approvals needed -- linked to ceiling increase review and approval |

Thanks, Jonna. We will ask OAA again.

*Andrew P. Clements, Ph.D.*
*Senior Scientific Advisor*
*Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health*
*U.S. Agency for International Development*
*Mobile phone: 1-571-345-4253*
*Email: aclements@usaid.gov*

On Oct 27, 2017, at 12:45 AM, Jonna Mazet <jkmazet@ucdavis.edu> wrote:

Dear Andrew & Alisa,

I am following up on the status of the ceiling increase for the PREDICT-2 Cooperative Agreement.

With Year 4 of PREDICT-2 under way, we are eager to issue subawards that have been incorporated in the ceiling increase process for review and approval. As you know, many of these subawards and subcontracts (together: subs) have been waiting for implementation of work planned in Year 3, including surveillance and lab testing activities. We are unable to complete the work planned under those subs until we receive the formal approval of the ceiling increase. Disruption in progress toward finalizing these subs is delaying the performance of the work as described in the Cooperative Agreement Program Description, resulting in an inability to meet all of our obligations under this agreement, and is having an adverse effect on our pipeline.

There are currently 53 new subs pending approval through this process (though it is possible that a couple of them will now not be employed for various reasons). Another 5 subrs incorporated in the ceiling increase approvals were previously approved in Year 3 for one year only; therefore, their continuation is also dependent on the ceiling increase approval.

Please advise on when we might expect to receive the formal approval of these subs through the ceiling increase process.

Thank you in advance,

Jonna

Jonna AK Mazet, DVM, MPVM, PhD
Professor of Epidemiology & Disease Ecology
Executive Director, One Health Institute
Global Director, PREDICT Project of USAID Emerging Pandemic Threats Program

School of Veterinary Medicine
University of California
1089 Veterinary Medicine Drive

Davis, CA 95616, USA
+1-530-752-3630
onehealthinstitute.net

For scheduling and logistical issues, please contact:
Ms. Brooke Genovese
bgenovese@ucdavis.edu

+1-530-752-3630

**Sent:** Tue, 31 Oct 2017 13:23:37 -0700
**Subject:** Fwd: [predict] [predict-outbreak] Kenya - Marburg
**From:** Jonna Mazet <jkmazet@ucdavis.edu>
**To:** "AOTR/Grant Manager Andrew Clements" <AClements@usaid.gov>, Alisa Pereira <apereira@usaid.gov>
**Cc:** PREDICT-outbreak <predict-outbreak@ucdavis.edu>

FYI,
J

---------- Forwarded message ----------
From: **Zimmerman, Dawn** <ZimmermanD@si.edu>
Date: Tue, Oct 31, 2017 at 1:21 PM
Subject: [predict] [predict-outbreak] Kenya - Marburg
To: "predict-outbreak@ucdavis.edu" <predict-outbreak@ucdavis.edu>
Cc: "jkamau@primateresearch.org" <jkamau@primateresearch.org>, "Murray, Suzan" <MurrayS@si.edu>, "Vodzak, Megan E." <VodzakME@si.edu>, "Valitutto, Marc" <ValituttoM@si.edu>

Dear Jonna, Chris, Tracey, et al.

Just a quick note that we've been informed of two Marburg cases in Kenya, we are still waiting on details and the Kenya CC, Dr. Joseph Kamau (cc'ed), is in touch with the Zoonotic Disease Unit. As it appears this is already diagnosed, we do not anticipate any aid will be requested, but will come back to you if any requests are made. Be in touch with confirmation soon….

Best,

Dawn

**Dawn Zimmerman, DVM, MS | Associate Program Director**

Global Health Program

Smithsonian Conservation Biology Institute

National Zoological Park | 3001 Connecticut Avenue NW | Washington DC 20008
T +01 202 633 2857 | F +01 202 673 4733 | zimmermand@si.edu

Smithsonian Institution

**From:** Andrew Clements <aclements@usaid.gov>
**Sent:** Wed, 1 Nov 2017 10:27:45 +0100
**Subject:** Re: [predict] [predict-outbreak] Kenya - Marburg
**To:** Jonna Mazet <jkmazet@ucdavis.edu>
**Cc:** Alisa Pereira <apereira@usaid.gov>, PREDICT-outbreak <predict-outbreak@ucdavis.edu>

Thanks, Jonna.

*Andrew P. Clements, Ph.D.*
*Senior Scientific Advisor*
*Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health*
*U.S. Agency for International Development*
*Mobile phone: 1-571-345-4253*
*Email: aclements@usaid.gov*

On Oct 31, 2017, at 9:25 PM, Jonna Mazet <jkmazet@ucdavis.edu> wrote:

FYI,
J

---------- Forwarded message ----------
From: **Zimmerman, Dawn** <ZimmermanD@si.edu>
Date: Tue, Oct 31, 2017 at 1:21 PM
Subject: [predict] [predict-outbreak] Kenya - Marburg
To: "predict-outbreak@ucdavis.edu" <predict-outbreak@ucdavis.edu>
Cc: "jkamau@primateresearch.org" <jkamau@primateresearch.org>, "Murray, Suzan" <MurrayS@si.edu>, "Vodzak, Megan E." <VodzakME@si.edu>, "Valitutto, Marc" <ValituttoM@si.edu>

Dear Jonna, Chris, Tracey, et al.

Just a quick note that we've been informed of two Marburg cases in Kenya, we are still waiting on details and the Kenya CC, Dr. Joseph Kamau (cc'ed), is in touch with the Zoonotic Disease Unit. As it appears this is already diagnosed, we do not anticipate any aid will be requested, but will come back to you if any requests are made. Be in touch with confirmation soon….

Best,

Dawn

**Dawn Zimmerman, DVM, MS | Associate Program Director**

Global Health Program

Smithsonian Conservation Biology Institute

National Zoological Park | 3001 Connecticut Avenue NW | Washington DC 20008
T +01 202 633 2857 | F +01 202 673 4733 | zimmermand@si.edu

<image001.jpg>

**From:** Amalhin Shek <ashek@usaid.gov>
**Sent:** Wed, 1 Nov 2017 14:26:46 -0400
**Subject:** Re: PREDICT involved in UC Davis One Health Day celebration.
**To:** Jonna Mazet <jkmazet@ucdavis.edu>
**Cc:** PREDICTMGT <predictmgt@usaid.gov>, "predict@ucdavis.edu" <predict@ucdavis.edu>

Thanks Jonna,

Do you know if EHA or any of the other consortium partners are engaging in Twitter chats/other Social Media on Friday?

Amalhin Shek | Budget & Communications
Emerging Threats Division, Office of Infectious Disease
USAID/Washington, Bureau for Global Health
Phone: 202-216-3541(o) REDACTED | RRB-3.6.056
Subscribe to our Newsletter!

USAID-HECFAA, VP of Community Engagement

On Wed, Nov 1, 2017 at 1:45 PM, Jonna Mazet <jkmazet@ucdavis.edu> wrote:

> Hi,
> We're doing a one day symposium with our Students for One Health Club.
> Flyer attached in case you are interested or collecting this info.
> Have a good day,
> Jonna

--
You received this message because you are subscribed to the Google Groups "PREDICTMGT" group.
To unsubscribe from this group and stop receiving emails from it, send an email to predictmgt+unsubscribe@usaid.gov.
To post to this group, send email to predictmgt@usaid.gov.
To view this discussion on the web visit
https://groups.google.com/a/usaid.gov/d/msgid/predictmgt/CAO5tDrE6myHi0qqgN46Ot7RPcj-ndXKNx2f_XoO80%2Bb%2BWeoAQg%40mail.gmail.com.

**From:** David [redacted]
**Sent:** Wed, 1 Nov 2017 11:42:37 -0700
**Subject:** Fwd: [predict] Re: PREDICT involved in UC Davis One Health Day celebration.
**To:** Anthony [redacted], "Prof. Jonna Mazet" <jkmazet@ucdavis.edu>, Evelyn [redacted], Molly [redacted] Peter Daszak <daszak@ecohealthalliance.org>, Kevin [redacted], Leilani [redacted], Jon Epstein <epstein@ecohealthalliance.org>, Ava [redacted]

Hey there,
Amalhin wants to know if you all are doing One Health Day Twitter chats or other social media campaigns. You have anything planned?

Also, there's a really big box on my desk from NYC from the Evelyn/Sullivan/Turner and EHA crew! That's really too sweet. You all are the best

Thanks!

David

---------- Forwarded message ----------
From: **Amalhin** [redacted]
Date: Wed, Nov 1, 2017 at 11:26 AM
Subject: [predict] Re: PREDICT involved in UC Davis One Health Day celebration.
To: Jonna Mazet <jkmazet@ucdavis.edu>
Cc: PREDICTMGT <predictmgt@usaid.gov>, "predict@ucdavis.edu" <predict@ucdavis.edu>

Thanks Jonna,

Do you know if EHA or any of the other consortium partners are engaging in Twitter chats/other Social Media on Friday?

Amalhin Shek I Budget & Communications
Emerging Threats Division, Office of Infectious Disease
USAID/Washington, Bureau for Global Health
Phone: 202-216-3541(o) 571-236-0989(c) I RRB-3.6.056
Subscribe to our Newsletter!

USAID-HECFAA, VP of Community Engagement

On Wed, Nov 1, 2017 at 1:45 PM, Jonna Mazet <jkmazet@ucdavis.edu> wrote:

> Hi,
> We're doing a one day symposium with our Students for One Health Club.
> Flyer attached in case you are interested or collecting this info.
> Have a good day,
> Jonna

--
You received this message because you are subscribed to the Google Groups "PREDICTMGT" group.
To unsubscribe from this group and stop receiving emails from it, send an email to predictmgt+unsubscribe@usaid.gov.
To post to this group, send email to predictmgt@usaid.gov.
To view this discussion on the web visit
https://groups.google.com/a/usaid.gov/d/msgid/predictmgt/CAO5tDrE6myHi0qqgN46Ot7RPcj-ndXKNx2f_XoO80%2Bb%2BWeoAQg%40mail.gmail.com.

**From:** Dennis Carroll <dcarroll@usaid.gov>
**Sent:** Wed, 8 Nov 2017 11:25:05 -0500
**Subject:** Re: GVP call notes, 11/6/17
**To:** Brooke Watson <watson@ecohealthalliance.org>
**Cc:** Alison Andre <andre@ecohealthalliance.org>, Cara Chrisman <cchrisman@usaid.gov>, Eddy Rubin <erubin@metabiota.com>, "Elnicki Taylor (telnicki@metabiota.com)" <telnicki@metabiota.com>, Jonna Mazet <jkmazet@ucdavis.edu>, Nathan Wolfe <nwolfe@metabiota.com>, Peter Daszak <daszak@ecohealthalliance.org>, Rebecca Benmahdi <rbenmahdi@metabiota.com>, Brooke Genovese <bgenovese@ucdavis.edu>

Great. Thanks Brooke.

d

On Wed, Nov 8, 2017 at 10:16 AM, Brooke Watson <watson@ecohealthalliance.org> wrote:

Hi team,
Attached are the notes from our GVP call on Monday afternoon.

Thanks for joining!

Best,

Brooke

--

**Brooke Watson, MSc**
*Research Scientist*

EcoHealth Alliance
460 West 34th Street – 17th floor
New York, NY 10001

1.212.380.4497 (direct)
REDACTED mobile)
1.212.380.4465 (fax)
www.ecohealthalliance.org

***EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that promote conservation and prevent pandemics.***

--

Dr. Dennis Carroll
Director, Emerging Threats Program
Bureau for Global Health
U.S. Agency for International Development

Office: 202-712-5009
Mobile: REDACTED

**From:** Andrew Clements <aclements@usaid.gov>
**Sent:** Wed, 8 Nov 2017 19:47:04 +0100
**Subject:** OIE: MERS-CoV In camels (Saudi Arabia)
**To:** [redacted], "Subhash Morzaria (FAORAP)" <[redacted]>, "Ahmed Elldrissi (AGAH)" [redacted], abubasha@just.edu.jo, dawson@ecohealthalliance.org, William Karesh <Karesh@ecohealthalliance.org>, lparish@usaid.gov, Christine Kreuder Johnson <ckjohnson@ucdavis.edu>, Jonna Mazet <jkmazet@ucdavis.edu>, [redacted] Dennis Carroll <dcarroll@usaid.gov>

FYI

http://www.oie.int/wahis_2/public/wahid.php/Reviewreport/Review?page_refer=MapFullEventReport&reportid=25182

*Andrew P. Clements, Ph.D.*
*Senior Scientific Advisor*
*Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health*
*U.S. Agency for International Development*
*Mobile phone: 1-571-345-4253*
*Email: aclements@usaid.gov*

**From:** Dennis Carroll <dcarroll@usaid.gov>
**Sent:** Mon, 13 Nov 2017 15:04:36 -0500
**Subject:** Fwd: Request for GVP materials for BCG team before Nov.21 meeting
**To:** [redacted], Brooke Watson <watson@ecohealthalliance.org>
**Cc:** Jonna Mazet <jkmazet@ucdavis.edu>, Peter Daszak <daszak@ecohealthalliance.org>

[redacted] and Brooke, as a follow up to the discussion I had with BCG - they have asked for the materials below. Can you pull these together? Some of these can be topics in our next phone call. Let me know if there are ones you dont have

thanks

d

Hello Dennis,
I hope your week has started off well.

I wanted to follow up here to confirm that you will be able to share the below materials, ideally by week's end, so that BCG and our team can get up to speed on everything before next week's meeting.

Please let us know if there's anyway that we can help you here.

Thanks,
Jen

**Materials Needed before Nov.21 from GVP technical team of Dennis, EcoHealth Alliance, UC-Davis and/or Metabiota**

- Table of investors/funders approached with feedback and current status of those discussions (Arie to provide?)
- Calendar of upcoming meetings with potential GVP investors
- List of countries interested in GVP and how they are interested in engaging
- Draft paper on the PREDICT project
- Published paper on MERS virus and its many variants
- Draft MOU in discussion with the Chan-Zuckerberg Biohub

--
Amy Lin
Senior Advisor, Market Access Team Lead
USAID | Global Health Bureau | Center for Accelerating Innovation and Impact (CII)
CP-3, 11012A, 1300 Pennsylvania Ave NW | Washington, DC 20523
571.551.7132 | amylin@usaid.gov

--
Jen Fluder | Senior Innovation and Partnership Advisor
**USAID** | Bureau for Global Health | Center for Accelerating Innovation and Impact
jfluder@usaid.gov | (571)551-7115

--
Jen Fluder | Senior Innovation and Partnership Advisor
**USAID** | Bureau for Global Health | Center for Accelerating Innovation and Impact
jfluder@usaid.gov | (571)551-7115

--
Dr. Dennis Carroll
Director, Emerging Threats Program
Bureau for Global Health
U.S. Agency for International Development

Office: 202-712-5009
Mobile: REDACTED

**From:** Dennis Carroll <dcarroll@usaid.gov>
**Sent:** Tue, 21 Nov 2017 12:34:32 -0500
**Subject:** Re: PMAC logistics
**To:** REDACTED
**Cc:** Jonna Mazet <jkmazet@ucdavis.edu>

Ok. Let's see if we can contact Cara

Dr Dennis Carroll
Director, Emerging Threats Program
U.S. Agency for International Development
Office: (202) 712-5009
REDACTED

On Nov 21, 2017, at 11:59 AM, Eri REDACTED wrote:

> Hi Dennis,
>
> Cara submitted the proposal, so it must be in her inbox. I do not have visibility on the submission. Is there someone I can reach out to?
>
> Best,
> REDACTED
>
> **From:** Dennis Carroll [mailto:dcarroll@usaid.gov]
> **Sent:** Tuesday, November 21, 2017 6:29 AM
> **To:** Eri REDACTED
> **Cc:** Jonna Mazet <jkmazet@ucdavis.edu>
> **Subject:** Re: PMAC logistics
>
> REDACTED Ihavent seen anything. I presume Cara and/or you sent it in. The email should come back to you. It is possible that it came back to Cara if she is the one who submitted. But she hasnt been checking her emails since she went on maternity leave. Do you have visability on the submission?
>
> On Mon, Nov 20, 2017 at 4:11 PM, REDACTED REDACTED wrote:
> Hi Dennis,
> I hope you had a great weekend. Jonna and I have a few questions as we start to plan logistics for PMAC.
> -Has our side meeting been officially accepted?
> -If so, shall we offer an invitation letter similar to Beijing for the Steering Committee and Work Group Leads?
> -In order to send the invitation letter, Jonna said that we should be ready to state if funding will be offered for travel. We have the same standard language from Beijing ready to go, but we wanted to be sure that you were okay with us potentially covering the costs for the approximately 36 invitees.
> -We will also need an agenda and/or the final PMAC side meeting submission to include with the invite letter. I have the draft before submission but am unsure if changes were made prior to submission.
> -We have received funding requests from Keiji, Sam and Gian Luca so far in response to the invites they received from PMAC.
> -Should we submit an ITA before sending invitation letters?
> Many thanks,
>
> REDACTED
>
> REDACTED REDACTED
> REDACTED

--
Dr. Dennis Carroll
Director, Emerging Threats Program
Bureau for Global Health
U.S. Agency for International Development

Office: 202-712-5009
REDACTED

**From:** Andrew Clements <aclements@usaid.gov>
**Sent:** Wed, 22 Nov 2017 01:19:44 -0800
**To:** Brian Bird <bhbird@ucdavis.edu>
**Cc:** PREDICTMGT <predictmgt@usaid.gov>, PREDICT-outbreak <predict-outbreak@ucdavis.edu>
**Subject:** [predict] [predict-outbreak] Re: PREDICT-DRC Cattle die-off event report 21Nov2017

Thanks, Brian.

*Andrew P. Clements, Ph.D.*
*Senior Scientific Advisor*
*Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health*
*U.S. Agency for International Development*
*Mobile phone: 1-571-345-4253*
*Email: aclements@usaid.gov*

On Nov 22, 2017, at 4:02 AM, Brian Bird <bhbird@ucdavis.edu> wrote:

> Hi everyone,
>
> Please find attached an update today from the DRC team. Testing using the PREDICT priority virus family protocols should begin shortly. Meeting held today with PREDICT, FAO, and GoDRC partners to develop an overall diagnostic testing plan. Still no reports of human illnesses associated with this mass cattle mortality/morbidity event.
>
> Have a great evening,
>
> -Brian
>
> Brian H. Bird DVM, MSPH, PhD
> One Health Institute
> 1089 Veterinary Medicine Dr.
> School of Veterinary Medicine
> University of California, Davis
> Email: bhbird@ucdavis.edu
> Skype: brianhbird1
> http://www.vetmed.ucdavis.edu/ohi/predict/index.cfm

--
You received this message because you are subscribed to the Google Groups "PREDICTMGT" group.
To unsubscribe from this group and stop receiving emails from it, send an email to predictmgt+unsubscribe@usaid.gov.
To post to this group, send email to predictmgt@usaid.gov.
To view this discussion on the web visit https://groups.google.com/a/usaid.gov/d/msgid/predictmgt/1BD04604-3511-4930-8E79-D05F2E7D97CE%40ucdavis.edu.

<PREDICT-DRC Cattle die-off_Bondo Bas-Uele 21Nov2017_final.doc>

**From:** Jonna Mazet <jkmazet@ucdavis.edu>
**To:** Andrew Clements <aclements@usaid.gov>
**CC:** David J Wolking <djwolking@ucdavis.edu>;Alisa Pereira <apereira@usaid.gov>
**Sent:** 11/27/2017 9:20:01 AM
**Subject:** Re: Ceiling increase update

Okay, thanks.
We'll anxiously await further guidance.
Hope you all had a happy Thanksgiving,
J

On Mon, Nov 27, 2017 at 7:17 AM, Andrew Clements <aclements@usaid.gov> wrote:
Just talked to OAA. They are supposed to send you questions in the next day or two. Supposedly, the questions are fairly minor.

They may want some additional information for subawards that are new (as opposed to those that are simply being extended). I haven't seen the question so don't know for sure.

Andrew

*Andrew P. Clements, Ph.D.*
*Senior Scientific Advisor*
*Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health*
*U.S. Agency for International Development*
*Mobile phone: 1-571-345-4253*
*Email: aclements@usaid.gov*

**From:** Andrew Clements <aclements@usaid.gov>
**Sent:** Tue, 28 Nov 2017 11:16:06 -0800
**Subject:** Did I miss the menu of testing options?
**To:** Jonna Mazet <jkmazet@ucdavis.edu>, Christine Kreuder Johnson <ckjohnson@ucdavis.edu>, djwolking@ucdavis.edu
**Cc:** Alisa Pereira <apereira@usaid.gov>, sgillette@usaid.gov

I didn't see anything come in, but I thought I heard you say it was sent.

*Andrew P. Clements, Ph.D.*
*Senior Scientific Advisor*
*Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health*
*U.S. Agency for International Development*
*Mobile phone: 1-571-345-4253*
*Email: aclements@usaid.gov*

**From:** Dennis Carroll <dcarroll@usaid.gov>
**Sent:** Tue, 28 Nov 2017 15:12:21 -0500
**Subject:** Re: GVP launch at PMAC?
**To:** Andrew Clements <aclements@usaid.gov>
**Cc:** "Sudarat Damrongwatanapokin (RDMA/OPH)" <sDamrongwatanapokin@usaid.gov>, "Daniel Schar (RDMA/OPH)" <dSchar@usaid.gov>, Jonna Mazet <jkmazet@ucdavis.edu>

I talked with Sudarat last night. She said it was, but is checking

d

On Tue, Nov 28, 2017 at 2:08 PM, Andrew Clements <aclements@usaid.gov> wrote:

> Hi Sudarat,
> Do you know if the GVP side meeting was approved?

Thanks!

Andrew

*Andrew P. Clements, Ph.D.*
*Senior Scientific Advisor*
*Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health*
*U.S. Agency for International Development*
*Mobile phone: 1-571-345-4253*
*Email: aclements@usaid.gov*

--
Dr. Dennis Carroll
Director, Emerging Threats Program
Bureau for Global Health
U.S. Agency for International Development

Office: 202-712-5009
Mobile: REDACTED

**Sent:** Tue, 28 Nov 2017 17:15:11 -0800
**Subject:** Re: GVP launch at PMAC?
**From:** Jonna Mazet <jkmazet@ucdavis.edu>
**To:** Dennis Carroll <dcarroll@usaid.gov>
**Cc:** Sudarat Damrongwatanapokin <sdamrongwatanapokin@usaid.gov>, Andrew Clements <aclements@usaid.gov>, "Daniel Schar (RDMA/OPH)" <dSchar@usaid.gov>

Hmmm... I have not been informed of the selection by the Secretariat.
Thanks for checking further, Sudarat,
Jonna

On Tue, Nov 28, 2017 at 3:40 PM, Dennis Carroll <dcarroll@usaid.gov> wrote:

Thanks sister

Dr Dennis Carroll
Director, Emerging Threats Program
U.S. Agency for International Development
Office: (202) 712-5009
Mobile: REDACTED

On Nov 28, 2017, at 6:06 PM, Sudarat Damrongwatanapokin <sdamrongwatanapokin@usaid.gov> wrote:

> Will check with PMAC Secretariat. The correspondence person is Jonna Mazet (from the concept note).
> Best regards,
> Sudarat

Sent from my mobile.

On Nov 29, 2017, at 3:12 AM, Dennis Carroll <dcarroll@usaid.gov> wrote:

> I talked with Sudarat last night. She said it was, but is checking

d

On Tue, Nov 28, 2017 at 2:08 PM, Andrew Clements <aclements@usaid.gov> wrote:

> Hi Sudarat,
> Do you know if the GVP side meeting was approved?

Thanks!

Andrew

*Andrew P. Clements, Ph.D.*
*Senior Scientific Advisor*
*Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health*
*U.S. Agency for International Development*
*Mobile phone: 1-571-345-4253*
*Email: aclements@usaid.gov*

--
Dr. Dennis Carroll
Director, Emerging Threats Program
Bureau for Global Health
U.S. Agency for International Development

Office: 202-712-5009
Mobile: REDACTED

**From:** Andrew Clements <aclements@usaid.gov>
**Sent:** Tue, 28 Nov 2017 22:53:20 -0800
**Subject:** Re: GVP launch at PMAC?
**To:** Sudarat Damrongwatanapokin <sdamrongwatanapokin@usaid.gov>
**Cc:** Dennis Carroll <dcarroll@usaid.gov>, "Daniel Schar (RDMA/OPH)" <dSchar@usaid.gov>, Jonna Mazet <jkmazet@ucdavis.edu>

Thanks. Jonna thought the POC was Cara.

*Andrew P. Clements, Ph.D.*
*Senior Scientific Advisor*
*Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health*
*U.S. Agency for International Development*
*Mobile phone: 1-571-345-4253*
*Email: aclements@usaid.gov*

On Nov 29, 2017, at 12:06 AM, Sudarat Damrongwatanapokin <sdamrongwatanapokin@usaid.gov> wrote:

> Will check with PMAC Secretariat. The correspondence person is Jonna Mazet (from the concept note).
> Best regards,
> Sudarat

Sent from my mobile.

On Nov 29, 2017, at 3:12 AM, Dennis Carroll <dcarroll@usaid.gov> wrote:

> I talked with Sudarat last night. She said it was, but is checking

d

On Tue, Nov 28, 2017 at 2:08 PM, Andrew Clements <aclements@usaid.gov> wrote:

> Hi Sudarat,
> Do you know if the GVP side meeting was approved?

Thanks!

Andrew

*Andrew P. Clements, Ph.D.*
*Senior Scientific Advisor*
*Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health*
*U.S. Agency for International Development*
*Mobile phone: 1-571-345-4253*
*Email: aclements@usaid.gov*

--
Dr. Dennis Carroll
Director, Emerging Threats Program
Bureau for Global Health

U.S. Agency for International Development

Office: 202-712-5009
Mobile: REDACTED

**From:** "William B. Karesh" <karesh@ecohealthalliance.org>
**To:** David Wolking <djwolking@ucdavis.edu>, Patrick Dawson <dawson@ecohealthalliance.org>
**Cc:** "predict@ucdavis.edu" <predict@ucdavis.edu>
**Sent:** Fri, 8 Dec 2017 15:49:48 +0000
**Subject:** [predict] Re: PLEASE ADVISE TODAY: Ain Shams Hospital stats

Hi David, I don't know any of these people, nor know what they are talking about.
Patrick??

BK

**William B. Karesh, D.V.M**
*Executive Vice President for Health and Policy*

EcoHealth Alliance
460 West 34th Street - 17th Floor
New York, NY 10001 USA

+1.212.380.4463 (direct)
+1.212.380.4465 (fax)
www.ecohealthalliance.org

President, OIE Working Group on Wildlife

Co-chair, IUCN Species Survival Commission - Wildlife Health Specialist Group

EPT Partners Liaison, USAID Emerging Pandemic Threats - PREDICT-2 Program

***EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that promote conservation and prevent pandemics.***

On Dec 8, 2017, at 10:41 AM, David J Wolking <djwolking@ucdavis.edu> wrote:

Patrick and Billy,

Either of you have any idea why I might be included on this USAID/Egypt thread? You know Akmal or Julie? Just confused by all the Hep C and hospital acquired infection content.

Thanks!

David

---------- Forwarded message ----------
From: **Katie Donohoe** <kdonohoe@usaid.gov>
Date: Fri, Dec 8, 2017 at 5:46 AM
Subject: Re: PLEASE ADVISE TODAY: Ain Shams Hospital stats
To: Akmal Elerian <aelerian@usaid.gov>
Cc: Julie Fossler <jfossler@usaid.gov>, Tara Simpson <tsimpson@usaid.gov>, David Wolking <djwolking@ucdavis.edu>

Here are our combined, edited inputs. Let us know if you need additional information.

Katie

**How many beneficiaries are served by the 86 hospitals? We have 3060 beds, but that doesn't speak to the number of beneficiaries.**

The program is implemented in intensive care units (ICUs) of 86 hospitals, with a total of 3060 ICU beds. Since program start-up in 2014, it has benefited more than 340,000 patients (340,888 patients). The system currently (86 hospitals - 3060 beds) benefits 128,340 patients per year.

**Also, what's the impact of the program on reducing Hep C infections specifically?**

The overall reduction rate in hospital-acquired infections at Ain Shams University Hospital is 34%. Most people in Egypt contract Hepatitis C in hospitals and doctor's offices due to poor infection control measures such as reusing syringes or surgical equipment. Through this project, hospital staff learns infection control measures that are helping control the spread of viral and bacterial infections. The surveillance systems helps hospitals track the number of infections that are occurring and helps them monitor if their infection control measures are effective.

Please note that there are no specific numbers for Hep C readily available; as the program does not focus only on Hep C, but rather works on blood borne infections (including Hep C) and air borne infections in intensive care units.

**If the Administrator is asked about the NAMRU office closure, what should his response be?**

USAID continues to have a strong relationship with NAMRU through their transition to a smaller platform as a result of the closure the NAMRU offices.

**What was transferred to Ain Shams from NAMRU - just lab work, or...?**

The labs at NAMRU were used to confirm that the blood samples obtained through the project were the specific type of virus or bacteria that the participating hospitals said that they were. As of a few months ago, no NAMRU lab equipment had been transferred to the Ain Shams lab because their lab already has the right equipment and is capable of doing work originally done in the NAMRU labs. NAMRU is providing technical assistance and support to the lab as it takes on the responsibility of being the project's reference lab; which enhances the sustainability of project's interventions and benefits.

**Julie Fossler**

**USAID/Egypt**
Sr. Development Outreach and Communications Officer | Press Officer

Office: (2-02) 2522-6553 | REDACTED | Email: jfossler@usaid.gov
www.usaid.gov/egypt | facebook.com/USAIDEgypt | @USAIDEgypt

On Fri, Dec 8, 2017 at 1:11 PM, Katie Donohoe <kdonohoe@usaid.gov> wrote:

Hi - I just talked to Akmal. He is out but will be home in an hour and will send further responses to these questions.
Katie

On Fri, Dec 8, 2017 at 12:44 PM, Tara Simpson <tsimpson@usaid.gov> wrote:

Hi All,
Someone will have to text Akmal about the beneficiaries question. He doesn't WhatsApp, so it would be difficult for me text him.

The link to Hep C is that most transmission of Hep C occurs in healthcare settings in Egypt. In other words, most people "get" Hep C in hospitals and doctors offices due to poor infection control measures such as reusing syringes or surgical equipment. Many Egyptians go into a hospital with one thing (for example, a heart attack) and then end up getting a secondary infection while they are in the hospital - and that infection is sometimes Hep C. The infection control measures that the staff are learning help control all kinds of viral and bacterial infections from spreading. The surveillance systems helps hospitals track the number of infections that are occurring in hospitals so that they can know more about what types of infections are being transmitted and helps them monitor if their infection control measures are effective. Given that most Hep C transmissions occur in health care settings, one of the more effective ways we can help decrease transmission rates is to improve infection control measures in hospitals. We work specifically in ICUs because that is where the most vulnerable or "sick" patients are located in the hospital.

If anyone asks about NAMRU, the Administrator should just acknowledge that it is a very unfortunate thing to have happened, but that we continue to have a strong working relationship with NAMRU even through their transition to a smaller platform. If he is speaking to an internal USG audience, he could even mention something about how USAID is happy to host NAMRU in our building while they are finding new office space. The truth of the matter is that we only work with NAMRU as a place to pass money through, and the technical partner on this program is CDC.

The labs at NAMRU were used for the "reference" checking of the blood samples obtained through the project. Basically they would double check some of the blood samples to make sure that they were the specific type of virus or bacteria that the hospitals participating in the program were determining that they were in their own hospital labs. It was determined that Ain Shams Hospital had a sophisticated enough lab with the right equipment and staff with the right training to take on the responsibility of being the reference lab. When we were there last (a few months ago) no equipment had been transferred to the lab from NAMRU, but the program is providing technical assistance and support for the lab to serve in this role. It is a big deal for the Ain Shams lab because we are acknowledging that they have a very strong lab that is capable of doing the work originally done in the NAMRU labs.

Hope that helps! Akmal can add more because he certainly knows more of the details than I do! Tara

On Fri, Dec 8, 2017 at 12:13 PM, Julie Fossler <jfossler@usaid.gov> wrote:

Hi folks,
Washington came back with questions - can you please answer them by 3pm today?
Thanks!!!!
Julie

How many beneficiaries are served by the 86 hospitals? We have 3060 beds, but that doesn't speak to the number of beneficiaries.

Also, what's the impact of the program on reducing Hep C infections specifically?

If the Administrator is asked about the NAMRU office closure, what should his response be?

What was transferred to Ain Shams from NAMRU - just lab work, or...?

**Julie Fossler**

**USAID/Egypt**
Sr. Development Outreach and Communications Officer | Press Officer

Office: (2-02) 2522-6553 | Mobile: REDACTED Email: jfossler@usaid.gov
www.usaid.gov/egypt | facebook.com/USAIDEgypt | @USAIDEgypt

--

**Tara Simpson**
**USAID/Egypt**
Deputy Director and Health Team Leader | Office of Education and Health
Office: (2-02) 2522-6896 | Mobile: REDACTED | US Number: (202) 216-6319 ext. 6896 Email: tsimpson@usaid.gov

www.usaid.gov/egypt | facebook.com/USAIDEgypt | twitter.com/USAIDEgypt

| | |
|---|---|
| **From:** | Kevin Olival, PhD <olival@ecohealthalliance.org> |
| **To:** | Dr. Jonna Mazet <jkmazet@ucdavis.edu>;David J Wolking <djwolking@ucdavis.edu> |
| **CC:** | Tracey Goldstein <tgoldstein@ucdavis.edu>;Brian Bird <bhbird@ucdavis.edu>;Christine Kreuder Johnson <ckjohnson@ucdavis.edu>;Woutrina Miller <wasmith@ucdavis.edu>;William B. Karesh" <karesh@ecohealthalliance.org>;Catherine Machalaba <machalaba@ecohealthalliance.org>;Corina Grigorescu Monagin <cgmonagin@ucdavis.edu>;Brooke Genovese <bgenovese@ucdavis.edu>;Peter Daszak <daszak@ecohealthalliance.org> |
| **Sent:** | 12/18/2017 11:15:28 AM |
| **Subject:** | Re: Y3 Annual Report M&E Section FOR REVIEW |

Edited version of the M&A pdf is here: https://www.dropbox.com/s/lcgdn2l136x4gbw/PREDICT%20Modeling%20M%26E_AnnualY3%20FINAL%20JM_KJO.pdf?dl=0
I only made changes to the first page, per Jonna's suggestions about swapping the words in the title and moving text around. I deleted her comment on the second page as that was resolved.

Also, couple of minor edits on the attached Excel sheet for Indicator 1.1b. The main change is highlighted in red: Row 4 'Cameroon', should be map #19.

Cheers,
Kevin

Produced in Native Format

**From:** "William B. Karesh" <karesh@ecohealthalliance.org>
**To:** Brooke Genovese <bgenovese@ucdavis.edu>
**Cc:** Amanda Andre <amanda.andre@ecohealthalliance.org>, Jonna Mazet <jkmazet@ucdavis.edu>, Matthew Blake <mblake@ucdavis.edu>, Katherine Leasure <kaleasure@ucdavis.edu>
**Subject:** Re: Urgent: External Advisors, Brussels Meeting
**Sent:** Mon, 8 Jan 2018 14:19:05 +0000

Thanks Brooke. We're all set. I have a 3-4 line agenda for Wednesday meeting and we will take notes from them, compile and have them edit post meeting.

Sent from my iPhone
**William B. Karesh, D.V.M**
*Executive Vice President for Health and Policy*

EcoHealth Alliance
460 West 34th Street - 17th Floor
New York, NY 10001 USA

+1.212.380.4463 (direct)
+1.212.380.4465 (fax)
www.ecohealthalliance.org

President, OIE Working Group on Wildlife

Co-chair, IUCN Species Survival Commission - Wildlife Health Specialist Group

EPT Partners Liaison, USAID Emerging Pandemic Threats - PREDICT-2 Program

***EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that promote conservation and prevent pandemics.***

On Jan 8, 2018, at 10:32 AM, Brooke Genovese <bgenovese@ucdavis.edu> wrote:

> Hi Amanda,
>
> Do you have an update on Billy's travel status and on the plans for the external advisors that he invited (has a "buddy system" been set up or special agenda needed)?
>
> Thanks in advance for the info!
> -Brooke
>
> Brooke Genovese
> PREDICT Project Support
> Executive Analyst
> One Health Institute
> School of Veterinary Medicine
> Tel: 530-752-6459
> bgenovese@ucdavis.edu

**From:** Ava Sullivan <sullivan@ecohealthalliance.org>
**Sent:** Wed, 10 Jan 2018 18:21:33 +0100
**To:** Katherine Leasure <kaleasure@ucdavis.edu>
**Cc:** Peter Daszak <daszak@ecohealthalliance.org>, Evelyn Luciano <luciano@ecohealthalliance.org>, Predict inbox <predict@ucdavis.edu>
**Subject:** [predict] ITA for A. Laudisoit
PREDICT ITA_ALaudisoit2018_CIV_1 (1).docx

Hello Katie,
We have an ITA for travel that is under the five-week mark. Peter and Andrew met to discuss this travel when they were together in Brussels, and they both agree that it is necessary. Andrew will have the full context for this late ITA when he receives it.

Thank you, and please forgive the late notice.

Ava

--
**Ava Sullivan**
*PREDICT-2 Program Assistant*
*Country Liaison, India*
*PREDICT Operations Team*

EcoHealth Alliance
460 West 34th Street – 17th floor
New York, NY 10001
646-868-4705 (direct)
REDACTED **(mobile) recently updated**
www.ecohealthalliance.org

***EcoHealth Alliance leads cutting-edge scientific research into the critical connections between human and wildlife health and delicate ecosystems. With this science, we develop solutions that prevent pandemics and promote conservation.***

**ITA PREDICT – ECOHEALTH ALLIANCE - COTE D'IVOIRE A. LAUDISOIT #2018.1**

EcoHealth Alliance would like to request travel approval for Dr. Anne Laudisoit from Brussels, Belgium to Abidjan, Côte d'Ivoire from January 18th 2018 to return to New York ,USA, 24th January 2018 for the USAID chargé d'affaire official visit of PREDICT site in CIV and finalize compliance for PREDICT in CIV (IRB renewal, wildlife permit renewal, PREDICT presentation to OIPR authorities).

**Trip purpose:** Following the request of USAID mission in CIV to present PREDICT work in CIV, Dr. Anne Laudisoit, the Country Liaison in Cote d'Ivoire, will join the CIV PREDICT team in the field and prepare the field visit of the chargé d'affaire. The visit will consists of showing PREDICT impact in the field site (concurrent site around the Marahoué NP), meet villagers benefiting from PREDICT local and global findings, and staff capacitated by PREDICT. The CIV team will also present the historical context and situational site selection. In Abidjan, the country liaison will ensure timely IACUC exemption letter is granted as there is no ethical committee in CIV and IRB renewal achieved. Finally as requested by OIPR, Dr Anne Laudisoit will meet with the OIPR team to present PREDICT in their HQ in Abidjan. Places where A. Laudisoit will stay are Abidjan, Bouaflé, and Yamoussoukro.

The flight is estimated at $1000 from Brussels to Abidjan return, from Abidjan to New York and the maximum per diem rate for Abidjan is $339, in Yamoussoukro 152$ and in other places 156$.

**From:** Dennis Carroll <dcarroll@usaid.gov>
**Sent:** Thu, 11 Jan 2018 09:37:34 -0800
**Subject:** Re: Materials for today
**To:** Brooke Watson <watson@ecohealthalliance.org>
**Cc:** "Sacchetti, Ben" <Sacchetti.Ben@bcg.com>, Jonna Mazet <jkmazet@ucdavis.edu>, [redacted], Peter Daszak <daszak@ecohealthalliance.org>, Eddy Rubin <[redacted]>, Nathan Wolfe <nwolfe@metabiota.com>, Jennifer Fluder <jfluder@usaid.gov>, Amy Lin <amylin@usaid.gov>, "Stroman, Trish" <Stroman.Trish@bcg.com>, "Harris, Samuel" <Harris.Samuel@bcg.com>, "Kabay, Kendra" <Kabay.Kendra@bcg.com>, Linda Patterson <linda.patterson@panoramaglobal.org>, Raelyn Campbell <raelyn.campbell@panoramaglobal.org>, Gabrielle Fitzgerald <gabrielle.fitzgerald@panoramaglobal.org>, "Rodriguez, Andrew" <rodriguez.andrew@bcg.com>

We will reschedule for a time when everyone isn't in the air

Dr Dennis Carroll
Director, Emerging Threats Program
U.S. Agency for International Development
Office: (202) 712-5009
Mobile: [redacted]

On Jan 11, 2018, at 9:41 AM, Brooke Watson <watson@ecohealthalliance.org> wrote:

> Hi Ben,
> Peter is still in Brussels and will not be able to attend the 1 PM call today. Apologies for any confusion.

Best,

Brooke

**From:** "William B. Karesh" <karesh@ecohealthalliance.org>
**To:** Mario Freddy Mondele <mmondele@usaid.gov>
**Cc:** Amanda Andre <amanda.andre@ecohealthalliance.org>, "GeeEA@state.gov" <GeeEA@state.gov>, Predict inbox <predict@ucdavis.edu>, Andrew Clements <AClements@usaid.gov>, Anne Laudisoit <laudisoit@ecohealthalliance.org>, "Ava Sullivan" <sullivan@ecohealthalliance.org>
**Sent:** Wed, 17 Jan 2018 18:46:48 +0000
**Subject:** [predict] RoC PREDICT-2 update - good news

Dear Mario,
Best wishes on the New Year and I hope this finds you and your family all doing well.

Just a few days ago, we were finally notified by USAID/W that they have approved EcoHealth Alliance to sub-award agreements with the Laboratoire National de Santé Publique (LNSP) Brazzaville and the Laboratoire de Diagnostic Vétérinaire Brazzaville (LNVB) for work on the PREDICT-2 Project in the Republic of Congo. With these approvals, we will be able to move forward with more detailed agreements. We do not have permission to sub-award with Direction de la Santé Militaire Congo (DCSS).

Thus, we will be selecting a new Country Coordinator for the project, most likely this will be Prof. Parra from the LNSP.

We would like to plan a trip for myself, Dr. Anne Laudisoit, and Dr. Leticia Gutierrez-Jimenez for the last week of February to meet with you, finalize agreements with LNSP if possible, and work in the laboratory for a few days to run through the testing procedures. We are submitting an ITA request today, so that should come across your desk in the next week or two.

Ambassador Haskell mentioned when we last met with him that he would like to see some local public awareness of USG investments. One opportunity might be to do some type of event with the official opening of the project laboratory at LNSP during our visit in late February. Please let us know if you think this is something we should begin to plan.

We are looking forward to finally getting the project running at full speed again. At a PREDICT-2 meeting last week, we were asked to complete all animal sampling by October 2018 and complete all testing by the end of the calendar year. A priority will be to ensure that testing capabilities at the LNSP laboratory are up and running smoothly. We do not plan to conduct sampling or testing of people, but wish to continue to work on behavior studies. The remaining project time in 2019 will be used to refine the final test results, conduct analysis of the results, and write reports.

Again, thank you all for your support and patience during this long period of waiting for USAID approval. We all look forward to working with you and a successful year.

All the Best,

Billy

**William B. Karesh, D.V.M**
*Executive Vice President for Health and Policy*

EcoHealth Alliance
460 West 34th Street - 17th Floor
New York, NY 10001 USA

+1.212.380.4463 (direct)
+1.212.380.4465 (fax)
www.ecohealthalliance.org

President, OIE Working Group on Wildlife

Co-chair, IUCN Species Survival Commission - Wildlife Health Specialist Group

EPT Partners Liaison, USAID Emerging Pandemic Threats - PREDICT-2 Program

***EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that promote conservation and prevent pandemics.***

**From:** Jonna Mazet <jkmazet@ucdavis.edu>
**To:** AOTR/Grant Manager Andrew Clements <AClements@usaid.gov>
**Sent:** 1/31/2018 2:38:00 AM
**Subject:** Fwd: Thanks

FYI,
J

---------- Forwarded message ---------
From: Jonna Mazet <jkmazet@ucdavis.edu>
Date: Wed, Jan 31, 2018 at 5:37 PM
Subject: Re: Thanks
To: Daniel Schar <dschar@usaid.gov>
CC: <sdamrongwatanapokin@usaid.gov>

Thanks, Dan!
I and the team appreciate the opportunity. Special thanks to Sudarat for organizing!
Have a good night,
Jonna

On Wed, Jan 31, 2018 at 5:09 PM Daniel Schar <dschar@usaid.gov> wrote:
Dear Jonna,

Quick note to thank you for taking the time to talk with the broader Asia team. I know they appreciate the opportunity to hear directly from you and predict colleagues. Congratulations on all the terrific work, and the exciting work that lies ahead.

All best

Dan

**From:** Andrew Clements <aclements@usaid.gov>
**Sent:** Tue, 6 Feb 2018 10:52:55 -0800
**Subject:** Re: Heads-up on two outbreak related requests
**To:** Brian Bird <bhbird@ucdavis.edu>
**Cc:** Jonna Mazet <jkmazet@ucdavis.edu>

I approve of the Bangladesh support as well. :)

*Andrew P. Clements, Ph.D.*
*Senior Scientific Advisor*
*Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health*
*U.S. Agency for International Development*
*Mobile phone: 1-571-345-4253*
*Email: aclements@usaid.gov*

On Feb 6, 2018, at 7:07 PM, Andrew Clements <aclements@usaid.gov> wrote:

Hi Brian,

I approve this request for Liberia since (a) CDC's vehicles are not available, (b) it's not much money, and (c) it won't interfere with PREDICT work.

Andrew

On Tue, Feb 6, 2018 at 5:57 PM, Brian Bird <bhbird@ucdavis.edu> wrote:

Hi Andrew,

Two things came in this morning. One I think is pretty straightforward the other less so.

1. Bangladesh Nipah outbreak support – there was a verbal request from GoB to do animal surveillance. The team is working on getting an official letter/email etc. I'll get the report form and details to you ASAP.
2. Liberia – request for a vehicle/driver to support a non-PREDICT related health event.
    a. The National Public Health lab has requested that they utilize one of the PREDICT vehicles to shuttle supplies up to the site of a likely cholera outbreak. The expected duration would be for approx. 5 days. The team in Liberia is not doing any field sampling this week so there isn't a direct impact on program activities.
    b. Jonna and I discussed and while this is outside of our "lane" per se it seems like a reasonable way to engender goodwill with the brand-new government there. But this would be a major exception to our general policies/guidance on outbreak assistance.
    c. The request is for one vehicle and driver, and the funds for fuel and driver per diem. Likely cost to program estimated $300-400. The country team is working to see if the NPHL could pay for fuel but I'll be that's doubtful.

Do you have strong thoughts on the Liberia request? The country team will make sure that folks know this is an unusual circumstance regardless.

Thanks,

-Brian

Brian H. Bird DVM, MSPH, PhD

Global Lead Sierra Leone and

Multi-Country Ebola operations

PREDICT-USAID

One Health Institute

1089 Veterinary Medicine Dr.

School of Veterinary Medicine

University of California, Davis

Email: bhbird@ucdavis.edu

Skype: brianhbird1

http://www.vetmed.ucdavis.edu/ohi/predict/index.cfm

--

Andrew Clements, Ph.D.
Senior Scientific Advisor
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
E-mail: aclements@usaid.gov

*For more information on USAID's Emerging Pandemic Threats program, see:* http://www.usaid.gov/ept2

**From:** Andrew Clements <aclements@usaid.gov>
**To:** Jonna Mazet <jkmazet@ucdavis.edu>;David J Wolking <djwolking@ucdavis.edu>;Elizabeth Leasure <ealeasure@ucdavis.edu>
**Sent:** 2/7/2018 6:37:04 AM
**Subject:** Fwd: Obligation Request-PREDICT 2

Looks like nothing further is needed.

---------- Forwarded message ----------
From: **Ryland Marbray** <rmarbray@usaid.gov>
Date: Wed, Feb 7, 2018 at 3:34 PM
Subject: Re: Obligation Request-PREDICT 2
To: Amalhin Shek <ashek@usaid.gov>
Cc: Melanie Davidson <mdavidson@usaid.gov>, Brittany Eborn <beborn@usaid.gov>, Tim Springer <tspringer@usaid.gov>, Andrew Clements <aclements@usaid.gov>

I completed this action January 31st.

On Tue, Feb 6, 2018 at 12:57 PM, Amalhin Shek <ashek@usaid.gov> wrote:
Hi Ryland,

Do we need to do anything else to complete this action?

Thanks in advance,

Amalhin Shek | Budget & Communications
Emerging Threats Division, Office of Infectious Disease
**USAID**/Washington, Bureau for Global Health
Phone: 202-216-3541(o) 571-236-0989(c) | RRB-3.6.056
Subscribe to our Newsletter!

USAID-HECFAA, VP of Community Engagement

On Tue, Jan 30, 2018 at 2:19 PM, Melanie Davidson <mdavidson@usaid.gov> wrote:
Hi Ryland,

Thank you Ryland, please disregard previous email, I found the REQM and the group is now closed.

On Tue, Jan 30, 2018 at 1:29 PM, Ryland Marbray <rmarbray@usaid.gov> wrote:
Hi Brittany,

I need some one to close this group so I can proceed.

Thanks

On Thu, Jan 18, 2018 at 12:26 PM, Brittany Eborn <beborn@usaid.gov> wrote:
Hi Amalhin,

I've attached the FAF for Predict 2.

Please let me know if anything else needs to be included.

Best,
Brittany

On Thu, Jan 18, 2018 at 9:59 AM, Amalhin Shek <ashek@usaid.gov> wrote:
Dear all,

Could you let us know if anything else is required to execute this action?

Thanks in advance,

Amalhin Shek | Budget & Communications
Emerging Threats Division, Office of Infectious Disease
**USAID**/Washington, Bureau for Global Health
Phone: 202-216-3541(o) 571-236-0989(c) | RRB-3.6.056
Subscribe to our Newsletter!

USAID-HECFAA, VP of Community Engagement

On Thu, Jan 11, 2018 at 11:13 AM, Amalhin Shek <ashek@usaid.gov> wrote:
Good morning team!

We would appreciate your assistance in creating the REQ-M and executing the following obligation action:

- $13,197,500 to Predict 2 (AID-OAA-A-14-00102) from GH-C-AI/17/18.
- Sub-obligate $200,000 of ES-OCO-278 currrently approved in FS database (Jordan buy-in)

Please feel free to let us know if you have any questions.

Thanks in advance,

Amalhin Shek | Budget & Communications
Emerging Threats Division, Office of Infectious Disease
**USAID**/Washington, Bureau for Global Health
Phone: 202-216-3541(o) 571-236-0989(c) | RRB-3.6.056
Subscribe to our Newsletter!

USAID-HECFAA, VP of Community Engagement

--

**Brittany Eborn**

**USAID |** Budget Program Analyst
GH/PPP/PIBM
U.S. Agency for International Development
2100 Crystal Drive, Arlington, VA 22202
Phone: 571.551.7351

**USAID**
E3
1300 Pennsylvania Ave., NW,

(202) 567-5328 rmarbray@usaid.gov

**USAID**

(202) 567-5328 rmarbray@usaid.gov

--

Andrew Clements, Ph.D.
Senior Scientific Advisor
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
E-mail: aclements@usaid.gov

*For more information on USAID's Emerging Pandemic Threats program, see:* http://www.usaid.gov/ept2

# MODIFICATION OF ASSISTANCE AWARD



| 1. MODIFICATION NUMBER: | 2. EFFECTIVE DATE OF MODIFICATION: | 3. AWARD NUMBER: | 4. EFFECTIVE DATE OF AWARD: |
|---|---|---|---|
| 11 | See Block 15 | AID-OAA-A-14-00102 | 10/01//2014 |

**5. RECIPIENT:**

University of California, Davis
School of Veterinary Medicine,
1850 Research Park Dr.
Davis, CA 95618

DUNS No.: 04-712-0084
TIN No.: 94-6036494 LOC: 29B8P

**6. ADMINISTERED BY:**

U.S. Agency for International Development
Office of Acquisition and Assistance
M/OAA/GH/HIDN
1300 Pennsylvania Ave., NW
SA-44, 549
Washington, DC 20532-7900

**7. FISCAL DATA:**

**Amount Obligated: $13,397,500.00**
**Detail: See page 2**

**8. TECHNICAL OFFICE:**
USAID/GH/HIDN

**9. PAYMENT OFFICE:**

U.S. Agency for International Development
M/FM/CMP/LOC
loc@usaid.gov

**10. FUNDING SUMMARY:**

| | Obligated Amount | Total Est. Amount |
|---|---|---|
| Amount Obligated prior to this Modification: | $ 99,582,500.00 | $138,400,000.00 |
| Change made by this Modification: | $ 13,397,500.00 | $ .00 |
| New/Current Total: | $112,980,000.00 | $138,400,000.00 |

**11. DESCRIPTION OF MODIFICATION:**

The purpose of this modification is to provide incremental funding in the amount of $13,397,500.00 increasing the total obligated amount from $99,582,500.00 to $112,980,000.00 with $25,420,000.00 remaining to be obligated against the total estimated cost of $138,400,000.00.

(See continuation pages)

**12. THIS MODIFICATION IS ENTERED INTO PURSUANT TO THE AUTHORITY OF THE FOREIGN ASSISTANCE ACT OF 1961, AS AMENDED. EXCEPT AS SPECIFICALLY AMENDED HEREIN, ALL TERMS AND CONDITIONS OF THE AWARD REFERENCED ON BLOCK #3 ABOVE, AS IT MAY HAVE HERETOFORE BEEN AMENDED, REMAIN UNCHANGED AND IN FULL FORCE AND EFFECT.**

| 13. RECIPIENT | | IS | X | IS NOT REQUIRED TO SIGN THIS DOCUMENT TO RECONFIRM ITS AGREEMENT WITH THE CHANGES EFFECTED HEREIN. |
|---|---|---|---|---|

**14. RECIPIENT:**

BY: _____

_____
*(Name Typed or Printed)*

TITLE: _____

DATE: _____

**15. THE UNITED STATES OF AMERICA**
**U.S. AGENCY FOR INTERNATIONAL DEVELOPMENT**

BY: _____

Ryland C. Marbray
*(Name Typed or Printed)*

TITLE: Agreement Officer

DATE: 1/31/2015

UCDUSR0011850

The Cooperative Agreement is modified as follows:

1) On the **COVER PAGE – A. GENERAL**:

- On Line 1., "Amount Obligated this Action", DELETE the amount of "$2,582,500.00" and REPLACE with "$13,397,500.00".
- On Line 3., "Total Obligated USAID Amount", DELETE the amount of "$99,582,500.00" and REPLACE with "$112,980,000.00".

2) On the **COVER PAGE – B. SPECIFIC**, add the following:

| Account ID | Accounting Template | BBFY | EBFY | Fund | OP | Prog Area | Dist Code | Prog Elem | BGA | OP Def | SOC | Funded Amount |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | GH-HN Program Funds | 2017 | 2018 | GH-C-AI | GH/ID | HL.4 | 936-4002 | (none) | 997 | (None) | 4100201 | $13,197,500.00 |

| Account ID | Accounting Template | BBFY | EBFY | Fund | OP | Prog Area | Dist Code | Prog Elem | BGA | OP Def | SOC | Funded Amount |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 27 | GH-HN Program Funds | 2015 | 2016 | ES-OCO-278 | JORDAN | A11 | 278-M | A051 | 278 | (None) | 4100201 | $119,682.00 |

| Account ID | Accounting Template | BBFY | EBFY | Fund | OP | Prog Area | Dist Code | Prog Elem | BGA | OP Def | SOC | Funded Amount |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 28 | GH-HN Program Funds | 2015 | 2016 | ES-OCO-278 | JORDAN | A11 | 278-M | A052 | 278 | (None) | 4100201 | $80,318.00 |

| | |
|---|---|
| Amount Obligated this Action: | $ 13,397,500.00 |
| Total Estimated USAID Amount: | $138,400,000.00 |
| Total Obligated USAID Amount: | $112,980,000.00 |
| Amount Remaining to be Obligated: | $ 25,420,000.00 |

3) In **ATTACHMENT A – SCHEDULE, A.3 AMOUNT OF AWARD AND PAYMENT**, paragraph 2., DELETE "USAID hereby obligates the amount of $99,582,500.00 for program expenditures during the period set forth in A.2 above." and REPLACE with "USAID hereby obligates the amount of $112,980,000.00 for program expenditures during the period set forth in A.2 above."

All terms and conditions remain unchanged.



UCDUSR0011851

**From:** Jonna Mazet <jkmazet@ucdavis.edu>
**To:** Andrew Clements <aclements@usaid.gov>
**CC:** David J Wolking <djwolking@ucdavis.edu>;Elizabeth Leasure <ealeasure@ucdavis.edu>
**Sent:** 2/7/2018 11:28:25 AM
**Subject:** Re: Obligation Request-PREDICT 2

Great -- fully executed,
Jonna

On Wed, Feb 7, 2018 at 6:37 AM, Andrew Clements <aclements@usaid.gov> wrote:
Looks like nothing further is needed.

---------- Forwarded message ----------
From: **Ryland Marbray** <rmarbray@usaid.gov>
Date: Wed, Feb 7, 2018 at 3:34 PM
Subject: Re: Obligation Request-PREDICT 2
To: Amalhin Shek <ashek@usaid.gov>
Cc: Melanie Davidson <mdavidson@usaid.gov>, Brittany Eborn <beborn@usaid.gov>, Tim Springer <tspringer@usaid.gov>, Andrew Clements <aclements@usaid.gov>

I completed this action January 31st.

On Tue, Feb 6, 2018 at 12:57 PM, Amalhin Shek <ashek@usaid.gov> wrote:
Hi Ryland,

Do we need to do anything else to complete this action?

Thanks in advance,

Amalhin Shek | Budget & Communications
Emerging Threats Division, Office of Infectious Disease
**USAID**/Washington, Bureau for Global Health
Phone: 202-216-3541(o) 571-236-0989(c) | RRB-3.6.056
Subscribe to our Newsletter!

USAID-HECFAA, VP of Community Engagement

On Tue, Jan 30, 2018 at 2:19 PM, Melanie Davidson <mdavidson@usaid.gov> wrote:
Hi Ryland,

Thank you Ryland, please disregard previous email, I found the REQM and the group is now closed.

On Tue, Jan 30, 2018 at 1:29 PM, Ryland Marbray <rmarbray@usaid.gov> wrote:
Hi Brittany,

I need some one to close this group so I can proceed.

Thanks

On Thu, Jan 18, 2018 at 12:26 PM, Brittany Eborn <beborn@usaid.gov> wrote:
Hi Amalhin,

I've attached the FAF for Predict 2.

Please let me know if anything else needs to be included.

Best,
Brittany

On Thu, Jan 18, 2018 at 9:59 AM, Amalhin Shek <ashek@usaid.gov> wrote:
Dear all,

Could you let us know if anything else is required to execute this action?

Thanks in advance,

Amalhin Shek | Budget & Communications
Emerging Threats Division, Office of Infectious Disease
**USAID**/Washington, Bureau for Global Health
Phone: 202-216-3541(o) 571-236-0989(c) | RRB-3.6.056
Subscribe to our Newsletter!

USAID-HECFAA, VP of Community Engagement

On Thu, Jan 11, 2018 at 11:13 AM, Amalhin Shek <ashek@usaid.gov> wrote:
Good morning team!

We would appreciate your assistance in creating the REQ-M and executing the following obligation action:

- $13,197,500 to Predict 2 (AID-OAA-A-14-00102) from GH-C-AI/17/18.
- Sub-obligate $200,000 of ES-OCO-278 currrently approved in FS database (Jordan buy-in)

Please feel free to let us know if you have any questions.

Thanks in advance,

Amalhin Shek | Budget & Communications
Emerging Threats Division, Office of Infectious Disease
**USAID**/Washington, Bureau for Global Health
Phone: 202-216-3541(o) 571-236-0989(c) | RRB-3.6.056
Subscribe to our Newsletter!

USAID-HECFAA, VP of Community Engagement

--

**Brittany Eborn**

**USAID** | Budget Program Analyst
GH/PPP/PIBM
U.S. Agency for International Development
2100 Crystal Drive, Arlington, VA 22202
Phone: 571.551.7351

**USAID**
E3
1300 Pennsylvania Ave., NW,

(202) 567-5328 rmarbray@usaid.gov

**USAID**

(202) 567-5328 rmarbray@usaid.gov

1-571-345-4253
aclements@usaid.gov

*For more information on USAID's Emerging Pandemic Threats program, see:* http://www.usaid.gov/ept2

**From:** Elizabeth Leasure <ealeasure@UCDAVIS.EDU>
**To:** Molly Turner <turner@ecohealthalliance.org>
**Cc:** Evelyn Luciano <luciano@ecohealthalliance.org>, Ava Sullivan <sullivan@ecohealthalliance.org>, Jon Epstein <epstein@ecohealthalliance.org>, Peter Daszak <daszak@ecohealthalliance.org>, Jonna Mazet <jkmazet@ucdavis.edu>, Predict inbox <predict@ucdavis.edu>, "David John Wolking" <djwolking@ucdavis.edu>
**Subject:** RE: Liberia information you requested
**Sent:** Sat, 10 Feb 2018 00:45:39 +0000
Liberia info for Liz.xlsx

Thanks, Molly. Based on the figures below and attached, it looks like you've got a nice sum available to spend in the Liberia budget. Given the available balance noted below, can you clarify why Jim is under the impression that there isn't any money available for project activities? He seems to think that UCD is holding onto the funding, but that clearly isn't the case based on the numbers. I'm just wondering where the disconnect is. Does it have anything to do with our needing to setup an advance payment subaward (which we're working on now)? Please clarify.

The amount obligated for Liberia in Y4 so far ($706K, inclusive of Global costs attributed to Liberia) is the amount that was included in the Y4 budget that was submitted to Andrew. That particular budget was incredibly challenging given our need (at the time) to hit specific targets (or caps) for each Ebola/EHP-funded country, so some country budgets needed to be adjusted to stay within the limits imposed by USAID. This doesn't mean that there isn't the possibility or intention of adding funds to your subaward for activities in Liberia, but it isn't something we can do until you spend down the large balance of funds you have on hand. My recollection from previous discussions during the budgeting process and in New York in September is that the $1.556M figure you mentioned did include carryover (others, please weigh in if I am not remembering this correctly, as that was quite some time ago).

Also, we have not yet received all of the EHP funding (though we did budget as if we had per AOR guidance). We're still waiting on the last $3M, which USAID has indicated will not be obligated until we significantly spend down the Ebola funds on-hand (another reason to not obligate additional funds for Liberia at this time). The previous guidance received regarding the lack of new funding for CIV and Liberia in Y5 still applies, as the decision to reallocate funds from other country budgets would need to be part of a broader discussion with the bigger PREDICT picture in mind. Since those discussions haven't happened, I can't provide any new guidance at this time.

Thanks,
Liz

*Elizabeth Leasure*
*Financial Operations Manager*
*One Health Institute*
REDACTED *(cell)*
*530-754-9034 (office)*
*Skype: ealeasure*

**From:** Molly Turner [mailto:turner@ecohealthalliance.org]
**Sent:** Friday, February 09, 2018 11:49 AM
**To:** Elizabeth Leasure
**Cc:** Evelyn Luciano; Ava Sullivan
**Subject:** Liberia information you requested

Hi Liz,

Here's the information you requested:

Remaining funds to spend in Liberia: $1,109,774
$403,159.59 of this is rollover from Year 3

(Liberia funds awards to date: $2,656,957
Liberia funds billed to UCD to date: $1,489,918
To be billed, January 2018: $57,264;
This is all worked out in the attached spreadsheet as well.)

Now that the cap issue has gone away, we are still trying to figure out is whether this is all of the funding we will be

receiving through September 2019 for CIV and Liberia, since we were told that your team requested and received the full amount of Ebola funding available (and had also been previously told that we should plan to make the GHSA/Ebola funds we receive last through Year 5).

I'm also a little confused by the fact that the Year 4 budget we agreed to had $1,555,932 budgeted for Liberia for Year 4; even if the 11.39 million target budget target for Year 4 included rollover (which I don't think it did), we requested and agreed to $944,467.85 in additional funding for Liberia for Year 4, and have thus far only been awarded $700,615.

We just want to be able to plan accordingly.

Thanks,
Molly
--
**Molly Turner**
*Federal Grants Coordinator*
*EcoHealth Alliance Operations*

EcoHealth Alliance
460 West 34th Street – 17th floor
New York, NY 10001

1.212.380.4461 (direct)
REDACTED
www.ecohealthalliance.org

***EcoHealth Alliance leads cutting-edge scientific research into the critical connections between human and wildlife health and delicate ecosystems. With this science, we develop solutions that prevent pandemics and promote conservation.***

Produced in Native Format

**From:** Evelyn Luciano <luciano@ecohealthalliance.org>
**To:** Elizabeth Leasure <ealeasure@ucdavis.edu>
**Cc:** Molly Turner <turner@ecohealthalliance.org>, Ava Sullivan <sullivan@ecohealthalliance.org>, Jon Epstein <epstein@ecohealthalliance.org>, Peter Daszak <daszak@ecohealthalliance.org>, Jonna Mazet <jkmazet@ucdavis.edu>, Predict inbox <predict@ucdavis.edu>, David John Wolking <djwolking@ucdavis.edu>
**Subject:** Re: Liberia information you requested
**Sent:** Mon, 12 Feb 2018 20:52:52 +0000

Hi Liz,
Great speaking to you just now. Just to reiterate, I spoke to Jim this morning and he has confirmed that his comment to Brian regarding funding, was not because he was under the impression that there wasn't funding available for project activities, nor because he thought UCD was withholding funds. Rather, Jim was referring to EHA's cash flow issues while we were waiting for our own payments. This is now all squared away.

Looking forward to ongoing discussions regarding Liberia funds.

Thanks, again.

Evelyn

On Feb 9, 2018, at 7:45 PM, Elizabeth Leasure <ealeasure@ucdavis.edu> wrote:

Thanks, Molly. Based on the figures below and attached, it looks like you've got a nice sum available to spend in the Liberia budget. Given the available balance noted below, can you clarify why Jim is under the impression that there isn't any money available for project activities? He seems to think that UCD is holding onto the funding, but that clearly isn't the case based on the numbers. I'm just wondering where the disconnect is. Does it have anything to do with our needing to setup an advance payment subaward (which we're working on now)? Please clarify.

The amount obligated for Liberia in Y4 so far ($706K, inclusive of Global costs attributed to Liberia) is the amount that was included in the Y4 budget that was submitted to Andrew. That particular budget was incredibly challenging given our need (at the time) to hit specific targets (or caps) for each Ebola/EHP-funded country, so some country budgets needed to be adjusted to stay within the limits imposed by USAID. This doesn't mean that there isn't the possibility or intention of adding funds to your subaward for activities in Liberia, but it isn't something we can do until you spend down the large balance of funds you have on hand. My recollection from previous discussions during the budgeting process and in New York in September is that the $1.556M figure you mentioned did include carryover (others, please weigh in if I am not remembering this correctly, as that was quite some time ago).

Also, we have not yet received all of the EHP funding (though we did budget as if we had per AOR guidance). We're still waiting on the last $3M, which USAID has indicated will not be obligated until we significantly spend down the Ebola funds on-hand (another reason to not obligate additional funds for Liberia at this time). The previous guidance received regarding the lack of new funding for CIV and Liberia in Y5 still applies, as the decision to reallocate funds from other country budgets would need to be part of a broader discussion with the bigger PREDICT picture in mind. Since those discussions haven't happened, I can't provide any new guidance at this time.

Thanks,
Liz

*Elizabeth Leasure*
*Financial Operations Manager*
*One Health Institute*
REDACTED *(cell)*
*530-754-9034 (office)*
*Skype: ealeasure*

**From:** Molly Turner [mailto:turner@ecohealthalliance.org]

**Sent:** Friday, February 09, 2018 11:49 AM
**To:** Elizabeth Leasure
**Cc:** Evelyn Luciano; Ava Sullivan
**Subject:** Liberia information you requested

Hi Liz,

Here's the information you requested:

Remaining funds to spend in Liberia: $1,109,774
$403,159.59 of this is rollover from Year 3

(Liberia funds awards to date: $2,656,957
Liberia funds billed to UCD to date: $1,489,918
To be billed, January 2018: $57,264;
This is all worked out in the attached spreadsheet as well.)

Now that the cap issue has gone away, we are still trying to figure out is whether this is all of the funding we will be receiving through September 2019 for CIV and Liberia, since we were told that your team requested and received the full amount of Ebola funding available (and had also been previously told that we should plan to make the GHSA/Ebola funds we receive last through Year 5).

I'm also a little confused by the fact that the Year 4 budget we agreed to had $1,555,932 budgeted for Liberia for Year 4; even if the 11.39 million target budget target for Year 4 included rollover (which I don't think it did), we requested and agreed to $944,467.85 in additional funding for Liberia for Year 4, and have thus far only been awarded $700,615.

We just want to be able to plan accordingly.

Thanks,
Molly
--
**Molly Turner**
*Federal Grants Coordinator*
*EcoHealth Alliance Operations*

EcoHealth Alliance
460 West 34th Street – 17th floor
New York, NY 10001

1.212.380.4461 (direct)
REDACTED (cell)
www.ecohealthalliance.org

***EcoHealth Alliance leads cutting-edge scientific research into the critical connections between human and wildlife health and delicate ecosystems. With this science, we develop solutions that prevent pandemics and promote conservation.***

<Liberia info for Liz.xlsx>

**From:** Andrew Clements <aclements@usaid.gov>
**Sent:** Wed, 14 Feb 2018 04:24:05 -0800
**To:** Brian Bird <bhbird@ucdavis.edu>
**Cc:** PREDICTMGT <predictmgt@usaid.gov>, PREDICT-outbreak <predict-outbreak@ucdavis.edu>
**Subject:** [predict] [predict-outbreak] Re: Updates PREDICT Bangladesh and Liberia outbreak responses 13Feb2018

Thanks

*Andrew P. Clements, Ph.D.*
*Senior Scientific Advisor*
*Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health*
*U.S. Agency for International Development*
*Mobile phone: 1-571-345-4253*
*Email: aclements@usaid.gov*

On Feb 14, 2018, at 5:48 AM, Brian Bird <bhbird@ucdavis.edu> wrote:

> Good evening all,
>
> Two updates:
>
> 1. Bangladesh: The field team is safely back at their home station. The bat roost collected samples were submitted to the laboratory for specific Nipah virus testing and the five priority viral families following PREDICT protocols.
> 2. Liberia: the logistical support (vehicle/driver) supplied by PREDICT for the human diarrheal outbreak has wrapped up.
>    a. Cause of diarrhea event was reported as *Shigella dysenteriae*.
>
> Hope all is well,
>
> -Brian
>
> Brian H. Bird DVM, MSPH, PhD
> Global Lead Sierra Leone and
> Multi-Country Ebola operations
> PREDICT-USAID
>
> One Health Institute
> 1089 Veterinary Medicine Dr.
> School of Veterinary Medicine
> University of California, Davis
> Email: bhbird@ucdavis.edu
> Skype: brianhbird1
> http://www.vetmed.ucdavis.edu/ohi/predict/index.cfm
>
> --

You received this message because you are subscribed to the Google Groups "PREDICTMGT" group.
To unsubscribe from this group and stop receiving emails from it, send an email to predictmgt+unsubscribe@usaid.gov.
To post to this group, send email to predictmgt@usaid.gov.
To view this discussion on the web visit https://groups.google.com/a/usaid.gov/d/msgid/predictmgt/DEF6F7B1-3F7D-40AE-BA01-334D79973BF0%40ucdavis.edu.

<Human Encephalitis_PREDICT Bangladesh_Gunahar_February_13_2018_final.pdf>

<PREDICT_Liberia_Human diarrheal disease_Firestone_February_13_2018_final.pdf>

**From:** "William B. Karesh" <karesh@ecohealthalliance.org>
**To:** David Wolking <djwolking@ucdavis.edu>
**Cc:** Amanda Andre <amanda.andre@ecohealthalliance.org>, "predict@ucdavis.edu" <predict@ucdavis.edu>, Terra Kelly <trkelly@ucdavis.edu>, Catherine Machalaba <machalaba@ecohealthalliance.org>
**Sent:** Thu, 22 Feb 2018 22:20:52 +0000
**Subject:** [predict] Re: Technical Brief for Chief Director

Thanks. Interesting.
BK

**William B. Karesh, D.V.M**
*Executive Vice President for Health and Policy*

EcoHealth Alliance
460 West 34th Street - 17th Floor
New York, NY 10001 USA

+1.212.380.4463 (direct)
+1.212.380.4465 (fax)
www.ecohealthalliance.org

President, OIE Working Group on Wildlife

Co-chair, IUCN Species Survival Commission - Wildlife Health Specialist Group

EPT Partners Liaison, USAID Emerging Pandemic Threats - PREDICT-2 Program

***EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that promote conservation and prevent pandemics.***

On Feb 22, 2018, at 4:43 PM, David J Wolking <djwolking@ucdavis.edu> wrote:

Billy and Terra,
This FAO technical brief on One Health from Ghana I think something you need?

Not sure how Liz was targeted :-)

David
---------- Forwarded message ----------
From: [redacted]>
Date: Wed, Feb 21, 2018 at 9:34 AM
Subject: FW: Technical Brief for Chief Director
To: David John Wolking <djwolking@ucdavis.edu>, Elizabeth Leasure <ealeasure@ucdavis.edu>
Cc: "predict@ucdavis.edu" <predict@ucdavis.edu>

Thanks Liz, looping David in.

[redacted]

**From:** predict-request@ucdavis.edu [mailto:predict-request@ucdavis.edu] **On Behalf Of** Elizabeth Leasure

**Sent:** Wednesday, February 21, 2018 9:27 AM
**To:** predict@ucdavis.edu
**Subject:** [predict] FW: Technical Brief for Chief Director

Not sure how this came to me and no one else, but here it is.

**From:** Akunzule, Anthony (FAORAF) [REDACTED]
**Sent:** Wednesday, February 21, 2018 9:19 AM
**To:** PUNGUYIRE, Damien; OHENE, Sally-Ann; Sow, Adama (FAORAF); SaidouniOulebsir, Asma (FAORAF); Gonde, Abdoulaye (FAORAF); Afakye, Kofi (FAORAF)
**Cc:** Elizabeth Leasure
**Subject:** Technical Brief for Chief Director

Dear All

Please, find attached a technical brief for discussion with Chief Directors of the ministries on One Health

This is for your comments and improvements

Warm Regards

Akunz

<Technical Brief - One Health for Chief Directors.docx>

| | |
|---|---|
| **From:** | Andrew Clements <aclements@usaid.gov> |
| **To:** | Katherine Leasure <kaleasure@ucdavis.edu> |
| **CC:** | PREDICTMGT <predictmgt@usaid.gov>;Jonna Mazet <jkmazet@ucdavis.edu>;Predict inbox <predict@ucdavis.edu> |
| **Sent:** | 2/25/2018 3:11:30 AM |
| **Subject:** | Re: PREDICT International Travel Requests |

Approved subject to mission concurrence

*Andrew P. Clements, Ph.D.*
*Senior Scientific Advisor*
*Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health*
*U.S. Agency for International Development*
*Mobile phone: 1-571-345-4253*
*Email: aclements@usaid.gov*

On Feb 24, 2018, at 2:34 AM, Katherine Leasure <kaleasure@ucdavis.edu> wrote:

*Please find below international travel requests for your review and approval. Please let me know if you have any questions. TDY form is attached for David McIver's requested travel to Laos. Thanks!*

1. McIver (Laos): $2200 airfare/$212 (Vientiane) max daily per diem
2. Ross (Kenya): $2100 airfare/$410 (Nairobi) max daily per diem
3. Latinne (Indonesia): $2200 airfare/$146 (North Sulawesi, Gorontalo, and Bogor) max daily per diem
4. Epstein (India): $5000 airfare/$291 (Lucknow) max daily per diem
5. Gilardi (Rwanda, Uganda): $2400 airfare/$291 (Kigali), $340 (Kampala) max daily per diems

Travel Requests –

1. Metabiota would like to request travel approval for Dr. David McIver, PREDICT Asia Regional Coordinator to travel from Nanaimo, British Columbia, Canada to Vientiane, Lao PDR from March 15-24, 2018 to launch human surveillance activities at Khong Hospital.

Trip purpose: While in Lao PDR, Dr. McIver will launch human surveillance activities at Khong Hospital including re-training regarding surveillance implementation and workflow as well as two days for oversight of enrolment of the first few patients.

2. EcoHealth Alliance would like to request travel approval for Dr. Noam Ross to travel from New York, NY, USA to Nairobi, Kenya from March 25-31, 2018 for a scenario-planning workshop with FAO and country stakeholders as part of the Africa Sustainable Livestock 2050 project.

**Trip purpose**: Noam will present EHA work under PREDICT characterizing risk of avian influenza outbreak to multiple partners and stakeholders involved in the ASL2050. Noam will participate in piloting FAO's scenario-planning process for developing future pathways of livestock development. EHA's participation in this pilot is essential in ensuring that it will elicit the information required to construct models of future disease outbreak risk, and that model outputs are useful to partner countries and stakeholders.

3. EcoHealth Alliance would like to request travel approval for Dr. Alice Latinne to travel from New York, NY, USA to Bogor, North Sulawesi and Gorontalo, Indonesia from April 4-25, 2018 for meetings with in-country partners and field work.

**Trip purpose**: In Bogor, Dr. Alice Latinne will meet with PREDICT team and attend a seminar at IPB (April 4-6). In North Sulawesi and Gorontalo, Dr. Alice Latinne will meet with local partners and assist the PREDICT Indonesia team in PREDICT concurrent wildlife and human community sampling (April 7-25).

4. EcoHealth Alliance would like to request travel approval for Dr. Jonathan Epstein to travel from New York, NY, USA to Lucknow, India from March 26-29, 2018 to conduct high-level meetings with implementing partners of PREDICT-2 India.

**Trip Purpose:** Dr. Jonathan Epstein will travel to Lucknow to participate in high-level meetings with PREDICT-2 India Senior Management Team member, Dr. Tapan Dhole, and additional members of SGPGIMS, including the Director of the institution, to discuss the implementation of Year 4 of the PREDICT project in India.

5. UC Davis would like to request travel approval for Dr. Kirsten Gilardi to travel from Davis, California, USA to Kigali, Rwanda and Kampala, Uganda from March 24 to April 8 2018 to meet with PREDICT staff and partners.

**Trip purpose**: This trip will enable Dr. Gilardi to meet with PREDICT Country Coordinators from Rwanda, Uganda and eastern Democratic Republic of the Congo at MGVP headquarters in Ruhengeri, Rwanda, and Kampala, Uganda, to conduct field site visits with staff and to check on Year 4 work in all three countries. Dr. Gilardi will also meet with Governments of Uganda and Rwanda laboratory partners to check on progress with sample testing and One Health capacity strengthening for staff and partners. ***Her tentative travel dates in each country are as follows – Rwanda: March 25 to April 2, Uganda: April 2-7***

**Katherine Leasure**
HR/Payroll/Financial Assistant
One Health Institute
University of California, Davis
530-752-7526
530-752-3318 FAX
kaleasure@ucdavis.edu

--
You received this message because you are subscribed to the Google Groups "PREDICTMGT" group.
To unsubscribe from this group and stop receiving emails from it, send an email to predictmgt+unsubscribe@usaid.gov.
To post to this group, send email to predictmgt@usaid.gov.
To view this discussion on the web visit https://groups.google.com/a/usaid.gov/d/msgid/predictmgt/049e01d3ad0f%24acfa8410%2406ef8c30%24%40ucdavis.edu.

**From:** Andrew Clements <aclements@usaid.gov>
**Sent:** Tue, 6 Mar 2018 10:34:49 -0800
**To:** David J Wolking <djwolking@ucdavis.edu>
**Cc:** "predict@ucdavis.edu" <predict@ucdavis.edu>, PREDICTMGT <predictmgt@usaid.gov>, William Karesh <karesh@ecohealthalliance.org>
**Subject:** Re: [predict] FW: Technical Brief for Chief Director

Thanks. Will share with Ricardo and a few other in ETD to see if they have comments.

*Andrew P. Clements, Ph.D.*
*Senior Scientific Advisor*
*Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health*
*U.S. Agency for International Development*
*Mobile phone: 1-571-345-4253*
*Email: aclements@usaid.gov*

On Mar 6, 2018, at 6:14 PM, David J Wolking <djwolking@ucdavis.edu> wrote:

> Hi Andrew,
> Just sharing this FAO technical briefing from Ghana on strenghtening One Health frameworks in-country. Also including some context from Dr. Terra Kelley and our PREDICT/Ghana team.
>
> > Thanks David! As part of the EPT 2 program in Ghana, FAO is working on efforts to institutionalize One Health. We had a call with USAID on Tuesday and met FAO's EPT-2 National Coordinator. He is requesting feedback on the brief and has identified this as an area where PREDICT and FAO might work together in Ghana on EPT 2 activities.
>
> Best,

David

---------- Forwarded message ----------
From: **Elizabeth Leasure** <ealeasure@ucdavis.edu>
Date: Wed, Feb 21, 2018 at 9:27 AM
Subject: [predict] FW: Technical Brief for Chief Director
To: "predict@ucdavis.edu" <predict@ucdavis.edu>

Not sure how this came to me and no one else, but here it is.

---

**From:** Akunzule, Anthony (FAORAF) [REDACTED]
**Sent:** Wednesday, February 21, 2018 9:19 AM
**To:** PUNGUYIRE, Damien; OHENE, Sally-Ann; Sow, Adama (FAORAF); SaidouniOulebsir, Asma (FAORAF); Gonde, Abdoulaye (FAORAF); Afakye, Kofi (FAORAF)
**Cc:** Elizabeth Leasure
**Subject:** Technical Brief for Chief Director

Dear All

Please, find attached a technical brief for discussion with Chief Directors of the ministries on One Health

This is for your comments and improvements

Warm Regards

Akunz

<Technical Brief - One Health for Chief Directors.docx>

**Sent:** Tue, 06 Mar 2018 23:06:24 +0000
**Subject:** Re: I'm back!
**From:** Jonna Mazet <jkmazet@ucdavis.edu>
**To:** [redacted]
**Cc:** Brooke Watson <watson@ecohealthalliance.org>, Cara Chrisman <cchrisman@usaid.gov>, Dennis Carroll <dcarroll@usaid.gov>, Eddy Rubin <erubin@metabiota.com>, Nathan Wolfe <nwolfe@metabiota.com>, Peter Daszak <daszak@ecohealthalliance.org>
image002.jpg
image001.jpg
image003.jpg

Me, too — so handsome!
Happy to have you back,
Jonna

On Tue, Mar 6, 2018 at 9:46 AM [redacted] wrote:

> Hi Cara,
>
> Welcome back, I'm excited to work with you again! Thank you for sharing the adorable pictures, I can't wait to meet him.
>
> Best,
>
> [redacted]
>
> **From:** Cara Chrisman [mailto:cchrisman@usaid.gov]
> **Sent:** Tuesday, March 06, 2018 6:11 AM
> **To:** Jonna Mazet <jkmazet@ucdavis.edu>; Peter Daszak <daszak@ecohealthalliance.org>; Brooke Watson <watson@ecohealthalliance.org>; Eddy Rubin <erubin@metabiota.com>; Nathan Wolfe <nwolfe@metabiota.com>; [redacted]
> **Cc:** Dennis Carroll <dcarroll@usaid.gov>
> **Subject:** I'm back!
>
> Hi GVP Team,
>
> I wanted to let you all know that I'm officially back in the office after my maternity leave! I'm in the middle of the move from our Reagan Bldg office to the Crystal City offices, so things are a little hectic, but it's been great to be back and start to catch up on things.
>
> I'm looking forward to touching base with all of you and hearing how things have been going, both personally and with work! I hope that you've all been well! On the GVP end, I had a chance to touch base with Dennis before he left and have times set up to speak with BCG and Amy & Jen. Sounds like there's a lot of great progress and looking forward to assisting in continuing to move things forward.
>
> In case you're curious how the little guy is doing, he hates napping, but is doing quite well otherwise (see attachments) and

continues to be super tall! We have had lots of long chats about the benefits of vaccination and have started on basic One Health principles, so he's very much looking forward to meeting you all one day :).

Best,

Cara

Cara J. Chrisman, PhD
Senior Infectious Diseases Technical Advisor
Emerging Threats Division
Office of Infectious Disease
Bureau for Global Health
U.S. Agency for International Development (USAID)

Desk: (202) 712-1161
Cell: REDACTED
E-mail: cchrisman@usaid.gov

REDACTED

REDACTED

**From:** Andrew Clements <aclements@usaid.gov>
**Sent:** Tue, 13 Mar 2018 10:27:53 +0100
**Subject:** Re: PREDICT Management Team Call - Tuesday February 6 2018 @ 10AM PST/1PM EST
**To:** Elizabeth Leasure <ealeasure@ucdavis.edu>
**Cc:** David John Wolking <djwolking@ucdavis.edu>, Jonna Mazet <jkmazet@ucdavis.edu>, Alisa Pereira <apereira@usaid.gov>

Thanks, Liz.

At the current expenditure rate, when would you expect to expend 100% of the Ebola funds?

Andrew

On Mon, Mar 12, 2018 at 11:26 PM, Elizabeth Leasure <ealeasure@ucdavis.edu> wrote:

> Hi Andrew. Based on current projections and anticipated spending increases, I'm estimating that we will have approximately 25% of the Ebola funds obligated to date remaining as of June 2018. Let me know if you have any questions or need any additional information.
>
> Thanks,
>
> Liz
>
> *Elizabeth Leasure*
>
> *Financial Operations Manager*
>
> *One Health Institute*
>
> REDACTED *(cell)*
>
> *530-754-9034 (office)*
>
> *Skype: ealeasure*
>
> ---
>
> **From:** Andrew Clements [mailto:aclements@usaid.gov]
> **Sent:** Monday, February 05, 2018 1:24 PM
> **To:** David John Wolking; Jonna Mazet; Elizabeth Leasure
> **Cc:** Alisa Pereira
> **Subject:** Re: PREDICT Management Team Call - Tuesday February 6 2018 @ 10AM PST/1PM EST
>
> On a related note, what's the current projection on how long Ebola funds will last with the reassignment among countries?
>
> I want to give as much of a heads up as possible.
>
> Thanks!

Andrew

*Andrew P. Clements, Ph.D.*

*Senior Scientific Advisor*

*Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health*

*U.S. Agency for International Development*

*Mobile phone: 1-571-345-4253*

*Email: aclements@usaid.gov*

On Feb 5, 2018, at 6:52 PM, David J Wolking <djwolking@ucdavis.edu> wrote:

Hi there,

Below and attached for quick reference is the agenda for tomorrow's PREDICT Management Team call.

Best,

David

**PREDICT Management Call Agenda**

**Tuesday, February 6, 2017**

**10:00-11:00AM PDT/1:00-2:00pm EDT**

REDACTED

**Standing items**

**USAID Updates**

1. **Administrative items**
   a. Core (regular) funding update
   b. Feedback on P2 additional testing request

2. **PMAC and GVP update (Jonna et al)**

3. **Mission communications roundup**

   a. Myanmar and viral testing plans with LBVD

   b. Guinea mission visit and updates

   c. Liberia and data sharing inquiry

4. **Outbreak updates (Liberia, Cameroon, others)**

6. **EPT partner collaboration/coordination updates (Billy)**

7. **Publication, media, and conference updates**

   - CUGH Global Health Conference, New York (March 15-18, 2018)
   - "Outbreak: Epidemics in a Connected World" exhibit at NMNH (May 2018)
   - One Health Congress Saskatoon (June 22-25, 2018)
   - International Conference on Emerging Infectious Diseases (ICEID) in Atlanta (August 26–29, 2018)
   - International Meeting on Emerging Diseases and Surveillance (IMED) 2018 in Vienna, Austria (November 9-12, 2018)
   - Others?

On Fri, Feb 2, 2018 at 8:10 AM, David J Wolking <djwolking@ucdavis.edu> wrote:

Hi there,

Just a reminder about next week's Management Team call on Tuesday February 6 2018 @ 10AM PST/1PM EST.

We will follow-up with an agenda early next week.

Enjoy the weekend,

David

<PREDICT MT Call (2.6.18).docx>

--

Andrew Clements, Ph.D.
Senior Scientific Advisor
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
E-mail: aclements@usaid.gov

*For more information on USAID's Emerging Pandemic Threats program, see:* http://www.usaid.gov/ept2

**From:** Elizabeth Leasure <ealeasure@UCDAVIS.EDU>
**To:** Ryland Marbray <rmarbray@usaid.gov>, Andrew Clements <aclements@usaid.gov>
**Cc:** "predict@ucdavis.edu" <predict@ucdavis.edu>, Jonna Mazet <jkmazet@ucdavis.edu>, David John Wolking <djwolking@ucdavis.edu>, "Alisa Pereira" <apereira@usaid.gov>
**Subject:** PREDICT-2 ATF approval request for WCS payments to National Laboratories
**Sent:** Thu, 29 Mar 2018 18:50:24 +0000

Hi Ryland and Andrew. By way of this email, we are requesting after-the-fact approval for costs incurred by our subrecipient, Wildlife Conservation Society (WCS). In the course of executing their role as primary implementing partner for PREDICT-2 activities in Mongolia and Viet Nam, WCS paid **$70,328.11** to national laboratories (including Viet Nam National University of Agriculture, Regional Animal Health Office No. 6 in Viet Nam, and State Central Veterinary Laboratory in Mongolia) for PREDICT sample testing services. While the services procured are necessary for completion of project objectives in Viet Nam and Mongolia and are otherwise allowable, allocable, and reasonable, prior approval to establish new subcontracts with these foreign governmental entities was not obtained in advance of initial payments being made. As such, we are now seeking AO approval to use available PREDICT-2 funds already obligated to cover these costs, as these labs are the most appropriate contractors in these countries. Details regarding the facts and circumstances of these expenditures are included below.

We became aware of this issue during the intensive budgeting process required for the PREDICT cooperative agreement ceiling increase when certain comments made by a WCS staff member caused us to solicit further details above and beyond normal subrecipient monitoring required for federal compliance and our own extended best practices. Once we became aware of the payments made, we instructed WCS that they may no longer invoice UC Davis for reimbursement of costs associated with services provided by the laboratories in question until USAID approval was obtained. We also notified you both by email on 10/17/2017 and requested further guidance regarding how best to address and resolve this issue. To date, no such guidance has been received, so we are suggesting and requesting retroactive approval of these costs as the best course of action to satisfactorily remedy the situation. Now that contracts with the laboratories in question have been approved, only these outstanding costs are pending resolution.

Upon review, it appears that the WCS analyst responsible (who is no longer employed by WCS) believed that fee-for-service activities were exempt from AO review/prior approval requirements and that AOR approval of the annual program budget constituted approval of all costs identified in that budget, which is not the case. Unfortunately, this misunderstanding occurred despite many discussions regarding prior approval requirements and our continual stressing that we (as prime) should be made aware in advance of all new subcontracts and subawards (especially those involving foreign governmental entities and parastatals) in order to ensure the necessary approvals were obtained. We do not believe WCS intended to circumvent USAID prior approval requirements, nor do we believe their actions are the result of gross negligence but rather the result of a misinformed former employee.

Given the circumstances described above, we believe it is in the best interest of the project for these costs to be approved. If you require any additional information, please let me know. Thank you for your continued efforts on behalf of PREDICT-2 and your consideration of this request.

Sincerely,

Liz

*Elizabeth Leasure*
*Financial Operations Manager*
*One Health Institute*
REDACTED *(cell)*
*530-754-9034 (office)*
*Skype: ealeasure*

**From:** Alisa Pereira <apereira@usaid.gov>
**To:** David J Wolking <djwolking@ucdavis.edu>
**CC:** Jonna Mazet <jkmazet@ucdavis.edu>;PREDICTMGT <predictmgt@usaid.gov>;Predict inbox <predict@ucdavis.edu>;Andrew (GH/HIDN) Clements <AClements@usaid.gov>;Cara Chrisman <cchrisman@usaid.gov>
**Sent:** 4/13/2018 4:03:52 PM
**Subject:** Re: Serendipity....

That timing works. Thanks!

Sent from my iPhone

On Apr 13, 2018, at 1:05 PM, David J Wolking <djwolking@ucdavis.edu> wrote:

Hi Alisa,

Great to hear and really exciting. Jonna is taking a well deserved vacation but we will discuss and get back to you very soon. I'll definitely have this on our next management team call agenda (scheduled for May 1st) but if you need any information or feedback before then please let us know.

Enjoy the weekend!

David

On Fri, Apr 13, 2018 at 11:18 AM, Alisa Pereira <apereira@usaid.gov> wrote:
Hi All!

As you will remember, I mentioned at the end of the P2 meeting this week that I was really impressed with so many aspects of what you are doing, and wanted to make more of an effort to get some of this information shared with our colleagues at USAID, and then a broader audience later in the year with the Smithsonian-type briefing.

As luck would have it, Ricardo circulated an article today with the catchy title "Did Deforestation cause the Ebola Outbreak?" That sparked a discussion around P2's work in Land Use Change, the preliminary analysis on the Deep Forest Project, and thoughts around Land Use Change being a focus of the "deep dive" for the behavioral work.

And just like that.....people are incredibly interested to hear P2's thoughts and preliminary analysis and plans. Andrew and I agree that you guys can decide what is ready for prime time and what is not, but there is an interest for a briefing in DC at USAID on this specific topic. Consider it more like a brown bag than a full court press event.

Please let me know if this is doable, and who I should coordinate with on your team to make it happen. This request is not intended to CREATE work. It is a more casual discussion about your work, progress, and plans.

Thanks
alisa

**Alisa Pereira, Senior Public Health Advisor**
Bureau for Global Health, Office of Infectious Disease, Emerging Threats Division
2100 Crystal Drive, CP3-0001, Arlington, VA 22202
Phone:202-997-9966
Email: apereira@usaid.gov

USAID Contractor
*GHSI-III - Social Solutions International, Inc.*

**From:** Andrew Clements <aclements@usaid.gov>
**Sent:** Tue, 17 Apr 2018 15:12:34 -0400
**Subject:** Re: PREDICT Management Team Call - Tuesday February 6 2018 @ 10AM PST/1PM EST
**To:** Elizabeth Leasure <ealeasure@ucdavis.edu>
**Cc:** David John Wolking <djwolking@ucdavis.edu>, Jonna Mazet <jkmazet@ucdavis.edu>, Alisa Pereira <apereira@usaid.gov>, Predict inbox <predict@ucdavis.edu>

Yep, that's fine. Enjoy the time off!

*Andrew P. Clements, Ph.D.*
*Senior Scientific Advisor*
*Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health*
*U.S. Agency for International Development*
*Mobile phone: 1-571-345-4253*
*Email: aclements@usaid.gov*

On Apr 17, 2018, at 8:17 PM, Elizabeth Leasure <ealeasure@ucdavis.edu> wrote:

> Hi Andrew. No, you didn't miss anything. I'm still working on this along with the multiple other financial reports that are due in the next couple weeks. You should get a response on this (and the core pipeline request) next week once Jonna and I are back from vacation. Does that timeline work?
>
> Thanks,
> Liz
>
> *Elizabeth Leasure*
> *Financial Operations Manager*
> *One Health Institute*
> *530-304-1403 (cell)*
> *530-754-9034 (office)*
> *Skype: ealeasure*
>
> ---
>
> **From:** Andrew Clements [mailto:aclements@usaid.gov]
> **Sent:** Monday, April 16, 2018 9:53 AM
> **To:** Elizabeth Leasure
> **Cc:** David John Wolking; Jonna Mazet; Alisa Pereira; Predict inbox
> **Subject:** Re: PREDICT Management Team Call - Tuesday February 6 2018 @ 10AM PST/1PM EST
>
> Hi Liz
>
> I was out of the office the week before last. Did I miss an email from you regarding how long the Ebola pipeline is projected to last (100% expenditure)?
>
> Thanks!
>
> Andrew
>
> *Andrew P. Clements, Ph.D.*
> *Senior Scientific Advisor*
> *Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health*
> *U.S. Agency for International Development*
> *Mobile phone: 1-571-345-4253*
> *Email: aclements@usaid.gov*
> On Mar 16, 2018, at 9:20 PM, Elizabeth Leasure <ealeasure@UCDAVIS.EDU> wrote:
>
> > Hi Andrew. I'm waiting on some additional information needed to help me respond to your question. Stay tuned.

Thanks! Have a great weekend!
Liz

*Elizabeth Leasure*
*Financial Operations Manager*
*One Health Institute*
REDACTED *(cell)*
*530-754-9034 (office)*
*Skype: ealeasure*

**From:** Andrew Clements [mailto:aclements@usaid.gov]
**Sent:** Tuesday, March 13, 2018 2:28 AM
**To:** Elizabeth Leasure
**Cc:** David John Wolking; Jonna Mazet; Alisa Pereira
**Subject:** Re: PREDICT Management Team Call - Tuesday February 6 2018 @ 10AM PST/1PM EST

Thanks, Liz.

At the current expenditure rate, when would you expect to expend 100% of the Ebola funds?

Andrew

On Mon, Mar 12, 2018 at 11:26 PM, Elizabeth Leasure <ealeasure@ucdavis.edu> wrote:
Hi Andrew. Based on current projections and anticipated spending increases, I'm estimating that we will have approximately 25% of the Ebola funds obligated to date remaining as of June 2018. Let me know if you have any questions or need any additional information.

Thanks,
Liz

*Elizabeth Leasure*
*Financial Operations Manager*
*One Health Institute*
REDACTED *(cell)*
*530-754-9034 (office)*
*Skype: ealeasure*

---

**From:** Andrew Clements [mailto:aclements@usaid.gov]
**Sent:** Monday, February 05, 2018 1:24 PM
**To:** David John Wolking; Jonna Mazet; Elizabeth Leasure
**Cc:** Alisa Pereira
**Subject:** Re: PREDICT Management Team Call - Tuesday February 6 2018 @ 10AM PST/1PM EST

On a related note, what's the current projection on how long Ebola funds will last with the reassignment among countries?

I want to give as much of a heads up as possible.

Thanks!

Andrew

*Andrew P. Clements, Ph.D.*
*Senior Scientific Advisor*
*Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health*
*U.S. Agency for International Development*
*Mobile phone: 1-571-345-4253*
*Email: aclements@usaid.gov*

On Feb 5, 2018, at 6:52 PM, David J Wolking <djwolking@ucdavis.edu> wrote:

Hi there,

Below and attached for quick reference is the agenda for tomorrow's PREDICT Management Team call.

Best,

David

**PREDICT Management Call Agenda**
**Tuesday, February 6, 2017**
**10:00-11:00AM PDT/1:00-2:00pm EDT**
**[redacted]**

**Standing items**
**USAID Updates**

1. **Administrative items**
   a. Core (regular) funding update
   b. Feedback on P2 additional testing request
2. **PMAC and GVP update (Jonna et al)**
3. **Mission communications roundup**
   a. Myanmar and viral testing plans with LBVD
   b. Guinea mission visit and updates
   c. Liberia and data sharing inquiry
4. **Outbreak updates (Liberia, Cameroon, others)**
6. **EPT partner collaboration/coordination updates (Billy)**
7. **Publication, media, and conference updates**
   - CUGH Global Health Conference, New York (March 15-18, 2018)
   - "Outbreak: Epidemics in a Connected World" exhibit at NMNH (May 2018)
   - One Health Congress Saskatoon (June 22-25, 2018)
   - International Conference on Emerging Infectious Diseases (ICEID) in Atlanta (August 26–29, 2018)
   - International Meeting on Emerging Diseases and Surveillance (IMED) 2018 in Vienna, Austria (November 9-12, 2018)

- Others?

On Fri, Feb 2, 2018 at 8:10 AM, David J Wolking <djwolking@ucdavis.edu> wrote:
Hi there,

Just a reminder about next week's Management Team call on Tuesday February 6 2018 @ 10AM PST/1PM EST.

We will follow-up with an agenda early next week.

Enjoy the weekend,

David

<PREDICT MT Call (2.6.18).docx>

--

Andrew Clements, Ph.D.
Senior Scientific Advisor
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
E-mail: aclements@usaid.gov

*For more information on USAID's Emerging Pandemic Threats program, see:* http://www.usaid.gov/ept2

**From:** Umesh Alavadi <ualavadi@usaid.gov>
**Sent:** Thu, 19 Apr 2018 09:33:03 +0530
**To:** Rajesh Bhatia <rajeshbhatia@ecohealthalliance.org>
**Cc:** "Clements, Andrew (GH/HIDN)" <aclements@usaid.gov>, Daniel Schar <dschar@usaid.gov>, Jon Epstein <epstein@ecohealthalliance.org>, predict@ucdavis.edu, Ava Sullivan <sullivan@ecohealthalliance.org>, predict@ucd.edu, predictmgt@ucdaid.gov, rajesh bhatia <[REDACTED]>, Reuben Swamickan <rswamickan@usaid.gov>, Brian Holler <bholler@usaid.gov>
**Subject:** [predict] Re: GHSA Report : Oct 2017-March 2018

Dear Dr. Bhatia,

Many thanks.

I would like to take this opportunity to introduce Mr. Brian Holler, Infectious Diseases Advisor, a new member of the Tuberculosis & Infectious Diseases team at USAID/India.
Brian comes with varied experiences from the development field, both in India and abroad. In his most recent job at Sambodhi he has helped establish systems in their MEL space and traveled widely in the field to garner a rich experience of the issues at ground level. Brian is a huge asset to the team and we are glad to have him onboard.

Regards

-Umesh

Dr. Umesh Alavadi | Project Management Specialist
**USAID** India | Health Office | Division of Tuberculosis & Infectious Diseases
American Embassy, Chanakya Puri, New Delhi - 110021
Tel: +91-11-24198000, Ext. 8502 | Mobile: [REDACTED]
E-mail: **ualavadi@usaid.gov** | Website: **http://www.usaid.gov/india**

On Wed, Apr 18, 2018 at 11:34 PM, Rajesh Bhatia <rajeshbhatia@ecohealthalliance.org> wrote:

Dear All,
Greetings from Predict India Team.

Please find attached a brief on the work done by Predict India Team during the period October 2017-March 2018 for your kind information and perusal.

We shall be happy to provide any additional information if needed.

Best wishes

Rajesh

Dr Rajesh Bhatia
Country Coordinator, India

**From:** rajesh bhatia <[redacted]
**Sent:** Thu, 19 Apr 2018 09:39:23 +0200
**To:** Umesh Alavadi <ualavadi@usaid.gov>
**Cc:** Rajesh Bhatia <rajeshbhatia@ecohealthalliance.org>, "Clements, Andrew (GH/HIDN)" <aclements@usaid.gov>, Daniel Schar <dschar@usaid.gov>, Jon Epstein <epstein@ecohealthalliance.org>, predict@ucdavis.edu, Ava Sullivan <sullivan@ecohealthalliance.org>, predict@ucd.edu, predictmgt@ucdaid.gov, Reuben Swamickan <rswamickan@usaid.gov>, Brian Holler <bholler@usaid.gov>
**Subject:** [predict] Re: GHSA Report : Oct 2017-March 2018

Dear Umesh,

Thank you very much for the mail and introducing Mr Brian Holler, Infectious Diseases Advisor at USAID/India.

On behalf of Eco Health Alliance, I welcome Brian and look forward to meeting him and work closely with him in our common pursuit of combating infectious diseases.

Best wishes and welcome Brian.

rajesh

On Thu, Apr 19, 2018 at 6:03 AM, Umesh Alavadi <ualavadi@usaid.gov> wrote:

> Dear Dr. Bhatia,
>
> Many thanks.
>
> I would like to take this opportunity to introduce Mr. Brian Holler, Infectious Diseases Advisor, a new member of the Tuberculosis & Infectious Diseases team at USAID/India.
> Brian comes with varied experiences from the development field, both in India and abroad. In his most recent job at Sambodhi he has helped establish systems in their MEL space and traveled widely in the field to garner a rich experience of the issues at ground level. Brian is a huge asset to the team and we are glad to have him onboard.
>
> Regards
>
> -Umesh
>
> Dr. Umesh Alavadi | Project Management Specialist
> **USAID** India | Health Office | Division of Tuberculosis & Infectious Diseases
> American Embassy, Chanakya Puri, New Delhi - 110021
> Tel: +91-11-24198000, Ext. 8502 | Mobile: [redacted]
> E-mail: **ualavadi@usaid.gov** | Website: **http://www.usaid.gov/india**

On Wed, Apr 18, 2018 at 11:34 PM, Rajesh Bhatia <rajeshbhatia@ecohealthalliance.org> wrote:

> Dear All,
> Greetings from Predict India Team.
>
> Please find attached a brief on the work done by Predict India Team during the period October 2017-March 2018 for your kind information and perusal.
>
> We shall be happy to provide any additional information if needed.
>
> Best wishes
>
> Rajesh
>
> Dr Rajesh Bhatia
> Country Coordinator, India

**From:** "Anthony, Simon J." <sja2127@cumc.columbia.edu>
**To:** Jonna Mazet <jkmazet@ucdavis.edu>, Peter Daszak <daszak@ecohealthalliance.org>, Billy Karesh <karesh@ecohealthalliance.org>, Christine Kreuder Johnson <ckjohnson@ucdavis.edu>, Tracey Goldstein <tgoldstein@ucdavis.edu>, Predict inbox <predict@ucdavis.edu>, "Catherine Mkindi" <cmkindi@ihi.or.tz>, Carlos Zambrana <zambrana@ecohealthalliance.org>, "Kevin J. Olival" <olival@ecohealthalliance.org>, Leilani Francisco <francisco@ecohealthalliance.org>
**Subject:** Re: Serendipity....
**Sent:** Tue, 24 Apr 2018 21:07:34 +0000

Sounds like a good idea to me. Certainly prepared to make time for it, if there is a consensus.

S.

---

**From:** <jonna.mazet@gmail.com> on behalf of Jonna Mazet <jkmazet@ucdavis.edu>
**Date:** Tuesday, April 24, 2018 at 4:12 PM
**To:** Peter Daszak <daszak@ecohealthalliance.org>, Billy Karesh <karesh@ecohealthalliance.org>, Christine Kreuder Johnson <ckjohnson@ucdavis.edu>, Tracey Goldstein <tgoldstein@ucdavis.edu>, "Anthony, Simon J." <sja2127@cumc.columbia.edu>, Predict inbox <predict@ucdavis.edu>, Catherine Mkindi <cmkindi@ihi.or.tz>, Carlos Zambrana <zambrana@ecohealthalliance.org>, "Kevin J. Olival" <olival@ecohealthalliance.org>, Leilani Francisco <francisco@ecohealthalliance.org>
**Subject:** Fwd: Serendipity....

Hi Guys,
We'll be having a call on May 1 with USAID MT (regular call), where this will be an agenda item. I'm inclined to offer an every month or even every two week brown bag for USAID EPT staff if you are agreeable and can fit the trips into your schedules. I think the items that would likely be up first would be the economic, One Health platform, and M&A-related stuff, including risk ranking and interfaces. Later in the session would be the surveillance and viral outcomes as more data come online. Probably later, we could do one or two on behavior and intervention rankings.
If we do these, we should try to start soon if possible for strategic reasons.
Please advise ASAP,
Jonna

Could you please let me know by Friday if you are on board with that approach, and if so, your windows of opportunity for casual presentations to USAID on these topics.
---------- Forwarded message ----------
From: **Alisa Pereira** <apereira@usaid.gov>
Date: Fri, Apr 13, 2018 at 11:18 AM
Subject: Serendipity....
To: Jonna Mazet <jkmazet@ucdavis.edu>, PREDICTMGT <predictmgt@usaid.gov>, Predict inbox <predict@ucdavis.edu>, "Andrew (GH/HIDN) Clements" <AClements@usaid.gov>, David J Wolking <djwolking@ucdavis.edu>, Cara Chrisman <cchrisman@usaid.gov>

Hi All!

As you will remember, I mentioned at the end of the P2 meeting this week that I was really impressed with so many aspects of what you are doing, and wanted to make more of an effort to get some of this information shared with our colleagues at USAID, and then a broader audience later in the year with the Smithsonian-type briefing.

As luck would have it, Ricardo circulated an article today with the catchy title "Did Deforestation cause the Ebola Outbreak?" That sparked a discussion around P2's work in Land Use Change, the preliminary analysis on the Deep Forest Project, and thoughts around Land Use Change being a focus of the "deep dive" for the behavioral work.

And just like that.....people are incredibly interested to hear P2's thoughts and preliminary analysis and plans. Andrew and I agree that you guys can decide what is ready for prime time and what is not, but there is an interest for a briefing in DC at USAID on this specific topic. Consider it more like a brown bag than a full court press event.

Please let me know if this is doable, and who I should coordinate with on your team to make it happen. This request is not intended to CREATE work. It is a more casual discussion about your work, progress, and plans.

Thanks
alisa

**Alisa Pereira, Senior Public Health Advisor**
Bureau for Global Health, Office of Infectious Disease, Emerging Threats Division
2100 Crystal Drive, CP3-0001, Arlington, VA 22202
Phone:202-997-9966
Email: apereira@usaid.gov

USAID Contractor
*GHSI-III - Social Solutions International, Inc.*

**From:** Jonna Mazet <jkmazet@ucdavis.edu>
**To:** William B. Karesh <karesh@ecohealthalliance.org>
**Sent:** 4/25/2018 8:44:21 PM
**Subject:** Re: Not really Serendipity....

Right? ... on the marula oil!
Can't wait to see ;)
J

On Wed, Apr 25, 2018 at 1:54 PM, William B. Karesh <karesh@ecohealthalliance.org> wrote:
The marula oil is impressive - visible difference in less than a week ;)

Have fun in Boston, just was at a meeting today with Scott Dowell and he mentioned it.

B.

On Apr 25, 2018, at 4:18 PM, Jonna Mazet <jkmazet@ucdavis.edu> wrote:

Alisa loves the idea for the repeating brown bag, so please think about availability and optimal timing for the various topics. We will discuss on MT call on May 1, so if you aren't normally on that call, please get that info to us on this chain in advance of that call.
Thanks again,
Jonna

On Tue, Apr 24, 2018 at 8:07 PM, Jonna Mazet <jkmazet@ucdavis.edu> wrote:
Wonderful -- thanks to all,
Jonna

On Tue, Apr 24, 2018 at 3:30 PM, William B. Karesh <karesh@ecohealthalliance.org> wrote:
Easy Peasy. Happy to contribute.

Catherine and I are in DC every couple of weeks for the next month or two anyway so it's easy to swing by the Reagan building for an hour.

BK

**William B. Karesh, D.V.M**
*Executive Vice President for Health and Policy*

EcoHealth Alliance
460 West 34th Street - 17th Floor
New York, NY 10001 USA

+1.212.380.4463 (direct)
+1.212.380.4465 (fax)
www.ecohealthalliance.org

President, OIE Working Group on Wildlife

Co-chair, IUCN Species Survival Commission - Wildlife Health Specialist Group

EPT Partners Liaison, USAID Emerging Pandemic Threats - PREDICT-2 Program

***EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that promote conservation and prevent pandemics.***

On Apr 24, 2018, at 4:11 PM, Jonna Mazet <jkmazet@ucdavis.edu> wrote:

Hi Guys,
We'll be having a call on May 1 with USAID MT (regular call), where this will be an agenda item. I'm inclined to offer an every month or even every two week brown bag for USAID EPT staff if you are agreeable and can fit the trips into your schedules. I think the items that would likely be up first would be the economic, One Health platform, and M&A-related stuff, including risk ranking and interfaces. Later in the session would be the surveillance and viral outcomes as more data come online. Probably later, we could do one or two on behavior and intervention rankings.
If we do these, we should try to start soon if possible for strategic reasons.
Please advise ASAP,
Jonna

Could you please let me know by Friday if you are on board with that approach, and if so, your windows of opportunity for casual presentations to USAID on these topics.
---------- Forwarded message ----------
From: **Alisa Pereira** <apereira@usaid.gov>
Date: Fri, Apr 13, 2018 at 11:18 AM
Subject: Serendipity....
To: Jonna Mazet <jkmazet@ucdavis.edu>, PREDICTMGT <predictmgt@usaid.gov>, Predict inbox <predict@ucdavis.edu>, "Andrew (GH/HIDN) Clements" <AClements@usaid.gov>, David J Wolking <djwolking@ucdavis.edu>, Cara Chrisman <cchrisman@usaid.gov>

Hi All!

As you will remember, I mentioned at the end of the P2 meeting this week that I was really impressed with so many aspects of what you are doing, and wanted to make more of an effort to get some of this information shared with our colleagues at USAID, and then a broader audience later in the year with the Smithsonian-type briefing.

As luck would have it, Ricardo circulated an article today with the catchy title "Did Deforestation cause the Ebola Outbreak?" That sparked a discussion around P2's work in Land Use Change, the preliminary analysis on the Deep Forest Project, and thoughts around Land Use Change being a focus of the "deep dive" for the behavioral work.

And just like that.....people are incredibly interested to hear P2's thoughts and preliminary analysis and plans. Andrew and I agree that you guys can decide what is ready for prime time and what is not, but there is an interest for a briefing in DC at USAID on this specific topic. Consider it more like a brown bag than a full court press event.

Please let me know if this is doable, and who I should coordinate with on your team to make it happen. This request is not intended to CREATE work. It is a more casual discussion about your work, progress, and plans.

Thanks
alisa

**Alisa Pereira, Senior**
**Public Health Advisor**
Bureau for Global Health, Office of Infectious Disease,
Emerging Threats Division
2100
Crystal Drive, CP3-0001, Arlington, VA 22202
Phone:202-997-9966

Email: apereira@usaid.gov

USAID Contractor
*GHSI-III - Social Solutions International, Inc.*

**From:** Jonna Mazet <jkmazet@ucdavis.edu>
**To:** Catherine Mkindi <cmkindi@ihi.or.tz>
**Sent:** 4/26/2018 8:38:13 AM
**Subject:** Re: Serendipity....

Thank you for your genuine & kind response, Catherine! I had intended the message for a different Catherine, but my computer was thinking of you. Looking forward to seeing you in a couple of week!
Jonna

On Wed, Apr 25, 2018 at 6:54 PM Catherine Mkindi <cmkindi@ihi.or.tz> wrote:
Dear Jonna
I am very glad to read from you and that one health activities are receiving so much interest over ther. In deed they are important activities, revealing so much unknows in the communities where the work in going on as well. For the brown bag discussions in DC, I hope it is convenient for colleagues in the US and from Tz we are happy to remotely contribute as needed. I hope I understood the message clearly.

Thanks and best regards from IHI, Bagamoyo. Looking fowards to meeting you on May 9/10 meeting in Bagamoyo.

Catherine Mkindi

On Wed, Apr 25, 2018 at 11:18 PM, Jonna Mazet <jkmazet@ucdavis.edu> wrote:
Alisa loves the idea for the repeating brown bag, so please think about availability and optimal timing for the various topics. We will discuss on MT call on May 1, so if you aren't normally on that call, please get that info to us on this chain in advance of that call.
Thanks again,
Jonna

On Tue, Apr 24, 2018 at 8:07 PM, Jonna Mazet <jkmazet@ucdavis.edu> wrote:
Wonderful -- thanks to all,
Jonna

On Tue, Apr 24, 2018 at 3:30 PM, William B. Karesh <karesh@ecohealthalliance.org> wrote:
Easy Peasy. Happy to contribute.

Catherine and I are in DC every couple of weeks for the next month or two anyway so it's easy to swing by the Reagan building for an hour.

BK

**William B. Karesh, D.V.M**
*Executive Vice President for Health and Policy*

EcoHealth Alliance
460 West 34th Street - 17th Floor
New York, NY 10001 USA

+1.212.380.4463 (direct)
+1.212.380.4465 (fax)
www.ecohealthalliance.org

President, OIE Working Group on Wildlife

Co-chair, IUCN Species Survival Commission - Wildlife Health Specialist Group

EPT Partners Liaison, USAID Emerging Pandemic Threats - PREDICT-2 Program

***EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that promote conservation and prevent pandemics.***

On Apr 24, 2018, at 4:11 PM, Jonna Mazet <jkmazet@ucdavis.edu> wrote:

Hi Guys,
We'll be having a call on May 1 with USAID MT (regular call), where this will be an agenda item. I'm inclined to offer an every month or even every two week brown bag for USAID EPT staff if you are agreeable and can fit the trips into your schedules. I think the items that would likely be up first would be the economic, One Health platform, and M&A-related stuff, including risk ranking and interfaces. Later in the session would be the surveillance and viral outcomes as more data come online. Probably later, we could do one or two on behavior and intervention rankings.
If we do these, we should try to start soon if possible for strategic reasons.
Please advise ASAP,
Jonna

Could you please let me know by Friday if you are on board with that approach, and if so, your windows of opportunity for casual presentations to USAID on these topics.
---------- Forwarded message ----------
From: **Alisa Pereira** <apereira@usaid.gov>
Date: Fri, Apr 13, 2018 at 11:18 AM
Subject: Serendipity....
To: Jonna Mazet <jkmazet@ucdavis.edu>, PREDICTMGT <predictmgt@usaid.gov>, Predict inbox <predict@ucdavis.edu>, "Andrew (GH/HIDN) Clements" <AClements@usaid.gov>, David J Wolking <djwolking@ucdavis.edu>, Cara Chrisman <cchrisman@usaid.gov>

Hi All!

As you will remember, I mentioned at the end of the P2 meeting this week that I was really impressed with so many aspects of what you are doing, and wanted to make more of an effort to get some of this information shared with our colleagues at USAID, and then a broader audience later in the year with the Smithsonian-type briefing.

As luck would have it, Ricardo circulated an article today with the catchy title "Did Deforestation cause the Ebola Outbreak?" That sparked a discussion around P2's work in Land Use Change, the preliminary analysis on the Deep Forest Project, and thoughts around Land Use Change being a focus of the "deep dive" for the behavioral work.

And just like that.....people are incredibly interested to hear P2's thoughts and preliminary analysis and plans. Andrew and I agree that you guys can decide what is ready for prime time and what is not, but there is an interest for a briefing in DC at USAID on this specific topic. Consider it more like a brown bag than a full court press event.

Please let me know if this is doable, and who I should coordinate with on your team to make it happen. This request is not intended to CREATE work. It is a more casual discussion about your work, progress, and plans.

Thanks
alisa

**Alisa Pereira,**
**Senior Public Health Advisor**
Bureau for Global Health, Office of Infectious
Disease, Emerging Threats Division
2100
Crystal Drive, CP3-0001, Arlington, VA 22202

Phone:202-997-9966
Email: apereira@usaid.gov

USAID Contractor
*GHSI-III - Social Solutions International, Inc.*

**From:** Elizabeth Leasure <ealeasure@UCDAVIS.EDU>
**To:** Peter Daszak <daszak@ecohealthalliance.org>
**Cc:** Jonna Mazet <jkmazet@ucdavis.edu>
**Subject:** RE: EB participation....
**Sent:** Tue, 1 May 2018 15:50:50 +0000

Hi Peter. Will Kevin be joining the EB call to provide an M&A update, or will Billy or Jon be able to give the update?

Thanks!
Liz

*Elizabeth Leasure*
*Financial Operations Manager*
*One Health Institute*
REDACTED
*530-754-9034 (office)*
*Skype: ealeasure*

---

**From:** predict-request@ucdavis.edu [mailto:predict-request@ucdavis.edu] **On Behalf Of** Peter Daszak
**Sent:** Monday, April 30, 2018 6:15 PM
**To:** Jonna Mazet
**Cc:** sja2127@cumc.columbia.edu; Catherine Mkindi; Tracey Goldstein; William B. Karesh; Catherine Machalaba; Leilani Francisco; Kevin Olival; Carlos Zambrana-Torrelio; Christine Kreuder Johnson; Predict inbox; Alison Andre
**Subject:** [predict] Re: Serendipity....

Sorry I can't be on the call - in Australia then China this week. But this is a great opportunity to get our messages out to USAID - count me in and I'll make sure I'm available in person for some of these. Great if one of these can be modeling & analytics and have CC'd alison Andre so she can work with y'all on dates

Cheers,

Peter

Peter Daszak
(Sent from my iPhone)

President
EcoHealth Alliance

460 West 34th Street, New York, NY10001, USA

www.EcoHealthAlliance.org
On Apr 26, 2018, at 6:19 AM, Jonna Mazet <jkmazet@ucdavis.edu> wrote:

> Alisa loves the idea for the repeating brown bag, so please think about availability and optimal timing for the various topics. We will discuss on MT call on May 1, so if you aren't normally on that call, please get that info to us on this chain in advance of that call.
> Thanks again,
> Jonna
>
> On Tue, Apr 24, 2018 at 8:07 PM, Jonna Mazet <jkmazet@ucdavis.edu> wrote:
> Wonderful -- thanks to all,
> Jonna
>
> On Tue, Apr 24, 2018 at 3:30 PM, William B. Karesh <karesh@ecohealthalliance.org> wrote:
> Easy Peasy. Happy to contribute.

Catherine and I are in DC every couple of weeks for the next month or two anyway so it's easy to swing by the Reagan building for an hour.

BK

**William B. Karesh, D.V.M**
*Executive Vice President for Health and Policy*

EcoHealth Alliance
460 West 34th Street - 17th Floor
New York, NY 10001 USA

+1.212.380.4463 (direct)
+1.212.380.4465 (fax)
www.ecohealthalliance.org

President, OIE Working Group on Wildlife

Co-chair, IUCN Species Survival Commission - Wildlife Health Specialist Group

EPT Partners Liaison, USAID Emerging Pandemic Threats - PREDICT-2 Program

***EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that promote conservation and prevent pandemics.***

On Apr 24, 2018, at 4:11 PM, Jonna Mazet <jkmazet@ucdavis.edu> wrote:

Hi Guys,
We'll be having a call on May 1 with USAID MT (regular call), where this will be an agenda item. I'm inclined to offer an every month or even every two week brown bag for USAID EPT staff if you are agreeable and can fit the trips into your schedules. I think the items that would likely be up first would be the economic, One Health platform, and M&A-related stuff, including risk ranking and interfaces. Later in the session would be the surveillance and viral outcomes as more data come online. Probably later, we could do one or two on behavior and intervention rankings.
If we do these, we should try to start soon if possible for strategic reasons.
Please advise ASAP,
Jonna

Could you please let me know by Friday if you are on board with that approach, and if so, your windows of opportunity for casual presentations to USAID on these topics.

---------- Forwarded message ----------
From: **Alisa Pereira** <apereira@usaid.gov>
Date: Fri, Apr 13, 2018 at 11:18 AM
Subject: Serendipity....
To: Jonna Mazet <jkmazet@ucdavis.edu>, PREDICTMGT <predictmgt@usaid.gov>, Predict inbox <predict@ucdavis.edu>, "Andrew (GH/HIDN) Clements" <AClements@usaid.gov>, David J Wolking <djwolking@ucdavis.edu>, Cara Chrisman <cchrisman@usaid.gov>

Hi All!

As you will remember, I mentioned at the end of the P2 meeting this week that I was really impressed with so many aspects of what you are doing, and wanted to make more of an effort to get some of this information shared with our colleagues at USAID, and then a broader audience later in the year with the Smithsonian-type briefing.

As luck would have it, Ricardo circulated an article today with the catchy title "Did Deforestation cause the Ebola Outbreak?" That sparked a discussion around P2's work in Land Use Change, the preliminary analysis on the Deep Forest Project, and thoughts around Land Use Change being a focus of the "deep dive" for the behavioral work.

And just like that.....people are incredibly interested to hear P2's thoughts and preliminary analysis and plans. Andrew and I agree that you guys can decide what is ready for prime time and what is not, but there is an interest for a briefing in DC at USAID on this specific topic. Consider it more like a brown bag than a full court press event.

Please let me know if this is doable, and who I should coordinate with on your team to make it happen. This request is not intended to CREATE work. It is a more casual discussion about your work, progress, and plans.

Thanks
alisa

**Alisa Pereira, Senior Public Health Advisor**
Bureau for Global Health, Office of Infectious Disease, Emerging Threats Division
2100 Crystal Drive, CP3-0001, Arlington, VA 22202
Phone:202-997-9966
Email: apereira@usaid.gov

USAID Contractor
*GHSI-III - Social Solutions International, Inc.*

**From:** Brooke Watson <watson@ecohealthalliance.org>
**Sent:** Fri, 4 May 2018 10:30:58 -0400
**Subject:** Response needed by May 8: GVP meeting June 11
**To:** Jonna Mazet <jkmazet@ucdavis.edu>, Katherine Leasure <kaleasure@ucdavis.edu>, REDACTED
REDACTED Cara Chrisman <cchrisman@usaid.gov>

Dear GVP Steering Committee colleagues,

In order to secure approval for international travel and confirm support if it is needed to facilitate travel arrangements for our meeting on Monday, June 11 in Washington, it is important to know which of you will be in attendance. We know that some of you will be in town for the National Academies workshop on June 12 and 13, but for others, will you **please respond to Jonna, Eri, Katie and myself (all cc'd) by 5 PM EST next Tuesday, May 8,** indicating**:**

1. Whether you will be able to attend the meeting on June 11 in person in Washington. DC
2. If not, whether you will be able to call in for all or some of the meeting from 10 AM - 4 PM EDT
3. If there are any caveats to your attendance (e.g., you can only attend after 12 PM EDT)
4. If you will need any support for your travel to Washington DC

If we do not receive your response by May 8, we will assume that you will not be joining in person.

Many thanks for your quick responses, and please don't hesitate to ask if you have any questions. A full agenda is forthcoming, but we want to ensure that the logistics teams have a full attendee list well in advance so we can move forward with preparations.

Best,

Brooke Watson

--

**Brooke Watson, MSc**
*Research Scientist*

EcoHealth Alliance
460 West 34th Street – 17th floor
New York, NY 10001

1.212.380.4497 (direct)
REDACTED (mobile)
1.212.380.4465 (fax)
www.ecohealthalliance.org

***EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that promote conservation and prevent pandemics.***

**From:** Andrew Clements <aclements@usaid.gov>
**Sent:** Mon, 7 May 2018 03:37:55 -0700
**Subject:** Prioritizing sampling of juvenile and symptomatic camels for MERS virus detection/isolation
**To:** [redacted], "Subhash Morzaria (FAORAP)" <[redacted]> "Juan (AGAH) ([redacted]>, William Karesh <Karesh@ecohealthalliance.org>, Jonna Mazet <jkmazet@ucdavis.edu>, Christine Kreuder Johnson <ckjohnson@ucdavis.edu>, [redacted]
**Cc:** Dennis Carroll <dcarroll@usaid.gov>, lparish@usaid.gov

Hi all,

Is there consensus among the main MERS researchers (including FAO, Predict, and WHO) that there should be a specific focus on sampling juvenile camels and camels of any age that are symptomatic, especially in herds with high turnover rates, in countries with seropositives in order to increase odds of detecting (and isolating) virus to facilitate comparison of viral genomes across countries and regions?

Thanks!

Andrew

*Andrew P. Clements, Ph.D.*
*Senior Scientific Advisor*
*Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health*
*U.S. Agency for International Development*
*Mobile phone: 1-571-345-4253*
*Email: aclements@usaid.gov*

Begin forwarded message:

**From:** Andrew Clements <aclements@usaid.gov>
**Date:** May 7, 2018 at 11:58:10 AM GMT+2
**To:** "Subhash Morzaria (FAORAP)" <[redacted]>, lparish@usaid.gov, Dennis Carroll <dcarroll@usaid.gov>, malkhateeb@usaid.gov, ahalverson@usaid.gov, akibria@usaid.gov, [redacted], "Ahmed ElIdrissi (AGAH)" <[redacted] William Karesh <Karesh@ecohealthalliance.org>, dawson@ecohealthalliance.org, [redacted], aelerian@usaid.gov, "Juan (AGAH) ([redacted]>
**Subject: Fwd: PRO/AH/EDR> MERS-CoV (14): Israel, animal reservoir, camelids**

FYI

*Andrew P. Clements, Ph.D.*
*Senior Scientific Advisor*
*Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health*
*U.S. Agency for International Development*
*Mobile phone: 1-571-345-4253*
*Email: aclements@usaid.gov*

Begin forwarded message:

**From:** Daniel Schar <dschar@usaid.gov>
**Date:** May 7, 2018 at 7:49:44 AM GMT+2
**To:** aclements@usaid.gov
**Subject: Fwd: PRO/AH/EDR> MERS-CoV (14): Israel, animal reservoir, camelids**

FYI

Begin forwarded message:

**From:** promed-edr@promedmail.org
**Date:** May 7, 2018 at 5:16:04 AM GMT+7
**To:** promed-post@promedmail.org, promed-edr-post@promedmail.org, promed-ahead-post@promedmail.org
**Subject: PRO/AH/EDR> MERS-CoV (14): Israel, animal reservoir, camelids**
**Reply-To:** promedNOREPLY@promedmail.org

MERS-COV (14): ISRAEL. ANIMAL RESERVOIR, CAMELIDS
**********
A ProMED-mail post
<http://www.promedmail.org>
ProMED-mail is a program of the
International Society for Infectious Diseases
<http://www.isid.org>

Date: Fri 4 May 2018
Source: One Health, Official Journal of the One Health Platform.
Article in Press, accepted manuscript. [summ., edited]
<https://www.sciencedirect.com/science/article/pii/S2352771418300053>

Citation: David D, Rotenberg D, Khinich E, Erster O, Bardenstein S, van Straten M, Okba NMA, Haagmans BL, Miculitzki M & Davidson I (2018). Middle East respiratory syndrome coronavirus specific antibodies in naturally exposed Israeli llamas, alpacas and camels.
<https://doi.org/10.1016/j.onehlt.2018.05.002>

Abstract:
Thus far, no human MERS-CoV infections have been reported from Israel. Evidence for the circulation of MERS-CoV in dromedaries has been reported from almost all the countries of the Middle East, except Israel. Therefore, we aimed to analyze MERS-CoV infection in Israeli camelids, sampled between 2012 and 2017. A total of 411 camels, 102 alpacas and 19 llamas' sera were tested for the presence of antibodies to MERS-CoV. Our findings indicate a lower MERS-CoV seropositivity among Israeli dromedaries than in the surrounding countries, and for the 1st time naturally infected llamas were identified. In addition, nasal swabs of 661 camels, alpacas and lamas, obtained from January 2015 to December 2017, were tested for the presence of MERS-CoV RNA. All nasal swabs were negative, indicating no evidence for MERS-CoV active circulation in these camelids during that time period.

--
Communicated by:
ProMED-mail
<promed@promedmail.org>

[The [slightly abridged] discussion chapter and the authors' conclusions in the above paper are herewith included for subscribers

convenience (references omitted).

## Discussion

We present the 1st serological and molecular survey for MERS-CoV infection among Israeli camelids, from 2012 to 2017. Camels showed an average MERS-CoV seroprevalence of 60.6 percent between 2012-2017 by VNT and an average seroprevalence of 62.9 percent by ELISA between 2015-2017, without any detection of viral RNA in the nasal swabs of the 540 camels. The presence of virus-specific neutralizing antibodies suggests that Israeli camels were exposed to MERS-CoV in the past. The VNT assay was more sensitive and more specific than the ELISA. Whereas the ELISA detects only IgG, the VNT detects any isotype of antibodies which could be IgG, IgM or IgA. The higher strength of the VNT assay as compared to ELISA might be attributed by the fact that borderline sera by ELISA were not considered.

For the period from 2012-2017, the proportion of camel sera with high VNT titers (higher than 320) in Israel was 27.3 percent, which is much lower than the proportion of sera with high VNT titers in the surrounding countries, such as Saudi Arabia, Qatar, UAE, Oman, Egypt, and Jordan, reaching to more than 90 percent. Moreover, the proportion of sera with low VNT titers (less than 320) in Israel was about 70.4 percent, whereas in the surrounding countries only about 10 percent of the sera had low VNT titers meaning that the MERS-CoV seroprevalence in Israel is lower than that in the surrounding countries.

The differences in seropositivity by year in Israel might be related to the camels included in the random sample.

In contrast, low (14.3 percent) seroprevalence and probably no virus circulation were documented in the Canary Islands.

In the present study we showed for the 1st time the presence of MERS-CoV antibodies in naturally infected llamas by ELISA and VNT. In our study 29.4 and 31.5 percent of Israeli alpacas and llamas, respectively, were seropositive using the VNT assay. Using ELISA only, 34.3 and 36.8 percent of alpacas and llamas, respectively were detected seropositive. The 2 camels co-housed with the llamas and alpacas were negative for antibodies and viral RNA using the 2 serological assays and PCR, respectively.

Previously, MERS-CoV neutralizing antibodies were detected in 15/15 alpacas in Qatar. Similar to our findings, lower neutralizing antibody titers were documented in alpacas and experimentally infected llamas than in camels.

Using a MERS-CoV specific RT-PCR we detected no MERS-CoV genomic RNA in the nasal swabs of camels, alpacas and llamas during the period of 2015 to 2017 providing no evidence for active MERS-CoV circulation.

## Conclusions

Altogether, the relatively low prevalence of antibodies to MERS-CoV, the low antibody titers, the absence of viral RNA in nasal swabs, and the absence of disease in humans, indicate limited MERS-CoV

circulation in Israeli camelids during the [timeframe] of our survey".

Israel's camel population is located mainly in the south, namely in the Negev arid region, bordering the Kingdom of Jordan on the east and Sinai (Egypt) on the west. Contacts of Israel's ca 3000-3500 strong camel population with Jordan's camels (reportedly, counting some 11 000 animals), may be uncommon but cannot be regarded as fully excluded. Regional scientific cooperation is desired for the deciphering of MERS enigmatic epidemiology in humans, in particular its apparently higher incidence in humans in Saudi Arabia compared with other Middle East countries with dromedary camel populations.

It deserves to be noted that the 'Egyptian tomb bat' (_Taphozous perforatus_) which was suspected, in 2013, as a reservoir of MERS CoV in Saudi Arabia, is known to be present also in Jordan and Israel, mainly along the (shared by both) Jordan valley. The largest, breeding cave on the Israeli side of the Jordan is situated near Kalia, on the northern shore of the Dead Sea, where 300-500 individuals were reportedly sighted in the spring months of 2013. It will be interesting to note if bats are subject to surveillance in the 2 countries.

A map of Israel: <http://healthmap.org/promed/p/90>. - Mod.AS]

[See Also:
MERS-CoV (68): Israel, animal reservoir, camels, serology, surveillance http://promedmail.org/post/20171105.5425773
MERS-CoV (66): Burkina Faso, animal reservoir, camels, FAO, RFI
http://promedmail.org/post/20171029.5411777
MERS-CoV (64): Saudi Arabia, animal reservoir, human, camel milk
http://promedmail.org/post/20171012.5375933
MERS-CoV (62): animal reservoir, camels, FAO, OIE, WHO
http://promedmail.org/post/20171002.5354608
MERS-CoV (21): Egypt, animal reservoir, camel, ex Sudan, control, RFI
http://promedmail.org/post/20170405.4948727
2016
---
MERS-CoV (87): Jordan, animal reservoir, camelids, OIE
http://promedmail.org/post/20160802.4385317
MERS-CoV (40): Egypt, animal reservoir, camel, ex Sudan, susp.
http://promedmail.org/post/20160316.4097730
2015
---
MERS-CoV (137): Saudi Arabia, Jordan, WHO
http://promedmail.org/post/20151002.3680716
MERS-CoV (135): Jordan, Saudi Arabia
http://promedmail.org/post/20150922.3660953
MERS-CoV (134): Saudi Arabia, Jordan, WHO
http://promedmail.org/post/20150918.3654724
MERS-CoV (129): Saudi Arabia, Jordan, WHO
http://promedmail.org/post/20150911.3635718
MERS-CoV (122): Jordan, Saudi Arabia, WHO
http://promedmail.org/post/20150902.3616013
MERS-CoV (121): Jordan, Saudi Arabia
http://promedmail.org/post/20150831.3613868

MERS-CoV (118): Saudi Arabia, Jordan ex Saudi Arabia ex Abroad, WHO, RFI http://promedmail.org/post/20150827.3605963
MERS-CoV (03): Saudi Arabia, new cases, new fatality, Jordan, WHO http://promedmail.org/post/20150107.3077259
2014
---
MERS-CoV - Eastern Mediterranean (76): Saudi Arabia, Jordan, UAE, ECDC assessment, WHO http://promedmail.org/post/20140604.2515846
MERS-CoV - Eastern Mediterranean (47): Saudi Arabia, Jordan, Egypt, WHO http://promedmail.org/post/20140502.2442560
2013
---
MERS-CoV - Eastern Mediterranean (98): animal reserv/camel, Jordan, Saudi Arabia http://promedmail.org/post/20131213.2114362
MERS-CoV - Eastern Mediterranean (31): Jordan, retro. case ID, WHO, RFI http://promedmail.org/post/20130617.1777989
MERS-CoV - Eastern Mediterranean (17): Saudi Arabia, Italy ex Jordan, WHO http://promedmail.org/post/20130602.1751356
MERS-CoV - Eastern Mediterranean (16): Italy ex Jordan, contact cases, WHO http://promedmail.org/post/20130602.1750425
MERS-CoV - Eastern Mediterranean (09): Saudi Arabia, WHO, Jordan http://promedmail.org/post/20130523.1733317]
.....arn/ec/dk
*############################################################*
**********

ProMED-mail makes every effort to verify the reports that are posted, but the accuracy and completeness of the information, and of any statements or opinions based thereon, are not guaranteed. The reader assumes all risks in using information posted or archived by ProMED-mail. ISID and its associated service providers shall not be held responsible for errors or omissions or held liable for any damages incurred as a result of use or reliance upon posted or archived material.

**********

Donate to ProMED-mail. Details available at:
<http://www.isid.org/donate/>

**********

Visit ProMED-mail's web site at <http://www.promedmail.org>.
Send all items for posting to: promed@promedmail.org (NOT to an individual moderator). If you do not give your full name name and affiliation, it may not be posted. You may unsubscribe at <http://ww4.isid.org/promedmail/subscribe.php>.
For assistance from a human being, send mail to:
<postmaster@promedmail.org>.

############################################################
############################################################

List-Unsubscribe: http://ww4.isid.org/promedmail/subscribe.php

**From:** "William B. Karesh" <karesh@ecohealthalliance.org>
**To:** Andrew Clements <AClements@usaid.gov>
**Cc:** "Dr VAN KERKHOVE, Maria" <[redacted]>, "Subhash Morzaria (FAORAP)" <[redacted]>, Yilma Makonnen <[redacted]>, Juan Lubroth <Juan.Lubroth@fao.org>, Jonna Mazet <jkmazet@ucdavis.edu>, Chris Johnson <ckjohnson@ucdavis.edu>, "Sophie Von dobschuetz" <[redacted]>, Dennis Carroll <dcarroll@usaid.gov>, "lparish@usaid.gov" <lparish@usaid.gov>, Patrick Dawson <dawson@ecohealthalliance.org>
**Subject:** Re: Prioritizing sampling of juvenile and symptomatic camels for MERS virus detection/isolation
**Sent:** Mon, 7 May 2018 16:55:39 +0000

Hi Andrew,
I think everyone is in agreement with that approach. It's consistent with what we found early on in Saudi Arabia four years ago.

Focusing on the juveniles is the way to go for people that want to maximize yields for isolating virus to look at strain diversity, etc. Across the spectrum of other questions, people may have different study designs of course.

For most of EPT-2, FAO (and their local partners) has been leading the efforts on the camel work.

And, to date, there has still not been any definitive work on camel to human transmission routes - though some good correlation work has been done.
For Jordan, PREDICT-2 is adding on a more in-depth prospective case controlled study with a medical anthropology approach on the human side and adding serology to see if we can better elucidate risk factors for human infection and come up with some ideas for practical intervention strategies.

BK

**William B. Karesh, D.V.M**
*Executive Vice President for Health and Policy*

EcoHealth Alliance
460 West 34th Street - 17th Floor
New York, NY 10001 USA

+1.212.380.4463 (direct)
+1.212.380.4465 (fax)
www.ecohealthalliance.org

President, OIE Working Group on Wildlife

Co-chair, IUCN Species Survival Commission - Wildlife Health Specialist Group

EPT Partners Liaison, USAID Emerging Pandemic Threats - PREDICT-2 Program

***EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that promote conservation and prevent pandemics.***

On May 7, 2018, at 6:37 AM, Andrew Clements <AClements@usaid.gov> wrote:

Hi all,

Is there consensus among the main MERS researchers (including FAO, Predict, and WHO) that there should be a specific focus on sampling juvenile camels and camels of any age that are symptomatic, especially in herds with high turnover rates, in countries with seropositives in order to increase odds of detecting (and isolating) virus

to facilitate comparison of viral genomes across countries and regions?

Thanks!

Andrew

*Andrew P. Clements, Ph.D.*
*Senior Scientific Advisor*
*Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health*
*U.S. Agency for International Development*
*Mobile phone: 1-571-345-4253*
*Email: aclements@usaid.gov*

Begin forwarded message:

**From:** Andrew Clements <aclements@usaid.gov>
**Date:** May 7, 2018 at 11:58:10 AM GMT+2
**To:** "Subhash Morzaria (FAORAP)" <[redacted]>, lparish@usaid.gov, Dennis Carroll <dcarroll@usaid.gov>, malkhateeb@usaid.gov, ahalverson@usaid.gov, akibria@usaid.gov, [redacted], "Ahmed ElIdrissi (AGAH)" <[redacted], William Karesh <Karesh@ecohealthalliance.org>, dawson@ecohealthalliance.org, [redacted], aelerian@usaid.gov, "Juan (AGAH) ([redacted]) Lubroth" <[redacted]>
**Subject: Fwd: PRO/AH/EDR> MERS-CoV (14): Israel, animal reservoir, camelids**

FYI

*Andrew P. Clements, Ph.D.*
*Senior Scientific Advisor*
*Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health*
*U.S. Agency for International Development*
*Mobile phone: 1-571-345-4253*
*Email: aclements@usaid.gov*

Begin forwarded message:

**From:** Daniel Schar <dschar@usaid.gov>
**Date:** May 7, 2018 at 7:49:44 AM GMT+2
**To:** aclements@usaid.gov
**Subject: Fwd: PRO/AH/EDR> MERS-CoV (14): Israel, animal reservoir, camelids**

FYI

Begin forwarded message:

**From:** promed-edr@promedmail.org
**Date:** May 7, 2018 at 5:16:04 AM GMT+7
**To:** promed-post@promedmail.org, promed-edr-post@promedmail.org, promed-ahead-post@promedmail.org
**Subject: PRO/AH/EDR> MERS-CoV (14): Israel, animal reservoir, camelids**

**Reply-To:** promedNOREPLY@promedmail.org

MERS-COV (14): ISRAEL. ANIMAL RESERVOIR, CAMELIDS
**********

A ProMED-mail post
<http://www.promedmail.org>
ProMED-mail is a program of the
International Society for Infectious Diseases
<http://www.isid.org>

Date: Fri 4 May 2018
Source: One Health, Official Journal of the One Health Platform.
Article in Press, accepted manuscript. [summ., edited]
<https://www.sciencedirect.com/science/article/pii/S2352771418300053>

Citation: David D, Rotenberg D, Khinich E, Erster O, Bardenstein S, van Straten M, Okba NMA, Haagmans BL, Miculitzki M & Davidson I (2018). Middle East respiratory syndrome coronavirus specific antibodies in naturally exposed Israeli llamas, alpacas and camels.
<https://doi.org/10.1016/j.onehlt.2018.05.002>

Abstract:
Thus far, no human MERS-CoV infections have been reported from Israel. Evidence for the circulation of MERS-CoV in dromedaries has been reported from almost all the countries of the Middle East, except Israel. Therefore, we aimed to analyze MERS-CoV infection in Israeli camelids, sampled between 2012 and 2017. A total of 411 camels, 102 alpacas and 19 llamas' sera were tested for the presence of antibodies to MERS-CoV. Our findings indicate a lower MERS-CoV seropositivity among Israeli dromedaries than in the surrounding countries, and for the 1st time naturally infected llamas were identified. In addition, nasal swabs of 661 camels, alpacas and lamas, obtained from January 2015 to December 2017, were tested for the presence of MERS-CoV RNA. All nasal swabs were negative, indicating no evidence for MERS-CoV active circulation in these camelids during that time period.

--
Communicated by:
ProMED-mail
<promed@promedmail.org>

[The [slightly abridged] discussion chapter and the authors' conclusions in the above paper are herewith included for subscribers convenience (references omitted).

Discussion
---
We present the 1st serological and molecular survey for MERS-CoV infection among Israeli camelids, from 2012 to 2017. Camels showed an average MERS-CoV seroprevalence of 60.6 percent between 2012-2017 by VNT and an average seroprevalence of 62.9 percent by ELISA between 2015-2017, without any detection of viral RNA in the nasal swabs of the 540 camels. The presence of virus-specific neutralizing antibodies suggests that Israeli camels were exposed to MERS-CoV in the past. The

VNT assay was more sensitive and more specific than the ELISA. Whereas the ELISA detects only IgG, the VNT detects any isotype of antibodies which could be IgG, IgM or IgA. The higher strength of the VNT assay as compared to ELISA might be attributed by the fact that borderline sera by ELISA were not considered.

For the period from 2012-2017, the proportion of camel sera with high VNT titers (higher than 320) in Israel was 27.3 percent, which is much lower than the proportion of sera with high VNT titers in the surrounding countries, such as Saudi Arabia, Qatar, UAE, Oman, Egypt, and Jordan, reaching to more than 90 percent. Moreover, the proportion of sera with low VNT titers (less than 320) in Israel was about 70.4 percent, whereas in the surrounding countries only about 10 percent of the sera had low VNT titers meaning that the MERS-CoV seroprevalence in Israel is lower than that in the surrounding countries.

The differences in seropositivity by year in Israel might be related to the camels included in the random sample.

In contrast, low (14.3 percent) seroprevalence and probably no virus circulation were documented in the Canary Islands.

In the present study we showed for the 1st time the presence of MERS-CoV antibodies in naturally infected llamas by ELISA and VNT. In our study 29.4 and 31.5 percent of Israeli alpacas and llamas, respectively, were seropositive using the VNT assay. Using ELISA only, 34.3 and 36.8 percent of alpacas and llamas, respectively were detected seropositive. The 2 camels co-housed with the llamas and alpacas were negative for antibodies and viral RNA using the 2 serological assays and PCR, respectively.

Previously, MERS-CoV neutralizing antibodies were detected in 15/15 alpacas in Qatar. Similar to our findings, lower neutralizing antibody titers were documented in alpacas and experimentally infected llamas than in camels.

Using a MERS-CoV specific RT-PCR we detected no MERS-CoV genomic RNA in the nasal swabs of camels, alpacas and llamas during the period of 2015 to 2017 providing no evidence for active MERS-CoV circulation.

Conclusions
---
Altogether, the relatively low prevalence of antibodies to MERS-CoV, the low antibody titers, the absence of viral RNA in nasal swabs, and the absence of disease in humans, indicate limited MERS-CoV circulation in Israeli camelids during the [timeframe] of our survey".

Israel's camel population is located mainly in the south, namely in the Negev arid region, bordering the Kingdom of Jordan on the east and Sinai (Egypt) on the west. Contacts of Israel's ca 3000-3500 strong camel population with Jordan's camels (reportedly, counting some 11 000 animals), may be uncommon but cannot be regarded as fully excluded. Regional scientific cooperation is desired for the deciphering of MERS enigmatic epidemiology in humans, in particular its apparently higher incidence in humans in Saudi Arabia compared

with other Middle East countries with dromedary camel populations.

It deserves to be noted that the 'Egyptian tomb bat' (_Taphozous perforatus_) which was suspected, in 2013, as a reservoir of MERS CoV in Saudi Arabia, is known to be present also in Jordan and Israel, mainly along the (shared by both) Jordan valley. The largest, breeding cave on the Israeli side of the Jordan is situated near Kalia, on the northern shore of the Dead Sea, where 300-500 individuals were reportedly sighted in the spring months of 2013. It will be interesting to note if bats are subject to surveillance in the 2 countries.

A map of Israel: <http://healthmap.org/promed/p/90>. - Mod.AS]

[See Also:
MERS-CoV (68): Israel, animal reservoir, camels, serology, surveillance http://promedmail.org/post/20171105.5425773
MERS-CoV (66): Burkina Faso, animal reservoir, camels, FAO, RFI http://promedmail.org/post/20171029.5411777
MERS-CoV (64): Saudi Arabia, animal reservoir, human, camel milk http://promedmail.org/post/20171012.5375933
MERS-CoV (62): animal reservoir, camels, FAO, OIE, WHO http://promedmail.org/post/20171002.5354608
MERS-CoV (21): Egypt, animal reservoir, camel, ex Sudan, control, RFI http://promedmail.org/post/20170405.4948727
2016
---
MERS-CoV (87): Jordan, animal reservoir, camelids, OIE http://promedmail.org/post/20160802.4385317
MERS-CoV (40): Egypt, animal reservoir, camel, ex Sudan, susp. http://promedmail.org/post/20160316.4097730
2015
---
MERS-CoV (137): Saudi Arabia, Jordan, WHO http://promedmail.org/post/20151002.3680716
MERS-CoV (135): Jordan, Saudi Arabia http://promedmail.org/post/20150922.3660953
MERS-CoV (134): Saudi Arabia, Jordan, WHO http://promedmail.org/post/20150918.3654724
MERS-CoV (129): Saudi Arabia, Jordan, WHO http://promedmail.org/post/20150911.3635718
MERS-CoV (122): Jordan, Saudi Arabia, WHO http://promedmail.org/post/20150902.3616013
MERS-CoV (121): Jordan, Saudi Arabia http://promedmail.org/post/20150831.3613868
MERS-CoV (118): Saudi Arabia, Jordan ex Saudi Arabia ex Abroad, WHO, RFI http://promedmail.org/post/20150827.3605963
MERS-CoV (03): Saudi Arabia, new cases, new fatality, Jordan, WHO http://promedmail.org/post/20150107.3077259
2014
---
MERS-CoV - Eastern Mediterranean (76): Saudi Arabia, Jordan, UAE, ECDC assessment, WHO http://promedmail.org/post/20140604.2515846
MERS-CoV - Eastern Mediterranean (47): Saudi Arabia, Jordan, Egypt, WHO http://promedmail.org/post/20140502.2442560
2013

---
MERS-CoV - Eastern Mediterranean (98): animal reserv/camel, Jordan, Saudi Arabia http://promedmail.org/post/20131213.2114362
MERS-CoV - Eastern Mediterranean (31): Jordan, retro. case ID, WHO, RFI http://promedmail.org/post/20130617.1777989
MERS-CoV - Eastern Mediterranean (17): Saudi Arabia, Italy ex Jordan, WHO http://promedmail.org/post/20130602.1751356
MERS-CoV - Eastern Mediterranean (16): Italy ex Jordan, contact cases, WHO http://promedmail.org/post/20130602.1750425
MERS-CoV - Eastern Mediterranean (09): Saudi Arabia, WHO, Jordan http://promedmail.org/post/20130523.1733317]
.....arn/ec/dk
*############################################################*
**********

ProMED-mail makes every effort to verify the reports that are posted, but the accuracy and completeness of the information, and of any statements or opinions based thereon, are not guaranteed. The reader assumes all risks in using information posted or archived by ProMED-mail. ISID and its associated service providers shall not be held responsible for errors or omissions or held liable for any damages incurred as a result of use or reliance upon posted or archived material.
**********

Donate to ProMED-mail. Details available at:
<http://www.isid.org/donate/>
**********

Visit ProMED-mail's web site at <http://www.promedmail.org>.
Send all items for posting to: promed@promedmail.org (NOT to an individual moderator). If you do not give your full name name and affiliation, it may not be posted. You may unsubscribe at <http://ww4.isid.org/promedmail/subscribe.php>.
For assistance from a human being, send mail to:
<postmaster@promedmail.org>.
############################################################
############################################################

List-Unsubscribe: http://ww4.isid.org/promedmail/subscribe.php

**From:** Andrew Clements <aclements@usaid.gov>
**Sent:** Mon, 7 May 2018 10:03:52 -0700
**Subject:** Re: Prioritizing sampling of juvenile and symptomatic camels for MERS virus detection/isolation
**To:** "William B. Karesh" <karesh@ecohealthalliance.org>
**Cc:** "Dr VAN KERKHOVE, Maria" [REDACTED], "Subhash Morzaria (FAORAP)" [REDACTED], Yilma Makonnen [REDACTED], Juan Lubroth [REDACTED], Jonna Mazet <jkmazet@ucdavis.edu>, Chris Johnson <ckjohnson@ucdavis.edu>, Sophie Von dobschuetz [REDACTED], Dennis Carroll <dcarroll@usaid.gov>, "lparish@usaid.gov" <lparish@usaid.gov>, Patrick Dawson <dawson@ecohealthalliance.org>

Thanks, Billy

*Andrew P. Clements, Ph.D.*
*Senior Scientific Advisor*
*Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health*
*U.S. Agency for International Development*
*Mobile phone: 1-571-345-4253*
*Email: aclements@usaid.gov*

On May 7, 2018, at 6:55 PM, William B. Karesh <karesh@ecohealthalliance.org> wrote:

> Hi Andrew,
> I think everyone is in agreement with that approach. It's consistent with what we found early on in Saudi Arabia four years ago.
>
> Focusing on the juveniles is the way to go for people that want to maximize yields for isolating virus to look at strain diversity, etc. Across the spectrum of other questions, people may have different study designs of course.
>
> For most of EPT-2, FAO (and their local partners) has been leading the efforts on the camel work.
>
> And, to date, there has still not been any definitive work on camel to human transmission routes - though some good correlation work has been done.
> For Jordan, PREDICT-2 is adding on a more in-depth prospective case controlled study with a medical anthropology approach on the human side and adding serology to see if we can better elucidate risk factors for human infection and come up with some ideas for practical intervention strategies.
>
> BK

**William B. Karesh, D.V.M**
*Executive Vice President for Health and Policy*

EcoHealth Alliance
460 West 34th Street - 17th Floor
New York, NY 10001 USA

+1.212.380.4463 (direct)
+1.212.380.4465 (fax)
www.ecohealthalliance.org

President, OIE Working Group on Wildlife

Co-chair, IUCN Species Survival Commission - Wildlife Health Specialist Group

EPT Partners Liaison, USAID Emerging Pandemic Threats - PREDICT-2 Program

***EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that promote conservation and prevent pandemics.***

On May 7, 2018, at 6:37 AM, Andrew Clements <AClements@usaid.gov> wrote:

Hi all,

Is there consensus among the main MERS researchers (including FAO, Predict, and WHO) that there should be a specific focus on sampling juvenile camels and camels of any age that are symptomatic, especially in herds with high turnover rates, in countries with seropositives in order to increase odds of detecting (and isolating) virus to facilitate comparison of viral genomes across countries and regions?

Thanks!

Andrew

*Andrew P. Clements, Ph.D.*
*Senior Scientific Advisor*
*Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health*
*U.S. Agency for International Development*
*Mobile phone: 1-571-345-4253*
*Email: aclements@usaid.gov*

Begin forwarded message:

**From:** Andrew Clements <aclements@usaid.gov>
**Date:** May 7, 2018 at 11:58:10 AM GMT+2
**To:** "Subhash Morzaria (FAORAP)" <[redacted]>, lparish@usaid.gov, Dennis Carroll <dcarroll@usaid.gov>, malkhateeb@usaid.gov, ahalverson@usaid.gov, akibria@usaid.gov, [redacted], "Ahmed ElIdrissi (AGAH)" <[redacted], William Karesh <Karesh@ecohealthalliance.org>, dawson@ecohealthalliance.org, [redacted], aelerian@usaid.gov, "Juan (AGAH) ([redacted]>
**Subject: Fwd: PRO/AH/EDR> MERS-CoV (14): Israel, animal reservoir, camelids**

FYI

*Andrew P. Clements, Ph.D.*
*Senior Scientific Advisor*
*Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health*
*U.S. Agency for International Development*
*Mobile phone: 1-571-345-4253*
*Email: aclements@usaid.gov*

Begin forwarded message:

**From:** Daniel Schar <dschar@usaid.gov>
**Date:** May 7, 2018 at 7:49:44 AM GMT+2

**To:** aclements@usaid.gov
**Subject: Fwd: PRO/AH/EDR> MERS-CoV (14): Israel, animal reservoir, camelids**

FYI

Begin forwarded message:

**From:** promed-edr@promedmail.org
**Date:** May 7, 2018 at 5:16:04 AM GMT+7
**To:** promed-post@promedmail.org, promed-edr-post@promedmail.org, promed-ahead-post@promedmail.org
**Subject: PRO/AH/EDR> MERS-CoV (14): Israel, animal reservoir, camelids**
**Reply-To:** promedNOREPLY@promedmail.org

MERS-COV (14): ISRAEL. ANIMAL RESERVOIR, CAMELIDS

**********

A ProMED-mail post
<http://www.promedmail.org>
ProMED-mail is a program of the
International Society for Infectious Diseases
<http://www.isid.org>

Date: Fri 4 May 2018
Source: One Health, Official Journal of the One Health Platform.
Article in Press, accepted manuscript. [summ., edited]
<https://www.sciencedirect.com/science/article/pii/S2352771418300053>

Citation: David D, Rotenberg D, Khinich E, Erster O, Bardenstein S, van Straten M, Okba NMA, Haagmans BL, Miculitzki M & Davidson I (2018). Middle East respiratory syndrome coronavirus specific antibodies in naturally exposed Israeli llamas, alpacas and camels.
<https://doi.org/10.1016/j.onehlt.2018.05.002>

Abstract:
Thus far, no human MERS-CoV infections have been reported from Israel. Evidence for the circulation of MERS-CoV in dromedaries has been reported from almost all the countries of the Middle East, except Israel. Therefore, we aimed to analyze MERS-CoV infection in Israeli camelids, sampled between 2012 and 2017. A total of 411 camels, 102 alpacas and 19 llamas' sera were tested for the presence of antibodies to MERS-CoV. Our findings indicate a lower MERS-CoV seropositivity among Israeli dromedaries than in the surrounding countries, and for the 1st time naturally infected llamas were identified. In addition, nasal swabs of 661 camels, alpacas and lamas, obtained from January 2015 to December 2017, were tested for the presence of MERS-CoV RNA. All nasal swabs were negative, indicating no evidence for MERS-CoV active circulation in these camelids during that time period.

--
Communicated by:

ProMED-mail
<promed@promedmail.org>

[The [slightly abridged] discussion chapter and the authors' conclusions in the above paper are herewith included for subscribers convenience (references omitted).

Discussion
---
We present the 1st serological and molecular survey for MERS-CoV infection among Israeli camelids, from 2012 to 2017. Camels showed an average MERS-CoV seroprevalence of 60.6 percent between 2012-2017 by VNT and an average seroprevalence of 62.9 percent by ELISA between 2015-2017, without any detection of viral RNA in the nasal swabs of the 540 camels. The presence of virus-specific neutralizing antibodies suggests that Israeli camels were exposed to MERS-CoV in the past. The VNT assay was more sensitive and more specific than the ELISA. Whereas the ELISA detects only IgG, the VNT detects any isotype of antibodies which could be IgG, IgM or IgA. The higher strength of the VNT assay as compared to ELISA might be attributed by the fact that borderline sera by ELISA were not considered.

For the period from 2012-2017, the proportion of camel sera with high VNT titers (higher than 320) in Israel was 27.3 percent, which is much lower than the proportion of sera with high VNT titers in the surrounding countries, such as Saudi Arabia, Qatar, UAE, Oman, Egypt, and Jordan, reaching to more than 90 percent. Moreover, the proportion of sera with low VNT titers (less than 320) in Israel was about 70.4 percent, whereas in the surrounding countries only about 10 percent of the sera had low VNT titers meaning that the MERS-CoV seroprevalence in Israel is lower than that in the surrounding countries.

The differences in seropositivity by year in Israel might be related to the camels included in the random sample.

In contrast, low (14.3 percent) seroprevalence and probably no virus circulation were documented in the Canary Islands.

In the present study we showed for the 1st time the presence of MERS-CoV antibodies in naturally infected llamas by ELISA and VNT. In our study 29.4 and 31.5 percent of Israeli alpacas and llamas, respectively, were seropositive using the VNT assay. Using ELISA only, 34.3 and 36.8 percent of alpacas and llamas, respectively were detected seropositive. The 2 camels co-housed with the llamas and alpacas were negative for antibodies and viral RNA using the 2 serological assays and PCR, respectively.

Previously, MERS-CoV neutralizing antibodies were detected in 15/15 alpacas in Qatar. Similar to our findings, lower neutralizing antibody titers were documented in alpacas and experimentally infected llamas than in camels.

Using a MERS-CoV specific RT-PCR we detected no MERS-CoV genomic RNA in the nasal swabs of camels, alpacas and llamas during the period of 2015 to 2017 providing no evidence for active MERS-CoV circulation.

Conclusions
---
Altogether, the relatively low prevalence of antibodies to MERS-CoV, the low antibody titers, the absence of viral RNA in nasal swabs, and the absence of disease in humans, indicate limited MERS-CoV circulation in Israeli camelids during the [timeframe] of our survey".

Israel's camel population is located mainly in the south, namely in the Negev arid region, bordering the Kingdom of Jordan on the east and Sinai (Egypt) on the west. Contacts of Israel's ca 3000-3500 strong camel population with Jordan's camels (reportedly, counting some 11 000 animals), may be uncommon but cannot be regarded as fully excluded. Regional scientific cooperation is desired for the deciphering of MERS enigmatic epidemiology in humans, in particular its apparently higher incidence in humans in Saudi Arabia compared with other Middle East countries with dromedary camel populations.

It deserves to be noted that the 'Egyptian tomb bat' (_Taphozous perforatus_) which was suspected, in 2013, as a reservoir of MERS CoV in Saudi Arabia, is known to be present also in Jordan and Israel, mainly along the (shared by both) Jordan valley. The largest, breeding cave on the Israeli side of the Jordan is situated near Kalia, on the northern shore of the Dead Sea, where 300-500 individuals were reportedly sighted in the spring months of 2013. It will be interesting to note if bats are subject to surveillance in the 2 countries.

A map of Israel: <http://healthmap.org/promed/p/90>. - Mod.AS]

[See Also:
MERS-CoV (68): Israel, animal reservoir, camels, serology, surveillance http://promedmail.org/post/20171105.5425773
MERS-CoV (66): Burkina Faso, animal reservoir, camels, FAO, RFI
http://promedmail.org/post/20171029.5411777
MERS-CoV (64): Saudi Arabia, animal reservoir, human, camel milk
http://promedmail.org/post/20171012.5375933
MERS-CoV (62): animal reservoir, camels, FAO, OIE, WHO
http://promedmail.org/post/20171002.5354608
MERS-CoV (21): Egypt, animal reservoir, camel, ex Sudan, control, RFI
http://promedmail.org/post/20170405.4948727
2016
---
MERS-CoV (87): Jordan, animal reservoir, camelids, OIE
http://promedmail.org/post/20160802.4385317
MERS-CoV (40): Egypt, animal reservoir, camel, ex Sudan, susp.
http://promedmail.org/post/20160316.4097730
2015
---
MERS-CoV (137): Saudi Arabia, Jordan, WHO
http://promedmail.org/post/20151002.3680716
MERS-CoV (135): Jordan, Saudi Arabia
http://promedmail.org/post/20150922.3660953
MERS-CoV (134): Saudi Arabia, Jordan, WHO
http://promedmail.org/post/20150918.3654724
MERS-CoV (129): Saudi Arabia, Jordan, WHO

http://promedmail.org/post/20150911.3635718
MERS-CoV (122): Jordan, Saudi Arabia, WHO
http://promedmail.org/post/20150902.3616013
MERS-CoV (121): Jordan, Saudi Arabia
http://promedmail.org/post/20150831.3613868
MERS-CoV (118): Saudi Arabia, Jordan ex Saudi Arabia ex Abroad, WHO, RFI http://promedmail.org/post/20150827.3605963
MERS-CoV (03): Saudi Arabia, new cases, new fatality, Jordan, WHO
http://promedmail.org/post/20150107.3077259
2014
---
MERS-CoV - Eastern Mediterranean (76): Saudi Arabia, Jordan, UAE, ECDC assessment, WHO http://promedmail.org/post/20140604.2515846
MERS-CoV - Eastern Mediterranean (47): Saudi Arabia, Jordan, Egypt, WHO http://promedmail.org/post/20140502.2442560
2013
---
MERS-CoV - Eastern Mediterranean (98): animal reserv/camel, Jordan, Saudi Arabia http://promedmail.org/post/20131213.2114362
MERS-CoV - Eastern Mediterranean (31): Jordan, retro. case ID, WHO, RFI http://promedmail.org/post/20130617.1777989
MERS-CoV - Eastern Mediterranean (17): Saudi Arabia, Italy ex Jordan, WHO http://promedmail.org/post/20130602.1751356
MERS-CoV - Eastern Mediterranean (16): Italy ex Jordan, contact cases, WHO http://promedmail.org/post/20130602.1750425
MERS-CoV - Eastern Mediterranean (09): Saudi Arabia, WHO, Jordan
http://promedmail.org/post/20130523.1733317]
.....arn/ec/dk
*############################################################*
**********

ProMED-mail makes every effort to verify the reports that are posted, but the accuracy and completeness of the information, and of any statements or opinions based thereon, are not guaranteed. The reader assumes all risks in using information posted or archived by ProMED-mail. ISID and its associated service providers shall not be held responsible for errors or omissions or held liable for any damages incurred as a result of use or reliance upon posted or archived material.

**********

Donate to ProMED-mail. Details available at:
<http://www.isid.org/donate/>

**********

Visit ProMED-mail's web site at <http://www.promedmail.org>.
Send all items for posting to: promed@promedmail.org (NOT to an individual moderator). If you do not give your full name name and affiliation, it may not be posted. You may unsubscribe at <http://ww4.isid.org/promedmail/subscribe.php>.
For assistance from a human being, send mail to:
<postmaster@promedmail.org>.

############################################################
############################################################

List-Unsubscribe: http://ww4.isid.org/promedmail/subscribe.php

**From:** "William B. Karesh" <karesh@ecohealthalliance.org>
**To:** Jonna Mazet <jkmazet@ucdavis.edu>
**Subject:** Re: Prioritizing sampling of juvenile and symptomatic camels for MERS virus detection/isolation
**Sent:** Tue, 8 May 2018 13:40:35 +0000

:)
New project name: "Chasing ProMED"

On May 7, 2018, at 5:58 PM, Jonna Mazet <jkmazet@ucdavis.edu> wrote:

Thanks!
J

On Mon, May 7, 2018 at 9:55 AM, William B. Karesh <karesh@ecohealthalliance.org> wrote:

Hi Andrew,
I think everyone is in agreement with that approach. It's consistent with what we found early on in Saudi Arabia four years ago.

Focusing on the juveniles is the way to go for people that want to maximize yields for isolating virus to look at strain diversity, etc. Across the spectrum of other questions, people may have different study designs of course.

For most of EPT-2, FAO (and their local partners) has been leading the efforts on the camel work.

And, to date, there has still not been any definitive work on camel to human transmission routes - though some good correlation work has been done.
For Jordan, PREDICT-2 is adding on a more in-depth prospective case controlled study with a medical anthropology approach on the human side and adding serology to see if we can better elucidate risk factors for human infection and come up with some ideas for practical intervention strategies.

BK

**William B. Karesh, D.V.M**
*Executive Vice President for Health and Policy*

EcoHealth Alliance
460 West 34th Street - 17th Floor
New York, NY 10001 USA

+1.212.380.4463 (direct)
+1.212.380.4465 (fax)
www.ecohealthalliance.org

President, OIE Working Group on Wildlife

Co-chair, IUCN Species Survival Commission - Wildlife Health Specialist Group

EPT Partners Liaison, USAID Emerging Pandemic Threats - PREDICT-2 Program

***EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that promote conservation and prevent pandemics.***

On May 7, 2018, at 6:37 AM, Andrew Clements <AClements@usaid.gov> wrote:

Hi all,

Is there consensus among the main MERS researchers (including FAO, Predict, and WHO) that there should be a specific focus on sampling juvenile camels and camels of any age that are symptomatic, especially in herds with high turnover rates, in countries with seropositives in order to increase odds of detecting (and isolating) virus to facilitate comparison of viral genomes across countries and regions?

Thanks!

Andrew

*Andrew P. Clements, Ph.D.*
*Senior Scientific Advisor*
*Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health*
*U.S. Agency for International Development*
*Mobile phone: 1-571-345-4253*
*Email: aclements@usaid.gov*

Begin forwarded message:

**From:** Andrew Clements <aclements@usaid.gov>
**Date:** May 7, 2018 at 11:58:10 AM GMT+2
**To:** "Subhash Morzaria (FAORAP)" <[redacted]>, lparish@usaid.gov, Dennis Carroll <dcarroll@usaid.gov>, malkhateeb@usaid.gov, ahalverson@usaid.gov, akibria@usaid.gov, [redacted] "Ahmed ElIdrissi (AGAH)" <[redacted]>, William Karesh <Karesh@ecohealthalliance.org>, dawson@ecohealthalliance.org, [redacted] aelerian@usaid.gov, "Juan (AGAH) ([redacted]
**Subject: Fwd: PRO/AH/EDR> MERS-CoV (14): Israel, animal reservoir, camelids**

FYI

*Andrew P. Clements, Ph.D.*
*Senior Scientific Advisor*
*Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health*
*U.S. Agency for International Development*
*Mobile phone: 1-571-345-4253*
*Email: aclements@usaid.gov*

Begin forwarded message:

**From:** Daniel Schar <dschar@usaid.gov>
**Date:** May 7, 2018 at 7:49:44 AM GMT+2

**To:** aclements@usaid.gov
**Subject: Fwd: PRO/AH/EDR> MERS-CoV (14): Israel, animal reservoir, camelids**

FYI

Begin forwarded message:

**From:** promed-edr@promedmail.org
**Date:** May 7, 2018 at 5:16:04 AM GMT+7
**To:** promed-post@promedmail.org, promed-edr-post@promedmail.org, promed-ahead-post@promedmail.org
**Subject: PRO/AH/EDR> MERS-CoV (14): Israel, animal reservoir, camelids**
**Reply-To:** promedNOREPLY@promedmail.org

MERS-COV (14): ISRAEL. ANIMAL RESERVOIR, CAMELIDS

**********

A ProMED-mail post
<http://www.promedmail.org>
ProMED-mail is a program of the
International Society for Infectious Diseases
<http://www.isid.org>

Date: Fri 4 May 2018
Source: One Health, Official Journal of the One Health Platform.
Article in Press, accepted manuscript. [summ., edited]
<https://www.sciencedirect.com/science/article/pii/S2352771418300053>

Citation: David D, Rotenberg D, Khinich E, Erster O, Bardenstein S, van Straten M, Okba NMA, Haagmans BL, Miculitzki M & Davidson I (2018). Middle East respiratory syndrome coronavirus specific antibodies in naturally exposed Israeli llamas, alpacas and camels.
<https://doi.org/10.1016/j.onehlt.2018.05.002>

Abstract:
Thus far, no human MERS-CoV infections have been reported from Israel. Evidence for the circulation of MERS-CoV in dromedaries has been reported from almost all the countries of the Middle East, except Israel. Therefore, we aimed to analyze MERS-CoV infection in Israeli camelids, sampled between 2012 and 2017. A total of 411 camels, 102 alpacas and 19 llamas' sera were tested for the presence of antibodies to MERS-CoV. Our findings indicate a lower MERS-CoV seropositivity among Israeli dromedaries than in the surrounding countries, and for the 1st time naturally infected llamas were identified. In addition, nasal swabs of 661 camels, alpacas and lamas, obtained from January 2015 to December 2017, were tested for the presence of MERS-CoV RNA. All nasal swabs were negative, indicating no evidence for MERS-CoV active circulation in these camelids during that time period.

--
Communicated by:

ProMED-mail
<promed@promedmail.org>

[The [slightly abridged] discussion chapter and the authors' conclusions in the above paper are herewith included for subscribers convenience (references omitted).

Discussion
---
We present the 1st serological and molecular survey for MERS-CoV infection among Israeli camelids, from 2012 to 2017. Camels showed an average MERS-CoV seroprevalence of 60.6 percent between 2012-2017 by VNT and an average seroprevalence of 62.9 percent by ELISA between 2015-2017, without any detection of viral RNA in the nasal swabs of the 540 camels. The presence of virus-specific neutralizing antibodies suggests that Israeli camels were exposed to MERS-CoV in the past. The VNT assay was more sensitive and more specific than the ELISA. Whereas the ELISA detects only IgG, the VNT detects any isotype of antibodies which could be IgG, IgM or IgA. The higher strength of the VNT assay as compared to ELISA might be attributed by the fact that borderline sera by ELISA were not considered.

For the period from 2012-2017, the proportion of camel sera with high VNT titers (higher than 320) in Israel was 27.3 percent, which is much lower than the proportion of sera with high VNT titers in the surrounding countries, such as Saudi Arabia, Qatar, UAE, Oman, Egypt, and Jordan, reaching to more than 90 percent. Moreover, the proportion of sera with low VNT titers (less than 320) in Israel was about 70.4 percent, whereas in the surrounding countries only about 10 percent of the sera had low VNT titers meaning that the MERS-CoV seroprevalence in Israel is lower than that in the surrounding countries.

The differences in seropositivity by year in Israel might be related to the camels included in the random sample.

In contrast, low (14.3 percent) seroprevalence and probably no virus circulation were documented in the Canary Islands.

In the present study we showed for the 1st time the presence of MERS-CoV antibodies in naturally infected llamas by ELISA and VNT. In our study 29.4 and 31.5 percent of Israeli alpacas and llamas, respectively, were seropositive using the VNT assay. Using ELISA only, 34.3 and 36.8 percent of alpacas and llamas, respectively were detected seropositive. The 2 camels co-housed with the llamas and alpacas were negative for antibodies and viral RNA using the 2 serological assays and PCR, respectively.

Previously, MERS-CoV neutralizing antibodies were detected in 15/15 alpacas in Qatar. Similar to our findings, lower neutralizing antibody titers were documented in alpacas and experimentally infected llamas than in camels.

Using a MERS-CoV specific RT-PCR we detected no MERS-CoV genomic RNA in the nasal swabs of camels, alpacas and llamas during the period of 2015 to 2017 providing no evidence for active MERS-CoV circulation.

Conclusions
---
Altogether, the relatively low prevalence of antibodies to MERS-CoV, the low antibody titers, the absence of viral RNA in nasal swabs, and the absence of disease in humans, indicate limited MERS-CoV circulation in Israeli camelids during the [timeframe] of our survey".

Israel's camel population is located mainly in the south, namely in the Negev arid region, bordering the Kingdom of Jordan on the east and Sinai (Egypt) on the west. Contacts of Israel's ca 3000-3500 strong camel population with Jordan's camels (reportedly, counting some 11 000 animals), may be uncommon but cannot be regarded as fully excluded. Regional scientific cooperation is desired for the deciphering of MERS enigmatic epidemiology in humans, in particular its apparently higher incidence in humans in Saudi Arabia compared with other Middle East countries with dromedary camel populations.

It deserves to be noted that the 'Egyptian tomb bat' (_Taphozous perforatus_) which was suspected, in 2013, as a reservoir of MERS CoV in Saudi Arabia, is known to be present also in Jordan and Israel, mainly along the (shared by both) Jordan valley. The largest, breeding cave on the Israeli side of the Jordan is situated near Kalia, on the northern shore of the Dead Sea, where 300-500 individuals were reportedly sighted in the spring months of 2013. It will be interesting to note if bats are subject to surveillance in the 2 countries.

A map of Israel: <http://healthmap.org/promed/p/90>. - Mod.AS]

[See Also:
MERS-CoV (68): Israel, animal reservoir, camels, serology, surveillance http://promedmail.org/post/20171105.5425773
MERS-CoV (66): Burkina Faso, animal reservoir, camels, FAO, RFI
http://promedmail.org/post/20171029.5411777
MERS-CoV (64): Saudi Arabia, animal reservoir, human, camel milk
http://promedmail.org/post/20171012.5375933
MERS-CoV (62): animal reservoir, camels, FAO, OIE, WHO
http://promedmail.org/post/20171002.5354608
MERS-CoV (21): Egypt, animal reservoir, camel, ex Sudan, control, RFI
http://promedmail.org/post/20170405.4948727
2016
---
MERS-CoV (87): Jordan, animal reservoir, camelids, OIE
http://promedmail.org/post/20160802.4385317
MERS-CoV (40): Egypt, animal reservoir, camel, ex Sudan, susp.
http://promedmail.org/post/20160316.4097730
2015
---
MERS-CoV (137): Saudi Arabia, Jordan, WHO
http://promedmail.org/post/20151002.3680716
MERS-CoV (135): Jordan, Saudi Arabia
http://promedmail.org/post/20150922.3660953
MERS-CoV (134): Saudi Arabia, Jordan, WHO
http://promedmail.org/post/20150918.3654724
MERS-CoV (129): Saudi Arabia, Jordan, WHO

http://promedmail.org/post/20150911.3635718
MERS-CoV (122): Jordan, Saudi Arabia, WHO
http://promedmail.org/post/20150902.3616013
MERS-CoV (121): Jordan, Saudi Arabia
http://promedmail.org/post/20150831.3613868
MERS-CoV (118): Saudi Arabia, Jordan ex Saudi Arabia ex Abroad, WHO, RFI http://promedmail.org/post/20150827.3605963
MERS-CoV (03): Saudi Arabia, new cases, new fatality, Jordan, WHO
http://promedmail.org/post/20150107.3077259
2014
---
MERS-CoV - Eastern Mediterranean (76): Saudi Arabia, Jordan, UAE, ECDC assessment, WHO http://promedmail.org/post/20140604.2515846
MERS-CoV - Eastern Mediterranean (47): Saudi Arabia, Jordan, Egypt, WHO http://promedmail.org/post/20140502.2442560
2013
---
MERS-CoV - Eastern Mediterranean (98): animal reserv/camel, Jordan, Saudi Arabia http://promedmail.org/post/20131213.2114362
MERS-CoV - Eastern Mediterranean (31): Jordan, retro. case ID, WHO, RFI http://promedmail.org/post/20130617.1777989
MERS-CoV - Eastern Mediterranean (17): Saudi Arabia, Italy ex Jordan, WHO http://promedmail.org/post/20130602.1751356
MERS-CoV - Eastern Mediterranean (16): Italy ex Jordan, contact cases, WHO http://promedmail.org/post/20130602.1750425
MERS-CoV - Eastern Mediterranean (09): Saudi Arabia, WHO, Jordan
http://promedmail.org/post/20130523.1733317]
.....arn/ec/dk
*############################################################*
**********

ProMED-mail makes every effort to verify the reports that are posted, but the accuracy and completeness of the information, and of any statements or opinions based thereon, are not guaranteed. The reader assumes all risks in using information posted or archived by ProMED-mail. ISID and its associated service providers shall not be held responsible for errors or omissions or held liable for any damages incurred as a result of use or reliance upon posted or archived material.

**********

Donate to ProMED-mail. Details available at:
<http://www.isid.org/donate/>

**********

Visit ProMED-mail's web site at <http://www.promedmail.org>.
Send all items for posting to: promed@promedmail.org (NOT to an individual moderator). If you do not give your full name name and affiliation, it may not be posted. You may unsubscribe at <http://ww4.isid.org/promedmail/subscribe.php>.
For assistance from a human being, send mail to:
<postmaster@promedmail.org>.

############################################################
############################################################

List-Unsubscribe: http://ww4.isid.org/promedmail/subscribe.php

**From:** Andrew Clements <aclements@usaid.gov>
**Sent:** Tue, 8 May 2018 18:19:35 +0200
**Subject:** Re: Prioritizing sampling of juvenile and symptomatic camels for MERS virus detection/isolation
**To:** "Lubroth, Juan (AGAH)" <REDACTED>
**Cc:** "[redacted]", "Morzaria, Subhash (TCE)" <REDACTED>, "Makonnen, Yilma (FAOKE)" <REDACTED>, William Karesh <Karesh@ecohealthalliance.org>, Jonna Mazet <jkmazet@ucdavis.edu>, Christine Kreuder Johnson <ckjohnson@ucdavis.edu>, "VonDobschuetz, Sophie (AGAH)" <REDACTED>, Dennis Carroll <dcarroll@usaid.gov>, "lparish@usaid.gov" <lparish@usaid.gov>, "Mahrous, Heba (AGAH)" <REDACTED>

Thanks, Juan.

How does the Kenya virus align with the virus Predict sequenced from a bat from Uganda?

On Tue, May 8, 2018 at 5:11 PM, Lubroth, Juan (AGAH) <REDACTED> wrote:

Dear Andrew and all,

We were triangulating some information and making sure we were on the same page.

We agree that for the specific objective of MERS-CoV virus detection and isolation, surveillance in camels is best targeted to higher-risk individuals and places, as outlined by you.

Given the remaining unknowns regarding MERS-CoV transmission and re-infection, we still suggest taking both swab and serum samples. Aging (by dentition), gender and information on the use of the camel (and for females, their lactation status) should be collected at all times.

We would like to update you on the status of the longitudinal surveillance in camels: Surveillance is ongoing in Kenya, Ethiopia and Egypt and will commence again soon in Jordan (upon signature of the new LOA with JUST).

While surveillance in Ethiopia did not yield PCR positives (yet), we have some interesting sequence results from Kenya as they show that the viruses do not cluster with Jordanian or Arabian Peninsula sequences (i.e distinct from both clade A and clade B viruses; no recombination with clade A or B viruses). The closest related sequence is a virus obtained from a camel in Egypt. Please note that these results have not been released by the government and should thus not be shared further for the moment.

Best regards,

Juan and team

JUAN LUBROTH, DVM, PhD, ACVPM

Chief Veterinary Officer

Animal Health Service C-549

Food and Agriculture Organization of the United Nations

Viale delle terme di Caracalla

00153 Rome, ITALY

Tel: +39 06 570 54184

Fax +39 06 570 53057

*The greatness of a nation and its moral progress can be judged by the way its animals are treated.*

- M Gandhi

Food and Agriculture Organization of the United Nations

---

**From:** Andrew Clements <aclements@usaid.gov>
**Sent:** 07 May 2018 12:38
**To:** [REDACTED] Morzaria, Subhash (TCE) <[REDACTED]>; Makonnen, Yilma (FAOKE) <[REDACTED]>; Lubroth, Juan (AGAH) <[REDACTED]>; William Karesh <Karesh@ecohealthalliance.org>; Jonna Mazet <jkmazet@ucdavis.edu>; Christine Kreuder Johnson <ckjohnson@ucdavis.edu>; VonDobschuetz, Sophie (AGAH) <[REDACTED]>
**Cc:** Dennis Carroll <dcarroll@usaid.gov>; lparish@usaid.gov
**Subject:** Prioritizing sampling of juvenile and symptomatic camels for MERS virus detection/isolation

Hi all,

Is there consensus among the main MERS researchers (including FAO, Predict, and WHO) that there should be a specific focus on sampling juvenile camels and camels of any age that are symptomatic, especially in herds with high turnover rates, in countries with seropositives in order to increase odds of detecting (and isolating) virus to facilitate comparison of viral genomes across countries and regions?

Thanks!

Andrew

*Andrew P. Clements, Ph.D.*

*Senior Scientific Advisor*

*Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health*

*U.S. Agency for International Development*

*Mobile phone: 1-571-345-4253*

*Email: aclements@usaid.gov*

Begin forwarded message:

**From:** Andrew Clements <aclements@usaid.gov>
**Date:** May 7, 2018 at 11:58:10 AM GMT+2
**To:** "Subhash Morzaria (FAORAP)" <[redacted]>, lparish@usaid.gov, Dennis Carroll <dcarroll@usaid.gov>, malkhateeb@usaid.gov, ahalverson@usaid.gov, akibria@usaid.gov, [redacted], "Ahmed ElIdrissi (AGAH)" <[redacted], William Karesh <Karesh@ecohealthalliance.org>, dawson@ecohealthalliance.org, [redacted], aelerian@usaid.gov, "Juan (AGAH) ([redacted]) Lubroth" <[redacted]>
**Subject: Fwd: PRO/AH/EDR> MERS-CoV (14): Israel, animal reservoir, camelids**

FYI

*Andrew P. Clements, Ph.D.*

*Senior Scientific Advisor*

*Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health*

*U.S. Agency for International Development*

*Mobile phone: 1-571-345-4253*

*Email: aclements@usaid.gov*

Begin forwarded message:

**From:** Daniel Schar <dschar@usaid.gov>
**Date:** May 7, 2018 at 7:49:44 AM GMT+2
**To:** aclements@usaid.gov
**Subject: Fwd: PRO/AH/EDR> MERS-CoV (14): Israel, animal reservoir, camelids**

FYI

Begin forwarded message:

**From:** promed-edr@promedmail.org
**Date:** May 7, 2018 at 5:16:04 AM GMT+7
**To:** promed-post@promedmail.org, promed-edr-post@promedmail.org, promed-ahead-post@promedmail.org
**Subject: PRO/AH/EDR> MERS-CoV (14): Israel, animal reservoir, camelids**
**Reply-To:** promedNOREPLY@promedmail.org

# MERS-COV (14): ISRAEL. ANIMAL RESERVOIR, CAMELIDS

**********

A ProMED-mail post
<http://www.promedmail.org>
ProMED-mail is a program of the
International Society for Infectious Diseases
<http://www.isid.org>

Date: Fri 4 May 2018
Source: One Health, Official Journal of the One Health Platform.
Article in Press, accepted manuscript. [summ., edited]
<https://www.sciencedirect.com/science/article/pii/S2352771418300053>

Citation: David D, Rotenberg D, Khinich E, Erster O, Bardenstein S, van Straten M, Okba NMA, Haagmans BL, Miculitzki M & Davidson I (2018). Middle East respiratory syndrome coronavirus specific antibodies in naturally exposed Israeli llamas, alpacas and camels.
<https://doi.org/10.1016/j.onehlt.2018.05.002>

Abstract:
Thus far, no human MERS-CoV infections have been reported from Israel. Evidence for the circulation of MERS-CoV in dromedaries has been reported from almost all the countries of the Middle East, except Israel. Therefore, we aimed to analyze MERS-CoV infection in Israeli camelids, sampled between 2012 and 2017. A total of 411 camels, 102 alpacas and 19 llamas' sera were tested for the presence of antibodies to MERS-CoV. Our findings indicate a lower MERS-CoV seropositivity among Israeli dromedaries than in the surrounding countries, and for the 1st time naturally infected llamas were identified. In addition, nasal swabs of 661 camels, alpacas and lamas, obtained from January 2015 to December 2017, were tested for the presence of MERS-CoV RNA. All nasal swabs were negative, indicating no evidence for MERS-CoV active circulation in these camelids during that time period.

--
Communicated by:
ProMED-mail
<promed@promedmail.org>

[The [slightly abridged] discussion chapter and the authors' conclusions in the above paper are herewith included for subscribers convenience (references omitted).

Discussion
---
We present the 1st serological and molecular survey for MERS-CoV infection among Israeli camelids, from 2012 to 2017. Camels showed an average MERS-CoV seroprevalence of 60.6 percent between 2012-2017 by VNT and an average seroprevalence of 62.9 percent by ELISA between 2015-2017, without any detection of viral RNA in the nasal swabs of the 540 camels. The presence of virus-specific neutralizing antibodies suggests that Israeli camels were exposed to MERS-CoV in the past. The VNT assay was more sensitive and more specific than the ELISA. Whereas the ELISA detects only IgG, the VNT detects any isotype of antibodies which could be IgG, IgM or IgA. The higher strength of the VNT assay

as compared to ELISA might be attributed by the fact that borderline sera by ELISA were not considered.

For the period from 2012-2017, the proportion of camel sera with high VNT titers (higher than 320) in Israel was 27.3 percent, which is much lower than the proportion of sera with high VNT titers in the surrounding countries, such as Saudi Arabia, Qatar, UAE, Oman, Egypt, and Jordan, reaching to more than 90 percent. Moreover, the proportion of sera with low VNT titers (less than 320) in Israel was about 70.4 percent, whereas in the surrounding countries only about 10 percent of the sera had low VNT titers meaning that the MERS-CoV seroprevalence in Israel is lower than that in the surrounding countries.

The differences in seropositivity by year in Israel might be related to the camels included in the random sample.

In contrast, low (14.3 percent) seroprevalence and probably no virus circulation were documented in the Canary Islands.

In the present study we showed for the 1st time the presence of MERS-CoV antibodies in naturally infected llamas by ELISA and VNT. In our study 29.4 and 31.5 percent of Israeli alpacas and llamas, respectively, were seropositive using the VNT assay. Using ELISA only, 34.3 and 36.8 percent of alpacas and llamas, respectively were detected seropositive. The 2 camels co-housed with the llamas and alpacas were negative for antibodies and viral RNA using the 2 serological assays and PCR, respectively.

Previously, MERS-CoV neutralizing antibodies were detected in 15/15 alpacas in Qatar. Similar to our findings, lower neutralizing antibody titers were documented in alpacas and experimentally infected llamas than in camels.

Using a MERS-CoV specific RT-PCR we detected no MERS-CoV genomic RNA in the nasal swabs of camels, alpacas and llamas during the period of 2015 to 2017 providing no evidence for active MERS-CoV circulation.

Conclusions
---
Altogether, the relatively low prevalence of antibodies to MERS-CoV, the low antibody titers, the absence of viral RNA in nasal swabs, and the absence of disease in humans, indicate limited MERS-CoV circulation in Israeli camelids during the [timeframe] of our survey".

Israel's camel population is located mainly in the south, namely in the Negev arid region, bordering the Kingdom of Jordan on the east and Sinai (Egypt) on the west. Contacts of Israel's ca 3000-3500 strong camel population with Jordan's camels (reportedly, counting some 11 000 animals), may be uncommon but cannot be regarded as fully excluded. Regional scientific cooperation is desired for the deciphering of MERS enigmatic epidemiology in humans, in particular its apparently higher incidence in humans in Saudi Arabia compared with other Middle East countries with dromedary camel populations.

It deserves to be noted that the 'Egyptian tomb bat' (_Taphozous

perforatus_) which was suspected, in 2013, as a reservoir of MERS CoV in Saudi Arabia, is known to be present also in Jordan and Israel, mainly along the (shared by both) Jordan valley. The largest, breeding cave on the Israeli side of the Jordan is situated near Kalia, on the northern shore of the Dead Sea, where 300-500 individuals were reportedly sighted in the spring months of 2013. It will be interesting to note if bats are subject to surveillance in the 2 countries.

A map of Israel: <http://healthmap.org/promed/p/90>. - Mod.AS]

[See Also:
MERS-CoV (68): Israel, animal reservoir, camels, serology, surveillance http://promedmail.org/post/20171105.5425773
MERS-CoV (66): Burkina Faso, animal reservoir, camels, FAO, RFI http://promedmail.org/post/20171029.5411777
MERS-CoV (64): Saudi Arabia, animal reservoir, human, camel milk http://promedmail.org/post/20171012.5375933
MERS-CoV (62): animal reservoir, camels, FAO, OIE, WHO http://promedmail.org/post/20171002.5354608
MERS-CoV (21): Egypt, animal reservoir, camel, ex Sudan, control, RFI http://promedmail.org/post/20170405.4948727
2016
---
MERS-CoV (87): Jordan, animal reservoir, camelids, OIE http://promedmail.org/post/20160802.4385317
MERS-CoV (40): Egypt, animal reservoir, camel, ex Sudan, susp. http://promedmail.org/post/20160316.4097730
2015
---
MERS-CoV (137): Saudi Arabia, Jordan, WHO http://promedmail.org/post/20151002.3680716
MERS-CoV (135): Jordan, Saudi Arabia http://promedmail.org/post/20150922.3660953
MERS-CoV (134): Saudi Arabia, Jordan, WHO http://promedmail.org/post/20150918.3654724
MERS-CoV (129): Saudi Arabia, Jordan, WHO http://promedmail.org/post/20150911.3635718
MERS-CoV (122): Jordan, Saudi Arabia, WHO http://promedmail.org/post/20150902.3616013
MERS-CoV (121): Jordan, Saudi Arabia http://promedmail.org/post/20150831.3613868
MERS-CoV (118): Saudi Arabia, Jordan ex Saudi Arabia ex Abroad, WHO, RFI http://promedmail.org/post/20150827.3605963
MERS-CoV (03): Saudi Arabia, new cases, new fatality, Jordan, WHO http://promedmail.org/post/20150107.3077259
2014
---
MERS-CoV - Eastern Mediterranean (76): Saudi Arabia, Jordan, UAE, ECDC assessment, WHO http://promedmail.org/post/20140604.2515846
MERS-CoV - Eastern Mediterranean (47): Saudi Arabia, Jordan, Egypt, WHO http://promedmail.org/post/20140502.2442560
2013
---
MERS-CoV - Eastern Mediterranean (98): animal reserv/camel, Jordan, Saudi Arabia http://promedmail.org/post/20131213.2114362

MERS-CoV - Eastern Mediterranean (31): Jordan, retro. case ID, WHO, RFI http://promedmail.org/post/20130617.1777989
MERS-CoV - Eastern Mediterranean (17): Saudi Arabia, Italy ex Jordan, WHO http://promedmail.org/post/20130602.1751356
MERS-CoV - Eastern Mediterranean (16): Italy ex Jordan, contact cases, WHO http://promedmail.org/post/20130602.1750425
MERS-CoV - Eastern Mediterranean (09): Saudi Arabia, WHO, Jordan http://promedmail.org/post/20130523.1733317]
.....arn/ec/dk
*############################################################*
**********

ProMED-mail makes every effort to verify the reports that are posted, but the accuracy and completeness of the information, and of any statements or opinions based thereon, are not guaranteed. The reader assumes all risks in using information posted or archived by ProMED-mail. ISID and its associated service providers shall not be held responsible for errors or omissions or held liable for any damages incurred as a result of use or reliance upon posted or archived material.

**********

Donate to ProMED-mail. Details available at:
<http://www.isid.org/donate/>

**********

Visit ProMED-mail's web site at <http://www.promedmail.org>.
Send all items for posting to: promed@promedmail.org (NOT to an individual moderator). If you do not give your full name name and affiliation, it may not be posted. You may unsubscribe at <http://ww4.isid.org/promedmail/subscribe.php>.
For assistance from a human being, send mail to:
<postmaster@promedmail.org>.

############################################################
############################################################

List-Unsubscribe: http://ww4.isid.org/promedmail/subscribe.php

--

Andrew Clements, Ph.D.
Senior Scientific Advisor
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
E-mail: aclements@usaid.gov

*For more information on USAID's Emerging Pandemic Threats program, see:* http://www.usaid.gov/ept2

**From:** Andrew Clements <aclements@usaid.gov>
**Sent:** Tue, 8 May 2018 23:51:50 -0700
**Subject:** Fwd: Bat Paper
**To:** William Karesh <Karesh@ecohealthalliance.org>, Jonna Mazet <jkmazet@ucdavis.edu>, "Daniel Schar (RDMA/OPH)" <dSchar@usaid.gov>, Christine Kreuder Johnson <ckjohnson@ucdavis.edu>, Kevin Olival PhD <olival@ecohealthalliance.org>, Jon Epstein <epstein@ecohealthalliance.org>, Tracey Goldstein <tgoldstein@ucdavis.edu>, "D. Phil Simon Anthony" <anthony@ecohealthalliance.org>, daszak@ecohealthalliance.org, bhbird@ucdavis.edu

FYI

*Andrew P. Clements, Ph.D.*
*Senior Scientific Advisor*
*Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health*
*U.S. Agency for International Development*
*Mobile phone: 1-571-345-4253*
*Email: aclements@usaid.gov*

Begin forwarded message:

**From:** Cara Chrisman <cchrisman@usaid.gov>
**Date:** May 8, 2018 at 6:59:54 PM GMT+2
**To:** Andrew Clements <aclements@usaid.gov>, Dennis Carroll <dcarroll@usaid.gov>
**Subject: Bat Paper**

Haven't gotten to read it yet, but looks interesting (and like Lin-Fa Wang is one of the co-authors),

A new paper shows that bat DNA carries the largest, most-diverse set of antiviral genes of any mammal. Author Joshua Hayward believes these genes stop viruses from replicating too fast and allow them to live happily inside of bats without killing them. Bats may be the first species to achieve this equilibrium: "It's a back and forth – over a long enough period of evolution, we think, that will lead to a sort of peace treaty," between virus and host.

The Sydney Morning Herald

Cara J. Chrisman, PhD
Senior Infectious Diseases Technical Advisor
Emerging Threats Division
Office of Infectious Disease
Bureau for Global Health
U.S. Agency for International Development (USAID)

Desk: (571) 551-7413
Cell: REDACTED
E-mail: cchrisman@usaid.gov

**From:** Andrew Clements <aclements@usaid.gov>
**To:** William Karesh <Karesh@ecohealthalliance.org>;Jonna Mazet <jkmazet@ucdavis.edu>
**Sent:** 5/12/2018 12:50:25 AM
**Subject:** Campagne Nationale de Deratisation et de Desinsectisation dans les Districts de Toamasina 1, Ankazoube, Faratsio et Ambalavao

Hi Billy and Jonna,

The Mission in Madagascar has??shared the updated rat control plan (attached). GOM and WHO are seeking support such as experts for training. ????

They are also asking if EcoHealth Alliance can review and comment on this document (in French) and/or provide a french speaking rat control expert for this training in country (June).

Andrew

*Andrew P. Clements, Ph.D.*
*Senior Scientific Advisor*
*Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health*
*U.S. Agency for International Development*
*Mobile phone: 1-571-345-4253*
*Email: aclements@usaid.gov*
.??

# Campagne nationale de dératisation et de désinsectisation en prévention de prochaines flambées épidémiques de peste à Madagascar

UCDUSR0011928

# Table des matières

I. Contexte et justification ..... 1

II. Objectifs ..... 2

III. Monographie succincte de la campagne au niveau des districts prioritaires ..... 3

IV. Activités prévues ..... 4

1. Positionnement des partenaires ..... 4

2. Achat des matériels ..... 4

a. Pièges à rats ..... 4

b. Insecticides ..... 5

c. Intrants pour le monitoring ..... 5

d. Ordinateur portable ..... 5

3. Elaboration du manuel de formation et des messages de sensibilisation ..... 6

4. Reprographie ..... 6

5. Formation des agents de santé et de la communauté ..... 7

a. Atelier de formation des formateurs ..... 7

b. Formation au niveau des 4 districts ciblés ..... 7

c. Formation au niveau de la communauté ..... 7

d. Information des ménages ..... 7

6. Acheminement des intrants ..... 8

7. Mobilisation sociale des communautés ..... 9

a. Réunion de plaidoyer ..... 9

b. Mass média ..... 9

8. Campagne de distribution de pièges à rats, d'insecticides et d'outils de collecte de données ..... 10

9. Evaluation de la campagne ..... 10

10. Monitoring des activités de dératisation ..... 11

a. Suivi du nombre de rats tués : Taux de capture des rongeurs .....11
b. Suivi passif de l'activité des rongeurs au sein des ménages .....11
c. Suivi des puces au sein des ménages .....12
11. Suivi des activités sur le terrain et circuit des informations .....12
ANNEXES .....14
1. Annexe 1 : Monographie des 4 districts pilotes .....14
2. Annexe 2 : Calendrier de mise en œuvre pour la campagne de dératisation .....15
Annexe 3 : Résumé du cout pour la mise en œuvre des activités de dératisation et de désinsectisation. .....16

## I. Contexte et justification

La peste est entrée à Madagascar en 1898 à partir du port de Toamasina suite à l'escale d'un bateau venant d'Inde. En 1921, elle arrive à Antananarivo et s'étend sur les hautes terres centrales en y provoquant des épidémies sans précédent pendant près de 20 ans. Jusqu'au début des années 1980, elle a persisté à bas bruit surtout en milieu rural, avant de connaître une recrudescence au point de constituer un véritable problème de santé publique à l'heure actuelle.

La peste est une maladie endémique à Madagascar. La saison favorable à la transmission de la maladie s'étale généralement entre septembre et avril et affecte principalement les hautes terres centrales du pays, situées à plus de 800 mètres d'altitude. Depuis les 20 dernières années, Madagascar est le pays du monde rapportant l'incidence de peste la plus élevée, soit entre 200 et 400 nouveaux cas par an, essentiellement de forme bubonique. La flambée épidémique de peste de 2017 était particulière du fait de son ampleur, de son caractère urbain affectant les grandes villes du pays et de la prédominance de la forme pulmonaire.

En raison de la persistance de foyers endémiques, Madagascar a mis au point des mécanismes de lutte contre la peste, notamment en termes de surveillance, de gestion des flambées épidémiques, de diagnostic clinique et de traitement des patients. Deux documents nationaux permettent d'organiser la lutte contre la maladie à l'heure actuelle : la Politique Nationale de lutte contre la peste à Madagascar et le Programme National de Lutte contre la Peste (PNLP).

La lutte contre les vecteurs de la maladie (les puces) est la méthode préconisée par la Politique Nationale actuelle afin d'éviter la transmission de la peste à l'homme. Elle est le plus souvent organisée pendant la saison pesteuse et nécessite le piégeage et la capture des rats vivants pour permettre à des équipes spécialisées d'éliminer les puces vectrices. Toutefois, réduire la densité murine est un élément clé de la prévention de la peste et de nombreuses preuves scientifiques démontrent que la diminution de la densité murine en dessous d'un certain seuil peut stopper la transmission de la peste à l'homme.

Ainsi, bien que la capture des rats vivants soit efficace pour la surveillance vectorielle, elle n'est généralement pas efficace en termes de réduction de la population murine. Les pièges de capture de rats vivants ont généralement un taux de réussite beaucoup plus faible que les pièges à ressort en raison de comportements néophobes particulièrement observés chez le genre *Rattus*. La politique devrait donc désormais considérer l'utilisation du piégeage à ressort



UCDUSR0011931

(qui tue le rat) comme un moyen écologiquement durable et rentable afin de réduire la population murine.

Il existe différents types de pièges à ressort et les derniers modèles développées sont plus sensible, plus efficace et plus simple à mettre en place et à utiliser. Pour réduire la population murine a un niveau écologiquement acceptable, le peuple malagasy doit être mobilisé, impliqué et formé sur l'utilisation des nouveaux modèles des pièges a ressort (à 90°). Par ailleurs, l'association des pièges avec la dispersion d'insecticide tout autour de ces derniers permettra de réduire le risque de dispersion des puces libres.

Ainsi, le Ministère de la Santé Publique avec les Partenaires Techniques et Financiers prévoit de réaliser une campagne de dératisation et de désinsectisation au niveau de 31 districts endémiques afin de prévenir les flambées épidémiques de la prochaine saison pesteuse.

Cette campagne repose sur l'utilisation massive de pièges à rats à ressort (90°) combinée à un épandage d'insecticide autour du piège. Le principe de cette mesure innovatrice est de tuer le maximum de rats aves les pièges distribués au niveau des ménages et de tuer les puces vectrices avec l'insecticide. Quatre (4) districts prioritaires vont débuter la campagne à partir du mois de juin 2018. Ces districts sont : Ankazobe, Toamasina I, Faratsiho et Ambalavao.

## II. Objectifs

**Objectif général :** Réduire la densité murine dans les quatre districts prioritaires pour la lutte contre la peste

**Objectifs spécifiques :**

- ✓ Renforcer les compétences des acteurs à tous les niveaux sur la lutte anti réservoir et anti vectorielle
- ✓ Renforcer la mobilisation et l'engagement communautaire pour l'utilisation des pièges à rat et des insecticides
- ✓ Assurer l'approvisionnement en pièges à rat et insecticides auprès de 100% des ménages des districts concernés
- ✓ Assurer le suivi de la densité murine et de l'activité vectorielle dans la communauté

## III. Monographie succincte de la campagne dans les districts prioritaires

Cette campagne se déroulera dans 4 districts répartis dans 4 régions. Ces districts font partie des 31 districts ciblés par la campagne.

Ainsi, 46 communes, 554 fokontany seront concernés.

La campagne couvrira la population totale des 4 districts, soit plus de 955 000 habitants[1]. Elle impliquera également 79 CSB et 2216 agents et mobilisateurs communautaires.

**Répartition géographique des 4 districts prioritaires dans 4 régions ciblées par la campagne de dératisation et de désinsectisation**




[1] Source : Polio 2018

## IV. Activités prévues

### 1. Positionnement des partenaires

La mise en œuvre de cette activité nécessite des fonds. Une réunion de positionnement des partenaires sera prévue à cet effet.

Résultats attendus : les partenaires se positionnent sur les activités qu'ils vont appuyer

Chronogramme : au début des activités

### 2. Achat des matériels

Des achats seront effectués pour acquérir les matériels de mise en œuvre et de suivi des activités.

#### a. Pièges à rats

Le nombre de pièges à rats nécessaires pour la conduite de cette campagne a été estimé à partir de la population de la base de la campagne polio de 2018, calculée selon une moyenne de 5 personnes[2] par ménage soit au total 286,516 ménages. La dotation étant d'un piège par ménage, nous avons tenu compte d'un stock de réserve de 10%.

Il y a deux principaux fournisseurs de pièges à rats dont la conception est identique.

- Barrettine Environmental, UK – nom du piège et le nom du piège est Romaxrat trap (https://www.barrettineenv.co.uk/25/785/romax-snap-r-rat-trap). Capacité de production : 1,5 millions de pièges par mois
- Kness Manufacturing, USA dont le nom du piège est Big Snap-E rat trap (http://www.kness.com/store/pc/Big-Snap-E-Rat-Trap-2p5.htm). Capacité de production : 100 000 pièges par mois

Les commandes doivent se faire en avance car il faut tenir compte des délais de production et de transport maritime.

[2] Source : RGPH

b. Insecticides

Dans le cadre de la désinsectisation, chaque ménage sera doté de 500g d'insecticide (fénitrothion) à utiliser pendant 6 mois. L'insecticide en poudre sera répendu tout autour du piège dans un rayon de 30 cm. Le Ministère de la Santé Publique au niveau du Service de lutte contre la peste dispose encore d'un stock auquel il faudrait ajouter la quantité suffisante pour couvrir toute durée de la campagne.

c. Intrants pour le monitoring

Le matériel de monitoring est constitué de :

- carreaux en céramique blanche (20X20), à surface lisse et brillante
- bougies,
- récipients en métal peu profonds,
- savon liquide,
- papier filtre,
- marqueurs permanents à pointe fine,
- feuilles transparentes

La plupart de ces matériels peut être trouvés à Madagascar.

d. Ordinateur portable

Les 4 régions, les 4 districts et le Service de lutte contre la peste seront dotés d'un ordinateur portable pour effectuer le suivi des activités (soit 10 ordinateurs au total).

Résultats attendus : commande des intrants passés ; intrants disponibles avant la campagne prévue pour le mois de juin 2018

Chronogramme : à partir de la troisième semaine du mois de mai

Ressources mobilisées :

1. Ressources humaines : Min San, PTF
2. Ressources financières : 953,540,082 ariary soit 297,981 USD

## 3. Elaboration du manuel de formation et des messages de sensibilisation

Cette campagne de dératisation et de désinsectisation est une nouvelle stratégie et nécessite une élaboration de documents de formation et des messages de sensibilisation.

Un atelier de 5 jours sera prévu à Antananarivo incluant les techniciens du Ministère de la Santé Publique et les partenaires techniques et financiers afin de standardiser les messages d'information et de sensibilisation véhiculés pendant la campagne. Ils seront divisés en deux groupes de travail : technique et mobilisation sociale.

Les manuels de formation, les guides pour les AC, les différents outils de collecte des données, les dépliants, les affiches et les supports de médiatisation (CD audio et DVD) seront déployés à partir de cet atelier. Tous ces supports seront utiliser au cours des formations et de la distribution et mettront en exergue des messages pour informer et sensibiliser la population.

Résultats attendus : les manuels de formation, les guides pour les AC, les différents outils de collecte des données, les dépliants, les affiches et les supports de médiatisation (CD audio et DVD).

A noter que cette rubrique de formation va prendre en compte toutes les régions concernées jusqu'au niveau des districts.

Chronogramme : dernière semaine du mois de mai 2018

Ressources mobilisées :

1. Ressources humaines : 36 personnes venant du Ministère de la santé (SG, DGS, DPS, FSP, Service peste, DVSSE, IPM, FSP)
2. Ressources financières : 20 946 025 ariary soit 6 546 USD

## 4. Reprographie

Tous les documents élaborés seront multipliés avant la formation en cascade.

Résultats attendus : tous les documents sont disponibles avant la formation

Chronogramme : première semaine du mois de juin 2018

Ressources mobilisées :

1. Ressources financières : 100,974,964 ariary soit 31,555 USD

## 5. Formation des agents de santé et de la communauté

Les curricula de formation étant disponibles, une formation en cascade sera prévue.

### a. Atelier de formation des formateurs

Un pool de formateur du niveau central (30 personnes) avec 2 représentants des DRS et 2 des SSD concernés assisteront à un atelier de formation des formateurs. Il consiste à les informer sur la conduite de la campagne et les activités prévues. Cette formation se fera à Antananarivo pendant 2 jours. Un travail de groupe terminera cet atelier où chaque équipe va planifier ses activités.

Pour 3 régions : Boeny, Bongolava et Sofia, où seul 1 district est concerné, la formation des responsables des DRS, SSD et CSB s'effectuera directement dans le district.

### b. Formation au niveau des 4 districts ciblés.

Une formation de 2 jours de tous les responsables des CSB sera réalisée par les responsables du SSD et les pools centraux au niveau de chaque district. Un manuel des CSB avec les activités et les messages à passer sera distribué à ce niveau.

### c. Formation au niveau de la communauté

Une formation des distributeurs communautaires sera dispensée par les chefs CSB pendant 1 jour sur le recensement de la population, la sensibilisation au niveau des foyers, l'utilisation des pièges et des insecticides, la conservation des produits et le rapportage des données des ménages.

Il est prévu qu'il y aura 4 distributeurs pour chaque fokontany dont 2 Agents Communautaires (AC) et 2 mobilisateurs. Chaque distributeur aura le guide des AC.

### d. Information des ménages

Au cours de la campagne de distribution des pièges à rat et d'insecticide, les chefs CSB et les distributeurs communautaires informeront les ménages sur:

- Comment appâter et positionner les pièges dans un bon endroit dans leur maison ;
- Comment installer le piège tous les jours, même s'ils n'attrapent pas de rat pendant un certain temps, en déplaçant le piège à différents endroits dans leur maison, à la recherche de preuves de présence de rats tels que des matières fécales ou des trous ;

- Comment poser et dégager les pièges et s'assurer que les enfants et les poules n'y sont pas exposés ;
- Comment placer la poudre insecticide autour des pièges 30 cm autour ;
- Comment conserver les flacons de poudre insecticide dans un endroit sec et sûr et hors de portée des enfants ;
- Comment sécuriser les pièges au cas où des chats ou d'autres rats tenteraient de manger les rats morts et d'enlever le piège ;
- Comment enlever et éliminer en toute sécurité les rats capturés ;
- Comment laver en toute sécurité les pièges et les mains après avoir manipulé les pièges et les rats ;
- La nécessité de rapporter chaque jour dans l'outil conçu à cet effet le nombre de rat tué et de donner mensuellement les fiches aux distributeurs communautaires

Résultats attendus : tous les acteurs concernés par la mise en œuvre seront formés et aptes à conduire la campagne et à véhiculer les messages

Chronogramme : à partir mi-juin 2018

Ressources mobilisées :

1. Ressources humaines :
    a. FDF : pool centraux 8, 2 personnes par DRS et 2 personnes par SSD
    b. Formation des CSB : 79 CSB
    c. Formation au niveau de la communauté : 2216 agents et mobilisateurs communautaires
2. Ressources financières : 53,123,364 ariary soit 16,601 USD

## 6. Acheminement des intrants

La logistique du Ministère de la santé avec l'appui technique des PTF acheminera les intrants au niveau des 4 districts pilotes. Les chefs CSB récupèreront les intrants au niveau des districts puis les AC et les mobilisateurs sociaux distribueront les intrants au niveau des ménages.

Les chefs CSB seront motivés et dotés de frais de déplacements pour l'acheminement des intrants et équipements des districts vers les CSB. Les AC et les mobilisateurs sociaux seront motivés au cours de la distribution.

Résultats attendus : les intrants sont disponibles auprès des CSB une semaine avant la tenue de la campagne

Chronogramme : au cours du mois de juin 2018

Ressources mobilisées :

1. Ressources humaines : Min San, PTF
2. Ressources financières : 19,805,392 ariary soit 6,189 USD

## 7. Mobilisation sociale des communautés

L'implication des communautés est une des conditions de réussite de la campagne en effet, sa mise à contribution est un gage de la pérennisation de cette activité de lutte. Vu l'envergure des régions et des districts concernés, il est prévu de réaliser une mobilisation au niveau des régions, des districts et de la communauté.

### a. Réunion de plaidoyer

Avant les formations des chefs CSB, il sera réalisé au niveau de chaque chef-lieu de district des séances de plaidoyer réunissant les autorités compétentes multisectorielles (50 personnes) qui seront présidées par le responsable du SSD, les responsables des DRS et les pools centraux.

Une réunion communale au niveau de chaque CSB avec les autorités compétentes multisectorielles (50 personnes) sera prévue.

A l'issu de cette réunion, les chefs fokontany avec les AC, sous la supervision des chefs CSB effectueront le dénombrement des chefs de ménage. Un numéro sera attribué à chaque ménage et chaque chef de ménage sera répertorié dans l'outil développé à cet effet.

Enfin, le dénombrement sera effectué 2 semaines avant la campagne de distribution.

### b. Mass média

Des messages et des spots seront diffusés à la télévision et au niveau des stations de radio régionales et locales deux semaines avant le début de la campagne.

Une conférence de presse des entités responsables (MSanP, OMS et autres PTF) sera programmée pour une diffusion d'informations sur les activités.

Résultats attendus : implication à tous les niveaux, activités de sensibilisation seront attribués aux autorités compétentes à tous les niveaux, aux mobilisateurs communautaires et aux journalistes

Chronogramme : une à deux semaines avant la réalisation de la campagne

Ressources mobilisées :

1. Ressources humaines : Ministère de la santé (central, DRS, SSD et CSB), ministères décentralisés, partenaires techniques et financiers à tous les niveaux, journalistes
2. Ressources financières : 23,150,000 ariary soit 7,234 USD

## 8. Campagne de distribution de pièges à rats, d'insecticides et d'outils de collecte de données

Un piège à rat accompagné de 500 g d'insecticides et une fiche de renseignements sur le nombre de rats tués seront distribués à chaque ménage par 2 AC et 2 mobilisateurs par fokontany au niveau des 4 districts. La campagne de distribution se déroulera pendant 7 jours. Les communautés seront approvisionnées au fur et à mesure en cas de dommages ou de perte des pièges. Toutefois lors des campagnes de sensibilisation et de formation, les ménages seront avisés de bien gérer et d'utiliser dans les normes leurs pièges et les insecticides selon les recommandations et les instructions.

Résultats attendus : 100% des foyers auront des pièges à rat et des insecticides

Chronogramme : fin juin 2018

Ressources mobilisées :

1. Ressources humaines : chefs CSB, AC et mobilisateurs
2. Ressources financières : 163,415,000 ariary soit 51,067 USD

## 9. Evaluation de la campagne

Cette activité permettra de calculer les différents indicateurs dont les plus importants sont:

- Couverture rapportée par les distributeurs

- Couverture observée au cours de l'enquête
- Quantité de pièges utilisée et restante

Résultats attendus : indicateurs disponibles

Chronogramme : en post campagne vers début juillet 2018

Ressources mobilisées :

1. Ressources humaines : chefs CSB, AC et mobilisateurs
2. Ressources financières : NA

## 10. Monitoring des activités de dératisation

Un mois après le début de la campagne de dératisation et de désinsectisation, il sera mené des activités de suivi au niveau de la communauté. Elles concerneront le :

### a. Suivi du nombre de rats tués : Taux de capture des rongeurs

Une fiche de renseignement sera mise à la disposition de chaque ménage ayant déjà bénéficié d'une information sur le remplissage, lors de la distribution des pièges. Les données des fiches seront collectées tous les mois par les agents communautaires (AC) et les mobilisateurs sociaux puis remises aux chefs CSB pour compilation et archivage.

### b. Suivi passif de l'activité des rongeurs au sein des ménages

Pour chaque centre de santé, 3 fokontany (qui représentent 10% des fokontany par district) seront sélectionnés chaque mois par tirage au sort. Dans chaque fokontany tiré au sort, 10 ménages seront tirés au sort pour effectuer le suivi de l'activité murine. Ce suivi est effectué grâce à l'utilisation de carreaux blancs.

Les carreaux sont maintenus près de la flamme de la lampe à huile jusqu'à ce que toute la surface soit noircie. Les deux carreaux sont placés dans chaque maison dans un endroit où une activité murine est suspectée. Le matin, les carreaux sont collectés et le nombre de cellules comportant des empreintes ou des marques de queue de rats sont enregistrées. D'autres marques peuvent appartenir à des insectes et des poulets, mais celles-ci sont généralement facilement différenciables des empreintes de rats. Seul le marquage évident des rongeurs doit être enregistré. Après l'enregistrement, les carreaux sont nettoyés avec un chiffon, renoircis et

remis dans la même position. Ceci est répété pendant trois nuits consécutives.1 AC par fokontany sera chargé de ce suivi.

c. Suivi des puces au sein des ménages

Afin d'apprécier le risque vectoriel, 10 autres ménages seront tirés au sort dans les mêmes fokontany précédemment sélectionnés.

Dans la soirée, les bougies sont allumées et fixées au centre d'un récipient peu profond. Le récipient est placé au centre de la pièce (chambre à coucher ou espace commun). Le récipient est rempli à moitié avec de l'eau puis une goutte de savon est ajoutée. La bougie doit rester allumée toute la nuit ou jusqu'à ce qu'elle soit consumée. Le matin, les puces sont recueillies dans l'eau. S'il n'y a pas beaucoup de puces, elles peuvent être soulevées directement de l'eau à l'aide d'un petit pinceau. S'il y a beaucoup de puces, l'eau peut être soigneusement versée à travers un papier filtre. Le nombre de puces par ménage sera collecté pendant trois jours par un AC au cours de cette activité de suivi.

Résultats attendus : indicateurs de suivi disponibles

Chronogramme : fin juillet à fin septembre 2018

Ressources mobilisées :

1. Ressources humaines : chefs CSB, AC et mobilisateurs
2. Ressources financières : 291,856,000 ariary soit 91,205 USD

## 11. Suivi des activités sur le terrain et circuit des informations

Une réunion devrait être organisée avec la communauté pour discuter des problèmes par rapport aux activités mais aussi pour recueillir les preuves de l'impact des interventions. Ce type de réunions devrait se tenir au moins tous les deux mois. Ces réunions surveilleront les quantités d'insecticide utilisées par les ménages (consommation des ménages en insecticides) et s'assureront également que ces derniers sont utilisés conformément aux recommandations dispensées. L'équipe devrait être en mesure de former à nouveau les communautés sur les procédures d'installation des pièges, de remplacer les pièges cassés, de réapprovisionner les ménages en poudre insecticide si elle est épuisée. Les équipes devront consigner tous les remplacements de pièges ainsi que tous les réapprovisionnements en poudre insecticide.

Les données collectées par les AC et les mobilisateurs seront transmises au niveau des CSB. Les CSB enverront ces données au SSD après compilation, puis les SSD partageront à leur tour les données avec le Service de lutte contre la peste.

Résultats attendus : complétudes et promptitudes des données au niveau du service de lutte contre la peste

Chronogramme : mi-juillet à fin septembre 2018

Ressources mobilisées :

1. Ressources humaines : AC, mobilisateurs, CSB, SSD et service de lutte contre la peste
2. Ressources financières : NA

## ANNEXES

### 1. Annexe 1 : Monographie des 4 districts pilotes

| Région | District | Nbre de CSB | Population totale année 2017 | Nbre de ménages | Nbre de Fkt |
|---|---|---|---|---|---|
| ANALAMANGA | ANKAZOBE | 24 | 169,286 | 50,786 | 146 |
| ATSINANANA | TOAMASINA I | 8 | 300,958 | 90,287 | 142 |
| HAUTE MATSIATRA | AMBALAVAO | 28 | 245,605 | 73,681 | 165 |
| VAKINANKARATRA | FARATSIHO | 19 | 239,205 | 71,762 | 101 |

## 2. Annexe 2 : Chronogramme de mise en œuvre pour la campagne de dératisation



**Annexe 3 : Résumé du coût pour la mise en œuvre des activités de dératisation et de désinsectisation.**

| Rubriques | Total (Ar) | Total USD |
|---|---|---|
| Atelier d'élaboration du curriculum de formation et des outils de gestion | 20,946,035 | 6,546 |
| Formation Du Pool De Formateurs | 46,509,330 | 14,534 |
| Formation De CSB | 27,639,364 | 8,637 |
| Formation Des Ac Et Mobilisateurs | 25,484,000 | 7,964 |
| Reprographie | 100,974,964 | 31,555 |
| Achat materiels | 953,540,082 | 297,981 |
| Mobilisation sociale | 23,150,000 | 7,234 |
| Campagne de distribution | 163,415,000 | 51,067 |
| Suivi | 291,856,000 | 91,205 |
| Récupération des intrants du district vers les CSB | 15,544,400 | 4,858 |
| Acheminement des intrants de Tana vers les 4 districts | 4,260,992 | 1,332 |
| **Total** | **1,673,320,168** | **522,913** |

**From:** Andrew Clements <aclements@usaid.gov>
**To:** William B. Karesh <karesh@ecohealthalliance.org>
**CC:** Jonna Mazet <jkmazet@ucdavis.edu>
**Sent:** 5/12/2018 9:14:10 AM
**Subject:** Re: Campagne Nationale de Deratisation et de Desinsectisation dans les Districts de Toamasina 1, Ankazoube, Faratsio et Ambalavao

Thanks, Billy. No need to respond until Monday.

*Andrew P. Clements, Ph.D.*
*Senior Scientific Advisor*
*Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health*
*U.S. Agency for International Development*
*Mobile phone: 1-571-345-4253*
*Email: aclements@usaid.gov*

On May 12, 2018, at 5:11 PM, William B. Karesh <karesh@ecohealthalliance.org> wrote:

Happy to ask Anne and maybe also Alice (both French speaking rodent ecologists) to review. Anne did the previous review and we had many reservations about the proposal.

I'm not sure they would be the best people as trainers for pest control. But, let me look at the document over the next few days and see what type of expertise they are looking for. (If it's purely pest control, I wonder if Jonna might have colleagues over in the Ag school at Davis that train people in integrated pest management, etc.)

BK

**William B. Karesh, D.V.M**
*Executive Vice President for Health and Policy*

EcoHealth Alliance
460 West 34th Street - 17th Floor
New York, NY 10001 USA

+1.212.380.4463 (direct)
+1.212.380.4465 (fax)
www.ecohealthalliance.org

President, OIE Working Group on Wildlife

Co-chair, IUCN Species Survival Commission - Wildlife Health Specialist Group

EPT Partners Liaison, USAID Emerging Pandemic Threats - PREDICT-2 Program

***EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that promote conservation and prevent pandemics.***

On May 12, 2018, at 3:50 AM, Andrew Clements <aclements@usaid.gov> wrote:

Hi Billy and Jonna,

The Mission in Madagascar has shared the updated rat control plan (attached). GOM and WHO are seeking support such as experts for training.

They are also asking if EcoHealth Alliance can review and comment on this document (in French) and/or provide a french speaking rat control expert for this training in country (June).

Andrew

*Andrew P. Clements, Ph.D.*
*Senior Scientific Advisor*
*Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health*
*U.S. Agency for International Development*
*Mobile phone: 1-571-345-4253*
*Email: aclements@usaid.gov*

.

**From:** Cara Chrisman <cchrisman@usaid.gov>
**Sent:** Wed, 16 May 2018 09:06:16 -0400
**Subject:** For Discussion Thurs: SC Mtg Agenda
**To:** Jonna Mazet <jkmazet@ucdavis.edu>, [redacted] Peter Daszak <daszak@ecohealthalliance.org>, Brooke Watson <watson@ecohealthalliance.org>, Eddy Rubin <erubin@metabiota.com>, Nathan Wolfe <nwolfe@metabiota.com>
**Cc:** Dennis Carroll <dcarroll@usaid.gov>, Andrew Clements <aclements@usaid.gov>
Draft SC Mtg Agenda DC 6.11.18 (1).docx

Hi Team,
Based on the RSVP list, we've been considering some updates to the Steering Committee mtg plans and have drafted an updated agenda to reflect that (attached and here).

Given the limited in-person attendees, the proposal is to instead limit the meeting to 3.5 hours and start at 9 am. The attendees will be mailed printouts of the documents next week for review in advance so that we can maximize the time during the meeting.

Looking forward to discussing this tomorrow!

Best,
Cara

Cara J. Chrisman, PhD
Senior Infectious Diseases Technical Advisor
Emerging Threats Division
Office of Infectious Disease
Bureau for Global Health
U.S. Agency for International Development (USAID)

Desk: (571) 551-7413
[redacted]
E-mail: cchrisman@usaid.gov

# Global Virome Project
# Steering Committee Meeting

June 11th, 2018, 10:00 am – 4:00 pm
Venue: National Academies Keck Center, Washington DC

## Meeting Objectives

1. X
2. Y
3. Z

## Agenda

| Time | Agenda Item | Presenters/Facilitators |
|---|---|---|
| 8:30 – 9:00 | Arrival & Registration | All Participants |
| 9:00 – 9:15 | Introduction<br>• Welcoming Remarks<br>• Introductions<br>• Rules of Order | TBD |
| 9:15 – 10:00 | Go Forward Vision | TBD |
| 10:00 – 10:45 | Towards a Governance Ecosystem | TBD |
| 10:45 – 11:15 | Establishing a Legal "Home" | TBD |
| 11:15 – 11:45 | Incubation Period Budget | All Participants |
| 11:45 – 12:15 | Global Outreach: Year One | TBD |
| 12:15 – 12:30 | Closing Remarks<br>• Summary of Decisions<br>• Next Steps | TBD |
| | | |
| | | |

**From:** Brooke Watson <watson@ecohealthalliance.org>
**Sent:** Thu, 17 May 2018 14:16:35 -0400
**Subject:** Re: Response needed by May 8: GVP meeting June 11
**To:** "Morzaria, Subhash (TCE)" <Subhash.Morzaria@fao.org>
**Cc:** Jonna Mazet <jkmazet@ucdavis.edu>, Katherine Leasure <kaleasure@ucdavis.edu>, REDACTED <REDACTED>, Cara Chrisman <cchrisman@usaid.gov>

Hi Subhash,
Great! Looking forward to seeing you.

Do you know yet whether you will need travel support. Katie Leasure (cc'd) is putting together International Travel Assistance requests, and will need your departure city if so. Please let us know at your earliest convenience.

Thank you!

Best,

Brooke

On Fri, May 4, 2018 at 10:34 AM, Morzaria, Subhash (TCE) <Subhash.Morzaria@fao.org> wrote:

> Dear Brooke,
>
> This is to confirm that I will be able to attend. I will let you know soonest if I will need support for travel.
>
> With best regards,
>
> Subhash

**From:** Brooke Watson [mailto:watson@ecohealthalliance.org]
**Sent:** Friday, May 04, 2018 4:31 PM
**To:** Jonna Mazet <jkmazet@ucdavis.edu>; Katherine Leasure <kaleasure@ucdavis.edu>; REDACTED <REDACTED>; Cara Chrisman <cchrisman@usaid.gov>
**Subject:** Response needed by May 8: GVP meeting June 11

Dear GVP Steering Committee colleagues,

In order to secure approval for international travel and confirm support if it is needed to facilitate travel arrangements for our meeting on Monday, June 11 in Washington, it is important to know which of you will be in attendance. We know that some of you will be in town for the National Academies workshop on June 12 and 13, but for others, will you **please respond to Jonna, Eri, Katie and myself (all cc'd) by 5 PM EST next Tuesday, May 8,** indicating**:**

1. Whether you will be able to attend the meeting on June 11 in person in Washington. DC
2. If not, whether you will be able to call in for all or some of the meeting from 10 AM - 4 PM EDT
3. If there are any caveats to your attendance (e.g., you can only attend after 12 PM EDT)
4. If you will need any support for your travel to Washington DC

If we do not receive your response by May 8, we will assume that you will not be joining in person.

Many thanks for your quick responses, and please don't hesitate to ask if you have any questions. A full agenda is forthcoming, but we want to ensure that the logistics teams have a full attendee list well in advance so we can move forward with preparations.

Best,

Brooke Watson

--

**Brooke Watson, MSc**
*Research Scientist*

EcoHealth Alliance
460 West 34th Street – 17th floor
New York, NY 10001

1.212.380.4497 (direct)
REDACTED (mobile)
1.212.380.4465 (fax)
www.ecohealthalliance.org

***EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that promote conservation and prevent pandemics.***

--

**Brooke Watson, MSc**
*Research Scientist*

EcoHealth Alliance
460 West 34th Street – 17th floor
New York, NY 10001

1.212.380.4497 (direct)
REDACTED (mobile)
1.212.380.4465 (fax)
www.ecohealthalliance.org

***EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that promote conservation and prevent pandemics.***

**From:** Dennis Carroll <dcarroll@usaid.gov>
**Sent:** Thu, 17 May 2018 19:25:20 -0400
**Subject:** Re: [gvp] Form Submission - New Form - Daily Telegraph article - virus hunting
**To:** [redacted]
**Cc:** Jonna Mazet <jkmazet@ucdavis.edu>, Cara Chrisman <cchrisman@usaid.gov>, Brooke Watson <watson@ecohealthalliance.org>, Peter Daszak <daszak@ecohealthalliance.org>, Eddy Rubin <erubin@metabiota.com>, Nathan Wolfe <nwolfe@metabiota.com>

I'm available. Thanks

Sent from my iPhone

On May 17, 2018, at 5:53 PM, [redacted] wrote:

> Hi everyone,
>
> Please see an interview request from the Telegraph, below. Would anybody be willing to speak with the reporter? FYI, he has reached out to PREDICT as well.
>
> Thanks,
> [redacted]
>
> **From:** gvp-request@ucdavis.edu [mailto:gvp-request@ucdavis.edu] **On Behalf Of** Squarespace
> **Sent:** Thursday, May 17, 2018 5:05 AM
> **To:** gvp@ucdavis.edu
> **Subject:** [gvp] Form Submission - New Form - Daily Telegraph article - virus hunting
>
> **Name:** Joe Shute
>
> **Email Address:** joe.shute@telegraph.co.uk
>
> **Subject:** Daily Telegraph article - virus hunting
>
> **Message:** Hello I'm Joe Shute, a feature writer on the Telegraph. I am getting in touch about a potential feature I am writing for our Saturday magazine. It is about the work being done to detect and predict viruses all over the world and would be a big high profile 3,000wd piece. Obviously I would love to include some of the work of the Global Virome Project in there and hopefully travel out to visit some of your teams in the field. Would somebody be able to contact me to discuss further please? joe.shute@telegraph.co.uk and 00447773380323
>
> Thanks
> Joe
>
> (Sent via *Global Virome Project*)

**From:** Elizabeth Leasure <ealeasure@UCDAVIS.EDU>
**To:** Peter Daszak <daszak@ecohealthalliance.org>
**Cc:** Molly Turner <turner@ecohealthalliance.org>, Jonathon Musser <musser@ecohealthalliance.org>, Evelyn Luciano <luciano@ecohealthalliance.org>, Jonna Mazet <jkmazet@ucdavis.edu>, "predict@ucdavis.edu" <predict@ucdavis.edu>, Hannah R Chale <hrchale@UCDAVIS.EDU>
**Subject:** Reduced spending clarification (PREDICT)
**Sent:** Fri, 18 May 2018 22:38:02 +0000

Hi Peter. After completing the Y4Q2 expenditure by country/category report for Andrew and comparing the figures to the previous quarter's report, we found that the total expenditures for two of your countries were less than the previous quarter (see below). Can you please provide a brief explanation for the reduction given our need to maintain or increase spending levels?

- CDI dropped $30K

- Thailand dropped by $170K

Thank you,
Liz

*Elizabeth Leasure*
*Financial Operations Manager*
*One Health Institute*
REDACTED *(cell)*
*530-754-9034 (office)*
*Skype: ealeasure*

**From:** Peter Daszak <daszak@ecohealthalliance.org>
**To:** Elizabeth Leasure <ealeasure@UCDAVIS.EDU>
**Cc:** Molly Turner <turner@ecohealthalliance.org>, Jonathon Musser <musser@ecohealthalliance.org>, Evelyn Luciano <luciano@ecohealthalliance.org>, Jonna Mazet <jkmazet@ucdavis.edu>, "predict@ucdavis.edu" <predict@ucdavis.edu>, Hannah R Chale <hrchale@UCDAVIS.EDU>, Aleksei Chmura <chmura@ecohealthalliance.org>, "Alison Andre" <andre@ecohealthalliance.org>
**Subject:** Re: Reduced spending clarification (PREDICT)
**Sent:** Tue, 22 May 2018 20:50:34 +0000

Hi Liz,
The reason for Côte d'Ivoire's decrease in expenditures between Q1 and Q2 is because we stopped paying Anne as a consultant; she is now part of EHA global salaries. We also had a lot of travel to CDI in Q1. Both of our partners there (IPCI and LANADA) are now billing us regularly and are on track to spend their Year 4 contract amounts. There will be a significant uptick in CDI spending next month as expenses from the recent lab training there hit the books; Anne has also recently placed several large supply orders for the sampling trip currently in progress. That said, we will be expending those funds rapidly.

In Thailand and six-months into our Year 4, Chulalongkorn is over 50% spent on their Year 4 contract. Q1 saw a higher burn rate as Chulalongkorn rolled over some Year 3 funds into Year 4. This means that we will end up at the end of Year 4 having spent the full budget.

I hope this is helpful.

Cheers,

Peter

**Peter Daszak**
*President*

EcoHealth Alliance
460 West 34th Street – 17th Floor
New York, NY 10001

Tel. +1 212-380-4474
www.ecohealthalliance.org
@PeterDaszak
@EcoHealthNYC

*EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that prevent pandemics and promote conservation.*

---

**From:** Elizabeth Leasure <ealeasure@UCDAVIS.EDU>
**Sent:** Friday, May 18, 2018 6:38 PM
**To:** Peter Daszak
**Cc:** Molly Turner; Jonathon Musser; Evelyn Luciano; Jonna Mazet; predict@ucdavis.edu; Hannah R Chale
**Subject:** Reduced spending clarification (PREDICT)

Hi Peter. After completing the Y4Q2 expenditure by country/category report for Andrew and comparing the figures to the previous quarter's report, we found that the total expenditures for two of your countries were less than the previous quarter (see below). Can you please provide a brief explanation for the reduction given our need to maintain or increase spending levels?

- CDI dropped $30K
- Thailand dropped by $170K

Thank you,
Liz

*Elizabeth Leasure*

*Financial Operations Manager*
*One Health Institute*
REDACTED *(cell)*
*530-754-9034 (office)*
*Skype: ealeasure*

**From:** "William B. Karesh" <karesh@ecohealthalliance.org>
**To:** David J Wolking <djwolking@ucdavis.edu>
**Cc:** "Prof. Woutrina Smith" <wasmith@ucdavis.edu>, Bridgette Phebean Smith <brpsmith@ucdavis.edu>, "predict@ucdavis.edu" <predict@ucdavis.edu>, Catherine Machalaba <machalaba@ecohealthalliance.org>
**Sent:** Wed, 23 May 2018 20:35:45 +0000
**Subject:** Re: [predict] Fwd: Re: SEAOHUN Fellowship Applications for PREDICT-2 Vietnam/WCS's consideration

Thanks David.

Sent from my iPhone
**William B. Karesh, D.V.M**
*Executive Vice President for Health and Policy*

EcoHealth Alliance
460 West 34th Street - 17th Floor
New York, NY 10001 USA

+1.212.380.4463 (direct)
+1.212.380.4465 (fax)
www.ecohealthalliance.org

President, OIE Working Group on Wildlife

Co-chair, IUCN Species Survival Commission - Wildlife Health Specialist Group

EPT Partners Liaison, USAID Emerging Pandemic Threats - PREDICT-2 Program

***EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that promote conservation and prevent pandemics.***

On May 23, 2018, at 2:43 PM, David J Wolking <djwolking@ucdavis.edu> wrote:

> Hey there,
> Just FYI that we have a OHW collaborative success in Viet Nam (Amanda's team just matched with a SEAOHUN fellow). Worth tracking for capacity team and for EPT-2 partner collaborations?

David

---------- Forwarded message ----------
From: **Amanda Fine** <REDACTED>
Date: Wed, May 23, 2018 at 12:03 AM
Subject: [predict] Fwd: Re: SEAOHUN Fellowship Applications for PREDICT-2 Vietnam/WCS's consideration
To: "predict@ucdavis.edu" <PREDICT@ucdavis.edu>
Cc: Sarah Olson <REDACTED>, "Churchill, Carolina" <REDACTED>

Hello David,

Reporting in to PREDICT that we have "matched" with a SEAOHUN fellow. Please forward to whoever you think needs to be updated. I will send more details once the scheduled time for the PREDICT-2/WCS Viet Nam fellowship is confirmed.

Cheers,

Amanda

-------- Forwarded Message --------

**Subject:** Re: SEAOHUN Fellowship Applications for PREDICT-2 Vietnam/WCS's consideration
**Date:** Wed, 23 May 2018 13:34:27 +0700
**From:** Jutamart Jattuchai <jutamart@seaohun.org>
**To:** Amanda Fine [redacted]
**CC:** Thuy Hoang <[redacted]>, Long Nguyen <[redacted]>, Vipat Kuruchittham <vipat@seaohun.org>, Ratsuda Poolsuk <ratsuda@seaohun.org>, Nguyen Nga <[redacted]>

Dear Amanda,

According to your kind advice, we would like to confirm that Ari Bagus, Prasetya, from Indonesia, has been selected as SEAOHUN fellow with PREDICT-2/WCS Viet Nam. We will confirm with the successful candidate and get them introduced/ connected with you soon, so that you can further discuss with her on the fellowship duration and schedule.

Thank you and best regards,
May

Jutamart Jattuchai (May), DVM
Program Officer
Southeast Asia One Health University Network
jutamart@seaohun.org
Office: +6653 948105
Mobile: [redacted]
Skype: jjutamart

On Thu, May 17, 2018 at 9:18 AM, Jutamart Jattuchai <jutamart@seaohun.org> wrote:

> Dear Amanda,
> Thank you very much for your kind advice on the top two candidates for fellowship with PREDICT-2 Vietnam and well noted for the preference/ availability. We will keep you updated on the final result and the upcoming process soon.
>
> Thank you and best regards,
> May
>
> Jutamart Jattuchai (May), DVM
> Program Officer
> Southeast Asia One Health University Network
> jutamart@seaohun.org
> Office: +6653 948105
> Mobile: [redacted]
> Skype: jjutamart

On Wed, May 16, 2018 at 6:28 PM, Amanda Fine <[redacted]> wrote:

> Dear May,
>
> We have reviewed the materials from the applicants you provided and have ranked the following two individuals as the number 1 and number 2 candidates for a placement with PREDICT-2/WCS Viet Nam. We are confident that PREDICT-2 will be a good placement for the number 1 candidate given his background and interests. We are less confident that our number 2 candidate would be fully satisfied by a placement with PREDICT-2 as she seems quite advanced in her career already. If she is matched with us we would want to make sure that she would be

interested in working on the behavioral risk surveillance components of our project. Just to clarify, we can only host one fellow in this round.

Our top choices:

1) Ari Bagus, Prasetya, from Indonesia

2) Sabreena, Safuan, from Malaysia

Thank you. Let us know if you have any further questions at this time.

Kind Regards,

Amanda

On 5/10/18 5:33 AM, Jutamart Jattuchai wrote:

> Dear Amanda and team,
>
> Thank you for your patience with the fellowship process. We are now pleased to update that there are 14 applicants who apply for PREDICT-2 Vietnam/WCS as their first and second choices of preference for the fellowship host organization. With this email, kindly find attached the list of all applicants and their full profile which can be accessed at https://drive.google.com/drive/folders/1ZumnZ7wYayTsqt_JE7wlCrYcCuGjKAQr?usp=sharing. The applicants are ranked according to the consideration of SEAOHUN Fellowship Screening Committee based on criterion of technical knowledge/ relevant experience/interest and motivation. Should you have any questions or problems opening the file/ link, please feel free to reach us.
>
> Kindly advise based on your organization's criterion/ preference and confirm the names of your top two potential candidates by Wednesday 16 May 2017. We very much appreciate your kind support.
>
> Thank you and best regards,
> May
>
> Jutamart Jattuchai (May), DVM
> Program Officer
> Southeast Asia One Health University Network
> jutamart@seaohun.org
> Office: +6653 948105
> Mobile: REDACTED
> Skype: jjutamart

Click here to report this email as spam.

--
Amanda E. Fine, VMD, PhD
Wildlife Health Program Associate Director - Asia
Wildlife Conservation Society (WCS)
A: No. 106, Building D, 3 Thanh Cong Street, Ba Dinh District,

Hanoi, Viet Nam
T: +84 435.149.750 ext: 23 | F: +84 435.190.383
M: [redacted]

**From:** Ryland Marbray <rmarbray@usaid.gov>
**Sent:** Thu, 24 May 2018 15:42:42 -0400
**Subject:** Re: PREDICT-2 ATF approval request for WCS payments to National Laboratories
**To:** Elizabeth Leasure <ealeasure@ucdavis.edu>
**Cc:** Andrew Clements <aclements@usaid.gov>, "predict@ucdavis.edu" <predict@ucdavis.edu>, Jonna Mazet <jkmazet@ucdavis.edu>, David John Wolking <djwolking@ucdavis.edu>, Alisa Pereira <apereira@usaid.gov>

Hi Elizabeth:

Here are my thoughts.

According to 2 CFR 200.308 "Revision of Budget and Program Plans", ADS 303.3.21, the prior approval for the sub-award was required. These two governmental organizations (in Vietnam and Mongolia) are sub-sub recipients under this award, however, the prior AO approval was still required. For this retroactive approval, the technical office should submit the following documents:

- Sole source justification for the selection of these organizations;

- Formal request from WCS for the approval

- Action Memo signed by the Head of Technical Office approving the retroactive action

- Sub-recipient agreements and the budget

- AOR Checklist

- AOR Concurrence and request for approval

- Signed D&F may be required and I'm currently verifying (Not sure but given that these are governmental organizations and with reference to ADS 303.3.21 this is a requirement)

Thanks

Ryland

On Wed, May 9, 2018 at 8:02 PM, Elizabeth Leasure <ealeasure@ucdavis.edu> wrote:

> Hi Ryland. Just following up regarding my email below. Please let me know if you need any additional information from me to proceed with processing this request.
>
> Thanks!
>
> Liz
>
> *Elizabeth Leasure*
>
> *Financial Operations Manager*
>
> *One Health Institute*
>
> REDACTED *(cell)*

*530-754-9034 (office)*

*Skype: ealeasure*

---

**From:** predict-request@ucdavis.edu [mailto:predict-request@ucdavis.edu] **On Behalf Of** Elizabeth Leasure
**Sent:** Thursday, March 29, 2018 11:50 AM
**To:** Ryland Marbray; Andrew Clements
**Cc:** predict@ucdavis.edu; Jonna Mazet; David John Wolking; Alisa Pereira
**Subject:** [predict] PREDICT-2 ATF approval request for WCS payments to National Laboratories

Hi Ryland and Andrew. By way of this email, we are requesting after-the-fact approval for costs incurred by our subrecipient, Wildlife Conservation Society (WCS). In the course of executing their role as primary implementing partner for PREDICT-2 activities in Mongolia and Viet Nam, WCS paid **$70,328.11** to national laboratories (including Viet Nam National University of Agriculture, Regional Animal Health Office No. 6 in Viet Nam, and State Central Veterinary Laboratory in Mongolia) for PREDICT sample testing services. While the services procured are necessary for completion of project objectives in Viet Nam and Mongolia and are otherwise allowable, allocable, and reasonable, prior approval to establish new subcontracts with these foreign governmental entities was not obtained in advance of initial payments being made. As such, we are now seeking AO approval to use available PREDICT-2 funds already obligated to cover these costs, as these labs are the most appropriate contractors in these countries. Details regarding the facts and circumstances of these expenditures are included below.

We became aware of this issue during the intensive budgeting process required for the PREDICT cooperative agreement ceiling increase when certain comments made by a WCS staff member caused us to solicit further details above and beyond normal subrecipient monitoring required for federal compliance and our own extended best practices. Once we became aware of the payments made, we instructed WCS that they may no longer invoice UC Davis for reimbursement of costs associated with services provided by the laboratories in question until USAID approval was obtained. We also notified you both by email on 10/17/2017 and requested further guidance regarding how best to address and resolve this issue. To date, no such guidance has been received, so we are suggesting and requesting retroactive approval of these costs as the best course of action to satisfactorily remedy the situation. Now that contracts with the laboratories in question have been approved, only these outstanding costs are pending resolution.

Upon review, it appears that the WCS analyst responsible (who is no longer employed by WCS) believed that fee-for-service activities were exempt from AO review/prior approval requirements and that AOR approval of the annual program budget constituted approval of all costs identified in that budget, which is not the case. Unfortunately, this misunderstanding occurred despite many discussions regarding prior approval requirements and our continual stressing that we (as prime) should be made aware in advance of all new subcontracts and subawards (especially those involving foreign governmental entities and parastatals) in order to ensure the necessary approvals were obtained. We do not believe WCS intended to circumvent USAID prior approval requirements, nor do we believe their actions are the result of gross negligence but rather the result of a misinformed former employee.

Given the circumstances described above, we believe it is in the best interest of the project for these costs to be approved. If you require any additional information, please let me know. Thank you for your continued efforts on behalf of PREDICT-2 and your consideration of this request.

Sincerely,

Liz

*Elizabeth Leasure*

*Financial Operations Manager*

*One Health Institute*

REDACTED *(cell)*

*530-754-9034 (office)*

*Skype: ealeasure*

--

Ryland Marbray
Agreements/Contracting Officer

**USAID** Office of Acquisition & Assistance
M/OAA/E3
1300 Pennsylvania Ave., NW,
Rm. 567-B, SA-44
Washington, DC 20523

Phone: (202) 567-5328|rmarbray@usaid.gov

**From:** Elizabeth Leasure <ealeasure@UCDAVIS.EDU>
**To:** Peter Daszak <daszak@ecohealthalliance.org>
**Cc:** Molly Turner <turner@ecohealthalliance.org>, Jonathon Musser <musser@ecohealthalliance.org>, Evelyn Luciano <luciano@ecohealthalliance.org>, Jonna Mazet <jkmazet@ucdavis.edu>, "predict@ucdavis.edu" <predict@ucdavis.edu>, Hannah R Chale <hrchale@UCDAVIS.EDU>, Aleksei Chmura <chmura@ecohealthalliance.org>, "Alison Andre" <andre@ecohealthalliance.org>
**Subject:** RE: Reduced spending clarification (PREDICT)
**Sent:** Sat, 2 Jun 2018 07:42:15 +0000

Hi Peter. Thanks for the context. I did see the CDI expenditures increase in the April invoice, which is great. For Anne's salary/benefits costs, those should be reported as a CDI specific expense (at least in part) to reflect her country-specific efforts, as that is how those costs were budgeted. The same holds true for other countries, as well. For example, a portion of Ava's and Jon's effort should be reported as India-specific per the approved Year 4 budget. Based on invoices received so far this year, I don't think these amounts have been reported as country-specific costs. If Molly and Jonathon could take a look at that and make the necessary corrections in the May invoicing/reporting, that would be great.

Molly/Jonathon-
Let me know if you have any questions.

Thanks,
Liz

*Elizabeth Leasure*
*Financial Operations Manager*
*One Health Institute*
REDACTED *(cell)*
*530-754-9034 (office)*
*Skype: ealeasure*

---

**From:** Peter Daszak <daszak@ecohealthalliance.org>
**Sent:** Tuesday, May 22, 2018 1:51 PM
**To:** Elizabeth Leasure <ealeasure@UCDAVIS.EDU>
**Cc:** Molly Turner <turner@ecohealthalliance.org>; Jonathon Musser <musser@ecohealthalliance.org>; Evelyn Luciano <luciano@ecohealthalliance.org>; Jonna Mazet <jkmazet@ucdavis.edu>; predict@ucdavis.edu; Hannah R Chale <hrchale@UCDAVIS.EDU>; Aleksei Chmura <chmura@ecohealthalliance.org>; Alison Andre <andre@ecohealthalliance.org>
**Subject:** Re: Reduced spending clarification (PREDICT)

Hi Liz,

The reason for Côte d'Ivoire's decrease in expenditures between Q1 and Q2 is because we stopped paying Anne as a consultant; she is now part of EHA global salaries. We also had a lot of travel to CDI in Q1. Both of our partners there (IPCI and LANADA) are now billing us regularly and are on track to spend their Year 4 contract amounts. There will be a significant uptick in CDI spending next month as expenses from the recent lab training there hit the books; Anne has also recently placed several large supply orders for the sampling trip currently in progress. That said, we will be expending those funds rapidly.
In Thailand and six-months into our Year 4, Chulalongkorn is over 50% spent on their Year 4 contract. Q1 saw a higher burn rate as Chulalongkorn rolled over some Year 3 funds into Year 4. This means that we will end up at the end of Year 4 having spent the full budget.
I hope this is helpful.
Cheers,
Peter

**Peter Daszak**
*President*

EcoHealth Alliance
460 West 34th Street – 17th Floor
New York, NY 10001

Tel. +1 212-380-4474
www.ecohealthalliance.org

@PeterDaszak
@EcoHealthNYC

*EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that prevent pandemics and promote conservation.*

---

**From:** Elizabeth Leasure <ealeasure@UCDAVIS.EDU>
**Sent:** Friday, May 18, 2018 6:38 PM
**To:** Peter Daszak
**Cc:** Molly Turner; Jonathon Musser; Evelyn Luciano; Jonna Mazet; predict@ucdavis.edu; Hannah R Chale
**Subject:** Reduced spending clarification (PREDICT)

Hi Peter. After completing the Y4Q2 expenditure by country/category report for Andrew and comparing the figures to the previous quarter's report, we found that the total expenditures for two of your countries were less than the previous quarter (see below). Can you please provide a brief explanation for the reduction given our need to maintain or increase spending levels?

- CDI dropped $30K
- Thailand dropped by $170K

Thank you,
Liz

*Elizabeth Leasure*
*Financial Operations Manager*
*One Health Institute*
REDACTED *(cell)*
*530-754-9034 (office)*
*Skype: ealeasure*

**From:** "William B. Karesh" <karesh@ecohealthalliance.org>
**To:** [redacted]
**Cc:** Amalhin Shek <ashek@usaid.gov>, Jonna Mazet <jkmazet@ucdavis.edu>
**Subject:** Re: USAID brownbag June 13
**Sent:** Tue, 5 Jun 2018 23:23:17 +0000

I've never heard of anything like that for USAID offices where we would have access to. Just a photo ID. Amalhin, any further thoughts.

BK

Sent from my iPhone
**William B. Karesh, D.V.M**
*Executive Vice President for Health and Policy*

EcoHealth Alliance
460 West 34th Street - 17th Floor
New York, NY 10001 USA

+1.212.380.4463 (direct)
+1.212.380.4465 (fax)
www.ecohealthalliance.org

President, OIE Working Group on Wildlife

Co-chair, IUCN Species Survival Commission - Wildlife Health Specialist Group

EPT Partners Liaison, USAID Emerging Pandemic Threats - PREDICT-2 Program

***EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that promote conservation and prevent pandemics.***

On Jun 5, 2018, at 6:55 PM, [redacted] wrote:

> Hi Amalhin and Billy,
>
> I will be in DC for the National Academies meeting next week, and Jonna suggested that I join the brown bag session on June 13 which would be great.
> Do you know if I need clearance to attend the session (non-American)?
>
> Thank you,
>
> [redacted]
> Fellow
> One Health Institute
> School of Veterinary Medicine
> University of California, Davis

| | |
|---|---|
| **From:** | Andrew Clements <aclements@usaid.gov> |
| **To:** | Katherine Leasure <kaleasure@ucdavis.edu> |
| **CC:** | PREDICTMGT <predictmgt@usaid.gov>;Predict inbox <predict@ucdavis.edu>;Jonna Mazet <Jkmazet@ucdavis.edu> |
| **Sent:** | 6/22/2018 12:56:07 AM |
| **Subject:** | Re: PREDICT International Travel Requests |

Approved subject to Mission concurrence.

*Andrew P. Clements, Ph.D.*
*Senior Scientific Advisor*
*Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health*
*U.S. Agency for International Development*
*Mobile phone: 1-571-345-4253*
*Email: aclements@usaid.gov*

On Jun 22, 2018, at 8:57 AM, Katherine Leasure <kaleasure@ucdavis.edu> wrote:

*Please find below international travel requests for your review and approval. Thanks!*

1. Zambrana-Torrelio (China): $2100 airfare/$377 (Beijing) max daily per diem
2. Merewether-Thompson (Tanzania): $2000 airfare/$309 (Dar es Salaam) max daily per diem
3. Sango, Mamy, Koivogui (Sierra Leone): $500 ground transport/$221 (Makeni) max daily per diem
4. Bird (Sierra Leone): $2000 airfare/$319 (Freetown) max daily per diem
5. Gutierrez Jimenez (Liberia): $2350 airfare/$295 (Monrovia) max daily per diem

Travel Requests -

1. EcoHealth Alliance would like to request travel approval for Dr. Carlos Zambrana-Torrelio to travel from New York, NY, USA to Beijing, China from July 12-15, 2018 to participate in the "GEO BON All Hands Meeting 2018" organized by the Group on Earth Observations Biodiversity Network.

**Trip purpose**: Dr. Zambrana-Torrelio will be traveling to Beijing, China to participate in a three-day meeting on optimal monitoring design for disease surveillance. The first day of the meeting will be an open symposium where Dr. Zambrana-Torrelio will present EcoHealth Alliance's preliminary work on the Global Virome Project. The following two days will be discussions on the implementation of a network for disease surveillance in China.

2. UC Davis would like to request travel approval for Vanessa Merewether-Thompson to travel from Freetown, Sierra Leone to Dar es Salaam, Tanzania from July 8 to August 3, 2018 to participate in a training workshop with PREDICT partners in-country.

**Trip purpose:** Ms. Thompson will participate in this hands-on training course to strengthen her zoonotic disease surveillance and lab techniques and understanding of One Health principles. The training will cover a wide range of multidisciplinary topics ranging from viral detection, disease ecology and outbreak responses to the design and implementation of integrated disease surveillance systems. Other individuals being trained come from other countries in Africa, Asia, Europe and North America, thus the training will also provide an excellent opportunity for networking and personal growth for Ms. Thompson and her ongoing and future career in Sierra Leone.

3. UC Davis would like to request travel approval for Mathias Sango, Marie Louise Mamy and Marian Koly Koivogui to travel from Conakry, Guinea to Makeni, Sierra Leone from July 18-28, 2018 for a behavioral training related to the PREDICT Ebola Host Project.

**Trip purpose:** This training will focus on the Ebola Host Project Behavioral study objectives and how to administer the human questionnaire. Topics will include ethical conduct, questionnaire administration, data entry, community engagement, and data analysis. The Sierra Leone behavioral team has over one year of experience working with this study and is well equipped to train the Guinea team in appropriate conduct and study design.

4. UC Davis would like to request travel approval for Dr. Brian Bird to travel from Dar es Salaam, Tanzania to Freetown, Sierra Leone from July 21 to August 2, 2018 for meetings with in-country PREDICT team members and other EPT partners.

**Trip purpose**: To meet and work with the Mission, GHSA partners, and GoSL Ministry and District-level officials, to

discuss and publicly present recent PREDICT related testing results at a mutually agreed upon time and venue during this travel window. Trip will also include direct community engagement led by the GoSL with PREDICT providing technical support for presentations to local stakeholders regarding impact of results and zoonotic disease risk reduction activities. **Travel to Dar es Salaam will be covered on non-PREDICT funds.*

5. EcoHealth Alliance would like to request travel approval for Dr. Leticia Gutierrez Jimenez to travel from New York City, NY, USA to Monrovia, Liberia from July 16-21, 2018 to strengthen local partnerships through meetings with the PREDICT-2 Liberia team in Monrovia and in the field, and to conduct a rodent training for the EHP team.

**Trip purpose**: Dr. Gutierrez Jimenez will travel to Monrovia to meet with PREDICT-Liberia Country Coordinator, Dr. James Desmond, regarding PREDICT-2 field activities. She will also conduct a rodent sampling training and bat sampling refresher. Dr. Gutierrez Jimenez will provide veterinary and ecological support to the PREDICT-2 EHP team for implementing the new rodent sampling guidance.

--
**Katherine Leasure**
HR/Payroll/Financial Assistant
One Health Institute
530-752-7526

--
You received this message because you are subscribed to the Google Groups "PREDICTMGT" group.
To unsubscribe from this group and stop receiving emails from it, send an email to predictmgt+unsubscribe@usaid.gov.
To post to this group, send email to predictmgt@usaid.gov.
To view this discussion on the web visit https://groups.google.com/a/usaid.gov/d/msgid/predictmgt/CAD6-xM%2BFmEx%2BFROTQnWGMgdhhe%3DLU6yBAWXQVqLgWHuBXmqSgw%40mail.gmail.com.

**From:** [redacted]
**To:** "William B. Karesh" <karesh@ecohealthalliance.org>, Beth Edison [redacted]
**Cc:** "predict-outbreak@ucdavis.edu" <predict-outbreak@ucdavis.edu>
**Sent:** Thu, 5 Jul 2018 22:06:13 +0000
**Subject:** [predict] RE: [predict-outbreak] Beth sent you files via WeTransfer

Hi Billy,

It's spam!

[redacted]

---

**From:** predict-outbreak-request@ucdavis.edu [mailto:predict-outbreak-request@ucdavis.edu] **On Behalf Of** William B. Karesh
**Sent:** Thursday, July 05, 2018 3:02 PM
**To:** Beth Edison [redacted]
**Cc:** predict-outbreak@ucdavis.edu
**Subject:** Re: [predict-outbreak] Beth sent you files via WeTransfer

Are these real? I've seen other "wetransfer" trofans or phishing scams.

BK

Sent from my iPhone

**William B. Karesh, D.V.M**
*Executive Vice President for Health and Policy*

EcoHealth Alliance
460 West 34th Street - 17th Floor
New York, NY 10001 USA

+1.212.380.4463 (direct)
+1.212.380.4465 (fax)
www.ecohealthalliance.org

President, OIE Working Group on Wildlife

Co-chair, IUCN Species Survival Commission - Wildlife Health Specialist Group

EPT Partners Liaison, USAID Emerging Pandemic Threats - PREDICT-2 Program

***EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that promote conservation and prevent pandemics.***

On Jul 5, 2018, at 1:22 PM, Beth Edison <bedison@mail.com> wrote:

---

predict-outbreak@ucdavis.edu,

you have received files and its availabe for download

Download Files

Please take a moment to review files sent to you.

Thank You

WeTransfer Team

**********

This email and any attached files may contain confidential and/or privileged information. It is intended solely for the addressee(s) predict-outbreak@ucdavis.edu.

**From:** [redacted]
**To:** Sudarat [redacted]
**Cc:** Jonna Mazet <jkmazet@ucdavis.edu>
**Subject:** FW: VCS training from Thailand
**Sent:** Mon, 13 Aug 2018 20:38:44 +0000

Hi Sudarat,

I'm following up on my message below. Do the proposed times work for you? If not, we can explore other options.

Best,
Eri

---

**From:** [redacted]
**Sent:** Wednesday, August 08, 2018 8:55 AM
**To:** 'Sudarat Damrongwatanapokin' <sdamrongwatanapokin@usaid.gov>; Jonna Mazet <jkmazet@ucdavis.edu>
**Cc:** Dennis Carroll <dcarroll@usaid.gov>; Cara [redacted]; Anchalee [redacted]; Daniel [redacted]
**Subject:** RE: VCS training from Thailand

Hi Sudarat,

Perhaps it is best to discuss these items over a call.
How about 8am Bangkok time on Aug 16 (6pm Davis time on Aug 15)? If not, does 8am Bangkok time on Aug 17 (6pm Davis time on Aug 16) work?

Best,
[redacted]

[redacted]

[redacted]

---

**From:** Sudarat [redacted]
**Sent:** Friday, August 03, 2018 11:21 PM
**To:** Jonna Mazet <jkmazet@ucdavis.edu>; [redacted]
**Cc:** Dennis Carroll <dcarroll@usaid.gov>; Cara [redacted]; Anchalee [redacted]; Daniel [redacted]
**Subject:** Fwd: VCS training from Thailand

Dear Jonna and [redacted]

I was looped in last minute for the conversation on VCS training. What I understand there is no clear information for the training, no training agenda, where the meeting (Ian Lipkin's Lab?), who pay for the bench fee, I don't expect that Thai will be responsible for their own stipend fee. if this is negotiated by Thanat (then it is OK for Thanat, not for other Thai colleagues). Is VCS the technique that will be used for GVP? Is one month is the appropriate time for the training (it seems too long for me). Can analysis part be trained on line?

If VCS is the technique that will be used for GVP, Thai colleagues suggest that the training can be conducted in Thailand ( Supaporn's , DMSC's, Department of Livestock Development and Mahidol have the same model of equipment as Colombia lab). The trainers can fly to Thailand to conduct the training to Thai colleagues which will be more economic impact. The networks are happy to have the training after the launching workshop when they already agree on the collaborative framework and how to move national GVP forward.

if it is not under GVP or PREDICT2 but to serve other purpose, please let us know to avoid the confusion among the Thai colleagues.

Look forward to getting more clarification from your end. Thank you.

Best regards,
Sudarat [redacted]

[redacted]

-------- ข้อความดั้งเดิม --------
จาก: Thanat [redacted]
วันที่: 31/7/18 10:07 (GMT+07:00)
ถึง: Jonna Mazet <jkmazet@ucdavis.edu>, [redacted]
Cc: S [redacted], Pratap [redacted]
เรื่อง: VCS training from Thailand

Dear Jonna and [redacted]

Supaporn (CCed here) and I would like to take this opportunity to thank you again for the kind offer to support Thai researchers for VirCapSeq (VCS) training.

I would like to take this opportunity to summarize the plan to put everyone on the same page. Supaporn's team will send two trainees (one for the lab and one for bioinformatics. I will go there by myself alone. The plan is to spend one month at Columbia to do the lab part of VCS and analyze the data.

It is my understanding that PREDICT will support bench fee, reagents, accommodation and air fare. The Thai party is expected to cover their own living stipend. It does not escape my attention that the cost incurred here is likely to exceed $ 100K . For that, we are very grateful.

I would like to propose a travel date in late September to October in order to fit the future GVP meeting in Thailand. I also would like to invite your team to work with us to pick the right samples to ensure quality and cost effectiveness.

I will work with Eri and the point of contact at CII on detail. Thanks again for your support.

Best wishes,
Thanat

Virus-free. www.avg.com

**From:** Andrew Clements <aclements@usaid.gov>
**Sent:** Tue, 28 Aug 2018 02:44:00 -0400
**To:** [redacted]
**Cc:** PREDICTMGT <predictmgt@usaid.gov>, "predict-outbreak@ucdavis.edu" <predict-outbreak@ucdavis.edu>
**Subject:** [predict] [predict-outbreak] Re: PREDICT Mongolia Bird die-off Report Aug 24, 2018

Thanks!

*Andrew P. Clements, Ph.D.*
*Senior Scientific Advisor*
*Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health*
*U.S. Agency for International Development*
*Mobile phone: 1-571-345-4253*
*Email: aclements@usaid.gov*

On Aug 27, 2018, at 11:12 PM, [redacted] wrote:

> Hi everyone,
>
> Please find the Aug 27 report for the bird die-off event in Mongolia (with updated map). The investigation in ongoing.
>
> Best,
> [redacted]
>
> [redacted]
> Fellow
> One Health Institute
> School of Veterinary Medicine
> University of California, Davis
>
> **From:** predict-outbreak-request@ucdavis.edu [mailto:predict-outbreak-request@ucdavis.edu] **On Behalf Of** [redacted]
> **Sent:** Friday, August 24, 2018 3:54 PM
> **To:** PREDICTMGT <predictmgt@usaid.gov>
> **Cc:** predict-outbreak@ucdavis.edu
> **Subject:** [predict] [predict-outbreak] Re: PREDICT Mongolia Bird die-off Report Aug 24, 2018
>
> Hi everyone,
>
> Please find the report for a new unusual event (wild bird die-off) in Mongolia.
> We are initially responding as part of our regular workplan, and will inform you if there is an additional request for assistance.
>
> Best wishes,
> [redacted]
>
> [redacted]
> Fellow
> One Health Institute
> School of Veterinary Medicine
> University of California, Davis
>
> --

You received this message because you are subscribed to the Google Groups "PREDICTMGT" group.
To unsubscribe from this group and stop receiving emails from it, send an email to predictmgt+unsubscribe@usaid.gov.
To post to this group, send email to predictmgt@usaid.gov.
To view this discussion on the web visit

https://groups.google.com/a/usaid.gov/d/msgid/predictmgt/BYAPR08MB413484AA3AEE69FF0A988740A30B0%40BYAPR08MB4134.namprd08.prod.outlook.com.

<20180827_MongoliaAvianOutbreakReport_final.pdf>

**From:** Andrew Clements <aclements@usaid.gov>
**Sent:** Tue, 18 Sep 2018 21:29:04 +0200
**Subject:** Re: Avian wild bird die-off Mongolia
**To:** Jonna Mazet <jkmazet@ucdavis.edu>
**Cc:** PREDICTMGT <predictmgt@usaid.gov>, PREDICT-outbreak <predict-outbreak@ucdavis.edu>, Amanda Fine <afine@wcs.org>

Thanks, Jonna.

Andrew Clements, Ph.D.
Senior Scientific Advisor
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
E-mail: aclements@usaid.gov

*For more information on USAID's Emerging Pandemic Threats program, see:* http://www.usaid.gov/ept2

On Tue, Sep 18, 2018 at 6:06 PM Jonna Mazet <jkmazet@ucdavis.edu> wrote:

> Please find attached an outbreak form for a wild bird die-off our team has been tracking. We have provided some assistance, as our team was headed that way for sampling already. We haven't had an official request for support, but the team did respond to verbal request for minor supplies and technical assistance.
> We will keep you apprised of developments or any official requests.
> Have a nice day,
> Jonna
>
> --
> You received this message because you are subscribed to the Google Groups "PREDICTMGT" group.
> To unsubscribe from this group and stop receiving emails from it, send an email to predictmgt+unsubscribe@usaid.gov.
> To post to this group, send email to predictmgt@usaid.gov.
> To view this discussion on the web visit
> https://groups.google.com/a/usaid.gov/d/msgid/predictmgt/CAO5tDrGYPU1Ubf7h%2BRnH9i1ejRJTjE0GyDXZkFv%2BWm8i7UOYrw%40mail.gmail.com.

**From:** Christine Kreuder Johnson <ckjohnson@UCDAVIS.EDU>
**To:** Peter Daszak <daszak@ecohealthalliance.org>, "sja2127@cumc.columbia.edu" <sja2127@cumc.columbia.edu>, Kevin Olival <olival@ecohealthalliance.org>
**Cc:** Megan M Doyle <mmdoyle@UCDAVIS.EDU>, Alice Latinne <latinne@ecohealthalliance.org>, Leilani Francisco <francisco@ecohealthalliance.org>, Jon Epstein <epstein@ecohealthalliance.org>, Tracey Goldstein <tgoldstein@ucdavis.edu>, Evelyn Luciano <luciano@ecohealthalliance.org>, Jonna Mazet <jkmazet@ucdavis.edu>
**Subject:** Re: global serology study
**Sent:** Fri, 21 Sep 2018 00:26:24 +0000
Serochip Virus List.xlsx

Hi Peter,
Definitely agree it'd be best to have Malaysia, Bangladesh, Thailand, and Indonesia participate in the CII sero-chip study. We also had samples from 100 individuals in Jordan in mind for the CII serochip if you agree that makes sense too. When we discussed sample selection for serology over the summer, CIV had only 2 people in the community and 9 people in the clinic sampled with data in EIDITH, so this was below our criteria for 100 individuals sampled at a single site along with triangulation of concurrent wildlife sampling - hoping this can be as rigorous scientifically as possible, given the inherent weaknesses in serology data.
We can only test 1,000 samples on the serochip in total and most of our countries have several hundred people sampled at a single site, yet only 10 countries could get a space on the serochip. I truly wish we could do more now but we are considering this a pilot phase, and certainly hope that we can find additional funding collaboratively through other grants to do more.
Simon shared the virus list for the new serochip on EB yesterday for discussion (attached here for you).
Also agree it's important to work on the other issues you note below – I'm gathering more info on these and will find a time to catch you on the phone once you're back. No worries about USAMRIID, but less discuss so I can better understand your reservations.
Thanks, and hope travels are going well.
/ckj

---

**From:** Peter Daszak <daszak@ecohealthalliance.org>
**Date:** Tuesday, September 18, 2018 at 10:02 AM
**To:** Christine Kreuder Johnson <ckjohnson@UCDAVIS.EDU>, Simon Anthony <sja2127@cumc.columbia.edu>, Kevin Olival <olival@ecohealthalliance.org>
**Cc:** Megan M Doyle <mmdoyle@UCDAVIS.EDU>, Alice Latinne <latinne@ecohealthalliance.org>, Leilani Francisco <francisco@ecohealthalliance.org>, Jon Epstein <epstein@ecohealthalliance.org>, Tracey Goldstein <tgoldstein@ucdavis.edu>, Evelyn Luciano <luciano@ecohealthalliance.org>, Jonna Mazet <jkmazet@ucdavis.edu>
**Subject:** global serology study

Hi Chris, Simon

I talked with everyone here about the serology study, and I'd already spoken with Simon about it earlier in the summer and said that I agree it's a great idea to do standardized testing across countries, and that I'm eager for EHA countries to be part of it. The only issue is that, given our longterm partnership with CII, and the existing agreements, I'd like to stick with the following for EHA's part of this – that we'll submit samples for participation in the CII sero-chip study from Malaysia, Bangladesh, Thailand, Indonesia and CIV (I hope CIV's applicable) which we'll be able to ship to CII. The aim is to have these tested only at CII, not at USAMRIID.

I also need to get confirmation of the following so we can get this moving and make sure our in-country partners are clear about what we're up to and fully supportive:

- Given we aren't planning on our samples to be tested at USAMRIID, can you confirm that each participating EHA country does in fact, have a spot for being tested at CII
- Can we have a finalized list of pathogens that will be tested for so we can explain to our in-country folk why this is a unique opportunity etc.
- Can we have agreement on authorship of any global paper from this study at this point. I know that's a pain, but we'll get too much pushback from in-country teams if we don't.
- Some countries will need a technician to accompany the samples to the US, and this is often built into the permit conditions – it's something they want to do for capacity building. I know they might not be able to work fully in the lab, but we need to show willing and allow them to observe the process for a day or so in the lab and help them learn the protocols. Happy to work with Simon on this as per previous testing – it should work without hassle.

I know this isn't exactly what you had planned, but I still think it allows the full global study if EHA country samples only go to CII – it's just a matter of coordination.

Let me know what you think and happy to talk on the phone when I'm back in the office.

Cheers,

Peter

**Peter Daszak**
*President*

EcoHealth Alliance
460 West 34th Street – 17th Floor
New York, NY 10001

Tel. +1 212-380-4474
www.ecohealthalliance.org
@PeterDaszak
@EcoHealthNYC

*EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that prevent pandemics and promote conservation.*

---

**From:** Christine Kreuder Johnson [mailto:ckjohnson@UCDAVIS.EDU]
**Sent:** Friday, August 31, 2018 8:23 PM
**To:** sja2127@cumc.columbia.edu; Kevin Olival
**Cc:** Megan M Doyle; Alice Latinne; Peter Daszak; Leilani Francisco
**Subject:** Re: Serology -- Thailand & Indonesia

Thanks everyone, for the great input and excellent ideas on how best to move this forward collaboratively and ensure that we adhere to best possible standards in recognizing in-country and global team contributions that have made all of this possible. I'm following up on the questions raised by Kevin and surveillance team, working with USAMRIID to ensure congruency with the approach Simon explained eloquently below, and will connect back with all on EB to make sure we feel comfortable in moving forward.
Hoping we get some great data worth publishing.
Happy long weekend
/ckj

---

**From:** Simon Anthony <sja2127@cumc.columbia.edu>
**Date:** Thursday, August 30, 2018 at 6:13 PM
**To:** Kevin Olival <olival@ecohealthalliance.org>
**Cc:** Megan M Doyle <mmdoyle@UCDAVIS.EDU>, Christine Kreuder Johnson <ckjohnson@UCDAVIS.EDU>, Alice Latinne <latinne@ecohealthalliance.org>, Peter Daszak <daszak@ecohealthalliance.org>, Leilani Francisco <francisco@ecohealthalliance.org>
**Subject:** Re: Serology -- Thailand & Indonesia

That sounds great. And thanks for coordinating with in-country partners to facilitate this!!! I realize how much work that involves.

☺

---

**From:** Kevin Olival <olival@ecohealthalliance.org>
**Date:** Thursday, August 30, 2018 at 3:39 PM
**To:** "Anthony, Simon J." <sja2127@cumc.columbia.edu>
**Cc:** Megan M Doyle <mmdoyle@ucdavis.edu>, Christine Kreuder Johnson <ckjohnson@UCDAVIS.EDU>, Alice Latinne

<latinne@ecohealthalliance.org>, Peter Daszak <daszak@ecohealthalliance.org>, Leilani Francisco <francisco@ecohealthalliance.org>
**Subject:** Re: Serology -- Thailand & Indonesia

Hi Simon,

Thanks for the quick reply. Give my best to everyone in Malaysia.

We had a good discussion about the serology study on today's Surveillance call. Will follow up with everyone as we have more questions on MTAs, staff accompanying specimen transport, costs for transport, etc.

I just cc'd you on my reply to Supaporn about coinciding this with the GVP training at CII in Sept, so thanks for the notice on timing regarding that.

Lastly, I didn't mean to be dismissive of the PREDICT group authorship - this is obviously a great way for us to give credit to the huge PREDICT team - esp. in cases where individual authorship is not possible or warrranted. However, I think given the sensitivities around human specimens in particular, including some recent events from Indonesia about authorship on human studies highlighted in Science, our collaborators would like confirmation that individual researchers will be acknowledged as coauthors, especially those that have had key roles in the human PREDICT work from our in-country and global teams. To me it seems feasible and acceptable if we have a global human serology paper from this pilot that includes ~15-20 countries, then we could have a big (e.g. 100s) authorship list. In any case, something that we could follow up with more on EB.

We're continuing to reach out to our countries to make sure they can be included in this study, which will not doubt have some interesting findings.

Cheers,
Kevin

**Kevin J. Olival, PhD**
*Vice President for Research*

EcoHealth Alliance
460 West 34th Street – 17th floor
New York, NY 10001

1.212.380.4478 (direct)
REDACTED (mobile)
@nycbat (twitter)
www.ecohealthalliance.org

***EcoHealth Alliance leads cutting-edge scientific research into the critical connections between human and wildlife health and delicate ecosystems. With this science, we develop solutions that prevent pandemics and promote conservation.***

On Aug 28, 2018, at 8:20 PM, Anthony, Simon J. <sja2127@cumc.columbia.edu> wrote:

Hi Kevin –

1. Happy to talk more about this. Of course, we want to make sure that in-country partners are given the proper opportunities to publish and that they get proper representation on global papers; this is the same philosophy we've adopted throughout PREDICT. We haven't had any EB-level discussions on authorship specific to this study – but I think everyone involved would be appropriately represented. In my mind this study is no different from the strategy

we've used elsewhere in PREDICT. If you think we need to discuss on EB we can add to the agenda. As I currently see it, Nischay/Ian will need a small paper focused on designing the assay (this is a custom build assay) and CKJ will drive the global analysis paper. Participating countries would then publish their own papers with authors in prime positions, and lab/bioinformatic staff and global partner (e.g EHA or UCD) well represented. What do people think? (As an aside, I want to be careful that we're not too dismissive of 'just the PREDICT Consortium' label. This was something we all discussed and agreed to and I don't want to undermine the contributions of all those currently listed as PREDICT Consortium co-authors).

2. September will be too soon to start on the serology samples, unfortunately. We won't have the chips delivered by then. Also – I am actually not sure that 'training' really makes sense here – though I can absolutely discuss it with Nischay and Ian to see what they think. Processing the samples (wet lab) is fairly straightforward but analyzing the data is FAR from straightforward. They would need to have extensive coding and bioinformatic skills to be able to do that, which I am guessing is not the case? I don't see any reason why they couldn't visit the lab for a day to see how the process works – but I'm not sure we could successfully 'train' someone in this technique just yet. If the visitors were able to bring the samples with them in Sept and shadow our techs for a day, just to see how the wet lab part is done, I think that could be arranged, though I would have to confirm that with Ian as it's not my team doing that. ...Side note – are we talking about the same visitors that are coming for VirCapSeq training? If so, it might be fine for them to shadow on SeroChip for a day, given that their focus will be VirCap?

Those be my musings for today. Hello from Sabah!!

S.

---

**From:** Kevin Olival <olival@ecohealthalliance.org>
**Date:** Tuesday, August 28, 2018 at 5:21 PM
**To:** Megan M Doyle <mmdoyle@ucdavis.edu>, Christine Kreuder Johnson <ckjohnson@UCDAVIS.EDU>, "Anthony, Simon J." <sja2127@cumc.columbia.edu>
**Cc:** Alice Latinne <latinne@ecohealthalliance.org>, Peter Daszak <daszak@ecohealthalliance.org>
**Subject:** Re: Serology -- Thailand & Indonesia

**Kevin J. Olival, PhD**
*Vice President for Research*

EcoHealth Alliance
460 West 34th Street – 17th floor
New York, NY 10001

1.212.380.4478 (direct)
REDACTED (mobile)
@nycbat (twitter)
www.ecohealthalliance.org

***EcoHealth Alliance leads cutting-edge scientific research into the critical connections between human and wildlife health and delicate ecosystems. With this science, we develop solutions that prevent pandemics and promote conservation.***

Hi Megan, CKJ, Simon,

We have identified specimens for both Thailand and Indonesia that fit the requested criteria and are working with our partners to get approval for export etc. Overall everyone is excited to be included in this and want to see more come from the samples we've collected.

A couple of questions we've gotten back:

1. Can we be clear about authorship with our in-country partners for this study? I know it's difficult to tell at this stage depending on how things shake out, but want to make sure that each country has good representation on authorship and not just "PREDICT Consortium". Have we come to an agreement on this yet for this serology study? If we could put out a country specific paper too, in addition to a global serology paper, that may help with this too. e.g. a Thailand paper published first that could have Supaporn and team as first and/or senior authors?

2. Many countries like for the specimens to be accompanied by a local scientist, which may include some level of training. Do we have budget to support this in any case? Specifically Indonesia has asked that one of the Eijkman staff come with the samples, so we said we would check. Also, Supaporn will be sending two of her staff to Ian Lipkin's lab in September for GVP training and she has specifically asked if they can also start working up the specimens for serology then. Simon, is this possible (will the assay and everything be ready at that time)? If so, that would be great, and Suapaporn needs to know asap to get export permits etc. sorted out.

Please let me know.

Thanks,
Kevin

On Aug 9, 2018, at 3:34 PM, Megan M Doyle <mmdoyle@ucdavis.edu> wrote:

Oops. For Indonesia syndromic samples it should be **Clinic concurrent site 4**. Sorry about that!
Megan

---

**From:** Megan M Doyle
**Sent:** Thursday, August 09, 2018 12:33 PM
**To:** Kevin Olival <olival@ecohealthalliance.org>; 'Alice Latinne' <latinne@ecohealthalliance.org>
**Cc:** Christine Kreuder Johnson <ckjohnson@UCDAVIS.EDU>
**Subject:** Serology -- Thailand & Indonesia

Hi Kevin/Alice,

We're following up to help identify samples to prioritize for serological testing of PREDICT human samples using platforms being developed at Columbia University and USAMRIID. Due to budget and time limitations, we can only support testing a fraction of the samples collected and thus need to prioritize samples for this effort. If you would like to participate, we've outlined target samples from your sites below.

Please identify serum samples from **100** humans in the community at **Concurrent site 1 OR 2** in **Thailand** (please identify which would be higher priority) and **100** humans in the community at **Concurrent site 2 OR 4** in **Indonesia** (same, please identify which would be higher priority) to be sent to Columbia (or USAMRIID) for testing on the zoonotic virus serochip. Be sure to prioritize samples from people who have had contact with bats, primates, and/or rodents (using question 56 from the human questionnaire) based on what has been targeted by your teams in concurrent sampling of animals at this site.

Also, please identify serum samples from **100** syndromic patients from **Clinic concurrent site 3** in **Thailand** and samples from **100** syndromic patients from **Clinic concurrent Site 4** in **Indonesia** that could be sent to USAMRIID for EBOV, MARV, LASV, CCHFV, RVFV, pan-alphavirus, pan-flavivirus, and pan HNTV serology. If you have convalescent serum from any patient (2 weeks after acute phase of fever), please include that as well. Based on the viruses in the testing platforms, we should prioritize patients with (1) hemorrhagic fever, (2) acute encephalitis and/or (3) severe acute respiratory illness. Try to maximize samples from people who have had exposure to bats, primates, and/or rodents (using question 56 from the human questionnaire).

Whenever possible, try to represent multiple livelihood groups in sample set.

Please reach out to us if you need help identifying the sample set. We also request that you work with

your team generate a sample list and share in advance of shipping. Shipping guidance including sample volume will follow shortly. Let us know if you need anything to prepare all necessary permits and shipping documents in advance.

We're hoping samples can be shipped before end of year 4 if at all possible, so let us know if timing is also feasible.
Thank you!
Megan

Produced in Native Format

**From:** Peter Daszak <daszak@ecohealthalliance.org>
**To:** Christine Kreuder Johnson <ckjohnson@UCDAVIS.EDU>, "sja2127@cumc.columbia.edu" <sja2127@cumc.columbia.edu>, Kevin Olival <olival@ecohealthalliance.org>
**Cc:** Megan M Doyle <mmdoyle@UCDAVIS.EDU>, Alice Latinne <latinne@ecohealthalliance.org>, Leilani Francisco <francisco@ecohealthalliance.org>, Jon Epstein <epstein@ecohealthalliance.org>, Tracey Goldstein <tgoldstein@ucdavis.edu>, Evelyn Luciano <luciano@ecohealthalliance.org>, Jonna Mazet <jkmazet@ucdavis.edu>
**Subject:** RE: global serology study
**Sent:** Fri, 21 Sep 2018 20:26:02 +0000

Great, thanks CKJ,

I spoke with Billy re. the Jordan samples, and Anne Laudisoit re. CIV. For Jordan, Billy thinks the in-country team will not be able to organize things in time re. the local IRB (and it might not be possible in the end anyway), so Jordan should be pulled from the study. For CIV, we actually have 200 human samples from the community – they're just not up in EIDITH yet because the team are having probs with EIDITH that Tammie is working with them on. Therefore Cote D'Ivoire should be part of the study (and we might find something interesting I think!)….

Cheers,

Peter

**Peter Daszak**
*President*

EcoHealth Alliance
460 West 34th Street – 17th Floor
New York, NY 10001

Tel. +1 212-380-4474
www.ecohealthalliance.org
@PeterDaszak
@EcoHealthNYC

*EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that prevent pandemics and promote conservation.*

---

**From:** Christine Kreuder Johnson [mailto:ckjohnson@UCDAVIS.EDU]
**Sent:** Thursday, September 20, 2018 8:26 PM
**To:** Peter Daszak; sja2127@cumc.columbia.edu; Kevin Olival
**Cc:** Megan M Doyle; Alice Latinne; Leilani Francisco; Jon Epstein; Tracey Goldstein; Evelyn Luciano; Jonna Mazet
**Subject:** Re: global serology study

Hi Peter,
Definitely agree it'd be best to have Malaysia, Bangladesh, Thailand, and Indonesia participate in the CII sero-chip study. We also had samples from 100 individuals in Jordan in mind for the CII serochip if you agree that makes sense too. When we discussed sample selection for serology over the summer, CIV had only 2 people in the community and 9 people in the clinic sampled with data in EIDITH, so this was below our criteria for 100 individuals sampled at a single site along with triangulation of concurrent wildlife sampling - hoping this can be as rigorous scientifically as possible, given the inherent weaknesses in serology data.
We can only test 1,000 samples on the serochip in total and most of our countries have several hundred people sampled at a single site, yet only 10 countries could get a space on the serochip. I truly wish we could do more now but we are considering this a pilot phase, and certainly hope that we can find additional funding collaboratively through other grants to do more.
Simon shared the virus list for the new serochip on EB yesterday for discussion (attached here for you).
Also agree it's important to work on the other issues you note below – I'm gathering more info on these and will find a time to catch you on the phone once you're back. No worries about USAMRIID, but less discuss so I can better understand your reservations.

Thanks, and hope travels are going well.
/ckj

---

**From:** Peter Daszak <daszak@ecohealthalliance.org>
**Date:** Tuesday, September 18, 2018 at 10:02 AM
**To:** Christine Kreuder Johnson <ckjohnson@UCDAVIS.EDU>, Simon Anthony <sja2127@cumc.columbia.edu>, Kevin Olival <olival@ecohealthalliance.org>
**Cc:** Megan M Doyle <mmdoyle@UCDAVIS.EDU>, Alice Latinne <latinne@ecohealthalliance.org>, Leilani Francisco <francisco@ecohealthalliance.org>, Jon Epstein <epstein@ecohealthalliance.org>, Tracey Goldstein <tgoldstein@ucdavis.edu>, Evelyn Luciano <luciano@ecohealthalliance.org>, Jonna Mazet <jkmazet@ucdavis.edu>
**Subject:** global serology study

Hi Chris, Simon

I talked with everyone here about the serology study, and I'd already spoken with Simon about it earlier in the summer and said that I agree it's a great idea to do standardized testing across countries, and that I'm eager for EHA countries to be part of it. The only issue is that, given our longterm partnership with CII, and the existing agreements, I'd like to stick with the following for EHA's part of this – that we'll submit samples for participation in the CII sero-chip study from Malaysia, Bangladesh, Thailand, Indonesia and CIV (I hope CIV's applicable) which we'll be able to ship to CII. The aim is to have these tested only at CII, not at USAMRIID.

I also need to get confirmation of the following so we can get this moving and make sure our in-country partners are clear about what we're up to and fully supportive:

- Given we aren't planning on our samples to be tested at USAMRIID, can you confirm that each participating EHA country does in fact, have a spot for being tested at CII
- Can we have a finalized list of pathogens that will be tested for so we can explain to our in-country folk why this is a unique opportunity etc.
- Can we have agreement on authorship of any global paper from this study at this point. I know that's a pain, but we'll get too much pushback from in-country teams if we don't.
- Some countries will need a technician to accompany the samples to the US, and this is often built into the permit conditions – it's something they want to do for capacity building. I know they might not be able to work fully in the lab, but we need to show willing and allow them to observe the process for a day or so in the lab and help them learn the protocols. Happy to work with Simon on this as per previous testing – it should work without hassle.

I know this isn't exactly what you had planned, but I still think it allows the full global study if EHA country samples only go to CII – it's just a matter of coordination.

Let me know what you think and happy to talk on the phone when I'm back in the office.

Cheers,

Peter

**Peter Daszak**
*President*

EcoHealth Alliance
460 West 34th Street – 17th Floor
New York, NY 10001

Tel. +1 212-380-4474
www.ecohealthalliance.org
@PeterDaszak

@EcoHealthNYC

*EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that prevent pandemics and promote conservation.*

---

**From:** Christine Kreuder Johnson [mailto:ckjohnson@UCDAVIS.EDU]
**Sent:** Friday, August 31, 2018 8:23 PM
**To:** sja2127@cumc.columbia.edu; Kevin Olival
**Cc:** Megan M Doyle; Alice Latinne; Peter Daszak; Leilani Francisco
**Subject:** Re: Serology -- Thailand & Indonesia

Thanks everyone, for the great input and excellent ideas on how best to move this forward collaboratively and ensure that we adhere to best possible standards in recognizing in-country and global team contributions that have made all of this possible. I'm following up on the questions raised by Kevin and surveillance team, working with USAMRIID to ensure congruency with the approach Simon explained eloquently below, and will connect back with all on EB to make sure we feel comfortable in moving forward.
Hoping we get some great data worth publishing.
Happy long weekend
/ckj

---

**From:** Simon Anthony <sja2127@cumc.columbia.edu>
**Date:** Thursday, August 30, 2018 at 6:13 PM
**To:** Kevin Olival <olival@ecohealthalliance.org>
**Cc:** Megan M Doyle <mmdoyle@UCDAVIS.EDU>, Christine Kreuder Johnson <ckjohnson@UCDAVIS.EDU>, Alice Latinne <latinne@ecohealthalliance.org>, Peter Daszak <daszak@ecohealthalliance.org>, Leilani Francisco <francisco@ecohealthalliance.org>
**Subject:** Re: Serology -- Thailand & Indonesia

That sounds great. And thanks for coordinating with in-country partners to facilitate this!!! I realize how much work that involves.

☺

---

**From:** Kevin Olival <olival@ecohealthalliance.org>
**Date:** Thursday, August 30, 2018 at 3:39 PM
**To:** "Anthony, Simon J." <sja2127@cumc.columbia.edu>
**Cc:** Megan M Doyle <mmdoyle@ucdavis.edu>, Christine Kreuder Johnson <ckjohnson@UCDAVIS.EDU>, Alice Latinne <latinne@ecohealthalliance.org>, Peter Daszak <daszak@ecohealthalliance.org>, Leilani Francisco <francisco@ecohealthalliance.org>
**Subject:** Re: Serology -- Thailand & Indonesia

Hi Simon,

Thanks for the quick reply. Give my best to everyone in Malaysia.

We had a good discussion about the serology study on today's Surveillance call. Will follow up with everyone as we have more questions on MTAs, staff accompanying specimen transport, costs for transport, etc.

I just cc'd you on my reply to Supaporn about coinciding this with the GVP training at CII in Sept, so thanks for the notice on timing regarding that.

Lastly, I didn't mean to be dismissive of the PREDICT group authorship - this is obviously a great way for us to give credit to the huge PREDICT team - esp. in cases where individual authorship is not possible or warrranted. However, I think given the sensitivities around human specimens in particular, including some recent events from Indonesia about authorship on human studies highlighted in Science, our collaborators would like confirmation that individual researchers will be acknowledged as coauthors, especially those that have had key roles in the human PREDICT work from our in-country and global teams. To me it seems feasible and acceptable if we have a global human serology paper from this pilot that includes ~15-20 countries, then we could have a big (e.g. 100s) authorship list. In any case, something that we could follow up with more on EB.

We're continuing to reach out to our countries to make sure they can be included in this study, which will not doubt have some interesting findings.

Cheers,
Kevin

**Kevin J. Olival, PhD**
*Vice President for Research*

EcoHealth Alliance
460 West 34th Street – 17th floor
New York, NY 10001

1.212.380.4478 (direct)
REDACTED (mobile)
@nycbat (twitter)
www.ecohealthalliance.org

***EcoHealth Alliance leads cutting-edge scientific research into the critical connections between human and wildlife health and delicate ecosystems. With this science, we develop solutions that prevent pandemics and promote conservation.***

On Aug 28, 2018, at 8:20 PM, Anthony, Simon J. <sja2127@cumc.columbia.edu> wrote:

Hi Kevin –

1. Happy to talk more about this. Of course, we want to make sure that in-country partners are given the proper opportunities to publish and that they get proper representation on global papers; this is the same philosophy we've adopted throughout PREDICT. We haven't had any EB-level discussions on authorship specific to this study – but I think everyone involved would be appropriately represented. In my mind this study is no different from the strategy we've used elsewhere in PREDICT. If you think we need to discuss on EB we can add to the agenda. As I currently see it, Nischay/Ian will need a small paper focused on designing the assay (this is a custom build assay) and CKJ will drive the global analysis paper. Participating countries would then publish their own papers with authors in prime positions, and lab/bioinformatic staff and global partner (e.g EHA or UCD) well represented. What do people think? (As an aside, I want to be careful that we're not too dismissive of 'just the PREDICT Consortium' label. This was something we all discussed and agreed to and I don't want to undermine the contributions of all those currently listed as PREDICT Consortium co-authors).

2. September will be too soon to start on the serology samples, unfortunately. We won't have the chips delivered by then. Also – I am actually not sure that 'training' really makes sense here – though I can absolutely discuss it with Nischay and Ian to see what they think. Processing the samples (wet lab) is fairly straightforward but analyzing the data is FAR from straightforward. They would need to have extensive coding and bioinformatic skills to be able to do that, which I am guessing is not the case? I don't see any reason why they couldn't visit the lab for a day to see how the process works – but I'm not sure we could successfully 'train' someone in this technique just yet. If the visitors were able to bring the samples with them in Sept and shadow our techs for a day, just to see how the wet lab part is done, I think that could be arranged, though I would have to confirm that with Ian as it's not my team doing that. …Side note – are we talking about the same visitors that are coming for VirCapSeq training? If so, it might be fine for them to shadow on SeroChip for a day, given that their focus will be VirCap?

Those be my musings for today. Hello from Sabah!!

S.

---

**From:** Kevin Olival <olival@ecohealthalliance.org>
**Date:** Tuesday, August 28, 2018 at 5:21 PM
**To:** Megan M Doyle <mmdoyle@ucdavis.edu>, Christine Kreuder Johnson <ckjohnson@UCDAVIS.EDU>, "Anthony, Simon J." <sja2127@cumc.columbia.edu>
**Cc:** Alice Latinne <latinne@ecohealthalliance.org>, Peter Daszak <daszak@ecohealthalliance.org>
**Subject:** Re: Serology -- Thailand & Indonesia

**Kevin J. Olival, PhD**
*Vice President for Research*

EcoHealth Alliance
460 West 34th Street – 17th floor
New York, NY 10001

1.212.380.4478 (direct)
REDACTED (mobile)
@nycbat (twitter)
www.ecohealthalliance.org

***EcoHealth Alliance leads cutting-edge scientific research into the critical connections between human and wildlife health and delicate ecosystems. With this science, we develop solutions that prevent pandemics and promote conservation.***

Hi Megan, CKJ, Simon,

We have identified specimens for both Thailand and Indonesia that fit the requested criteria and are working with our partners to get approval for export etc. Overall everyone is excited to be included in this and want to see more come from the samples we've collected.

A couple of questions we've gotten back:

1. Can we be clear about authorship with our in-country partners for this study? I know it's difficult to tell at this stage depending on how things shake out, but want to make sure that each country has good representation on authorship and not just "PREDICT Consortium". Have we come to an agreement on this yet for this serology study? If we could put out a country specific paper too, in addition to a global serology paper, that may help with this too. e.g. a Thailand paper published first that could have Supaporn and team as first and/or senior authors?

2. Many countries like for the specimens to be accompanied by a local scientist, which may include some level of training. Do we have budget to support this in any case? Specifically Indonesia has asked that one of the Eijkman staff come with the samples, so we said we would check. Also, Supaporn will be sending two of her staff to Ian Lipkin's lab in September for GVP training and she has specifically asked if they can also start working up the specimens for serology then. Simon, is this possible (will the assay and everything be ready at that time)? If so, that would be great, and Suapaporn needs to know asap to get export permits etc. sorted out.

Please let me know.

Thanks,
Kevin

On Aug 9, 2018, at 3:34 PM, Megan M Doyle <mmdoyle@ucdavis.edu> wrote:

Oops. For Indonesia syndromic samples it should be **Clinic concurrent site 4**. Sorry about that!
Megan

---

**From:** Megan M Doyle
**Sent:** Thursday, August 09, 2018 12:33 PM
**To:** Kevin Olival <olival@ecohealthalliance.org>; 'Alice Latinne' <latinne@ecohealthalliance.org>
**Cc:** Christine Kreuder Johnson <ckjohnson@UCDAVIS.EDU>
**Subject:** Serology -- Thailand & Indonesia

Hi Kevin/Alice,

We're following up to help identify samples to prioritize for serological testing of PREDICT human samples using platforms being developed at Columbia University and USAMRIID. Due to budget and time limitations, we can only support testing a fraction of the samples collected and thus need to prioritize samples for this effort. If you would like to participate, we've outlined target samples from your sites below.

Please identify serum samples from **100** humans in the community at **Concurrent site 1 OR 2** in **Thailand** (please identify which would be higher priority) and **100** humans in the community at **Concurrent site 2 OR 4** in **Indonesia** (same, please identify which would be higher priority) to be sent to Columbia (or USAMRIID) for testing on the zoonotic virus serochip. Be sure to prioritize samples from people who have had contact with bats, primates, and/or rodents (using question 56 from the human questionnaire) based on what has been targeted by your teams in concurrent sampling of animals at this site.

Also, please identify serum samples from **100** syndromic patients from **Clinic concurrent site 3** in **Thailand** and samples from **100** syndromic patients from **Clinic concurrent Site 4** in **Indonesia** that could be sent to USAMRIID for EBOV, MARV, LASV, CCHFV, RVFV, pan-alphavirus, pan-flavivirus, and pan HNTV serology. If you have convalescent serum from any patient (2 weeks after acute phase of fever), please include that as well. Based on the viruses in the testing platforms, we should prioritize patients with (1) hemorrhagic fever, (2) acute encephalitis and/or (3) severe acute respiratory illness. Try to maximize samples from people who have had exposure to bats, primates, and/or rodents (using question 56 from the human questionnaire).

Whenever possible, try to represent multiple livelihood groups in sample set.

Please reach out to us if you need help identifying the sample set. We also request that you work with your team generate a sample list and share in advance of shipping. Shipping guidance including sample volume will follow shortly. Let us know if you need anything to prepare all necessary permits and shipping documents in advance.

We're hoping samples can be shipped before end of year 4 if at all possible, so let us know if timing is also feasible.
Thank you!
Megan

| | |
|---|---|
| **From:** | Andrew Clements <aclements@usaid.gov> |
| **To:** | Katherine Leasure <kaleasure@ucdavis.edu> |
| **CC:** | PREDICTMGT <predictmgt@usaid.gov>;predict@ucdavis.edu <predict@ucdavis.edu>;jkmazet@ucdavis.edu <jkmazet@ucdavis.edu> |
| **Sent:** | 9/24/2018 2:36:59 AM |
| **Subject:** | Re: Change to Approved ITA - J. Belhiria (USA) |

Thanks, Katie

*Andrew P. Clements, Ph.D.*
*Senior Scientific Advisor*
*Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health*
*U.S. Agency for International Development*
*Mobile phone: 1-571-345-4253*
*Email: aclements@usaid.gov*

On Sep 21, 2018, at 9:22 PM, Katherine Leasure <kaleasure@ucdavis.edu> wrote:

Hi Andrew. Please note that there has been a small change to the previously approved ITA for Jaber Belkhiria (below for reference). During his stay in California, he will travel to Los Angeles for 3 days for meetings with Corina Monagin to review PREDICT activities in Guinea and Senegal and review work plans, budgets and travel for the upcoming year.

UC Davis would like to request travel approval for Dr. Jaber Belkhiria to travel from Tunis, Tunisia to Davis, California, USA from September 5 to October 17, 2018 for meetings with the PREDICT team members at UC Davis.

**Trip Purpose:** Dr. Belkhiria will meet with the OHI PREDICT team members to coordinate Y5 PREDICT activities and discuss collaborative findings and potential scientific manuscripts.

**Katherine Leasure**
One Health Institute
University of California, Davis
530-752-7526
530-752-3318 FAX
kaleasure@ucdavis.edu

--
You received this message because you are subscribed to the Google Groups "PREDICTMGT" group.
To unsubscribe from this group and stop receiving emails from it, send an email to predictmgt+unsubscribe@usaid.gov.
To post to this group, send email to predictmgt@usaid.gov.
To view this discussion on the web visit https://groups.google.com/a/usaid.gov/d/msgid/predictmgt/018901d451e0%2463667450%242a335cf0%24%40ucdavis.edu.

**From:** "Daniel O'Rourke" <dorourke@metabiota.com>
**Sent:** Thu, 27 Sep 2018 11:06:53 -0700
**Subject:** Re: [predict-surveillance] Joint call this Thurs, Sept 27th @ 10am PT/1pm ET
**To:** Megan M Doyle <mmdoyle@ucdavis.edu>
**Cc:** predict-surveillance@ucdavis.edu, machalaba@ecohealthalliance.org, "William B. Karesh" <karesh@ecohealthalliance.org>, "Prof. Jonna Mazet" <jkmazet@ucdavis.edu>
Species Extract_ITIS.xlsx

Hi All,
Attached is the species extract from EIDITH. It contains all the species data for all countries. If the "Multiple English Names" column says "yes" that means there is multiple English names for that species across the data set, there may only be 1 English name within a single country.

Please let me know if you have any questions,

***Daniel O'Rourke***

*Health Information Developer*

*Metabiota*

*Emerging Pandemic Threats - PREDICT Program*

*Skype: dorourke_Metabiota*

*URL: www.metabiota.com · www.eidith.org*

On Tue, Sep 25, 2018 at 8:55 PM Megan M Doyle <mmdoyle@ucdavis.edu> wrote:

> Hi PREDICT Surveillance Team,
>
> Our next joint surveillance/behavior/pathogen detection call is this Thurs, Sept 27th @ 10am PT/1pm ET. Agenda, reminders, & call info are below. As always, please let us know if you have other items to discuss. Also, please find attached notes from our last call.
>
> Agenda
>
> - Serology planning discussion (Chris)
> - Pathogen detection/lab update (Tracey)
>  - Testing timeline
>  - Barcoding
>  - Species identification in EIDITH
> - Behavior team update (Leilani)
> - Others?

Action Items and Reminders:

1. We will need to hear from each country regarding willingness and capabilities to participate in the serology testing funded globally in order to finalize selection of samples.

Join from PC, Mac, Linux, iOS or Android: [redacted]

Or iPhone one-tap :

US: +[redacted]#

Or Telephone:

Dial(for higher quality, dial a number based on your current location):

US: +[redacted]

Meeting ID: REDACTED

International numbers available: [redacted]

Talk to you soon!

Megan

Produced in Native Format

**From:** Christine Kreuder Johnson <ckjohnson@UCDAVIS.EDU>
**To:** Peter Daszak <daszak@ecohealthalliance.org>, "sja2127@cumc.columbia.edu" <sja2127@cumc.columbia.edu>, Kevin Olival <olival@ecohealthalliance.org>
**Cc:** Megan M Doyle <mmdoyle@UCDAVIS.EDU>, Alice Latinne <latinne@ecohealthalliance.org>, Leilani Francisco <francisco@ecohealthalliance.org>, Jon Epstein <epstein@ecohealthalliance.org>, Tracey Goldstein <tgoldstein@ucdavis.edu>, Evelyn Luciano <luciano@ecohealthalliance.org>, Jonna Mazet <jkmazet@ucdavis.edu>
**Subject:** Re: global serology study
**Sent:** Thu, 27 Sep 2018 20:22:32 +0000

Thanks Peter,
Makes sense for Jordan. For CIV – we just need to make sure sampling there has been along the same lines as the other countries planned for the serochip as the real value for interpretation (given this is developing technology) will be in combination with individual risk data and concurrent animal viral findings.
We've been checking, and it looks like the team is still working on getting data into EIDITH so I can't tell what the focus of their sampling has been. In lieu of data in EIDITH, could the CIV team share the number of people sampled at their preferred site, with info on the interface/module completed, and their symptoms if relevant? Also will need to know the animal sampling effort (by taxa) at the specific site (and timing of that).
/ckj

---

**From:** Peter Daszak <daszak@ecohealthalliance.org>
**Date:** Friday, September 21, 2018 at 1:26 PM
**To:** Christine Kreuder Johnson <ckjohnson@UCDAVIS.EDU>, Simon Anthony <sja2127@cumc.columbia.edu>, Kevin Olival <olival@ecohealthalliance.org>
**Cc:** Megan M Doyle <mmdoyle@UCDAVIS.EDU>, Alice Latinne <latinne@ecohealthalliance.org>, Leilani Francisco <francisco@ecohealthalliance.org>, Jon Epstein <epstein@ecohealthalliance.org>, Tracey Goldstein <tgoldstein@ucdavis.edu>, Evelyn Luciano <luciano@ecohealthalliance.org>, Jonna Mazet <jkmazet@ucdavis.edu>
**Subject:** RE: global serology study

Great, thanks CKJ,

I spoke with Billy re. the Jordan samples, and Anne Laudisoit re. CIV. For Jordan, Billy thinks the in-country team will not be able to organize things in time re. the local IRB (and it might not be possible in the end anyway), so Jordan should be pulled from the study. For CIV, we actually have 200 human samples from the community – they're just not up in EIDITH yet because the team are having probs with EIDITH that Tammie is working with them on. Therefore Cote D'Ivoire should be part of the study (and we might find something interesting I think!)….

Cheers,

Peter

**Peter Daszak**
*President*

EcoHealth Alliance
460 West 34th Street – 17th Floor
New York, NY 10001

Tel. +1 212-380-4474
www.ecohealthalliance.org
@PeterDaszak
@EcoHealthNYC

*EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate*

*ecosystems. With this science we develop solutions that prevent pandemics and promote conservation.*

---

**From:** Christine Kreuder Johnson [mailto:ckjohnson@UCDAVIS.EDU]
**Sent:** Thursday, September 20, 2018 8:26 PM
**To:** Peter Daszak; sja2127@cumc.columbia.edu; Kevin Olival
**Cc:** Megan M Doyle; Alice Latinne; Leilani Francisco; Jon Epstein; Tracey Goldstein; Evelyn Luciano; Jonna Mazet
**Subject:** Re: global serology study

Hi Peter,
Definitely agree it'd be best to have Malaysia, Bangladesh, Thailand, and Indonesia participate in the CII sero-chip study. We also had samples from 100 individuals in Jordan in mind for the CII serochip if you agree that makes sense too. When we discussed sample selection for serology over the summer, CIV had only 2 people in the community and 9 people in the clinic sampled with data in EIDITH, so this was below our criteria for 100 individuals sampled at a single site along with triangulation of concurrent wildlife sampling - hoping this can be as rigorous scientifically as possible, given the inherent weaknesses in serology data.
We can only test 1,000 samples on the serochip in total and most of our countries have several hundred people sampled at a single site, yet only 10 countries could get a space on the serochip. I truly wish we could do more now but we are considering this a pilot phase, and certainly hope that we can find additional funding collaboratively through other grants to do more.
Simon shared the virus list for the new serochip on EB yesterday for discussion (attached here for you).
Also agree it's important to work on the other issues you note below – I'm gathering more info on these and will find a time to catch you on the phone once you're back. No worries about USAMRIID, but less discuss so I can better understand your reservations.
Thanks, and hope travels are going well.
/ckj

---

**From:** Peter Daszak <daszak@ecohealthalliance.org>
**Date:** Tuesday, September 18, 2018 at 10:02 AM
**To:** Christine Kreuder Johnson <ckjohnson@UCDAVIS.EDU>, Simon Anthony <sja2127@cumc.columbia.edu>, Kevin Olival <olival@ecohealthalliance.org>
**Cc:** Megan M Doyle <mmdoyle@UCDAVIS.EDU>, Alice Latinne <latinne@ecohealthalliance.org>, Leilani Francisco <francisco@ecohealthalliance.org>, Jon Epstein <epstein@ecohealthalliance.org>, Tracey Goldstein <tgoldstein@ucdavis.edu>, Evelyn Luciano <luciano@ecohealthalliance.org>, Jonna Mazet <jkmazet@ucdavis.edu>
**Subject:** global serology study

Hi Chris, Simon

I talked with everyone here about the serology study, and I'd already spoken with Simon about it earlier in the summer and said that I agree it's a great idea to do standardized testing across countries, and that I'm eager for EHA countries to be part of it. The only issue is that, given our longterm partnership with CII, and the existing agreements, I'd like to stick with the following for EHA's part of this – that we'll submit samples for participation in the CII sero-chip study from Malaysia, Bangladesh, Thailand, Indonesia and CIV (I hope CIV's applicable) which we'll be able to ship to CII. The aim is to have these tested only at CII, not at USAMRIID.

I also need to get confirmation of the following so we can get this moving and make sure our in-country partners are clear about what we're up to and fully supportive:

- Given we aren't planning on our samples to be tested at USAMRIID, can you confirm that each participating EHA country does in fact, have a spot for being tested at CII
- Can we have a finalized list of pathogens that will be tested for so we can explain to our in-country folk why this is a unique opportunity etc.
- Can we have agreement on authorship of any global paper from this study at this point. I know that's a pain, but we'll get too much pushback from in-country teams if we don't.
- Some countries will need a technician to accompany the samples to the US, and this is often built into the permit conditions – it's something they want to do for capacity building. I know they might not be able to work fully in the lab, but we need to show willing and allow them to observe the process for a day or so in the lab and help them learn the protocols. Happy to work with Simon on this as per previous testing – it should work without hassle.

I know this isn't exactly what you had planned, but I still think it allows the full global study if EHA country samples only go to CII – it's just a matter of coordination.

Let me know what you think and happy to talk on the phone when I'm back in the office.

Cheers,

Peter

**Peter Daszak**
*President*

EcoHealth Alliance
460 West 34th Street – 17th Floor
New York, NY 10001

Tel. +1 212-380-4474
www.ecohealthalliance.org
@PeterDaszak
@EcoHealthNYC

*EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that prevent pandemics and promote conservation.*

---

**From:** Christine Kreuder Johnson [mailto:ckjohnson@UCDAVIS.EDU]
**Sent:** Friday, August 31, 2018 8:23 PM
**To:** sja2127@cumc.columbia.edu; Kevin Olival
**Cc:** Megan M Doyle; Alice Latinne; Peter Daszak; Leilani Francisco
**Subject:** Re: Serology -- Thailand & Indonesia

Thanks everyone, for the great input and excellent ideas on how best to move this forward collaboratively and ensure that we adhere to best possible standards in recognizing in-country and global team contributions that have made all of this possible. I'm following up on the questions raised by Kevin and surveillance team, working with USAMRIID to ensure congruency with the approach Simon explained eloquently below, and will connect back with all on EB to make sure we feel comfortable in moving forward.
Hoping we get some great data worth publishing.
Happy long weekend
/ckj

---

**From:** Simon Anthony <sja2127@cumc.columbia.edu>
**Date:** Thursday, August 30, 2018 at 6:13 PM
**To:** Kevin Olival <olival@ecohealthalliance.org>
**Cc:** Megan M Doyle <mmdoyle@UCDAVIS.EDU>, Christine Kreuder Johnson <ckjohnson@UCDAVIS.EDU>, Alice Latinne <latinne@ecohealthalliance.org>, Peter Daszak <daszak@ecohealthalliance.org>, Leilani Francisco <francisco@ecohealthalliance.org>
**Subject:** Re: Serology -- Thailand & Indonesia

That sounds great. And thanks for coordinating with in-country partners to facilitate this!!! I realize how much work that involves.

☺

---

**From:** Kevin Olival <olival@ecohealthalliance.org>
**Date:** Thursday, August 30, 2018 at 3:39 PM
**To:** "Anthony, Simon J." <sja2127@cumc.columbia.edu>
**Cc:** Megan M Doyle <mmdoyle@ucdavis.edu>, Christine Kreuder Johnson <ckjohnson@UCDAVIS.EDU>, Alice Latinne <latinne@ecohealthalliance.org>, Peter Daszak <daszak@ecohealthalliance.org>, Leilani Francisco

<francisco@ecohealthalliance.org>
**Subject:** Re: Serology -- Thailand & Indonesia

Hi Simon,

Thanks for the quick reply. Give my best to everyone in Malaysia.

We had a good discussion about the serology study on today's Surveillance call. Will follow up with everyone as we have more questions on MTAs, staff accompanying specimen transport, costs for transport, etc.

I just cc'd you on my reply to Supaporn about coinciding this with the GVP training at CII in Sept, so thanks for the notice on timing regarding that.

Lastly, I didn't mean to be dismissive of the PREDICT group authorship - this is obviously a great way for us to give credit to the huge PREDICT team - esp. in cases where individual authorship is not possible or warrranted. However, I think given the sensitivities around human specimens in particular, including some recent events from Indonesia about authorship on human studies highlighted in Science, our collaborators would like confirmation that individual researchers will be acknowledged as coauthors, especially those that have had key roles in the human PREDICT work from our in-country and global teams. To me it seems feasible and acceptable if we have a global human serology paper from this pilot that includes ~15-20 countries, then we could have a big (e.g. 100s) authorship list. In any case, something that we could follow up with more on EB.

We're continuing to reach out to our countries to make sure they can be included in this study, which will not doubt have some interesting findings.

Cheers,
Kevin

**Kevin J. Olival, PhD**
*Vice President for Research*

EcoHealth Alliance
460 West 34th Street – 17th floor
New York, NY 10001

1.212.380.4478 (direct)
REDACTED (mobile)
@nycbat (twitter)
www.ecohealthalliance.org

***EcoHealth Alliance leads cutting-edge scientific research into the critical connections between human and wildlife health and delicate ecosystems. With this science, we develop solutions that prevent pandemics and promote conservation.***

On Aug 28, 2018, at 8:20 PM, Anthony, Simon J. <sja2127@cumc.columbia.edu> wrote:

Hi Kevin –

1. Happy to talk more about this. Of course, we want to make sure that in-country partners are given the proper opportunities to publish and that they get proper representation on global papers; this is the same philosophy we've adopted throughout PREDICT. We haven't had any EB-level discussions on authorship specific to this study – but I think everyone involved would be appropriately represented. In my mind this study is no different from the strategy we've used elsewhere in PREDICT. If you think we need to discuss on EB we can add to the agenda. As I currently see

it, Nischay/Ian will need a small paper focused on designing the assay (this is a custom build assay) and CKJ will drive the global analysis paper. Participating countries would then publish their own papers with authors in prime positions, and lab/bioinformatic staff and global partner (e.g EHA or UCD) well represented. What do people think? (As an aside, I want to be careful that we're not too dismissive of 'just the PREDICT Consortium' label. This was something we all discussed and agreed to and I don't want to undermine the contributions of all those currently listed as PREDICT Consortium co-authors).

2. September will be too soon to start on the serology samples, unfortunately. We won't have the chips delivered by then. Also – I am actually not sure that 'training' really makes sense here – though I can absolutely discuss it with Nischay and Ian to see what they think. Processing the samples (wet lab) is fairly straightforward but analyzing the data is FAR from straightforward. They would need to have extensive coding and bioinformatic skills to be able to do that, which I am guessing is not the case? I don't see any reason why they couldn't visit the lab for a day to see how the process works – but I'm not sure we could successfully 'train' someone in this technique just yet. If the visitors were able to bring the samples with them in Sept and shadow our techs for a day, just to see how the wet lab part is done, I think that could be arranged, though I would have to confirm that with Ian as it's not my team doing that. …Side note – are we talking about the same visitors that are coming for VirCapSeq training? If so, it might be fine for them to shadow on SeroChip for a day, given that their focus will be VirCap?

Those be my musings for today. Hello from Sabah!!

S.

---

**From:** Kevin Olival <olival@ecohealthalliance.org>
**Date:** Tuesday, August 28, 2018 at 5:21 PM
**To:** Megan M Doyle <mmdoyle@ucdavis.edu>, Christine Kreuder Johnson <ckjohnson@UCDAVIS.EDU>, "Anthony, Simon J." <sja2127@cumc.columbia.edu>
**Cc:** Alice Latinne <latinne@ecohealthalliance.org>, Peter Daszak <daszak@ecohealthalliance.org>
**Subject:** Re: Serology -- Thailand & Indonesia

**Kevin J. Olival, PhD**
*Vice President for Research*

EcoHealth Alliance
460 West 34th Street – 17th floor
New York, NY 10001

1.212.380.4478 (direct)
REDACTED (mobile)
@nycbat (twitter)
www.ecohealthalliance.org

***EcoHealth Alliance leads cutting-edge scientific research into the critical connections between human and wildlife health and delicate ecosystems. With this science, we develop solutions that prevent pandemics and promote conservation.***

Hi Megan, CKJ, Simon,

We have identified specimens for both Thailand and Indonesia that fit the requested criteria and are working with our partners to get approval for export etc. Overall everyone is excited to be included in this and want to see more come from the samples we've collected.

A couple of questions we've gotten back:

1. Can we be clear about authorship with our in-country partners for this study? I know it's difficult to tell at this stage depending on how things shake out, but want to make sure that each country has good representation on authorship and not just "PREDICT Consortium". Have we come to an agreement on this yet for this serology study? If we could put out a country specific paper too, in addition to a global serology paper, that may help with this too. e.g. a Thailand paper published first that could have Supaporn and team as first and/or senior authors?

2. Many countries like for the specimens to be accompanied by a local scientist, which may include some level of training. Do we have budget to support this in any case? Specifically Indonesia has asked that one of the Eijkman staff come with the samples, so we said we would check. Also, Supaporn will be sending two of her staff to Ian Lipkin's lab in September for GVP training and she has specifically asked if they can also start working up the specimens for serology then. Simon, is this possible (will the assay and everything be ready at that time)? If so, that would be great, and Suapaporn needs to know asap to get export permits etc. sorted out.

Please let me know.

Thanks,
Kevin

On Aug 9, 2018, at 3:34 PM, Megan M Doyle <mmdoyle@ucdavis.edu> wrote:

Oops. For Indonesia syndromic samples it should be **Clinic concurrent site 4**. Sorry about that!
Megan

---

**From:** Megan M Doyle
**Sent:** Thursday, August 09, 2018 12:33 PM
**To:** Kevin Olival <olival@ecohealthalliance.org>; 'Alice Latinne' <latinne@ecohealthalliance.org>
**Cc:** Christine Kreuder Johnson <ckjohnson@UCDAVIS.EDU>
**Subject:** Serology -- Thailand & Indonesia

Hi Kevin/Alice,

We're following up to help identify samples to prioritize for serological testing of PREDICT human samples using platforms being developed at Columbia University and USAMRIID. Due to budget and time limitations, we can only support testing a fraction of the samples collected and thus need to prioritize samples for this effort. If you would like to participate, we've outlined target samples from your sites below.

Please identify serum samples from **100** humans in the community at **Concurrent site 1 OR 2** in **Thailand** (please identify which would be higher priority) and **100** humans in the community at **Concurrent site 2 OR 4** in **Indonesia** (same, please identify which would be higher priority) to be sent to Columbia (or USAMRIID) for testing on the zoonotic virus serochip. Be sure to prioritize samples from people who have had contact with bats, primates, and/or rodents (using question 56 from the human questionnaire) based on what has been targeted by your teams in concurrent sampling of animals at this site.

Also, please identify serum samples from **100** syndromic patients from **Clinic concurrent site 3** in **Thailand** and samples from **100** syndromic patients from **Clinic concurrent Site 4** in **Indonesia** that could be sent to USAMRIID for EBOV, MARV, LASV, CCHFV, RVFV, pan-alphavirus, pan-flavivirus, and pan HNTV serology. If you have convalescent serum from any patient (2 weeks after acute phase of fever), please include that as well. Based on the viruses in the testing platforms, we should prioritize patients with (1) hemorrhagic fever, (2) acute encephalitis and/or (3) severe acute respiratory illness. Try to maximize samples from people who have had exposure to bats, primates, and/or rodents (using question 56 from the human questionnaire).

Whenever possible, try to represent multiple livelihood groups in sample set.

Please reach out to us if you need help identifying the sample set. We also request that you work with

your team generate a sample list and share in advance of shipping. Shipping guidance including sample volume will follow shortly. Let us know if you need anything to prepare all necessary permits and shipping documents in advance.

We're hoping samples can be shipped before end of year 4 if at all possible, so let us know if timing is also feasible.
Thank you!
Megan

**From:** "William B. Karesh" <karesh@ecohealthalliance.org>
**To:** Amanda Fine [REDACTED]
**Cc:** "predict@ucdavis.edu" <PREDICT@ucdavis.edu>, Catherine Machalaba <machalaba@ecohealthalliance.org>
**Sent:** Wed, 3 Oct 2018 14:58:35 +0000
**Subject:** [predict] Re: JRA pilot in Viet Nam

Great timing Amanda and thanks for the heads-up.
I'm copying Catherine here because she is actually meeting with WHO this week and will be able to get some information from their side.

We will let you know if we find anything that's wasn't covered in the email chain.

BK

**William B. Karesh, D.V.M**
*Executive Vice President for Health and Policy*

EcoHealth Alliance
460 West 34th Street - 17th Floor
New York, NY 10001 USA

+1.212.380.4463 (direct)
+1.212.380.4465 (fax)
www.ecohealthalliance.org

President, OIE Working Group on Wildlife

Co-chair, IUCN Species Survival Commission - Wildlife Health Specialist Group

EPT Partners Liaison, USAID Emerging Pandemic Threats - PREDICT-2 Program

***EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that promote conservation and prevent pandemics.***

On Oct 3, 2018, at 5:35 AM, Amanda Fine <[REDACTED]> wrote:

Hello Billy,

FAO and WHO are talking about organizing a "Joint Risk Assessment" pilot workshop in Viet Nam in January. Long e-mail trail below. I have been copied in throughout, I think because the idea is to use data from LISN at least as an example but I have just reached out to Pawin at FAO to clarify the LISN component. It is possible that FAO and WHO are planning to use the funds they have from LISN for a national data analysis and risk assessment workshop to put on the event discussed in these e-mails and in the material attached. Again, I am seeking clarification but I wanted to give you a heads up and was also wondering if you have hear anything about these JRAs.

I am planning to be on the EB call today for at least the start. This may be relevant to the agenda item regarding influenza surveillance in SE Asia. More on the call.

Cheers,

Amanda

-------- Forwarded Message --------

**Subject:** RE: JRA pilot in Viet Nam
**Date:** Tue, 2 Oct 2018 09:03:44 +0000
**From:** MUMFORD, Elizabeth [REDACTED]
**To:** Brioudes, Aurelie (FAORAP) [REDACTED], Padungtod, Pawin (FAOVN) [REDACTED], OTSU, Satoko [REDACTED], DO, Thi Hong Hien [REDACTED], Loth, Leopold (FAOVN) [REDACTED], CONDELL, Orla [REDACTED], VonDobschuetz, Sophie (AGAH) [REDACTED]
**CC:** Wongsathapornchai, Kachen (FAORAP) [REDACTED], Sinclair, Julie (CDC/OID/NCEZID) <bwg5@cdc.gov>, PHUC, Nguyen Thi [REDACTED], LE, Van Tuan [REDACTED], Amanda Fine [REDACTED], Jeffrey McFarland [REDACTED], Inui, Ken (FAOVN) [REDACTED], Moore, Matt (CDC/CGH/DGHP) <zdn4@cdc.gov>, RYAN, Caroline [REDACTED]

Dear Aurelie and the team

Thank you so much – congratulations on getting this moving so quickly!

I could make myself available to help facilitate this pilot.

Just a quick reminder that we would highly suggest having three days of workshop as well as a facilitator training day – or at least ½ day facilitator training, and 2.5 days of workshop. But as mentioned in Rome, we can make anything work assuming available funds.

Hien and Aurelie: The updated materials from the Rome workshop – e.g. the logistics and agenda document and the new tool version - will soon be on the new shared drive, but here attached is the latest version of the logistics document if you need to support your planning.

Best

Liz

Dr Elizabeth Mumford
One Health Country Operations team
Department of Country Health Emergency Preparedness and IHR
World Health Organization
1211 Geneva 27
Switzerland
REDACTED

---

**From:** Brioudes, Aurelie (FAORAP) [REDACTED]
**Sent:** Tuesday, October 2, 2018 4:45
**To:** Padungtod, Pawin (FAOVN) [REDACTED]
**Cc:** OTSU, Satoko [REDACTED]; DO, Thi Hong Hien [REDACTED]; Loth, Leopold (FAOVN) [REDACTED]; CONDELL, Orla [REDACTED]; VonDobschuetz, Sophie (AGAH) [REDACTED]; Wongsathapornchai, Kachen (FAORAP) [REDACTED]; MUMFORD, Elizabeth [REDACTED]; Sinclair, Julie (CDC/OID/NCEZID) [REDACTED]; PHUC, Nguyen Thi [REDACTED]; LE, Van Tuan [REDACTED]; Amanda Fine [REDACTED]; Jeffrey McFarland [REDACTED]; Inui, Ken (FAOVN) [REDACTED]; Moore, Matt (CDC/CGH/DGHP) [REDACTED]
**Subject:** RE: JRA pilot in Viet Nam

Thanks for this clarification. That makes it logistically easier!

Waiting to hear back from JRA Secretariat colleagues with their views on their involvement in this VN pilot, knowing well enough how difficult it is to identify a week that suit both Human and Animal sectors within the country so hopefully the suggested week will suit at least one of them.

Best regards,

Aurelie

**From:** Padungtod, Pawin (FAOVN)
**Sent:** Tuesday, October 02, 2018 9:37 AM
**To:** Brioudes, Aurelie (FAORAP) <[redacted]>
**Cc:** OTSU, Satoko <[redacted]>; DO, Thi Hong Hien <[redacted]>; Loth, Leopold (FAOVN) <[redacted]>; CONDELL, Orla <[redacted]>; VonDobschuetz, Sophie (AGAH) <[redacted]>; Wongsathapornchai, Kachen (FAORAP) <[redacted]>; MUMFORD, Elizabeth <[redacted]>; Sinclair, Julie (CDC/OID/NCEZID) <bwg5@cdc.gov>; PHUC, Nguyen Thi <[redacted]>; LE, Van Tuan <[redacted]>; Amanda Fine <[redacted]>; Jeffrey McFarland <[redacted]>; Inui, Ken (FAOVN) <[redacted]>; Moore, Matt (CDC/CGH/DGHP) <zdn4@cdc.gov>
**Subject:** Re: JRA pilot in Viet Nam

Dear Aurélie,

Your understanding is correct. All training and workshop will be in January. Apology for the confusion.

With best regards,

**Celebrating 40 years in Viet Nam - #40yearsUNFAO**

**Pawin Padungtod**
Senior Technical Coordinator
Emergency Centre for Transboundary Animal Diseases (ECTAD)

**Food and Agriculture Organization of the United Nations (FAO)**
**Country Office for Viet Nam**
Green One UN House Building
No. 304, Kim Ma Street, Hanoi, Viet Nam
**Tel:** +84945436161, +84438501841
**Website:** FAO Viet Nam I FAO ECTAD Viet Nam

On 2 Oct 2018, at 09:08, Padungtod, Pawin (FAOVN) <[redacted]> wrote:

> Dear Aurelie,
>
> The training is planned for 7 December 2018 back to back with ARES meeting in Hanoi. The workshop is planned for 8-9 January 2019 before OIE AMU workshop also in Hanoi.
>
> Thank you and best regards,
>
> **Celebrating 40 years in Viet Nam - #40yearsUNFAO**
>
> **Pawin Padungtod**
> Senior Technical Coordinator
> Emergency Centre for Transboundary Animal Diseases (ECTAD)
>
> **Food and Agriculture Organization of the United Nations (FAO)**
> **Country Office for Viet Nam**
> Green One UN House Building
> No. 304, Kim Ma Street, Hanoi, Viet Nam
> **Tel:** +84945436161, +84438501841
> **Website:** FAO Viet Nam I FAO ECTAD Viet Nam

On 2 Oct 2018, at 08:55, Brioudes, Aurelie (FAORAP) <[redacted]> wrote:

Dear all,

Very glad to see that Vietnam is moving quickly on this matter!

While Hien and I attended the JRA training in Rome few weeks ago and will thus help conducting and facilitating the JRA pilot in Vietnam, it was mentioned during the training that at least one Master Trainer from the JRA Secretariat would be expected to participate in the pilots so they can i) lead/assist with the JRA facilitation; ii) Compile feedback from this pilot (in Vietnam and the ones that will be done in other countries latter on) in view of ultimately fine-tuning and finalizing the JRA tool. So I am here including Master trainers - FAO/OIE/WHO JRA Coordinators (Kachen & Sophie, Liz and Julie) to this email list.

Dear Sophie, Liz and Julie,

Vietnam is tentatively planning to conduct the JRA pilot the week of 7 January 2019. Would this week work for at least one of you to come (I suppose it would take place in Hanoi) and conduct this JRA with Hien (WHO Vietnam) and I (FAO RAP). Kachen will still be on contract break that week and will not be able to make it unfortunately.

Dear Pawin and Satoko,

Thanks again for connecting with GoV (MoH/GDPM and MARD/DAH) and advocating for this JRA pilot in Vietnam. While option 3 seems to be the consensus, would it be possible to plan the activities towards the end of that week (Wed-Fri) instead? I (and others I suspect depending on who would come from FAO/WHO/OIE HQ?) will just be back from End Of the Year Holidays on 7 Jan so starting the pilot from Monday would not work for me (understanding that it was meant 7 January in Pawin's email below; not 7 Dec).

Thanks and best regards,
Aurelie

---

**From:** OTSU, Satoko [redacted]]
**Sent:** Tuesday, October 02, 2018 7:06 AM
**To:** Padungtod, Pawin (FAOVN) <[redacted]>; DO, Thi Hong Hien <[redacted]>; Loth, Leopold (FAOVN) <[redacted]>; CONDELL, Orla <[redacted]>
**Cc:** PHUC, Nguyen Thi <[redacted]>; LE, Van Tuan <[redacted]>; Brioudes, Aurelie (FAORAP) <[redacted]>; Amanda Fine <[redacted]>; Jeffrey McFarland <[redacted]>; Inui, Ken (FAOVN) <[redacted]>; 'Moore, Matt (CDC/CGH/DGHP)' <zdn4@cdc.gov>
**Subject:** RE: JRA pilot in Viet Nam

Dear Pawin, Hien,

Thank you for your leadership and proactive action!

I do agree with option 3, too. But do we need two concept notes? If it covers the same purpose I think one is enough?
A current concept note is already detailed and well written. Also from WHO point of view, it is easier to make it in one DFC.

But of course, I am open and leave it on you if you have any issue administratively.

Thanks - Satoko

---

**From:** Padungtod, Pawin (FAOVN) [redacted]
**Sent:** Tuesday, October 2, 2018 6:46 AM

**To:** DO, Thi Hong Hien; OTSU, Satoko; Loth, Leopold (FAOVN); CONDELL, Orla
**Cc:** PHUC, Nguyen Thi; LE, Van Tuan; Brioudes, Aurelie (FAORAP); Amanda Fine; Jeffrey McFarland; Inui, Ken (FAOVN); 'Moore, Matt (CDC/CGH/DGHP)'
**Subject:** Re: JRA pilot in Viet Nam

Dear Hien,

I do agree with option 3 and will confirm with DAH today.
If it is confirmed, we will need TWO concept note;

1. One-day JRA training (7DEC) for facilitator only
2. Two-day National Coordinated Surveillance Risk Assessment Workshop (8-9JAN2018?). We can do JRA on the first day with technical staff and include leaders on the second day for information sharing and advocacy.

Thank you and best regards,

**Celebrating 40 years in Viet Nam - #40yearsUNFAO**
--
**Pawin Padungtod**
Senior Technical Coordinator
Emergency Centre for Transboundary Animal Diseases (ECTAD)

**Food and Agriculture Organization of the United Nations (FAO)**
**Country Office for Viet Nam**
Green One UN House Building
No. 304, Kim Ma Street, Hanoi, Viet Nam
**Tel:** +84945436161, +842438501841
**Website:** FAO Viet Nam | FAO ECTAD Viet Nam



**From:** "DO, Thi Hong Hien" <[REDACTED]>
**Date:** Monday, 1 October AD 2018 17:25
**To:** "Padungtod, Pawin (FAOVN)" <[REDACTED]>, Satoko Otsu <[REDACTED]>, "Loth, Leopold (FAOVN)" <[REDACTED]>, "CONDELL, Orla" <[REDACTED]>
**Cc:** "PHUC, Nguyen Thi" <[REDACTED]>, "LE, Van Tuan" <[REDACTED]>, "Brioudes, Aurelie (FAORAP)" <[REDACTED]>, Amanda Fine <[REDACTED]>, Jeffrey McFarland <[REDACTED]>, "Inui, Ken (FAOVN)" <[REDACTED]>, "'Moore, Matt (CDC/CGH/DGHP)'" <zdn4@cdc.gov>
**Subject:** RE: JRA pilot in Viet Nam

Dear Pawin and all,

Thank you very much for your email.
I have discussed with GDPM on this proposed activity. In principles, they agreed on the objectives, scope and participants for the Coordinated Surveillance Risk Assessment Workshop.
Regarding the dates, they have proposed the following three options, each with pros and cons for our consideration and continued discussion:

- **Option 1**: from afternoon Thu 6 Dec to noon Sat 8 Dec (if ARES indeed can't be finished within 2 days 4-5 Dec). According to GDPM the dates for ARES 4-6 Dec have been confirmed and will be difficult to change. Pls re-discuss this with DAH, GDPM and those involved.
- **Option 2**: ARES finishes on 6 Dec. On Fri 7 Dec to organize a pre-training on JRA for facilitators. Then on JRA workshop to be conducted on 10-11 Dec, ideally outside of

Ha Noi to ensure optimal participation and quality outcome.

- **Option 3**: **which is most preferable by GDPM** is to conduct this event in the week of 7 January 2019. In their opinion, December will be pretty occupied for all government agencies due to approaching the end of government fiscal year, thus no assurance on good turn-out of relevant participants. They think first 2 weeks of January would be much more optimistic. However they also understand the complex nature of getting multi-sectoral agreement on the timeframe thus is willing to try their best to accommodate what works best for all.

I will send you the revised concept note in a separate email.
Happy to discuss further.

Hien

---

**From:** Padungtod, Pawin (FAOVN) [REDACTED]
**Sent:** 27 September 2018 08:37
**To:** DO, Thi Hong Hien; OTSU, Satoko; Loth, Leopold (FAOVN); CONDELL, Orla
**Cc:** PHUC, Nguyen Thi; LE, Van Tuan; Brioudes, Aurelie (FAORAP); Amanda Fine; Jeffrey McFarland; Inui, Ken (FAOVN)
**Subject:** Re: JRA pilot in Viet Nam

Dear all,

Dr Thuy (DAH) informed me yesterday that the ARES will be combined with tripartite meeting from 4-5 December only. OHP is providing logistic support to organize this event and we may have to coordinate with OHP to confirm the programme and participants.

Dr Thuy (DAH) also agreed to join the LISN National Workshop 6-7 December as we proposed with the understanding that GDPM will organize the event with financial support from WHO while FAO will support animal health participants. As agreed over Bun Cha, we will apply the JRA tool to LISN data during the LISN National Workshop, and I would like to propose the following way forward;

1. Update the LISN workshop concept note (attached) to include JRA application in the agenda (Leo, Hien). If you agree, we can use the title Coordinated Surveillance Risk Assessment Workshop"
2. Liaise with GDPM, DAH to fix the date and agreement on the agenda and participants (Satoko, Pawin)
3. Organized a one-day meeting among FAO, WHO, WCS and CDC to review the data requirement and availability (tentatively in November)

I am copying Amanda and Jeff as well. Any comment or suggestion is welcome. Once again, thank you very much for your kind collaboration.

With best regards,

**Celebrating 40 years in Viet Nam - #40yearsUNFAO**
--
**Pawin Padungtod**
Senior Technical Coordinator
Emergency Centre for Transboundary Animal Diseases (ECTAD)

**Food and Agriculture Organization of the United Nations (FAO)**
**Country Office for Viet Nam**

Green One UN House Building
No. 304, Kim Ma Street, Hanoi, Viet Nam
**Tel:** +84945436161, +842438501841
**Website:** FAO Viet Nam | FAO ECTAD Viet Nam

<image002.png>

---

**From:** "DO, Thi Hong Hien" <REDACTED>
**Date:** Tuesday, 25 September AD 2018 16:53
**To:** "Padungtod, Pawin (FAOVN)" <REDACTED>, Satoko Otsu REDACTED>, "Loth, Leopold (FAOVN)" <REDACTED>, "CONDELL, Orla" <REDACTED>
**Cc:** "PHUC, Nguyen Thi" <REDACTED>, "LE, Van Tuan" <REDACTED>
**Subject:** RE: JRA pilot in Viet Nam

Dear all,

Thank you for a very nice and productive lunch meeting today.
As discussed, attached pls find the following documents, for your review and reference:

- Latest version of JRA operational tool
- JRA 2 pager – WHO_WHE_CPI_CME document
- JRA Concept note and Agenda for the facilitator training in Rome
- JRA scenarios (pls note: of the 4 scenarios included, we did not work on the Ebola one but it was partially used in the first day discussion)
- Reporting back templates (in PPT form)
- Reporting back templates (in word form)
- Examples of group work reporting back for Rabies and AMR

Pls take your time to go through as we continue to explore a possibility of doing this in Viet Nam. If you think it would be helpful to meet and go through the docs together, I am happy to do so.

P.S. looping Dr Tuan from HCMC in from now on as he's the focal point for LISN in the South and is also knowledgeable on RA.

Best --- Hien

---

**From:** Padungtod, Pawin (FAOVN) REDACTED
**Sent:** 24 September 2018 15:47
**To:** OTSU, Satoko; DO, Thi Hong Hien; Loth, Leopold (FAOVN); PHUC, Nguyen Thi
**Cc:** CONDELL, Orla
**Subject:** RE: JRA pilot in Viet Nam

Dear Hien,

Tomorrow afternoon is fine. Otherwise, we can have lunch meeting at Bun Cha place (Nem Cua Bien).
If possible, please send outlook invitation.

With best regards,

**Celebrating 40 years in Viet Nam - #40yearsUNFAO**

**Pawin Padungtod**
Senior Technical Coordinator
Emergency Centre for Transboundary Animal Diseases (ECTAD)

**Food and Agriculture Organization of the United Nations (FAO)**
**Country Office for Viet Nam**

Green One UN House Building
No. 304, Kim Ma Street, Hanoi, Viet Nam
**Tel:** +84945436161, +84438501841
**Website:** FAO Viet Nam I FAO ECTAD Viet Nam

<image003.jpg>

---

**From:** OTSU, Satoko [REDACTED]
**Sent:** Monday, September 24, 2018 3:14 PM
**To:** DO, Thi Hong Hien <[REDACTED]>; Padungtod, Pawin (FAOVN) <[REDACTED]>; Loth, Leopold (FAOVN) <[REDACTED]>; PHUC, Nguyen Thi <[REDACTED]>
**Cc:** CONDELL, Orla <[REDACTED]>
**Subject:** RE: JRA pilot in Viet Nam

Dear Hien,
Welcome back!
Tomorrow is the best suit for me-☺
Thanks- Satoko

---

**From:** DO, Thi Hong Hien
**Sent:** Monday, September 24, 2018 3:00 PM
**To:** OTSU, Satoko; Padungtod, Pawin (FAOVN); [REDACTED]; PHUC, Nguyen Thi
**Cc:** CONDELL, Orla
**Subject:** JRA pilot in Viet Nam
**Importance:** High

Dear Satoko and all,

I just came back from the facilitator training workshop on Joint Risk Assessment (JRA), jointly conducted by FAO-OIE-WHO in Rome from 19-21 Sep.
First time for me to visit the FAO headquarters and it was nice ☺
May I propose that we meet again to discuss on our plan to have this JRA tool to be piloted in Viet Nam later this year. I will update you more when we meet on what we have learned and how we can be supported to conduct this pilot.

Pls let me know what of the following proposed time slots would work for you:

- Tuesday: between 15:00 -17:00
- Wednesday: between 10:00 -12:00 or 15:00 – 17:00
- Thursday: between 09:30 -12:00

Thank you very much,
Hien

<JRA OT pilots logistics and agenda_v3.docx>

**From:** "William B. Karesh" <karesh@ecohealthalliance.org>
**To:** Amanda Fine <[redacted]>
**Cc:** "predict@UCDAVIS.EDU" <predict@ucdavis.edu>
**Sent:** Fri, 5 Oct 2018 14:02:06 +0000
**Subject:** [predict] Fwd: JRA pilot in Viet Nam

FYI

Begin forwarded message:

**From:** Catherine Machalaba <machalaba@ecohealthalliance.org>
**Date:** October 4, 2018 at 5:22:28 PM EDT
**To:** "William B. Karesh" <karesh@ecohealthalliance.org>
**Subject: Re: JRA pilot in Viet Nam**

It's a new tool ;) It brings together human and animal risk assessment methods (developed by Liz and Sophie). I talked with Liz and she said the host government selects the hazard issue (it seems like it will be flu in Vietnam, but could be anything), frames the questions and concerns, and selects the assessment team based on the issue. The assessment team is tasked with bringing the data needed to answer the question in risk. WHO headquarters is helping to support the country by making the tool available and providing training for facilitators, but very hands-off on the actual workshop to ensure it's country-led.
I don't think it's an issue that LISN is behind schedule in Vietnam, because the JRA process will likely identify gaps and it's up to the country to prioritize what's needed. Even if they don't have new data to bring to it, it might put info together in new ways and help strengthen overall risk assessment capacity for the country.

It will be great if Amanda can join if she's available. Liz said it's fine for us to share this info with her and the wider PREDICT-2 team, though they're not sharing the tool itself until it goes through this round of country piloting.

Thanks!!!

Kind regards,
Catherine

**Catherine Machalaba, MPH**
*Policy Advisor*

EcoHealth Alliance
460 West 34th Street – 17th floor
New York, NY 10001

[redacted]
www.ecohealthalliance.org

*Chair*, Veterinary Public Health Special Primary Interest Group, American Public Health Association

*Program Officer*, IUCN SSC Wildlife Health Specialist Group

*Science Officer,* Future Earth oneHEALTH Project

***EcoHealth Alliance leads cutting-edge scientific research into the critical connections between human and wildlife health and delicate ecosystems. With this science, we develop solutions that prevent pandemics and promote conservation.***

On Oct 4, 2018, at 10:03 AM, William B. Karesh <karesh@ecohealthalliance.org> wrote:

Is the JRA a new name for something else? Or is it really a another new tool?
BK

Sent from my iPhone

**William B. Karesh, D.V.M**
*Executive Vice President for Health and Policy*

EcoHealth Alliance
460 West 34th Street - 17th Floor
New York, NY 10001 USA

+1.212.380.4463 (direct)
+1.212.380.4465 (fax)
www.ecohealthalliance.org

President, OIE Working Group on Wildlife

Co-chair, IUCN Species Survival Commission - Wildlife Health Specialist Group

EPT Partners Liaison, USAID Emerging Pandemic Threats - PREDICT-2 Program

***EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that promote conservation and prevent pandemics.***

Begin forwarded message:

**From:** Amanda Fine <REDACTED>
**Date:** October 4, 2018 at 2:19:32 AM EDT
**To:** "karesh@ecohealthalliance.org" <karesh@ecohealthalliance.org>, Catherine Machalaba <Machalaba@ecohealthalliance.org>
**Cc:** Tracey Goldstein <tgoldstein@ucdavis.edu>, Christine Kreuder Johnson <ckjohnson@ucdavis.edu>, Sarah Olson <REDACTED>
**Subject: Fwd: Re: JRA pilot in Viet Nam**

Dear Billy and Catherine,

See below Pawin's reply to my inquiry confirming that FAO and WHO in Viet Nam envision applying the JRA tool to LISN data at the January 2019 workshop. Note that as I mentioned on the PREDICT EB call, FAO (and WHO) are way behind in what they planned to do under LISN. Pawin is still talking about "samples to be tested this year" and we all know that if samples are not already in the testing phase that we are unlikely to have final results, interpretation, and clearance by government in time for a January 2019 workshop. Though in Vietnam things can move fast when government wants them to.....

I will add these issues to my "talking points" as we prepare for the LISN review that Andrew Clements has requested. Copying Chris, Tracey, and Sarah to keep them in the loop on these LISN related points.

No need to reply. Just wanted to keep you informed and aware of the description Pawin has provided below about the FAO/WHO goals for the JRA pilot in Vietnam.

Cheers,

Amanda

-------- Forwarded Message --------
**Subject:**Re: JRA pilot in Viet Nam
**Date:**Wed, 3 Oct 2018 22:39:53 +0000
**From:**Padungtod, Pawin (FAOVN) <REDACTED>
**To:**Amanda Fine <REDACTED>

Dear Amanda,

The JRA is a tripartite tool developed by HQ (FAO-OIE-WHO) which was piloted in Indonesia earlier. The plan is to use it in Viet Nam and we (FAO-WHO) agree that it would be useful to apply this JRA tool to LISN data (otherwise, we do not see additional benefit on top of what we are already doing).

I have asked Ken to prepare summary of the results and samples to be tested this year before the call with USAID (still don't know when). There may be a pre-call meeting where we can share update results.

Cheers,

**Celebrating 40 years in Viet Nam - #40yearsUNFAO**
--
**Pawin Padungtod**
Senior Technical Coordinator
Emergency Centre for Transboundary Animal Diseases (ECTAD)

**Food and Agriculture Organization of the United Nations (FAO)**
**Country Office for Viet Nam**
Green One UN House Building
No. 304, Kim Ma Street, Hanoi, Viet Nam
**Tel:** +84945436161, +842438501841
**Website:** FAO Viet Nam | FAO ECTAD Viet Nam



---

**From:** Amanda Fine <[REDACTED]
**Organization:** WCS
**Date:** Wednesday, 3 October AD 2018 16:29
**To:** "Padungtod, Pawin (FAOVN)" <[REDACTED]
**Subject:** Fwd: RE: JRA pilot in Viet Nam

Hello Pawin,

I have been catching up on this e-mail chain, and appreciate being included, but since I missed the in-person meeting I just wanted to ask or clarify if this workshop is being proposed as part of LISN and/or FAO's broader influenza surveillance work? Either way we are happy to participate and be involved.

I am back in Hanoi now after a couple weeks away. It would be good to catch up over lunch sometime soon. We still need to figure out our issues with getting influenza samples typed. I heard via the grapevine that Ken was not able to figure out the problems during his time at RAHO6 in September.

Cheers,

Amanda

-------- Forwarded Message --------

**Subject:** RE: JRA pilot in Viet Nam

**Date:** Tue, 2 Oct 2018 09:03:44 +0000

**From:** MUMFORD, Elizabeth [REDACTED]

**To:** Brioudes, Aurelie (FAORAP) [REDACTED], Padungtod, Pawin

(FAOVN) <[redacted]>

**CC:** OTSU, Satoko <[redacted]>, DO, Thi Hong Hien <[redacted]>, Loth, Leopold (FAOVN) <[redacted]>, CONDELL, Orla <condello@who.int>, VonDobschuetz, Sophie (AGAH) <[redacted]>, Wongsathapornchai, Kachen (FAORAP) <[redacted]>, Sinclair, Julie (CDC/OID/NCEZID) <bwg5@cdc.gov>, PHUC, Nguyen Thi <[redacted]> LE, Van Tuan <[redacted]>, Amanda Fine <[redacted]>, Jeffrey McFarland <[redacted]>, Inui, Ken (FAOVN) <[redacted]>, Moore, Matt (CDC/CGH/DGHP) <zdn4@cdc.gov>, RYAN, Caroline [redacted]

Dear Aurelie and the team

Thank you so much – congratulations on getting this moving so quickly!

I could make myself available to help facilitate this pilot.

Just a quick reminder that we would highly suggest having three days of workshop as well as a facilitator training day – or at least ½ day facilitator training, and 2.5 days of workshop. But as mentioned in Rome, we can make anything work assuming available funds.

Hien and Aurelie: The updated materials from the Rome workshop – e.g. the logistics and agenda document and the new tool version - will soon be on the new shared drive, but here attached is the latest version of the logistics document if you need to support your planning.

Best

Liz

Dr Elizabeth Mumford
One Health Country Operations team
Department of Country Health Emergency Preparedness and IHR
World Health Organization
1211 Geneva 27
Switzerland
[redacted]

---

**From:** Brioudes, Aurelie (FAORAP) <[redacted]>
**Sent:** Tuesday, October 2, 2018 4:45
**To:** Padungtod, Pawin (FAOVN) <[redacted]>
**Cc:** OTSU, Satoko <[redacted]>; DO, Thi Hong Hien <[redacted]>; Loth, Leopold (FAOVN) <[redacted]>; CONDELL, Orla <[redacted]>; VonDobschuetz, Sophie (AGAH) <[redacted]>; Wongsathapornchai, Kachen (FAORAP) <[redacted]>; MUMFORD, Elizabeth <[redacted]>; Sinclair, Julie (CDC/OID/NCEZID) <bwg5@cdc.gov>; PHUC, Nguyen Thi <[redacted]>; LE, Van Tuan <[redacted]> Amanda Fine<[redacted]>; Jeffrey McFarland <[redacted]>; Inui, Ken (FAOVN) <[redacted]>; Moore, Matt (CDC/CGH/DGHP) <zdn4@cdc.gov>
**Subject:** RE: JRA pilot in Viet Nam

Thanks for this clarification. That makes it logistically easier!

Waiting to hear back from JRA Secretariat colleagues with their views on their involvement

in this VN pilot, knowing well enough how difficult it is to identify a week that suit both Human and Animal sectors within the country so hopefully the suggested week will suit at least one of them.

Best regards,
Aurelie

---

**From:** Padungtod, Pawin (FAOVN)
**Sent:** Tuesday, October 02, 2018 9:37 AM
**To:** Brioudes, Aurelie (FAORAP) <[redacted]>
**Cc:** OTSU, Satoko <[redacted]>; DO, Thi Hong Hien <[redacted]>; Loth, Leopold (FAOVN) <[redacted]>; CONDELL, Orla <[redacted]>; VonDobschuetz, Sophie (AGAH) <[redacted]>; Wongsathapornchai, Kachen (FAORAP) <[redacted]>; MUMFORD, Elizabeth <[redacted]>; Sinclair, Julie (CDC/OID/NCEZID) <bwg5@cdc.gov>; PHUC, Nguyen Thi <[redacted]>; LE, Van Tuan [redacted]>; Amanda Fine <[redacted]>; Jeffrey McFarland <[redacted]>; Inui, Ken (FAOVN) <[redacted]>; Moore, Matt (CDC/CGH/DGHP) <zdn4@cdc.gov>
**Subject:** Re: JRA pilot in Viet Nam

Dear Aurélie,

Your understanding is correct. All training and workshop will be in January. Apology for the confusion.

With best regards,

**Celebrating 40 years in Viet Nam - #40yearsUNFAO**

**Pawin Padungtod**
Senior Technical Coordinator
Emergency Centre for Transboundary Animal Diseases (ECTAD)

**Food and Agriculture Organization of the United Nations (FAO)**
**Country Office for Viet Nam**
Green One UN House Building
No. 304, Kim Ma Street, Hanoi, Viet Nam
**Tel:** +84945436161, +84438501841
**Website:** FAO Viet Nam | FAO ECTAD Viet Nam

On 2 Oct 2018, at 09:08, Padungtod, Pawin (FAOVN) <[redacted]> wrote:

> Dear Aurelie,
>
> The training is planned for 7 December 2018 back to back with ARES meeting in Hanoi. The workshop is planned for 8-9 January 2019 before OIE AMU workshop also in Hanoi.
>
> Thank you and best regards,
>
> **Celebrating 40 years in Viet Nam - #40yearsUNFAO**
>
> **Pawin Padungtod**
> Senior Technical Coordinator
> Emergency Centre for Transboundary Animal Diseases (ECTAD)

**Food and Agriculture Organization of the United Nations (FAO)**
**Country Office for Viet Nam**
Green One UN House Building
No. 304, Kim Ma Street, Hanoi, Viet Nam
**Tel:** +84945436161, +84438501841
**Website:** FAO Viet Nam | FAO ECTAD Viet Nam

On 2 Oct 2018, at 08:55, Brioudes, Aurelie (FAORAP) <[REDACTED]> wrote:

Dear all,

Very glad to see that Vietnam is moving quickly on this matter!

While Hien and I attended the JRA training in Rome few weeks ago and will thus help conducting and facilitating the JRA pilot in Vietnam, it was mentioned during the training that at least one Master Trainer from the JRA Secretariat would be expected to participate in the pilots so they can i) lead/assist with the JRA facilitation; ii) Compile feedback from this pilot (in Vietnam and the ones that will be done in other countries latter on) in view of ultimately fine-tuning and finalizing the JRA tool. So I am here including Master trainers - FAO/OIE/WHO JRA Coordinators (Kachen & Sophie, Liz and Julie) to this email list.

Dear Sophie, Liz and Julie,

Vietnam is tentatively planning to conduct the JRA pilot the week of 7 January 2019. Would this week work for at least one of you to come (I suppose it would take place in Hanoi) and conduct this JRA with Hien (WHO Vietnam) and I (FAO RAP). Kachen will still be on contract break that week and will not be able to make it unfortunately.

Dear Pawin and Satoko,

Thanks again for connecting with GoV (MoH/GDPM and MARD/DAH) and advocating for this JRA pilot in Vietnam. While option 3 seems to be the consensus, would it be possible to plan the activities towards the end of that week (Wed-Fri) instead? I (and others I suspect depending on who would come from FAO/WHO/OIE HQ?) will just be back from End Of the Year Holidays on 7 Jan so starting the pilot from Monday would not work for me (understanding that it was meant 7 January in Pawin's email below; not 7 Dec).

Thanks and best regards,
Aurelie

---

**From:** OTSU, Satoko [[REDACTED]]
**Sent:** Tuesday, October 02, 2018 7:06 AM
**To:** Padungtod, Pawin (FAOVN) <[REDACTED]>; DO, Thi Hong Hien <[REDACTED]>; Loth, Leopold (FAOVN) <[REDACTED]>; CONDELL, Orla <[REDACTED]>
**Cc:** PHUC, Nguyen Thi <[REDACTED]>; LE, Van Tuan <[REDACTED]>; Brioudes, Aurelie (FAORAP) <[REDACTED]>; Amanda Fine <[REDACTED]>; Jeffrey McFarland <[REDACTED]>; Inui, Ken (FAOVN) <[REDACTED]>; 'Moore, Matt (CDC/CGH/DGHP)' <zdn4@cdc.gov>

**Subject:** RE: JRA pilot in Viet Nam

Dear Pawin, Hien,

Thank you for your leadership and proactive action!

I do agree with option 3, too. But do we need two concept notes? If it covers the same purpose I think one is enough?
A current concept note is already detailed and well written. Also from WHO point of view, it is easier to make it in one DFC.

But of course, I am open and leave it on you if you have any issue administratively.

Thanks - Satoko

---

**From:** Padungtod, Pawin (FAOVN)
[REDACTED]
**Sent:** Tuesday, October 2, 2018 6:46 AM
**To:** DO, Thi Hong Hien; OTSU, Satoko; Loth, Leopold (FAOVN); CONDELL, Orla
**Cc:** PHUC, Nguyen Thi; LE, Van Tuan; Brioudes, Aurelie (FAORAP); Amanda Fine; Jeffrey McFarland; Inui, Ken (FAOVN); 'Moore, Matt (CDC/CGH/DGHP)'
**Subject:** Re: JRA pilot in Viet Nam

Dear Hien,

I do agree with option 3 and will confirm with DAH today.
If it is confirmed, we will need TWO concept note;

1. One-day JRA training (7DEC) for facilitator only
2. Two-day National Coordinated Surveillance Risk Assessment Workshop (8-9JAN2018?). We can do JRA on the first day with technical staff and include leaders on the second day for information sharing and advocacy.

Thank you and best regards,

**Celebrating 40 years in Viet Nam - #40yearsUNFAO**
--
**Pawin Padungtod**
Senior Technical Coordinator
Emergency Centre for Transboundary Animal Diseases (ECTAD)

**Food and Agriculture Organization of the United Nations (FAO)**
**Country Office for Viet Nam**
Green One UN House Building
No. 304, Kim Ma Street, Hanoi, Viet Nam
**Tel:** +84945436161, +842438501841
**Website:** FAO Viet Nam | FAO ECTAD Viet Nam

<image001.png>

---

**From:** "DO, Thi Hong Hien" <[REDACTED]>
**Date:** Monday, 1 October AD 2018 17:25
**To:** "Padungtod, Pawin (FAOVN)" <[REDACTED]>, Satoko Otsu <[REDACTED]>, "Loth, Leopold (FAOVN)" <[REDACTED]>, "CONDELL, Orla"

<[REDACTED]>
**Cc:** "PHUC, Nguyen Thi" <[REDACTED]>, "LE, Van Tuan" <[REDACTED]>, "Brioudes, Aurelie (FAORAP)" <[REDACTED]>, Amanda Fine <[REDACTED]>, Jeffrey McFarland <[REDACTED]>, "Inui, Ken (FAOVN)" <[REDACTED]>, "'Moore, Matt (CDC/CGH/DGHP)'" <zdn4@cdc.gov>
**Subject:** RE: JRA pilot in Viet Nam

Dear Pawin and all,

Thank you very much for your email.
I have discussed with GDPM on this proposed activity. In principles, they agreed on the objectives, scope and participants for the Coordinated Surveillance Risk Assessment Workshop. Regarding the dates, they have proposed the following three options, each with pros and cons for our consideration and continued discussion:

- **Option 1**: from afternoon Thu 6 Dec to noon Sat 8 Dec (if ARES indeed can't be finished within 2 days 4-5 Dec). According to GDPM the dates for ARES 4-6 Dec have been confirmed and will be difficult to change. Pls re-discuss this with DAH, GDPM and those involved.
- **Option 2**: ARES finishes on 6 Dec. On Fri 7 Dec to organize a pre-training on JRA for facilitators. Then on JRA workshop to be conducted on 10-11 Dec, ideally outside of Ha Noi to ensure optimal participation and quality outcome.
- **Option 3**: **which is most preferable by GDPM** is to conduct this event in the week of 7 January 2019. In their opinion, December will be pretty occupied for all government agencies due to approaching the end of government fiscal year, thus no assurance on good turn-out of relevant participants. They think first 2 weeks of January would be much more optimistic. However they also understand the complex nature of getting multi-sectoral agreement on the timeframe thus is willing to try their best to accommodate what works best for all.

I will send you the revised concept note in a separate email.
Happy to discuss further.

Hien

**From:** Padungtod, Pawin (FAOVN)
[[REDACTED]]
**Sent:** 27 September 2018 08:37
**To:** DO, Thi Hong Hien; OTSU, Satoko; Loth, Leopold (FAOVN); CONDELL, Orla
**Cc:** PHUC, Nguyen Thi; LE, Van Tuan; Brioudes, Aurelie (FAORAP); Amanda Fine; Jeffrey McFarland; Inui, Ken (FAOVN)
**Subject:** Re: JRA pilot in Viet Nam

Dear all,

Dr Thuy (DAH) informed me yesterday that the ARES will be combined with tripartite meeting from 4-5 December only. OHP is providing logistic support to organize this event and we may have to coordinate with OHP to confirm the programme and participants.

Dr Thuy (DAH) also agreed to join the LISN National Workshop 6-7 December as we proposed with the understanding that GDPM will organize the event with financial support from WHO while FAO will support animal health participants. As agreed over Bun Cha, we will apply the JRA tool to LISN data during the LISN National Workshop, and I would like to propose the following way forward;

1. Update the LISN workshop concept note (attached) to include JRA application in the agenda (Leo, Hien). If you agree, we can use the title Coordinated Surveillance Risk Assessment Workshop"
2. Liaise with GDPM, DAH to fix the date and agreement on the agenda and participants (Satoko, Pawin)
3. Organized a one-day meeting among FAO, WHO, WCS and CDC to review the data requirement and availability (tentatively in November)

I am copying Amanda and Jeff as well. Any comment or suggestion is welcome. Once again, thank you very much for your kind collaboration.

With best regards,

**Celebrating 40 years in Viet Nam - #40yearsUNFAO**
--
**Pawin Padungtod**
Senior Technical Coordinator
Emergency Centre for Transboundary Animal Diseases (ECTAD)

**Food and Agriculture Organization of the United Nations (FAO)**
**Country Office for Viet Nam**
Green One UN House Building
No. 304, Kim Ma Street, Hanoi, Viet Nam
**Tel:** +84945436161, +842438501841
**Website:** FAO Viet Nam I FAO ECTAD Viet Nam

<image002.png>

---

**From:** "DO, Thi Hong Hien" <REDACTED>
**Date:** Tuesday, 25 September AD 2018 16:53
**To:** "Padungtod, Pawin (FAOVN)" <REDACTED>, Satoko Otsu <REDACTED>, "Loth, Leopold (FAOVN)" <REDACTED>, "CONDELL, Orla" <REDACTED>
**Cc:** "PHUC, Nguyen Thi" <REDACTED>, "LE, Van Tuan" <REDACTED>
**Subject:** RE: JRA pilot in Viet Nam

Dear all,

Thank you for a very nice and productive lunch meeting today. As discussed, attached pls find the following documents, for your review and reference:

- Latest version of JRA operational tool
- JRA 2 pager – WHO_WHE_CPI_CME document
- JRA Concept note and Agenda for the facilitator training in Rome
- JRA scenarios (pls note: of the 4 scenarios included, we did not work on the Ebola one but it was partially used in the first day discussion)
- Reporting back templates (in PPT form)
- Reporting back templates (in word form)
- Examples of group work reporting back for Rabies and AMR

Pls take your time to go through as we continue to explore a possibility of doing this in Viet Nam. If you think it would be helpful to meet and go through the docs together, I am happy to do so.

P.S. looping Dr Tuan from HCMC in from now on as he's the focal point for LISN in the South and is also knowledgeable on RA.

Best --- Hien

---

**From:** Padungtod, Pawin (FAOVN) [REDACTED]
**Sent:** 24 September 2018 15:47
**To:** OTSU, Satoko; DO, Thi Hong Hien; Loth, Leopold (FAOVN); PHUC, Nguyen Thi
**Cc:** CONDELL, Orla
**Subject:** RE: JRA pilot in Viet Nam

Dear Hien,

Tomorrow afternoon is fine. Otherwise, we can have lunch meeting at Bun Cha place (Nem Cua Bien).
If possible, please send outlook invitation.

With best regards,

**Celebrating 40 years in Viet Nam - #40yearsUNFAO**

**Pawin Padungtod**
Senior Technical Coordinator
Emergency Centre for Transboundary Animal Diseases (ECTAD)

**Food and Agriculture Organization of the United Nations (FAO)**
**Country Office for Viet Nam**
Green One UN House Building
No. 304, Kim Ma Street, Hanoi, Viet Nam
**Tel:** +84945436161, +84438501841
**Website:** FAO Viet Nam I FAO ECTAD Viet Nam



---

**From:** OTSU, Satoko [REDACTED]
**Sent:** Monday, September 24, 2018 3:14 PM
**To:** DO, Thi Hong Hien <[REDACTED]>; Padungtod, Pawin (FAOVN) <[REDACTED]>; Loth, Leopold (FAOVN) <[REDACTED]>; PHUC, Nguyen

Thi <[redacted]>
**Cc:** CONDELL, Orla <[redacted]>
**Subject:** RE: JRA pilot in Viet Nam

Dear Hien,
Welcome back!
Tomorrow is the best suit for me-☺
Thanks- Satoko

---

**From:** DO, Thi Hong Hien
**Sent:** Monday, September 24, 2018 3:00 PM
**To:** OTSU, Satoko; Padungtod, Pawin (FAOVN); [redacted]; PHUC, Nguyen Thi
**Cc:** CONDELL, Orla
**Subject:** JRA pilot in Viet Nam
**Importance:** High

Dear Satoko and all,

I just came back from the facilitator training workshop on Joint Risk Assessment (JRA), jointly conducted by FAO-OIE-WHO in Rome from 19-21 Sep.
First time for me to visit the FAO headquarters and it was nice ☺
May I propose that we meet again to discuss on our plan to have this JRA tool to be piloted in Viet Nam later this year. I will update you more when we meet on what we have learned and how we can be supported to conduct this pilot.

Pls let me know what of the following proposed time slots would work for you:

- Tuesday: between 15:00 -17:00
- Wednesday: between 10:00 -12:00 or 15:00 – 17:00
- Thursday: between 09:30 -12:00

Thank you very much,
Hien

**From:** [redacted]
**To:** Cara Chrisman <cchrisman@usaid.gov>, Dennis Carroll <dcarroll@usaid.gov>, Samantha Maher <maher@ecohealthalliance.org>, Peter Daszak <daszak@ecohealthalliance.org>, "nwolfe@metabiota.com" <nwolfe@metabiota.com>, Eddy Rubin <erubin@metabiota.com>, Jonna Mazet <jkmazet@ucdavis.edu>
**Subject:** Finalize GVP script for animated video
**Sent:** Tue, 6 Nov 2018 23:35:04 +0000
REDACTED Animation Script_1hf (002)_et.docx

Hi everyone,
The script for the GVP animated video is in! We have until Monday Nov 12 to finalize the script. After that, no more revisions. Please send general comments or specific revision requests to me by our call this Thursday Nov 8. Some specific questions below:

- Dennis and Cara – Would you prefer to cut out the mention for USAID (and PREDICT?) altogether?
- Peter and Sam – Can you double check the numbers that are used in the script (i.e. "1.5 million viruses")?
- Eddy and Nathan – Are you comfortable with how the database is described and its accessibility?
- All – do we want specific mention of the Human Genome Project? Any general comments, revisions, thoughts?

I have copied the script for your convenience. Details of the animations and scene changes are outlined in the document attached.

**Script:**

Did you know that 75% of emerging infectious diseases are originally found in animals? You might be surprised to learn that there are 1.5 million viruses which can be transmitted to us from other animals. Viruses which can be transmitted to humans from other animals are called zoonotic viruses, and their health and economic impacts can be devastating. Zoonotic viruses are emerging at an ever-increasing rate and the cost of controlling them is astronomical. To better prepare for future outbreaks and pandemics, a change in attitude is required - from being reactive, to proactive.

The international team behind the Global Virome Project are leading the way towards better preparedness for future pandemics. This pioneering global partnership between organisations in the environmental, animal, and human health sectors will detect and characterise unknown viral threats from wild animals from around the world. The huge scope of this project encompasses collecting genetic information on viruses, as well as the ecological data to be stored in a database. This database will be used to better understand not only the viral traits, but also  of viruses. To achieve this, the Global Virome Project uses a targeted surveillance strategy to sample from wildlife. This database is not a prediction tool for future pandemics but will work to monitor trends and patterns in viral outbreaks.  By ensuring viral threats in animal populations are properly monitored this project will help to prevent spill over to humans.

Data collection of this scale is a mammoth undertaking and could appear overwhelming. However, the viability of the Global Virome Project has already been proven by the success of a previous project. The PREDICT project, by USAID, has operated in over 30 countries for more than nine years. So far the PREDICT project has discovered over 1000 viruses. The Global Virome Project will build on this existing system and share initiatives to achieve even greater success in the future. The PREDICT project is not the only established initiative which the Global Virome Project takes inspiration from. The Human Genome Project, established in the late 1980s, proved itself revolutionary by stimulating increased investment and interest in genomics. The high expectations established for the Global Virome Project see it set to match the phenomenal Halo effect created by the Human Genome Project. The unprecedented amount of available data will lead to great strides in the advancement of global health practices. Ultimately, the work conducted by the Global Virome Project encourages the global community to act proactively to save human lives from zoonotic viruses.

Thanks!

[redacted]

**From:** Hannah [mailto:hannah@sciani.com]
**Sent:** Tuesday, November 06, 2018 1:08 AM
**To:** [redacted]
**Subject:** SCI ANI: Voiceover script approval
**Importance:** High

Dear [redacted]

I hope you're well.

The draft voiceover script for your animation is now ready for approval. Please find attached.

Please be aware that once the script is approved it will be sent to the voiceover artist. Once approval is given, **the script is considered finalised**. **Any changes to the script after this point will mean an extra charge and could potentially affect the agreed deadline date.** ***We recommend that you circulate the script across the company and team at this stage to avoid later changes.***

Please can you:

1. **Check through the script** - please read through it carefully.
   If there are any changes you would like made, please either email them or edit the document directly (using Track Changes).
   Bear in mind:

   a. To fill the video's 3-minute timeframe the script must not exceed 420 words. So, while we will do our best, we cannot add substantial information to the script.

2. **Check the scene descriptions**. These describe what will happen at each moment in the animation. If you need more detail or would like to see changes, please just let us know. We want to make sure you are happy before we move on to animation stage in order to keep any amends to simple tweaks.
3. **Respond to queries**. Where we need some information or example images from you, we have indicated this in the queries column. Providing images will help our animation team to create accurate images first time round.

Once you have checked the full draft script, please send it back to me. I will then make any changes and send it to the animator. Once the animation is completed, I will send it to you for your feedback and approval – we will not publish anything without your approval.

Please can you check the draft script and get back to me by Monday 12th November.

I look forward to receiving your feedback.

Best regards,

Hannah Fraser
Animation Editor
Sci Ani

**T:** +44 (0)1453 827934
**W**: www.sciani.com
**E:** hannah@sciani.com

Sci Ani
SCIENCE ANIMATED

IMPORTANT INFORMATION
This email may contain information that is privileged, confidential or otherwise protected from disclosure. It may not be used by, or its contents copied or disclosed to, persons other than the address(ees). If you have received this email in error please notify the sender immediately and delete the email.

Whilst Research Publishing International Ltd has taken every reasonable precaution to minimise the risk of viruses, we cannot accept liability for any damage that is sustained as a result of software viruses which may be contained in this email.

If you do not wish to receive emails from Research Publishing International Ltd in the future please reply to this email with 'remove' in the subject line.

# Animation Script for Approval

| | |
|---|---|
| **Client Name** | REDACTED **on behalf of the Global Virome Project Steering Committee** |
| **Title** | **Mapping Zoonotic Viruses Goes Global; Zoonotic Viruses Around the World** |
| **Word Count** | **420** |
| **Format and Length** | **2D with 3D elements (x2)- 03.00** |

| Word Count | Text | Scene description | Client comments/queries | Notes for Animator |
|---|---|---|---|---|
| 9 | 1. Did you know that 75% of emerging infectious diseases are originally found in animals? | A large question mark appears as a watermark in the background with the following text on screen:<br><br>Did you know you can catch viruses from animals? | For the question mark or background colour: we usually use green in our materials (Global Virome Project theme colour). | |
| 21 | 2. You might be surprised to learn that there are 1.5 million viruses which can be transmitted to us from other animals. | A 3D image of the world and figures of animals, stylised viruses and humans. | For stylised viruses, we can have more variety in "viruses" than the spherical structure with the same spikes (i.e. model the structure of filovirus (long and string-like) and rhabdovirus (bullet shaped), in addition to the commonly used coronavirus-like spherical and spikey) | |
| 23 | 3. Viruses which can be transmitted to humans from other animals are | A virus passes between an animal and a human.<br>The human becomes ill (could turn | Instead of spots, we prefer to have the human changing colour. | |

| | | | | |
|---|---|---|---|---|
| | 4. called zoonotic viruses, and their health and economic impacts can be devastating. | green/develop spots etc). | | |
| 17 | 5. Zoonotic viruses are emerging at an ever-increasing rate and the cost of controlling them is astronomical. | Virus symbols popping up all over the globe (shown earlier- now in 2D). Pound/dollar/Euro/Thai Baht/Chinese Yuan/Japanese Yen symbols popping up over the globe wherever the virus symbols have been. | Can we have virus symbols pop up over the globe, then have a lot of different currencies piling on top of where the virus was, as if to "extinguish" it like a fire? (I hope that makes sense) | |
| 17 | 6. To better prepare for future outbreaks and pandemics, a change in attitude is required - from being reactive, to proactive. | Group of scientists at a clipboard/computer planning. | Perhaps we can have the word "Reactive", then overlap/push away/overwrite with the word "Proactive". | |
| 24 | 7. The international team behind the Global Virome Project are leading the way towards better preparedness for future pandemics. | A team of scientists and policy makers of various nationalities positioned around the globe. | | Make this a diverse team (gender and ethnically). Some people in business suits, some in white coats, some in coveralls (fieldworkers). |
| 23 | 8. This pioneering global partnership between organisations in the environmental, animal, and human health | A magnifying glass zooms in on an animal (suggest a bat or primate as mentioned in paper) and a 3D virus is shown. | In order of preference for choice of animals: bat, rodent, primate | |

| | | | | |
|---|---|---|---|---|
| | 9. sectors will detect and characterise unknown viral threats from wild animals from around the world. | | | |
| 18 | 10. The huge scope of this project encompasses collecting genetic information on viruses, as well as the ecological data to be stored in a database. | Computer screen with multiple lines of data scrolling past. | | |
| 17 | 11. This database will be used to better understand not only the viral traits, but also of viruses. | The magnifying glass now zooms in on the virus. This is the second 3D image. The virus rotates showing its features. | | |
| 17 | 12. To achieve this, the Global Virome Project uses a targeted surveillance strategy to sample from wildlife. | As the magnifying glass zooms out, a long line of animal icons can be seen. | Please include bats, rats, mice, ducks, and monkeys, among other animals. I deleted humans for now. | |
| 22 | 13. This database is not a prediction tool for future pandemics but will work to monitor trends and patterns in viral outbreaks. | A computer screen shows a globe with a flashing red virus symbol.<br><br>The data is recorded on a spreadsheet. | | |

| | | | | |
|---|---|---|---|---|
| 20 | 14. By ensuring viral threats in animal populations are properly monitored this project will help to prevent spill over to humans. | Scientists form a barrier between animals carrying viruses (shown with symbols above them) and humans. | | |
| 13 | 15. Data collection of this scale is a mammoth undertaking and could appear overwhelming. | Piles of paper shown beside a previous shot of queue of animals and humans. | | |
| 19 | 16. However, the viability of the Global Virome Project has already been proven by the success of a previous project. | GVP organisation symbol with a large green tick alongside. | | Logos here: https://www.dropbox.com/sh/zeoy2vn7lkkh0p6/AAC9_HbIIa6-w0q7RBHA8m5Aa?dl=0 |
| 16 | 17. The PREDICT project, by USAID, has operated in over 30 countries for more than nine years. | Countries light up around the world with the PREDICT logo/symbol. | **Predict logo to be provided** | |
| 10 | 18. So far the PREDICT project has discovered over 1000 viruses. | The PREDICT logo appears and is overshadowed by "1000." | **Predict logo to be provided** | |
| 21 | 19. The Global Virome Project will build on this existing system and share initiatives to | Two scientists shaking hands- one wears GVP logo, the other wears PREDICT logo. | **Predict logo to be provided** | Logos here: https://www.dropbox.com/sh/zeoy2vn7lkkh0p6/AAC9_HbIIa6-w0q7RBHA8m5Aa?dl=0 |

| | | | | |
|---|---|---|---|---|
| | 20. achieve even greater success in the future. | | | |
| 17 | 21. The PREDICT project is not the only established initiative which the Global Virome Project takes inspiration from. | A thought bubble appears showing the words Human Genome Project. | | |
| 21 | 22. The Human Genome Project, established in the late 1980s, proved itself revolutionary by stimulating increased investment and interest in genomics. | Crowds of people and piles of money pop up surrounding the text Human Genome Project. | | |
| 27 | 23. The high expectations established for the Global Virome Project see it set to match the phenomenal Halo effect created by the Human Genome Project. | The text Global Virome Project break through the imagery from the previous scene.<br>The text Global Virome Project are surrounded by a glowing halo. | | |
| 23 | 24. The unprecedented amount of available data will lead to great strides in the advancement of global | Scientists of assorted nationalities surround a computer in a lab. | | |

| | | | | |
|---|---|---|---|---|
| | 25. health practices. | | | |
| 26 | 26. Ultimately, the work conducted by the Global Virome Project encourages the global community to act proactively to save human lives from zoonotic viruses. | The scientists work (labs/microscopes/discussion groups).<br><br>The globe appears again and this time the virus symbols disappear. | | |
| | | Logos to end the animation | | Logos here: https://www.dropbox.com/sh/zeoy2vn7lkkh0p6/AAC9_HbIIa6-w0q7RBHA8m5Aa?dl=0 |

**From:** Dennis Carroll <dcarroll@usaid.gov>
**Sent:** Tue, 6 Nov 2018 16:41:38 -0800
**Subject:** Re: Finalize GVP script for animated video
**To:** [redacted]>
**Cc:** Cara Chrisman <cchrisman@usaid.gov>, Samantha Maher <maher@ecohealthalliance.org>, Peter Daszak <daszak@ecohealthalliance.org>, "nwolfe@metabiota.com" <nwolfe@metabiota.com>, Eddy Rubin <erubin@metabiota.com>, Jonna Mazet <jkmazet@ucdavis.edu>

No need to cut out references to USAID or Predict (say it loud, say it proud) but more importantly there needs to be emphasis on "this is a global partnership and despite the proof of concept NOT A USG project"

Dr Dennis Carroll
Director
Emerging Threats
Global Health
USAID
301-646-6235

On Nov 6, 2018, at 6:35 PM, [redacted] wrote:

Hi everyone,
The script for the GVP animated video is in! We have until Monday Nov 12 to finalize the script. After that, no more revisions. Please send general comments or specific revision requests to me by our call this Thursday Nov 8. Some specific questions below:

- Dennis and Cara – Would you prefer to cut out the mention for USAID (and PREDICT?) altogether?
- Peter and Sam – Can you double check the numbers that are used in the script (i.e. "1.5 million viruses")?
- Eddy and Nathan – Are you comfortable with how the database is described and its accessibility?
- All – do we want specific mention of the Human Genome Project? Any general comments, revisions, thoughts?

I have copied the script for your convenience. Details of the animations and scene changes are outlined in the document attached.

**Script:**

Did you know that 75% of emerging infectious diseases are originally found in animals? You might be surprised to learn that there are 1.5 million viruses which can be transmitted to us from other animals. Viruses which can be transmitted to humans from other animals are called zoonotic viruses, and their health and economic impacts can be devastating. Zoonotic viruses are emerging at an ever-increasing rate and the cost of controlling them is astronomical. To better prepare for future outbreaks and pandemics, a change in attitude is required - from being reactive, to proactive.

The international team behind the Global Virome Project are leading the way towards better preparedness for future pandemics. This pioneering global partnership between organisations in the environmental, animal, and human health sectors will detect and characterise unknown viral threats from wild animals from around the world. The huge scope of this project encompasses collecting genetic information on viruses, as well as the ecological data to be stored in a database. This database will be used to better understand not only the viral traits, but also  of viruses. To achieve this, the Global Virome Project uses a targeted surveillance strategy to sample from wildlife. This database is not a prediction tool for future pandemics but will work to monitor trends and patterns in viral outbreaks.  By

ensuring viral threats in animal populations are properly monitored this project will help to prevent spill over to humans.

Data collection of this scale is a mammoth undertaking and could appear overwhelming. However, the viability of the Global Virome Project has already been proven by the success of a previous project. The PREDICT project, by USAID, has operated in over 30 countries for more than nine years. So far the PREDICT project has discovered over 1000 viruses. The Global Virome Project will build on this existing system and share initiatives to achieve even greater success in the future. The PREDICT project is not the only established initiative which the Global Virome Project takes inspiration from. The Human Genome Project, established in the late 1980s, proved itself revolutionary by stimulating increased investment and interest in genomics. The high expectations established for the Global Virome Project see it set to match the phenomenal Halo effect created by the Human Genome Project. The unprecedented amount of available data will lead to great strides in the advancement of global health practices. Ultimately, the work conducted by the Global Virome Project encourages the global community to act proactively to save human lives from zoonotic viruses.

Thanks!

[redacted]

---

**From:** Hannah [mailto:hannah@sciani.com]
**Sent:** Tuesday, November 06, 2018 1:08 AM
**To:** [redacted]
**Subject:** SCI ANI: Voiceover script approval
**Importance:** High

Dear [redacted]

I hope you're well.

The draft voiceover script for your animation is now ready for approval. Please find attached.

Please be aware that once the script is approved it will be sent to the voiceover artist. Once approval is given, **the script is considered finalised**. **Any changes to the script after this point will mean an extra charge and could potentially affect the agreed deadline date.** ***We recommend that you circulate the script across the company and team at this stage to avoid later changes.***

Please can you:

1. **Check through the script** - please read through it carefully.
   If there are any changes you would like made, please either email them or edit the document directly (using Track Changes). Bear in mind:

   a. To fill the video's 3-minute timeframe the script must not exceed 420 words. So, while we will do our best, we cannot add substantial information to the script.
2. **Check the scene descriptions**. These describe what will happen at each moment in the animation. If you need more detail or would like to see changes, please just let us know. We want to make sure you are happy before we move on to animation stage in order to keep any amends to simple tweaks.
3. **Respond to queries**. Where we need some information or example images from you, we have indicated this in the queries column. Providing images will help our animation team to create accurate images first time round.

Once you have checked the full draft script, please send it back to me. I will then make any changes and send it to the

animator. Once the animation is completed, I will send it to you for your feedback and approval – we will not publish anything without your approval.

Please can you check the draft script and get back to me by Monday 12th November.

I look forward to receiving your feedback.

Best regards,

Hannah Fraser
Animation Editor
Sci Ani

**T:** +44 (0)1453 827934
**W**: www.sciani.com
**E:** hannah@sciani.com

<image001.png>

IMPORTANT INFORMATION
This email may contain information that is privileged, confidential or otherwise protected from disclosure. It may not be used by, or its contents copied or disclosed to, persons other than the address(ees). If you have received this email in error please notify the sender immediately and delete the email.

Whilst Research Publishing International Ltd has taken every reasonable precaution to minimise the risk of viruses, we cannot accept liability for any damage that is sustained as a result of software viruses which may be contained in this email.

If you do not wish to receive emails from Research Publishing International Ltd in the future please reply to this email with 'remove' in the subject line.

<Eri Togami Animation Script_1hf (002)_et.docx>

**From:** [redacted]>
**To:** Dennis Carroll <dcarroll@usaid.gov>
**Cc:** Cara Chrisman <cchrisman@usaid.gov>, Samantha Maher <maher@ecohealthalliance.org>, Peter Daszak <daszak@ecohealthalliance.org>, "nwolfe@metabiota.com" <nwolfe@metabiota.com>, Eddy Rubin <erubin@metabiota.com>, Jonna Mazet <jkmazet@ucdavis.edu>
**Subject:** RE: Finalize GVP script for animated video
**Sent:** Wed, 7 Nov 2018 22:58:21 +0000

Thank you Dennis for the feedback. Noted, I will add that sentence and keep the USAID/PREDICT reference!
Best,
[redacted]

---

**From:** Dennis Carroll [mailto:dcarroll@usaid.gov]
**Sent:** Tuesday, November 06, 2018 4:42 PM
**To:** [redacted]
**Cc:** Cara Chrisman <cchrisman@usaid.gov>; Samantha Maher <maher@ecohealthalliance.org>; Peter Daszak <daszak@ecohealthalliance.org>; nwolfe@metabiota.com; Eddy Rubin <erubin@metabiota.com>; Jonna Mazet <jkmazet@ucdavis.edu>
**Subject:** Re: Finalize GVP script for animated video

No need to cut out references to USAID or Predict (say it loud, say it proud) but more importantly there needs to be emphasis on "this is a global partnership and despite the proof of concept NOT A USG project"

Dr Dennis Carroll
Director
Emerging Threats
Global Health
USAID
301-646-6235
On Nov 6, 2018, at 6:35 PM, [redacted]> wrote:

Hi everyone,
The script for the GVP animated video is in! We have until Monday Nov 12 to finalize the script. After that, no more revisions. Please send general comments or specific revision requests to me by our call this Thursday Nov 8. Some specific questions below:

- Dennis and Cara – Would you prefer to cut out the mention for USAID (and PREDICT?) altogether?
- Peter and Sam – Can you double check the numbers that are used in the script (i.e. "1.5 million viruses")?
- Eddy and Nathan – Are you comfortable with how the database is described and its accessibility?
- All – do we want specific mention of the Human Genome Project? Any general comments, revisions, thoughts?

I have copied the script for your convenience. Details of the animations and scene changes are outlined in the document attached.

**Script:**

Did you know that 75% of emerging infectious diseases are originally found in animals? You might be surprised to learn that there are 1.5 million viruses which can be transmitted to us from other animals. Viruses which can be transmitted to humans from other animals are called zoonotic viruses, and their health and economic impacts can be devastating. Zoonotic viruses are emerging at an ever-increasing rate and the cost of controlling them is astronomical. To better prepare for future outbreaks and pandemics, a change in attitude is required - from being reactive, to proactive.

The international team behind the Global Virome Project are leading the way towards better preparedness for future pandemics. This pioneering global partnership between

organisations in the environmental, animal, and human health sectors will detect and characterise unknown viral threats from wild animals from around the world. The huge scope of this project encompasses collecting genetic information on viruses, as well as the ecological data to be stored in a database. This database will be used to better understand not only the viral traits, but also  of viruses. To achieve this, the Global Virome Project uses a targeted surveillance strategy to sample from wildlife. This database is not a prediction tool for future pandemics but will work to monitor trends and patterns in viral outbreaks.  By ensuring viral threats in animal populations are properly monitored this project will help to prevent spill over to humans.

Data collection of this scale is a mammoth undertaking and could appear overwhelming. However, the viability of the Global Virome Project has already been proven by the success of a previous project. The PREDICT project, by USAID, has operated in over 30 countries for more than nine years. So far the PREDICT project has discovered over 1000 viruses. The Global Virome Project will build on this existing system and share initiatives to achieve even greater success in the future. The PREDICT project is not the only established initiative which the Global Virome Project takes inspiration from. The Human Genome Project, established in the late 1980s, proved itself revolutionary by stimulating increased investment and interest in genomics. The high expectations established for the Global Virome Project see it set to match the phenomenal Halo effect created by the Human Genome Project. The unprecedented amount of available data will lead to great strides in the advancement of global health practices. Ultimately, the work conducted by the Global Virome Project encourages the global community to act proactively to save human lives from zoonotic viruses.

Thanks!

REDACTED

---

**From:** Hannah [mailto:hannah@sciani.com]
**Sent:** Tuesday, November 06, 2018 1:08 AM
**To:** REDACTED
**Subject:** SCI ANI: Voiceover script approval
**Importance:** High

Dear REDACTED

I hope you're well.

The draft voiceover script for your animation is now ready for approval. Please find attached.

Please be aware that once the script is approved it will be sent to the voiceover artist. Once approval is given, **the script is considered finalised**. **Any changes to the script after this point will mean an extra charge and could potentially affect the agreed deadline date.** ***We recommend that you circulate the script across the company and team at this stage to avoid later changes.***

Please can you:

1. **Check through the script** - please read through it carefully.
   If there are any changes you would like made, please either email them or edit the document directly (using Track Changes). Bear in mind:

   To fill the video's 3-minute timeframe the script must not exceed 420 words. So, while we will do our best, we cannot add substantial information to the script.

2. **Check the scene descriptions**. These describe what will happen at each moment in the animation. If you need more detail or would like to see changes, please just let us know. We want to make sure you are happy before we move on to animation stage in order to keep any amends to simple tweaks.
3. **Respond to queries**. Where we need some information or example images from you, we have indicated this in the queries column. Providing images will help our animation team to create accurate images first time round.

Once you have checked the full draft script, please send it back to me. I will then make any changes and send it to the animator. Once the animation is completed, I will send it to you for your feedback and approval – we will not publish anything without your approval.

Please can you check the draft script and get back to me by Monday 12th November.

I look forward to receiving your feedback.

Best regards,

Hannah Fraser
Animation Editor
Sci Ani

**T:** +44 (0)1453 827934
**W**: www.sciani.com
**E:** hannah@sciani.com

<image001.png>

IMPORTANT INFORMATION
This email may contain information that is privileged, confidential or otherwise protected from disclosure. It may not be used by, or its contents copied or disclosed to, persons other than the address(ees). If you have received this email in error please notify the sender immediately and delete the email.

Whilst Research Publishing International Ltd has taken every reasonable precaution to minimise the risk of viruses, we cannot accept liability for any damage that is sustained as a result of software viruses which may be contained in this email.

If you do not wish to receive emails from Research Publishing International Ltd in the future please reply to this email with 'remove' in the subject line.

<Eri Togami Animation Script_1hf (002)_et.docx>

**From:** [redacted]>
**To:** Samantha Maher <maher@ecohealthalliance.org>
**Cc:** Peter Daszak <daszak@ecohealthalliance.org>, Jonna Mazet <jkmazet@ucdavis.edu>
**Subject:** RE: Finalize GVP script for animated video
**Sent:** Wed, 7 Nov 2018 23:12:54 +0000

Hi Sam,

Thanks for checking the numbers. So, it sounds like "You might be surprised to learn that there are 1.5 million viruses which can be transmitted from other animals." can be changed to "You might be surprised to learn that there are more than half a million viruses which can be transmitted from other animals". What do you think?

We can keep the "75%" as it is widely used in the community.

Best,

REDACTED

**From:** Samantha Maher [mailto:maher@ecohealthalliance.org]
**Sent:** Wednesday, November 07, 2018 10:08 AM
**To:** [redacted]>
**Subject:** Re: Finalize GVP script for animated video

Thanks Eri!

On Wed, Nov 7, 2018 at 12:20 PM Samantha Maher <maher@ecohealthalliance.org> wrote:
Hi Eri,

Where it says "You might be surprised to learn that there are 1.5 million viruses which can be transmitted to us from other animals," that number is referring to the estimated total number of undiscovered viruses. The number for those transmissible to humans (as cited in the Science paper) is between "631,000 and 827,000." As for the 75% statistic, I'm going to double check that because in the Science paper it just says, "Nearly all recent pandemics have a viral etiology with animal origins."

Cheers,

Sam

On Tue, Nov 6, 2018 at 6:35 PM [redacted]> wrote:
Hi everyone,
The script for the GVP animated video is in! We have until Monday Nov 12 to finalize the script. After that, no more revisions. Please send general comments or specific revision requests to me by our call this Thursday Nov 8. Some specific questions below:

- Dennis and Cara – Would you prefer to cut out the mention for USAID (and PREDICT?) altogether?
- Peter and Sam – Can you double check the numbers that are used in the script (i.e. "1.5 million viruses")?
- Eddy and Nathan – Are you comfortable with how the database is described and its accessibility?
- All – do we want specific mention of the Human Genome Project? Any general comments, revisions, thoughts?

I have copied the script for your convenience. Details of the animations and scene changes are outlined in the document attached.

**Script**:
Did you know that 75% of emerging infectious diseases are originally found in animals? You might be

surprised to learn that there are 1.5 million viruses which can be transmitted to us from other animals. Viruses which can be transmitted to humans from other animals are called zoonotic viruses, and their health and economic impacts can be devastating. Zoonotic viruses are emerging at an ever-increasing rate and the cost of controlling them is astronomical. To better prepare for future outbreaks and pandemics, a change in attitude is required - from being reactive, to proactive.

The international team behind the Global Virome Project are leading the way towards better preparedness for future pandemics. This pioneering global partnership between organisations in the environmental, animal, and human health sectors will detect and characterise unknown viral threats from wild animals from around the world. The huge scope of this project encompasses collecting genetic information on viruses, as well as the ecological data to be stored in a database. This database will be used to better understand not only the viral traits, but also  of viruses. To achieve this, the Global Virome Project uses a targeted surveillance strategy to sample from wildlife. This database is not a prediction tool for future pandemics but will work to monitor trends and patterns in viral outbreaks.  By ensuring viral threats in animal populations are properly monitored this project will help to prevent spill over to humans.

Data collection of this scale is a mammoth undertaking and could appear overwhelming. However, the viability of the Global Virome Project has already been proven by the success of a previous project. The PREDICT project, by USAID, has operated in over 30 countries for more than nine years. So far the PREDICT project has discovered over 1000 viruses. The Global Virome Project will build on this existing system and share initiatives to achieve even greater success in the future. The PREDICT project is not the only established initiative which the Global Virome Project takes inspiration from. The Human Genome Project, established in the late 1980s, proved itself revolutionary by stimulating increased investment and interest in genomics. The high expectations established for the Global Virome Project see it set to match the phenomenal Halo effect created by the Human Genome Project. The unprecedented amount of available data will lead to great strides in the advancement of global health practices. Ultimately, the work conducted by the Global Virome Project encourages the global community to act proactively to save human lives from zoonotic viruses.

Thanks!

REDACTED

---

**From:** Hannah [mailto:hannah@sciani.com]
**Sent:** Tuesday, November 06, 2018 1:08 AM
**To:** REDACTED
**Subject:** SCI ANI: Voiceover script approval
**Importance:** High

Dear REDACTED

I hope you're well.

The draft voiceover script for your animation is now ready for approval. Please find attached.

Please be aware that once the script is approved it will be sent to the voiceover artist. Once approval is given, **the script is considered finalised**. **Any changes to the script after this point will mean an extra charge and could potentially affect the agreed deadline date.** ***We recommend that you circulate the script across the company and team at this stage to avoid later changes.***

Please can you:

1. **Check through the script -** please read through it carefully.
If there are any changes you would like made, please either email them or edit the document directly (using Track Changes). Bear in mind:

    a. To fill the video's 3-minute timeframe the script must not exceed 420 words. So, while we will do our best, we cannot add substantial information to the script.

2. **Check the scene descriptions**. These describe what will happen at each moment in the animation. If you need more detail or would like to see changes, please just let us know. We want to make sure you are happy before we move on to animation stage in order to keep any amends to simple tweaks.
3. **Respond to queries**. Where we need some information or example images from you, we have indicated this in the queries column. Providing images will help our animation team to create accurate images first time round.

Once you have checked the full draft script, please send it back to me. I will then make any changes and send it to the animator. Once the animation is completed, I will send it to you for your feedback and approval – we will not publish anything without your approval.

Please can you check the draft script and get back to me by Monday 12th November.

I look forward to receiving your feedback.

Best regards,

Hannah Fraser
Animation Editor
Sci Ani

**T:** +44 (0)1453 827934
**W**: www.sciani.com
**E:** hannah@sciani.com

IMPORTANT INFORMATION
This email may contain information that is privileged, confidential or otherwise protected from disclosure. It may not be used by, or its contents copied or disclosed to, persons other than the address(ees). If you have received this email in error please notify the sender immediately and delete the email.

Whilst Research Publishing International Ltd has taken every reasonable precaution to minimise the risk of viruses, we cannot accept liability for any damage that is sustained as a result of software viruses which may be contained in this email.

If you do not wish to receive emails from Research Publishing International Ltd in the future please reply to this email with 'remove' in the subject line.

--

**Samantha M.L. Maher, MESc**
*Research Assistant, Conservation and Health*

EcoHealth Alliance
460 West 34th Street – 17th floor
New York, NY 10001

1.212.380.4464 (direct)
1.713.818.6867 (mobile)
1.212.380.4465 (fax)
www.ecohealthalliance.org

***EcoHealth Alliance leads cutting-edge scientific research into the critical connections between human and wildlife health and delicate ecosystems. With this science, we develop solutions that prevent pandemics and promote conservation.***

--

**Samantha M.L. Maher, MESc**
*Research Assistant, Conservation and Health*

EcoHealth Alliance
460 West 34th Street – 17th floor
New York, NY 10001

1.212.380.4464 (direct)
1.713.818.6867 (mobile)
1.212.380.4465 (fax)
www.ecohealthalliance.org

***EcoHealth Alliance leads cutting-edge scientific research into the critical connections between human and wildlife health and delicate ecosystems. With this science, we develop solutions that prevent pandemics and promote conservation.***

**From:** [redacted]
**To:** Eddy Rubin <erubin@metabiota.com>
**Cc:** Cara Chrisman <cchrisman@usaid.gov>, Dennis Carroll <dcarroll@usaid.gov>, "maher@ecohealthalliance.org" <maher@ecohealthalliance.org>, Peter Daszak <daszak@ecohealthalliance.org>, Nathan Wolfe <nwolfe@metabiota.com>, Jonna Mazet <jkmazet@ucdavis.edu>
**Subject:** Re: Finalize GVP script for animated video
**Sent:** Thu, 8 Nov 2018 16:58:09 +0000

Thank you Eddy, I will make those edits!

[redacted]

Sent from my iPhone, please excuse any typos.

---

**From:** Eddy Rubin <erubin@metabiota.com>
**Sent:** Thursday, November 8, 2018 08:12
**To:** [redacted]
**Cc:** Cara Chrisman; Dennis Carroll; maher@ecohealthalliance.org; Peter Daszak; Nathan Wolfe; Jonna Mazet
**Subject:** Re: Finalize GVP script for animated video

[redacted]

Small suggestion.
replace "This database will be used to better understand not only the viral traits, but also of viruses"
with something like:

"The information in the database will enable researchers to discover where viruses are found in nature and to understand them at a resolution never previously approached."
Eddy

On Wed, Nov 7, 2018 at 12:35 AM [redacted] wrote:

> Hi everyone,
>
> The script for the GVP animated video is in! We have until Monday Nov 12 to finalize the script. After that, no more revisions. Please send general comments or specific revision requests to me by our call this Thursday Nov 8. Some specific questions below:
>
> - Dennis and Cara – Would you prefer to cut out the mention for USAID (and PREDICT?) altogether?
> - Peter and Sam – Can you double check the numbers that are used in the script (i.e. "1.5 million viruses")?
> - Eddy and Nathan – Are you comfortable with how the database is described and its accessibility?
> - All – do we want specific mention of the Human Genome Project? Any general comments, revisions, thoughts?
>
> I have copied the script for your convenience. Details of the animations and scene changes are outlined in the document attached.
>
> **Script**:
>
> Did you know that 75% of emerging infectious diseases are originally found in animals? You might be

surprised to learn that there are 1.5 million viruses which can be transmitted to us from other animals. Viruses which can be transmitted to humans from other animals are called zoonotic viruses, and their health and economic impacts can be devastating. Zoonotic viruses are emerging at an ever-increasing rate and the cost of controlling them is astronomical. To better prepare for future outbreaks and pandemics, a change in attitude is required - from being reactive, to proactive.

The international team behind the Global Virome Project are leading the way towards better preparedness for future pandemics. This pioneering global partnership between organisations in the environmental, animal, and human health sectors will detect and characterise unknown viral threats from wild animals from around the world. The huge scope of this project encompasses collecting genetic information on viruses, as well as the ecological data to be stored in a database. This database will be used to better understand not only the viral traits, but also  of viruses. To achieve this, the Global Virome Project uses a targeted surveillance strategy to sample from wildlife. This database is not a prediction tool for future pandemics but will work to monitor trends and patterns in viral outbreaks.  By ensuring viral threats in animal populations are properly monitored this project will help to prevent spill over to humans.

Data collection of this scale is a mammoth undertaking and could appear overwhelming. However, the viability of the Global Virome Project has already been proven by the success of a previous project. The PREDICT project, by USAID, has operated in over 30 countries for more than nine years. So far the PREDICT project has discovered over 1000 viruses. The Global Virome Project will build on this existing system and share initiatives to achieve even greater success in the future. The PREDICT project is not the only established initiative which the Global Virome Project takes inspiration from. The Human Genome Project, established in the late 1980s, proved itself revolutionary by stimulating increased investment and interest in genomics. The high expectations established for the Global Virome Project see it set to match the phenomenal Halo effect created by the Human Genome Project. The unprecedented amount of available data will lead to great strides in the advancement of global health practices. Ultimately, the work conducted by the Global Virome Project encourages the global community to act proactively to save human lives from zoonotic viruses.

Thanks!

REDACTED

---

**From:** Hannah [mailto:hannah@sciani.com]
**Sent:** Tuesday, November 06, 2018 1:08 AM
**To:** REDACTED
**Subject:** SCI ANI: Voiceover script approval
**Importance:** High

Dear REDACTED

I hope you're well.

The draft voiceover script for your animation is now ready for approval. Please find attached.

Please be aware that once the script is approved it will be sent to the voiceover artist. Once approval is given, **the script is considered finalised**. **Any changes to the script after this point will mean an extra charge and could potentially affect the agreed deadline date.** ***We recommend that you circulate the script across the company and team at this stage to avoid later changes.***

Please can you:

1. **Check through the script** - please read through it carefully.

If there are any changes you would like made, please either email them or edit the document directly (using Track Changes). Bear in mind:

a. To fill the video's 3-minute timeframe the script must not exceed 420 words. So, while we will do our best, we cannot add substantial information to the script.

2. **Check the scene descriptions**. These describe what will happen at each moment in the animation. If you need more detail or would like to see changes, please just let us know. We want to make sure you are happy before we move on to animation stage in order to keep any amends to simple tweaks.
3. **Respond to queries**. Where we need some information or example images from you, we have indicated this in the queries column. Providing images will help our animation team to create accurate images first time round.

Once you have checked the full draft script, please send it back to me. I will then make any changes and send it to the animator. Once the animation is completed, I will send it to you for your feedback and approval – we will not publish anything without your approval.

Please can you check the draft script and get back to me by Monday 12th November.

I look forward to receiving your feedback.

Best regards,

Hannah Fraser

Animation Editor

Sci Ani

**T:** +44 (0)1453 827934

**W**: www.sciani.com

**E:** hannah@sciani.com



IMPORTANT INFORMATION

This email may contain information that is privileged, confidential or otherwise protected from disclosure. It may not be used by, or its contents copied or disclosed to, persons other than the address(ees). If you have received this email in error please notify the sender immediately and delete the email.

Whilst Research Publishing International Ltd has taken every reasonable precaution to minimise the risk of viruses, we cannot accept liability for any damage that is sustained as a result of software viruses which may be contained in this email.

If you do not wish to receive emails from Research Publishing International Ltd in the future please reply to this email with 'remove' in the subject line.

**From:** [redacted]
**To:** Cara Chrisman <cchrisman@usaid.gov>
**Cc:** Eddy Rubin <erubin@metabiota.com>, Dennis Carroll <dcarroll@usaid.gov>, "maher@ecohealthalliance.org" <maher@ecohealthalliance.org>, Peter Daszak <daszak@ecohealthalliance.org>, Nathan Wolfe <nwolfe@metabiota.com>, Jonna Mazet <jkmazet@ucdavis.edu>
**Subject:** RE: Finalize GVP script for animated video
**Sent:** Thu, 8 Nov 2018 18:25:13 +0000

Thanks Cara, received.

[redacted]

**From:** Cara Chrisman [mailto:cchrisman@usaid.gov]
**Sent:** Thursday, November 08, 2018 10:01 AM
**To:** [redacted]
**Cc:** Eddy Rubin <erubin@metabiota.com>; Dennis Carroll <dcarroll@usaid.gov>; maher@ecohealthalliance.org; Peter Daszak <daszak@ecohealthalliance.org>; Nathan Wolfe <nwolfe@metabiota.com>; Jonna Mazet <jkmazet@ucdavis.edu>
**Subject:** Re: Finalize GVP script for animated video

Hi [redacted]

Thanks for sharing and pushing this along! Please see suggested edits attached (didn't include other edits from this stream).

Best,
Cara

Cara J. Chrisman, PhD
Senior Infectious Diseases Technical Advisor
U.S. Agency for International Development (USAID) Contractor
Bureau for Global Health, Office of Infectious Disease, Emerging Threats Division
2100 Crystal Drive, CP3-8091A, Arlington, VA 22202
Desk: (571) 551-7413
Cell: [redacted]
E-mail: cchrisman@usaid.gov

*GHSI-III - Social Solutions International, Inc. prime contractor*

On Thu, Nov 8, 2018 at 11:58 AM [redacted] wrote:
Thank you Eddy, I will make those edits!
Eri

Sent from my iPhone, please excuse any typos.

---

**From:** Eddy Rubin <erubin@metabiota.com>
**Sent:** Thursday, November 8, 2018 08:12
**To:** [redacted]
**Cc:** Cara Chrisman; Dennis Carroll; maher@ecohealthalliance.org; Peter Daszak; Nathan Wolfe; Jonna Mazet
**Subject:** Re: Finalize GVP script for animated video

[redacted]

Small suggestion.
replace "This database will be used to better understand not only the viral traits, but also of viruses"
with something like:

"The information in the database will enable researchers to discover where viruses are found in nature and to understand them at a resolution never previously approached."
Eddy

On Wed, Nov 7, 2018 at 12:35 AM [redacted] wrote:

Hi everyone,

The script for the GVP animated video is in! We have until Monday Nov 12 to finalize the script. After that, no more revisions. Please send general comments or specific revision requests to me by our call this Thursday Nov 8. Some specific questions below:

- Dennis and Cara – Would you prefer to cut out the mention for USAID (and PREDICT?) altogether?
- Peter and Sam – Can you double check the numbers that are used in the script (i.e. "1.5 million viruses")?
- Eddy and Nathan – Are you comfortable with how the database is described and its accessibility?
- All – do we want specific mention of the Human Genome Project? Any general comments, revisions, thoughts?

I have copied the script for your convenience. Details of the animations and scene changes are outlined in the document attached.

**Script**:

Did you know that 75% of emerging infectious diseases are originally found in animals? You might be surprised to learn that there are 1.5 million viruses which can be transmitted to us from other animals. Viruses which can be transmitted to humans from other animals are called zoonotic viruses, and their health and economic impacts can be devastating. Zoonotic viruses are emerging at an ever-increasing rate and the cost of controlling them is astronomical. To better prepare for future outbreaks and pandemics, a change in attitude is required - from being reactive, to proactive.

The international team behind the Global Virome Project are leading the way towards better preparedness for future pandemics. This pioneering global partnership between organisations in the environmental, animal, and human health sectors will detect and characterise unknown viral threats from wild animals from around the world. The huge scope of this project encompasses collecting genetic information on viruses, as well as the ecological data to be stored in a database. This database will be used to better understand not only the viral traits, but also  of viruses. To achieve this, the Global Virome Project uses a targeted surveillance strategy to sample from wildlife. This database is not a prediction tool for future pandemics but will work to monitor trends and patterns in viral outbreaks.  By ensuring viral threats in animal populations are properly monitored this project will help to prevent spill over to humans.

Data collection of this scale is a mammoth undertaking and could appear overwhelming. However, the viability of the Global Virome Project has already been proven by the success of a previous project. The PREDICT project, by USAID, has operated in over 30 countries for more than nine years. So far the PREDICT project has discovered over 1000 viruses. The Global Virome Project will build on this existing system and share initiatives to achieve even greater success in the future. The PREDICT project is not the only established initiative which the Global Virome Project takes inspiration from. The Human Genome Project, established in the late 1980s, proved itself revolutionary by stimulating increased investment and interest in genomics. The high expectations established for the Global Virome Project see it set to match the phenomenal Halo effect created by the Human Genome Project. The unprecedented amount of available data will lead to great strides in the advancement of global health practices. Ultimately, the work conducted by the Global Virome Project encourages the global community to act proactively to save human lives from zoonotic viruses.

Thanks!
REDACTED

**From:** Hannah [mailto:hannah@sciani.com]
**Sent:** Tuesday, November 06, 2018 1:08 AM
**To:** REDACTED
**Subject:** SCI ANI: Voiceover script approval
**Importance:** High

Dear REDACTED

I hope you're well.

The draft voiceover script for your animation is now ready for approval. Please find attached.

Please be aware that once the script is approved it will be sent to the voiceover artist. Once approval is given, **the script is considered finalised**. **Any changes to the script after this point will mean an extra charge and could potentially affect the agreed deadline date.** ***We recommend that you circulate the script across the company and team at this stage to avoid later changes.***

Please can you:

1. **Check through the script** - please read through it carefully.
If there are any changes you would like made, please either email them or edit the document directly (using Track Changes). Bear in mind:

    a. To fill the video's 3-minute timeframe the script must not exceed 420 words. So, while we will do our best, we cannot add substantial information to the script.

2. **Check the scene descriptions**. These describe what will happen at each moment in the animation. If you need more detail or would like to see changes, please just let us know. We want to make sure you are happy before we move on to animation stage in order to keep any amends to simple tweaks.
3. **Respond to queries**. Where we need some information or example images from you, we have indicated this in the queries column. Providing images will help our animation team to create accurate images first time round.

Once you have checked the full draft script, please send it back to me. I will then make any changes and send it to the animator. Once the animation is completed, I will send it to you for your feedback and approval – we will not publish anything without your approval.

Please can you check the draft script and get back to me by Monday 12th November.

I look forward to receiving your feedback.

Best regards,

Hannah Fraser
Animation Editor
Sci Ani

**T:** +44 (0)1453 827934
**W**: www.sciani.com
**E:** hannah@sciani.com

IMPORTANT INFORMATION
This email may contain information that is privileged, confidential or otherwise protected from disclosure. It may not be used by, or its contents copied or disclosed to, persons other than the address(ees). If you have received this email in error please notify the sender immediately and delete the email.

Whilst Research Publishing International Ltd has taken every reasonable precaution to minimise the risk of viruses, we cannot accept liability for any damage that is sustained as a result of software viruses which may be contained in this email.

If you do not wish to receive emails from Research Publishing International Ltd in the future please reply to this email with 'remove' in the subject line.

**From:** David J Wolking <djwolking@ucdavis.edu>
**Sent:** Fri, 21 Dec 2018 11:14:28 -0800
**Subject:** Happy Holidays & don't forget about the NYC Meeting!
**To:** Amanda Fine [redacted], Brian Bird <bhbird@ucdavis.edu>, Christine Kreuder Johnson <ckjohnson@ucdavis.edu>, Corina Grigorescu Monagin <cgmonagin@ucdavis.edu>, Dawn Zimmerman <Zimmermand@si.edu>, Emma Lane <lane@ecohealthalliance.org>, Evelyn Luciano <luciano@ecohealthalliance.org>, Jon Epstein <epstein@ecohealthalliance.org>, Karen Saylors <ksaylors@metabiota.com>, Leilani Franciso <francisco@ecohealthalliance.org>, Marc Valitutto <ValituttoM@si.edu>, Molly Turner <turner@ecohealthalliance.org>, "Murray, Suzan" <MurrayS@si.edu>, Peter Daszak <daszak@ecohealthalliance.org>, "Prof. Jonna Mazet" <jkmazet@ucdavis.edu>, "Prof. Woutrina Smith" <wasmith@ucdavis.edu>, Sarah Olson <[redacted]>, Simon Anthony <sja2127@columbia.edu>, "Tammie O'Rourke" <torourke@metabiota.com>, Tracey Goldstein <tgoldstein@ucdavis.edu>, "William B. Karesh" <karesh@ecohealthalliance.org>
**Cc:** Alison Andre <andre@ecohealthalliance.org>, Amanda Andre <amanda.andre@ecohealthalliance.org>, Ava Sullivan <sullivan@ecohealthalliance.org>, Brooke Genovese <bgenovese@ucdavis.edu>, "predict@ucdavis.edu" <predict@ucdavis.edu>, "Churchill, Carolina" <[redacted]>
P2 2018 NYC Semi-annual Meeting Agenda.docx

Hi there Executive Board Members,
Before we all take a well deserved holiday break, I wanted to put back on our collective radar the need to circulate sharable versions of the slide decks all technical team members so excellently presented at Bronx Zoo meeting. I've attached the meeting agenda as a quick reference of all presentation topics,

I've set up a Box folder for archival, so please share with me your slides as soon as you can (after you are comfortable with their content for consortium distribution of course). As many are now traveling, I'll send another reminder to follow-up on this item in the new year.

Thanks in advance and happy holidays,

David

**PREDICT Semi-annual Consortium Meeting**
**Bronx Zoo**
**November 29-30, 2018**

***Agenda***
***Day 1 – November 29: Schiff Hall, Bronx Zoo (USAID in Attendance)***
***Hotel: Hyatt Yonkers (Shuttle available from Hotel to Zoo, with pick up time at 8 am)***

| | |
|---|---|
| **9:00 am** | Welcome and Plans for the Next Two Days (Paul Calle [5 min] and Jonna) |
| **9:15 am** | Surveillance Summary (Chris) |
| **9:25 am** | EHP Summary (Brian) |
| **9:30 am** | Global One Health and Policy Development (Billy and Catherine) |
| **10:00 am** | Break |
| **10:15 am** | Capacity Strengthening (Woutrina) |
| **10:30 am** | Viral Discovery (Tracey and Simon) |
| **10:45 am** | Behavioral Risk (Leilani and Karen) |
| **11:00 am** | Stakeholder/Community Engagement, Results Dissemination (Jonna + Discussion) |
| **12:00 pm** | Lunch |
| **1:00 pm** | M&A/IMPACT Summary (Peter) |
| **1:30 pm** | Data Discussion: Country Round-up on Plans for Data Analysis, Data Dissemination and Sharing, and Long-term Data Storage and Access (EIDITH & HealthMap) – (David & Corina + Discussion) |
| **3:00 pm** | Break |
| **3:15 pm** | Project Deliverables, Analysis and Wrap up (Including Government Reporting and Final Results, Sample Disposition/Banking Plans, etc. ) - (Group Discussion Moderated by David/Corina) |
| **4:30 pm** | Telling the "PREDICT Story" and Final Report Planning/End of Project Meeting Planning and Location Selection (David, Corina et al...) |

**6:00 pm** Cocktail Reception at Madagascar Exhibit (with invited WCS staff). Dinner to follow at Schiff Hall, Bronx Zoo

**9:00 pm** Shuttle Pick-up Time for Guests Traveling Back to Hyatt Hotel.

***Day 2 – November 30: Schiff Hall, Bronx Zoo*** DRAFT

***Hotel: Hyatt Yonkers (Two shuttles available from Hotel to Zoo, pick up time 7:30 am for those interested in a hot breakfast at Bronx Zoo, and 8:15 am for those taking breakfast at the hotel)***

**8:00 am** Hot Breakfast

**9:00 am** Overview and Plans for the Day

**9:15 am** Surveillance Wrap Up (Chris)

**10:00 am** Viral Discovery Wrap Up (Tracey and Simon)

**10:45 am** Break

**10:50 am** Behavioral Risk Wrap Up (Leilani and Karen)

**11:30 am** Road Map Wrap Up for Project Completion, Interventions and Bridging Strategies for Sustainability, and the Future (Jonna + discussion)

**12:00 pm** Lunch

**Optional Tour of Wildlife Health Center (First group tour starts at 12:45 pm and a second group tour will start at 1:15 pm)**

****Room Available until 3pm for Breakout Sessions****

**Zoom Links for Remote Participation:**

**Day 1:**
Join URL: [redacted]
Password: REDACTED

**Day 2:**
Join URL [redacted]
Password: REDACTED

**From:** Jonna Mazet <jkmazet@ucdavis.edu>
**To:** William B. Karesh <karesh@ecohealthalliance.org>
**Sent:** 2/14/2019 9:21:39 PM
**Subject:** Re: [predict] Re: [predict-outbreak] Request for assistance with encephalitis outbreak in Bangladesh

Sounds good -- will add now!
J

On Thu, Feb 14, 2019 at 8:12 PM William B. Karesh <karesh@ecohealthalliance.org> wrote:
I'm going to call in while I'm at the GHSA Steering Committee meeting Tuesday and would love to "remind" the group why the GHSA was created by the US and partners (because WHO and FAO are unable to deal with outbreaks and pandemics).
So give me a bit of time to bather on about that. ;)

Sent from my iPhone

**William B. Karesh, D.V.M**
*Executive Vice President for Health and Policy*

EcoHealth Alliance
460 West 34th Street - 17th Floor
New York, NY 10001 USA

+1.212.380.4463 (direct)
+1.212.380.4465 (fax)
www.ecohealthalliance.org

President, OIE Working Group on Wildlife

Co-chair, IUCN Species Survival Commission - Wildlife Health Specialist Group

EPT Partners Liaison, USAID Emerging Pandemic Threats - PREDICT-2 Program

***EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that promote conservation and prevent pandemics.***

On Feb 14, 2019, at 10:31 PM, Jonna Mazet <jkmazet@ucdavis.edu> wrote:

Proceed under current economic protocol, please. I'm not opposed to adding a site if practical & achievable. We will also discuss with USAID on Tuesday.
Thanks to all,
Jonna

On Thu, Feb 14, 2019 at 11:44 AM Dr. Melinda Rostal <rostal@ecohealthalliance.org> wrote:
Dear Brian and David,
Thank you for letting us know. We will inform the government. They are, of course, aware that it is Year 5 and PREDICT's ability to respond to outbreaks is limited.

Regarding the economic study, as David indicated this work is entirely in line with the ongoing Y5 work plan and IRB in every way except in the location. We would like to pursue this IRB amendment if possible and move forward with that. As it will take some time and it is in-line with our previously planned work, I do not

believe that the economic work needs to considered "outbreak response," unless you would like it to.

Please confirm if you want to classify the economic work as an outbreak response or we should proceed under our current protocol for the economic study.

Kind regards,
Mindy
**Melinda Rostal DVM, MPH**
*Senior Research Scientist*

*PREDICT 2 Surveillance Coordinator for EcoHealth Alliance*

*Rift Valley Fever Virus Project Manager*

EcoHealth Alliance
460 West 34th Street – 17th floor
New York, NY 10001

1.212.380.4489 (direct)
1.212.380.4465 (fax)
www.ecohealthalliance.org

Visit our blog: www.ecohealthalliance.org/blog

***EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that promote conservation and prevent pandemics.***

On Feb 14, 2019, at 2:26 PM, David J Wolking <djwolking@ucdavis.edu> wrote:

Hi there

Just for clarity on the economics piece, there is an existing scope (cost of outbreaks) with IRB already in place and the study is underway, so it would not be a totally new add, just an additional site to collect some of this data from a new outbreak site. Budget implications of course but likely not a ton of extra work or cost though I defer to EHA team to weigh in on that piece.

David

On Thu, Feb 14, 2019 at 11:10 AM Brian Bird <bhbird@ucdavis.edu> wrote:

Hi everyone,

I discussed this with the team here at headquarters, and we will decline this request for a variety of reasons including that PREDICT teams and have stopped animal sampling across the project, the lack of budget, and shift to Year 5 activities. Additionally, we need to be communicating clearly to our government partners that we aren't in the position to conduct these kinds of activities any more due to the close-out of the project. The sooner we make that clear the better.

Supporting the GoB through technical advice etc. would be helpful and beneficial of course and nicely fit with our Year 5 transition aims/goals. This would also be a good opportunity to help them work towards implementing their own active teams and make One Health wildlife surveillance a sustainable reality in Bangladesh, long after PREDICT is but a fond memory.

It seems that the same applies for the economic assessment. While interesting, that would be a new scope of work, without standing IRB coverage, or dedicated budget. So I'm not sure how feasible that is especially given the delays before implementation?

Yours,

-Brian

**From:** "predict-outbreak-request@ucdavis.edu" <predict-outbreak-request@ucdavis.edu> on behalf of "Dr. Melinda Rostal" <rostal@ecohealthalliance.org>
**Date:** Thursday, February 14, 2019 at 9:36 AM
**To:** PREDICT-outbreak <predict-outbreak@ucdavis.edu>
**Cc:** "epstein@ecohealthalliance.org" <epstein@ecohealthalliance.org>, Emily Hagan <hagan@ecohealthalliance.org>, Arif Islam <arif@ecohealthalliance.org>, Catherine Machabala <machalaba@ecohealthalliance.org>, Evelyn Luciano <luciano@ecohealthalliance.org>, Ava Sullivan <sullivan@ecohealthalliance.org>, Molly Turner <turner@ecohealthalliance.org>
**Subject:** [predict-outbreak] Request for assistance with encephalitis outbreak in Bangladesh

Dear outbreak team,

Our Bangladesh PREDICT team was asked to assist in the outbreak response to a suspected Nipah outbreak in Bangladesh. They have requested that we assist both in sampling wildlife and in conducting a One Health economic assessment of the outbreak costs (through the work of our economic fellow). For the former, we do still have on staff several people from the field team that are currently cleaning data, entering lab data into EIDITH, and assisting with analyses. Thus our team would have the capacity to respond and collect wildlife samples should we get permission. For the economic assessment, while our Economic Fellow is available to assist, unfortunately this district is not among those covered by our IRB. However, Catherine will be speaking to the team at UCD today about the possibility of making an amendment in order to allow us to collect these data. Likewise the team in Bangladesh will speak to the local IRB to see if it would be possible to rapidly process an IRB amendment with only one small change.

We look forward to hearing your and USAID's responses.

Please let me know if you have any questions. The initial outbreak report is attached.

Kind regards,

Mindy

**From:** "William B. Karesh" <karesh@ecohealthalliance.org>
**To:** Amalhin Shek <ashek@usaid.gov>
**Cc:** PREDICTMGT <predictmgt@usaid.gov>, Dennis Carroll <dcarroll@usaid.gov>, Jonna Mazet <jkmazet@ucdavis.edu>, Peter Daszak <daszak@ecohealthalliance.org>
**Subject:** Re: Decade of ---Brainstorming
**Sent:** Mon, 4 Mar 2019 21:46:18 +0000

Hi Amalhin,
Happy to discuss. It could get a little complicated by other requests I've got going but maybe we can figure out some alternatives.

Right now, I'm tentatively set to meet with senior leadership in the House next week and might be able to get a sense of interest and what's possible if the opportunity arises.

BK

**William B. Karesh, D.V.M**
*Executive Vice President for Health and Policy*

EcoHealth Alliance
460 West 34th Street - 17th Floor
New York, NY 10001 USA

+1.212.380.4463 (direct)
+1.212.380.4465 (fax)
www.ecohealthalliance.org

President, OIE Working Group on Wildlife

Co-chair, IUCN Species Survival Commission - Wildlife Health Specialist Group

EPT Partners Liaison, USAID Emerging Pandemic Threats - PREDICT-2 Program

***EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that promote conservation and prevent pandemics.***

On Mar 4, 2019, at 4:17 PM, Amalhin Shek <ashek@usaid.gov> wrote:

Hi Billy,

Writing to follow up on this.

Hope to chat soon!

**Amalhin Shek | Budget & Communications Analyst**
Bureau for Global Health, Office of Infectious Disease, Emerging Threats Division
Phone: 571-551-7102(o) REDACTED | CP3 8092

USAID-HECFAA, VP of Community Engagement

USAID **Contractor**
*GHSI-III - Social Solutions International, Inc.*

On Mon, Feb 11, 2019 at 5:48 PM Amalhin Shek <ashek@usaid.gov> wrote:

Hello Billy!

I hope this message finds you well. Cara mentioned that the last time she saw you in speaking about the concept of celebrating our ten years of EPT programming with a series of events. She told me you had some ideas regarding the different folks outside of the program partners that we could engage. Please let me know what you think and when a call will be possible to further discuss.

Thanks in advance,
Amalhin

**Amalhin Shek | Budget & Communications Analyst**
Bureau for Global Health, Office of Infectious Disease, Emerging Threats Division
Phone: 571-551-7102(o) REDACTED | CP3 8092
Subscribe to our Newsletter!

USAID-HECFAA, VP of Community Engagement

USAID **Contractor**
*GHSI-III - Social Solutions International, Inc.*

**From:** Andrew Clements <aclements@usaid.gov>
**Sent:** Fri, 15 Mar 2019 13:15:41 +0100
**Subject:** Re: TVPA justification for DRC, Guinea, China, and ROC
**To:** Jonna Mazet <jkmazet@ucdavis.edu>
**Cc:** Alisa [redacted], PREDICTMGT <predictmgt@usaid.gov>, Predict inbox <predict@ucdavis.edu>

Thanks, Jonna. Will share with the appropriate people.

Andrew Clements, Ph.D.
Senior Scientific Advisor
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
E-mail: aclements@usaid.gov

*For more information on USAID's Emerging Pandemic Threats program, see:* http://www.usaid.gov/ept2

On Fri, Mar 15, 2019 at 4:38 AM Jonna Mazet <jkmazet@ucdavis.edu> wrote:

> Dear Andrew & Alisa,
> As discussed and requested, we have prepared a justification and enumerated implications/consequences if we have to limit or stop work in the TVPA-restricted countries.
> We are not sure whether or not these explanations will be useful, but we did think you should have them.
> Have a nice day,
> Jonna

**From:** David McIver <dmciver@metabiota.com>
**Subject:** Re: Updated Asia Bat Book with new sections for review
**Sent:** Fri, 24 May 2019 10:41:08 -0700
**Cc:** Jonna Mazet <jkmazet@ucdavis.edu>, Christine Johnson <ckjohnson@ucdavis.edu>, David John Wolking <djwolking@ucdavis.edu>, Brian H Bird <bhbird@gmx.ucdavis.edu>, Corina Grigorescu Monagin <cgmonagin@ucdavis.edu>, Sarah [redacted]>, Amanda Fine <[redacted], Carolina <[redacted], Marc Valitutto <ValituttoM@si.edu>, Dawn Zimmerman <Zimmermand@si.edu>, Suzan <MurrayS@si.edu>, Woutrina A Smith <wasmith@ucdavis.edu>, Karen Saylors <[redacted], Tammie O'Rourke <torourke@metabiota.com>, Jason Euren <jeuren@metabiota.com>, Peter Daszak <daszak@ecohealthalliance.org>, "William B. Karesh" <karesh@ecohealthalliance.org>, Jon Epstein <epstein@ecohealthalliance.org>, Kevin Olival <olival@ecohealthalliance.org>, Thomas Hughes <tom.hughes@ecohealthalliance.org>, Aleksei Chmura <chmura@ecohealthalliance.org>, Stephanie Martinez <martinez@ecohealthalliance.org>, Ava Sullivan <sullivan@ecohealthalliance.org>, Tracey Goldstein <tgoldstein@ucdavis.edu>
**To:** Emily Hagan <hagan@ecohealthalliance.org>

Hi Emily and Behaviour Team,
Echoing the previous thoughts, thanks so much for all your hard work and getting this finished up so quickly! I'll get back to you with any thoughts or edits.

Cheers,
Dave

David McIver, PhD
Senior Scientist
Metabiota

e: dmciver@metabiota.com
c: +1 778-269-2965

CONFIDENTIALITY NOTICE: The information contained in this electronic mail (email) transmission (including attachments), is intended by Metabiota for the use of the named individual or entity to which it is addressed and may contain information that is privileged or otherwise confidential. It is not intended for transmission to, or receipt by, any individual or entity other than the named addressee except as otherwise expressly permitted in this email transmission. If you have received this email in error, please delete it without copying or forwarding it, and notify the sender of the error by email reply.

On May 24, 2019, at 8:26 AM, Tracey Goldstein <tgoldstein@ucdavis.edu> wrote:

Thanks Emily! Will review get back to you.
Best Tracey

On Thu, May 23, 2019 at 4:11 PM Emily Hagan <hagan@ecohealthalliance.org> wrote:

Dear EB and Bat Book Team,

Again, thank you for all of your help with the success of the bat book to date. It has been great to hear about how it has been used and plans for future use.
We have completed the adaption of the bat book for use in our Asia partner countries, which contains two new sections: 'What to do if contact with bat feces is unavoidable' and 'Basic ways to protect yourself in caves and other bat sites'.

The new version can be found at the following link: Asia Bat Book

We are happy to receive comments, edits, or suggestions via PDF or a scanned printed copy.

We'd appreciated your feedback by Friday, May 31st. We will then collate the responses and incorporate your feedback the following week.

Sincerely,

Emily

--

**Emily** REDACTED
*Behavioral Risk Program Manager*
*Research Scientist*
*PREDICT 2 Country Liaison, Bangladesh*

EcoHealth Alliance
460 West 34th Street – 17th floor
New York, NY 10001

1.212.380.4491 (direct)
REDACTED
REDACTED

www.ecohealthalliance.org

***EcoHealth Alliance leads cutting-edge scientific research into the critical connections between human and wildlife health and delicate ecosystems. With this science, we develop solutions that prevent pandemics and promote conservation.***

--

Tracey REDACTED
One Health Institute
School of Veterinary Medicine
University of California
Davis, CA 95616
Phone: (530) 752-0412
Fax: (530) 752-3318
REDACTED

| | |
|---|---|
| **From:** | Jonna Mazet <jkmazet@ucdavis.edu> |
| **To:** | AOTR/Grant Manager Andrew Clements <AClements@usaid.gov>;Amalhin Shek <ashek@usaid.gov>;Alisa Pereira <apereira@usaid.gov>;Cara Chrisman <cchrisman@usaid.gov>;Dennis Carroll <DCarroll@usaid.gov> |
| **CC:** | Predict inbox <predict@ucdavis.edu> |
| **Sent:** | 6/18/2019 10:10:17 PM |
| **Subject:** | Update please |

Hello from Global Health Security 2019,
The Predict Project accomplishments and activities have been met with extreme enthusiasm here.

Could I please have an update on our ability to continue? My understanding from Thursday discussions is that somebody in USAID Global Health has to push a button to approve the funding being released from OAA. OAA indicated that it will be a very rapid process from that point.
Has that button pushing (i.e., approval) been accomplished? If not, why not & what impediments stand in the way at this point? Does someone in the unit need to go and sit with whoever pushes the button to move this along? If so, I am begging one of you to do so, as I am at a loss as to what to do to keep the project on track.

Please advise,
Jonna

**From:** David [redacted]
**Sent:** Tue, 2 Jul 2019 08:24:30 -0700
**To:** "Clements, [redacted], Alisa [redacted], "Cara [redacted]>, Amalhin [redacted]>
**Cc:** "predict@ucdavis.edu" <predict@ucdavis.edu>
**Subject:** Fwd: [predict] FW: Invitation to EPT2 Program Review, Novotel Hotel, Da Nang, July 11-12, 2019
EPT2 Review - Invitation 11-12 July 2019.pdf
EPT2 Concept Note.docx
EPT2 Review Agenda July 11.docx
EPT2 Review Agenda July 12.docx

Hi Andrew,
I'm assuming you're well aware of this EPT-2 5 year review meeting in Viet Nam next week as I see USAID/W represented on the agenda. Amanda and our WCS team will of course represent PREDICT. Please let us know if you have any questions or guidance for this particular event.

Best,

David

---------- Forwarded message ---------
From: **Fine, Amanda** [redacted]
Date: Tue, Jul 2, 2019 at 1:50 AM
Subject: [predict] FW: Invitation to EPT2 Program Review, Novotel Hotel, Da Nang, July 11-12, 2019
To: predict@ucdavis.edu <predict@ucdavis.edu>, Olson, Sarah [redacted]>, Churchill, Carolina [redacted]

Hello David, Sarah, and Carolina,

Forwarding this invitation, concept, and agenda for the EPT2 program review meeting July 11-12, 2019. Our WCS/PREDICT team and laboratory partners will be attending and participating.

Cheers,
Amanda
—
Amanda E. Fine, VMD, PhD
[redacted]
Tel: +84 24 3514 9750 (ext: 23)
Fax: +84 24 3519 0383
Mobile/WhatsApp: +[redacted]
Skype: [redacted]

---

**From:** Nguyen Nga
**Date:** Tuesday, July 2, 2019 at 3:38 PM
**To:** Amanda Fine, "Hwang, Jusun", Thuy Hoang
**Cc:** "Pham, Ngoc"
**Subject:** Fw: Invitation to EPT2 Program Review, Novotel Hotel, Da Nang, July 11-12, 2019

Dear all,

I know C. Thuy and Amanda may received this email as well. So, I just want to copy Jusun in here and lets all of us discuss about who will come for this meeting when Amanda's back to office on this Wed (Jul 04). Then I can work on

logistic preparation for this trip.

Thanks,

Nga

---

**From:** Michael OLeary <moleary@usaid.gov>
**Sent:** Tuesday, July 2, 2019 3:29 PM
**To:** OHP Secretariat; Oanh Kim Thuy (HANOI/OH)
**Subject:** Invitation to EPT2 Program Review, Novotel Hotel, Da Nang, July 11-12, 2019

Dear all,

We are pleased to invite you to a review of USAID's 5-year EPT2 program and consideration of future priorities, to be convened at the Novotel Hotel in Da Nang on July 11-12, 2019.

**Objectives:**

- To review major achievements in Vietnam during the 5 years (2015-2019) of the EPT2 program, in building capacity to prevent, detect, and respond to zoonotic diseases, antimicrobial resistance, and emerging pandemic threats.
- To consider the remaining challenges, gaps, and priorities for sustaining and expanding those capacities in Vietnam.

**Venue:** Novotel Hotel, Da Nang

**Date and Time:** July 11 - 12, 2019 (Thursday and Friday)
*Draft agenda attached. Some participants may attend only Day 2.*

For further information and confirmation of participation, please contact by July 6, 2019:

- Mr. Le Thanh Hai, Mobile: 091 396 2636, email: oh.partnership@gmail.com and
- Dr. Kim Thuy Oanh, USAID, 098 736 3539, okim@usaid.gov,

The Organizer will cover accommodation and travel expenses for delegates from Vietnam's Government agencies according to UNDP cost-norms via reimbursement (bank transfer). Regarding travel and logistics support, Government delegates please contact:

- Ms. Nguyen Huyen Trang, Mobile: 098 958 3455, email: trangnh.oh@gmail.com

Further information is in the attachments: Invitation, Concept note, and Agenda for the meeting.

Thank you very much. We look forward to your attendance, and contributions to the meeting.

Michael O'Leary
Kim Thuy Oanh
USAID Vietnam
--

**MICHAEL J. O'LEARY, MD, MPH**
Senior Infectious Diseases Advisor | Office of Health
**U.S. AGENCY FOR INTERNATIONAL DEVELOPMENT**
6 [redacted], REDACTED
T REDACTED | moleary@usaid.gov | vietnam.usaid.gov | @USAIDVietnam | Flickr | YouTube

USAID | VIETNAM
FROM THE AMERICAN PEOPLE

**Subject: Invitation to the Emerging Pandemic Threats Program Review**

**[CORRECTION of earlier notice: Please note a change in dates and venue]**

Dear Sir / Madame,

USAID will convene a review of the 5-year **Emerging Pandemic Threats (EPT-2)** program in Vietnam, and a look forward to priorities for action in the next period, from 2020.

**Background:** Through EPT2, USAID has supported the Government of Vietnam and local partners by engaging with international implementing partners, and in collaboration with members of the One Health Partnership, to further strengthen capacities to prepare for, identify, mitigate, and control emerging and re-emerging infectious disease threats. EPT2 focused on zoonotic diseases from a One Health perspective. EPT2 has also collaborated in U.S. support to the Global Health Security Agenda. The 5-year EPT2 ends in 2019. USAID is engaged in a transition in its support in Vietnam. The **Emerging Threats – Next Generation** program will be underway in late 2019 / 2020.

**Objectives:**

1. To review major achievements in Vietnam during the 5 years (2015-2019) of the EPT2 program, in building capacity to prevent, detect, and respond to zoonotic diseases, antimicrobial resistance, and emerging pandemic threats.

2. To consider the remaining challenges, gaps, and priorities for sustaining and expanding those capacities in Vietnam.

**Venue:** Novotel Hotel, Da Nang

**Date and Time:** July 11 - 12, 2019 (Thursday and Friday)

*Draft agenda enclosed. Some participants may attend only Day 2.*

For further information and confirmation of participation, please contact by July 6, 2019:

- Mr. Le Thanh Hai, SCOH2 Knowledge Management Officer,
  Mobile: 091 396 2636, email: oh.partnership@gmail.com and
- Dr. Kim Thuy Oanh, USAID, 098 736 3539, okim@usaid.gov,

The Organizer will cover accommodation and travel expenses for delegates from Vietnam's Government agencies according to UNDP cost-norms via reimbursement (bank transfer).

Regarding travel and logistics support, Government delegates please contact:

- Ms. Nguyen Huyen Trang, SCOH2 Accountant,
  Mobile: 098 958 3455, email: trangnh.oh@gmail.com

Thank you very much. We look forward to your attendance, and contributions to the meeting.

Michael REDACTED
USAID Office of Health

U.S. Agency for International Development
15/F, Tung Shing Square
#2 Ngo Quyen Street,
Hanoi, Vietnam

Tel: +84-4-3935-1260
Fax: +84-4-3935-1265

UCDUSR0012060

# EPT2 Review Summary, and Future Directions
# Novotel, Da Nang
# Friday 12 July 2019

## Objectives

- To review major achievements in Vietnam during the 5 years (2105-2019) of the EPT2 program, in building capacity to prevent, detect, and respond to zoonotic diseases and emerging pandemic threats.
- To consider the remaining challenges, gaps, and priorities for sustaining and expanding capacities in Vietnam to identify and address emerging threats and antimicrobial resistance in both animal and human populations.

## Expected outputs

- Achieve a consensus on major achievements 2015–2019 (supported or facilitated by EPT2)
- Determine priorities for action in the next 3-5 years.
- Identify key considerations to achieve sustainability of priority activities.

**Agenda**

| Friday<br>12 July 2019 | Agenda Items | Responsible |
|---|---|---|
| 09:00 – 09:15 | **Opening**<br>• Welcome remarks from USAID<br>• Welcome remarks from senior representative, GVN | GVN and USAID |
| 09:15 – 10:00 | **Summary from July 11 Group Work**<br>• Summary conclusions on achievements, sustainability, challenges, gaps. | One rapporteur for:<br>• Group 1/2<br>• Group 3/4<br>• Group 5/6 |
| 10:00 – 10:15 | Q & A, discussion | |
| 10:15 – 10:45 | Photo and BREAK | |
| 10:45 – 11:45 | **Plenary Comments**<br>• National and international One Health / GHSA partners provide comments on achievements and future collaboration. | Plenary inputs |
| 11:45 – 12:00 | Plenary Q&A | |
| 12:00 – 13:00 | Lunch | |
| 13:00 – 13:45 | **PANEL: Way forward/ Sustaining priorities**<br>Presentations by MARD and MOH key EPT-2 counterparts:<br>• Priorities for infectious disease control in coming years;<br>• Potential inputs from partners;<br>• Perspectives on sustainable capacities. | • DAH<br>• GDPM<br>• ICD MARD |
| 13:45 – 14:00 | **Emerging Threats - Next Generation**<br>• Perspectives from USAID | USAID / W |

| | | |
|---|---|---|
| 14:00 – 14:45 | Plenary questions and discussion | |
| 14:45 – 15:00 | Closing | |

# EPT2 Review, 2015 – 2019
# Novotel, Da Nang
# Thursday 11 July 2019

## Objectives

- To review major achievements in Vietnam during the 5 years (2105-2019) of the EPT2 program, in building capacity to prevent, detect, and respond to zoonotic diseases and emerging pandemic threats.
- To consider the remaining challenges, gaps, and priorities for sustaining and expanding capacities in Vietnam to identify and address emerging threats and antimicrobial resistance in both animal and human populations.

## Expected outputs

- Achieve a consensus on major achievements 2015–2019 (supported or facilitated by EPT2)
- Determine priorities for action in the next 3-5 years.
- Identify key considerations to achieve sustainability of priority activities.

## Agenda

| **Thursday 11 July 2019** | | **Responsible** |
|---|---|---|
| | **Morning Session** | |
| 08:30 – 08:45 | **Opening**<br>• Welcome remarks from USAID<br>• Welcome remarks from senior representative, GVN | USAID<br>GVN |
| 08:45 – 09:45 | **Overview of main achievements** by EPT2 partners, 2015-2019<br>• Briefly list major EPT2 – GVN achievements.<br>• Introduce and orient to posters. | FAO<br>WHO<br>WCS<br>VOHUN<br>OHP Secretariat |
| 09:45 – 10:00 | Plenary Q & A on presentations | |
| 10:00 – 10:05 | Explanation of poster checklist | |
| 10:05 – 10:30 | Photo and Break | |
| 10:30 – 12:00 | **Poster walk**<br>• EPT2 partners will display posters with important details of activities, outputs, and achievements, 2015-2019.<br>• Each participant will complete a poster checklist. | All |
| 12:00 – 13:00 | Lunch | |

| | Afternoon Session | |
|---|---|---|
| 13:00 – 13:30 | **Plenary discussion**: Initial feedback on posters | |
| | **Group work: Expected Outputs**<br>• 3-5 major achievements in technical areas under discussion.<br>• Which of these are priorities to sustain in the next 3-5 years?<br>• How can these be sustained?<br>• Remaining challenges and gaps.<br>• Outputs on flip charts. | |
| 13:30 – 14:15 | **Groups 1 and 2:**<br>• Laboratory<br>• Biosafety and biosecurity<br>• AMR and infection prevention and control<br>**Groups 3 and 4**<br>• Preparedness<br>• Surveillance and reporting<br>• Outbreak investigation<br>**Groups 5 and 6**<br>• Workforce development<br>• One Health coordination and communication | Participants divided into 6 groups.<br><br>One Rapporteur and one Facilitator for each group. |
| 14:15 – 14:45 | **World Café Presentation/ Discussion 1**<br>• Rapporteurs and facilitators from Groups 1 and 2 join together, and present results to participants from two other groups, who cluster around for discussion.<br>• Same for Groups 3 and 4; and Groups 5 and 6. | |
| 14:45 – 15:15 | **World Café Presentation Discussion 2**<br>• As above: Participants move to another cluster to hear from a different set of rapporteurs and facilitators. | |
| 15:15 – 15:30 | BREAK | |
| 15:30 – 16:00 | MARD and MOH panel member perspectives / reflections on EPT2 | • DAH<br>• GDPM<br>• ICD MARD |
| 16:00 – 16:30 | Plenary discussion | |
| 16:30 – 17:00 | Wrap-up | |

# EPT2 Review: Background and Overview

*Da Nang, July 2019*

## Background

USAID's 5-year **Emerging Pandemic Threats program (EPT2)** will transition in 2019 to a new program of support. EPT2 was itself an expansion of a previous 5-year EPT program, and, even earlier, a program of support focused on avian influenza. EPT2 has provided U.S. support in 20 countries in East and Central Africa and Southeast Asia, to support Governments in strengthening capacity for zoonotic and emerging infectious disease control. Implementing partners were engaged in this effort, including FAO and WHO, and three consortia: the One Health Workforce represented in Vietnam by the One Health University Network; PREDICT-2 represented by the Wildlife Conservation Society; and Preparedness and Response represented by Development Alternatives Inc. In Vietnam, UNDP was an additional partner, through which support was provided to a Secretariat of the One Health Partnership (OHP), based at International Cooperation Department, Ministry of Agriculture and Rural Development.

EPT2 partners developed annual work plans with Government of Vietnam (GVN) counterparts in both human and animal health, and worked in collaboration with other partners through the OHP. The focus of EPT2 was to further strengthen capacities to prevent, identify, mitigate, and control emerging and re-emerging infectious disease threats, especially zoonotic diseases which spillover from wildlife and livestock to humans, and to foster multi-sectoral coordination under a One Health framework. EPT2 has also collaborated in U.S. support to the Global Health Security Agenda, and expanded its work during the project period to encompass antimicrobial resistance as well.

As the 5-year funding for EPT2 ends in 2019, USAID is engaged in a transition in its support in Vietnam, through the new **Emerging Threats – Next Generation** program, underway in late 2019 / 2020. To aid this transition, USAID is convening an EPT2 Review in Da Nang in July 2019; to assess major achievements over the last 5 years, identify remaining gaps and challenges, and consider priorities for sustained action in the future.

## Participation

Invitations to the 2-day meeting are extended to about 60 partners from GVN ministries, national and regional institutes and departments, universities, research and international organizations involved in day-to-day implementation of activities related to EPT-2 or GHSA goals and objectives. An additional 30 or so affiliated and senior counterparts are invited on the second day, to provide inputs on the achievements and challenges identified on day 1, and to advise on future priorities, and multi-sectoral collaboration.

Session Chairs, speakers, and rapporteurs will be identified and contacted separately.

## Timing and Location

This EPT2 Review will take place on July 11-12, 2019 in Da Nang, Vietnam, at the Novotel Hotel.

## Meeting contents

The EPT2 Review Agenda is expected to include the following key sections:

- Overview of main achievements 2015-2019
- Poster / Gallery walk prepared by EPT2 partners
- Working Groups to identify achievements and gaps in key technical areas
- Government of Vietnam (GVN) perspectives on EPT2 achievements and challenges

- Presentation of key findings to other participants and senior leaders
- GVN priorities and plans for sustaining collaboration and further building capacity
- USAID perspectives on a next generation of activities

**From:** Peter Daszak <daszak@ecohealthalliance.org>
**To:** Kirsten Gilardi <kvgilardi@ucdavis.edu>
**Cc:** Jonna Mazet <jkmazet@ucdavis.edu>, Carlos Zambrana-Torrelio <zambrana@ecohealthalliance.org>, Aleksei Chmura <chmura@ecohealthalliance.org>, Erica Johnson <johnson@ecohealthalliance.org>, Evelyn Luciano <luciano@ecohealthalliance.org>
**Subject:** RE: Time Sensitive!! Resurrecting our Coupled Natural-Human Systems proposal to NSF on DEEP FOREST
**Sent:** Fri, 20 Oct 2017 12:43:37 +0000

Great – the timeframe is that we have to submit on Nov 21st. We'll need the usual forms (CV, past and current funding etc) a week in advance.

We can draft text, but we need you and Benard to review it ahead of time and approve what we're proposing and the budget…

Anyway – let us know what conclusion you come to with Benard and look forward to hearing back…

Cheers,

Peter

**Peter Daszak**
*President*

EcoHealth Alliance
460 West 34th Street – 17th Floor
New York, NY 10001

Tel. +1 212-380-4473
www.ecohealthalliance.org

*EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that prevent pandemics and promote conservation.*

---

**From:** Kirsten Gilardi [mailto:kvgilardi@ucdavis.edu]
**Sent:** Thursday, October 19, 2017 12:41 AM
**To:** Peter Daszak
**Cc:** Jonna Mazet; Carlos Zambrana-Torrelio; Aleksei Chmura; Erica Johnson; Evelyn Luciano
**Subject:** Re: Time Sensitive!! Resurrecting our Coupled Natural-Human Systems proposal to NSF on DEEP FOREST

Thanks Peter, and understood re. value of multi-year studies. I will see Benard on Monday and discuss. What sort of timeframe are we looking at? -K

> On Oct 18, 2017, at 11:40 AM, Peter Daszak <daszak@ecohealthalliance.org> wrote:
>
> No problem. We'll continue right now with the plan of including Uganda and start pulling together the draft.
>
> That said, I hope you'll be interested in doing more work on DF in Uganda Kirsten. I know it was a hassle to organize last time round, but we could simplify it by just focusing on bat/rodent sampling/testing and no extra human behavior work. By the way – the rationale for carrying on the project is that for ecological studies you normally have to do multi-year sampling to make sure that multi-year changes in weather etc. are not driving the patterns.
>
> Anyway – think about it, and let us know as soon as you can. I'm ready to talk by email or phone over the next few days/weeks, and we will be crunching on the re-write during that time…

Cheers,

Peter

**Peter Daszak**
*President*

EcoHealth Alliance
460 West 34th Street – 17th Floor
New York, NY 10001

Tel. +1 212-380-4473
www.ecohealthalliance.org

*EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that prevent pandemics and promote conservation.*

**From:** [redacted] **On Behalf Of** Jonna Mazet
**Sent:** Tuesday, October 17, 2017 11:50 PM
**To:** Peter Daszak; kvgilardi@ucdavis.edu
**Cc:** Carlos Zambrana-Torrelio; Aleksei Chmura; Erica Johnson; Evelyn Luciano
**Subject:** Re: Time Sensitive!! Resurrecting our Coupled Natural-Human Systems proposal to NSF on DEEP FOREST

I'm supportive, but it's really up to Kirsten to evaluate the feasibility and pros & cons in our current operating climate. She is currently on her way to Uganda & Rwanda, so she may be delayed in responding for a couple of days.
Thanks for asking,
J

On Tue, Oct 17, 2017 at 12:05 PM, Peter Daszak <daszak@ecohealthalliance.org> wrote:
Hi Jonna and Kirsten – a few years ago we submitted a DEEP FOREST proposal to NSF CNH and got semi-decent comments back. We'd like to resurrect it and would like to keep the current focus on DEEP FOREST countries. The plan is to use the DF data from Brazil, Uganda and Malaysia as the basis, but ditch Brazil as a country we're going to continue to work in so that the continued fieldwork will be in Malaysia and Uganda.

The deadline is Nov 21st. Carlos is pulling together the draft and the response to reviewers (reviewer comments attached).

I want to first check with you both that you are interested in doing this – I definitely think it's worth a shot considering the fairly positive reviewers' comments. If so, we'll need to rapidly line up all the paper work, budgets, etc. I've cc'd Carlos and Evelyn who will be able to coordinate.

Hope you'll be part of this and looking forward to getting this grant funded!

Cheers,

Peter

**Peter Daszak**
*President*

EcoHealth Alliance
460 West 34th Street – 17th Floor
New York, NY 10001

Tel. +1 212-380-4473
www.ecohealthalliance.org

*EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that prevent pandemics and promote conservation.*